hr-20240331

0001360604-24-000045.txt : 20240507 0001360604-24-000045.hdr.sgml : 20240507 20240507063645 ACCESSION NUMBER: 0001360604-24-000045 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 72 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240507 DATE AS OF CHANGE: 20240507 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Healthcare Realty Trust Inc CENTRAL INDEX KEY: 0001360604 STANDARD INDUSTRIAL CLASSIFICATION: REAL ESTATE INVESTMENT TRUSTS [6798] ORGANIZATION NAME: 05 Real Estate & Construction IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35568 FILM NUMBER: 24919498 BUSINESS ADDRESS: STREET 1: 3310 WEST END AVENUE, SUITE 700 CITY: NASHVILLE STATE: TN ZIP: 37203 BUSINESS PHONE: 615-269-8175 MAIL ADDRESS: STREET 1: 3310 WEST END AVENUE, SUITE 700 CITY: NASHVILLE STATE: TN ZIP: 37203 FORMER COMPANY: FORMER CONFORMED NAME: HEALTHCARE TRUST OF AMERICA, INC. DATE OF NAME CHANGE: 20160802 FORMER COMPANY: FORMER CONFORMED NAME: Healthcare Trust of America Holdings, Inc. DATE OF NAME CHANGE: 20160802 FORMER COMPANY: FORMER CONFORMED NAME: Healthcare Trust of America Holdings, LP DATE OF NAME CHANGE: 20160802 10-Q 1 hr-20240331.htm 10-Q hr-20240331

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_______________

FORM 10-Q


(Mark One)
☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the quarterly period ended:	March 31, 2024
OR
☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to

Commission File Number: 001-35568 (Healthcare Realty Trust Incorporated)

HEALTHCARE REALTY TRUST INCORPORATED

(Exact name of Registrant as specified in its charter)


Maryland						20-4738467

(State or other jurisdiction of Incorporation or organization)						(I.R.S. Employer Identification No.)

3310 West End Avenue, Suite 700

Nashville, Tennessee 37203

(Address of principal executive offices)

(615) 269-8175

(Registrant's telephone number, including area code)


www.healthcarerealty.com
(Internet address)

Securities Registered Pursuant to Section 12(b) of the Act:

Title of Each Class

Trading Symbol

Name of Each Exchange on Which Registered

Class A Common Stock, $0.01 par value per share

New York Stock Exchange

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Sections 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

☒

Yes

☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

☒

Yes

☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

☒

Large accelerated filer

☐

Accelerated filer

☐

Non-accelerated filer

☐

Smaller reporting company

☐

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.


			☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

☐

Yes

☒

As of May 3, 2024, the Registrant had 378,544,088 shares of Common Stock outstanding.

HEALTHCARE REALTY TRUST INCORPORATED

FORM 10-Q

March 31, 2024

Table of Contents


PART I - FINANCIAL INFORMATION
Item 1	Financial Statements	1
	Condensed Consolidated Balance Sheets	1
	Condensed Consolidated Statements of Operations	2
	Condensed Consolidated Statements of Comprehensive Loss	3
	Condensed Consolidated Statements of Equity and Redeemable Non-Controlling Interests	4
	Condensed Consolidated Statements of Cash Flows	5
	Notes to the Condensed Consolidated Financial Statements	6
Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	20
Item 3	Quantitative and Qualitative Disclosures about Market Risk	29
Item 4	Controls and Procedures	29

PART II - OTHER INFORMATION
Item 1	Legal Proceedings	29
Item 1A	Risk Factors	29
Item 2	Unregistered Sales of Equity and Use of Proceeds	30
Item 5	Other Information	30
Item 6	Exhibits	30

SIGNATURE		32

Table of Contents

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

Healthcare Realty Trust Incorporated

Condensed Consolidated Balance Sheets

Amounts in thousands, except per share data


ASSETS
	Unaudited MARCH 31, 2024		DECEMBER 31, 2023
Real estate properties
Land	$	1,342,895	$	1,343,265
Buildings and improvements	10,902,835		10,881,373
Lease intangibles	816,303		836,302
Personal property	12,720		12,718
Investment in financing receivable, net	122,001		122,602
Financing lease right-of-use assets	81,805		82,209
Construction in progress	70,651		60,727
Land held for development	59,871		59,871
Total real estate properties	13,409,081		13,399,067
Less accumulated depreciation and amortization	(2,374,047)		(2,226,853)
Total real estate properties, net	11,035,034		11,172,214
Cash and cash equivalents	26,172		25,699


Assets held for sale, net	30,968		8,834
Operating lease right-of-use assets	273,949		275,975
Investments in unconsolidated joint ventures	309,754		311,511
Goodwill	—		250,530
Other assets, net	605,047		592,368
Total assets	$	12,280,924	$	12,637,131

LIABILITIES AND STOCKHOLDERS' EQUITY
Liabilities
Notes and bonds payable	$	5,108,279	$	4,994,859
Accounts payable and accrued liabilities	163,172		211,994
Liabilities of assets held for sale	700		295
Operating lease liabilities	229,223		229,714
Financing lease liabilities	74,769		74,503
Other liabilities	197,763		202,984
Total liabilities	5,773,906		5,714,349
Commitments and contingencies
Redeemable non-controlling interests	3,880		3,868
Stockholders' equity
Preferred stock, $.01 par value per share; 200,000 shares authorized; none issued and outstanding	—		—
Class A Common stock, $.01 par value per share; 1,000,000 shares authorized; 381,502 and 380,964 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	3,815		3,810
Additional paid-in capital	9,609,530		9,602,592
Accumulated other comprehensive income (loss)	4,791		(10,741)
Cumulative net income attributable to common stockholders	717,958		1,028,794
Cumulative dividends	(3,920,199)		(3,801,793)
Total stockholders' equity	6,415,895		6,822,662
Non-controlling interest	87,243		96,252
Total equity	6,503,138		6,918,914
Total liabilities and equity	$	12,280,924	$	12,637,131

The accompanying notes, together with the Notes to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, are an integral part of these financial statements.

Table of Contents

Healthcare Realty Trust Incorporated

Condensed Consolidated Statements of Operations

For the Three Months Ended March 31, 2024 and 2023

Amounts in thousands, except per share data

Unaudited


	THREE MONTHS ENDED March 31,
	2024		2023
Revenues
Rental income	$	318,076	$	324,093
Interest income	4,538		4,214

Other operating	4,191		4,618
	326,805		332,925
Expenses
Property operating	121,078		122,040
General and administrative	14,787		14,935
Transaction costs	395		287
Merger-related costs	—		4,855
Depreciation and amortization	178,119		184,479


	314,379		326,596
Other income (expense)
Gain on sales of real estate properties	22		1,007
Interest expense	(61,054)		(63,759)


Impairment of real estate properties and credit loss reserves	(15,937)		(31,422)
Impairment of goodwill	(250,530)		—
Equity loss from unconsolidated joint ventures	(422)		(780)
Interest and other income, net	275		547
	(327,646)		(94,407)






Net loss	$	(315,220)	$	(88,078)
Net loss attributable to non-controlling interests	4,384		953
Net loss attributable to common stockholders	$	(310,836)	$	(87,125)



Basic earnings per common share	$	(0.82)	$	(0.23)


Diluted earnings per common share	$	(0.82)	$	(0.23)

Weighted average common shares outstanding - basic	379,455		378,840
Weighted average common shares outstanding - diluted	379,455		378,840

Table of Contents

Healthcare Realty Trust Incorporated

Condensed Consolidated Statements of Comprehensive Loss

For the Three Months Ended March 31, 2024 and 2023

Amounts in thousands

Unaudited


	THREE MONTHS ENDED March 31,
	2024		2023
Net loss	$	(315,220)	$	(88,078)
Other comprehensive income


Interest rate derivatives
Reclassification adjustments for gains included in interest expense	(3,865)		(2,284)
Gains (losses) arising during the period on interest rate swaps	19,611		(8,541)

	15,746		(10,825)
Comprehensive loss	(299,474)		(98,903)
Less: comprehensive loss attributable to non-controlling interests	4,170		1,084
Comprehensive loss attributable to common stockholders	$	(295,304)	$	(97,819)

Table of Contents

Healthcare Realty Trust Incorporated

Condensed Consolidated Statements of Equity and Redeemable Non-Controlling Interests

For the Three Months Ended March 31, 2024 and 2023

Amounts in thousands, except per share data

Unaudited


	Common Stock		Additional Paid-In Capital		Accumulated Other Comprehensive Income (Loss)		Cumulative Net Income		Cumulative Dividends		Total Stockholders’ Equity		Non-controlling Interests		Total Equity		Redeemable Non-controlling Interests
Balance at December 31, 2023	$	3,810	$	9,602,592	$	(10,741)	$	1,028,794	$	(3,801,793)	$	6,822,662	$	96,252	$	6,918,914	$	3,868
Issuance of common stock, net of issuance costs	—		104		—		—		—		104		—		104		—


Common stock redemptions	—		(135)		—		—		—		(135)		—		(135)		—
Conversion of OP Units to common stock	2		3,410		—		—		—		3,412		(3,412)		—		—
Share-based compensation	3		3,559		—		—		—		3,562		—		3,562		—

Net loss	—		—		—		(310,836)		—		(310,836)		(4,384)		(315,220)		—
Reclassification adjustments for gains included in net income (interest expense)	—		—		(3,813)		—		—		(3,813)		(52)		(3,865)		—
Gains arising during the period on interest rate swaps	—		—		19,345		—		—		19,345		266		19,611		—
Contributions from redeemable non-controlling interests	—		—		—		—		—		—		—		—		13
Adjustments to redemption value of redeemable non-controlling interests	—		—		—		—		—		—		—		—		(1)
Dividends to common stockholders and distributions to non-controlling interest holders ($0.31 per share)	—		—		—		—		(118,406)		(118,406)		(1,427)		(119,833)		—
Balance at March 31, 2024	$	3,815	$	9,609,530	$	4,791	$	717,958	$	(3,920,199)	$	6,415,895	$	87,243	$	6,503,138	$	3,880

	Common Stock		Additional Paid-In Capital		Accumulated Other Comprehensive Income (Loss)		Cumulative Net Income		Cumulative Dividends		Total Stockholders’ Equity		Non-controlling Interests		Total Equity		Redeemable Non-controlling Interests
Balance at December 31, 2022	$	3,806	$	9,587,637	$	2,140	$	1,307,055	$	(3,329,562)	$	7,571,076	$	108,742	$	7,679,818	$	2,014
Issuance of common stock, net of issuance costs	—		51		—		—		—		51		—		51		—


Common stock redemptions	(1)		(1,483)		—		—		—		(1,484)		—		(1,484)		—
Share-based compensation	3		4,989		—		—		—		4,992		—		4,992		—

Net loss	—		—		—		(87,125)		—		(87,125)		(953)		(88,078)		—
Reclassification adjustments for gains included in net income (interest expense)	—		—		(2,256)		—		—		(2,256)		(28)		(2,284)		—
Losses arising during the period on interest rate swaps	—		—		(8,438)		—		—		(8,438)		(103)		(8,541)		—
Adjustments to redemption value of redeemable non-controlling interests	—		—		—		—		—		—		—		—		(14)
Dividends to common stockholders and distributions to non-controlling interest holders ($0.31 per share)	—		—		—		—		(118,188)		(118,188)		(1,447)		(119,635)		—
Balance at March 31, 2023	$	3,808	$	9,591,194	$	(8,554)	$	1,219,930	$	(3,447,750)	$	7,358,628	$	106,211	$	7,464,839	$	2,000

Table of Contents

Healthcare Realty Trust Incorporated

Condensed Consolidated Statements of Cash Flows

For the Three Months Ended March 31, 2024 and 2023

Amounts in thousands

Unaudited


OPERATING ACTIVITIES
	THREE MONTHS ENDED March 31,
	2024		2023
Net loss	$	(315,220)	$	(88,078)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	178,119		184,479
Other amortization	11,829		11,104
Share-based compensation	3,562		4,992
Amortization of straight-line rent receivable (lessor)	(8,568)		(9,783)
Amortization of straight-line rent on operating leases (lessee)	935		1,537
Gain on sales of real estate properties	(22)		(1,007)

Impairment of real estate properties and credit loss reserves	15,937		31,422
Impairment of goodwill	250,530		—
Equity loss from unconsolidated joint ventures	422		780
Distributions from unconsolidated joint ventures	1,335		2,542

Non-cash interest from financing and notes receivable	(242)		(1,385)
Changes in operating assets and liabilities:
Other assets, including right-of-use-assets	(14,989)		(8,360)
Accounts payable and accrued liabilities	(52,163)		(66,954)
Other liabilities	4,687		7,901
Net cash provided by operating activities	76,152		69,190

INVESTING ACTIVITIES
Acquisitions of real estate	—		(30,725)
Development of real estate	(8,383)		(6,707)
Additional long-lived assets	(50,388)		(60,159)
Funding of mortgages and notes receivable	(1,052)		(6,230)
Investments in unconsolidated joint ventures	—		(3,824)
Investment in financing receivable	746		(302)
Contributions from redeemable non-controlling interests	13		—
Proceeds from sales of real estate properties and additional long-lived assets	226		149,171
Proceeds from notes receivable repayments	277		336


Net cash (used in) provided by investing activities	(58,561)		41,560

FINANCING ACTIVITIES
Net borrowings on unsecured credit facility	120,000		—



Repayments of notes and bonds payable	(17,326)		(667)


Dividends paid	(118,269)		(118,052)

Net proceeds from issuance of common stock	104		51
Common stock redemptions	(318)		(1,729)
Distributions to non-controlling interest holders	(1,199)		(1,272)



Payments made on finance leases	(110)		(101)
Net cash used in financing activities	(17,118)		(121,770)

Increase (decrease) in cash and cash equivalents	473		(11,020)
Cash and cash equivalents at beginning of period	25,699		60,961
Cash and cash equivalents at end of period	$	26,172	$	49,941

Supplemental Cash Flow Information


Interest paid	$	73,518	$	75,082
Mortgage note receivables taken in connection with sale of real estate	$	—	$	45,000
Invoices accrued for construction, tenant improvements and other capitalized costs	$	35,777	$	28,138

Capitalized interest	$	942	$	570

Table of Contents

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Note 1. Summary of Significant Accounting Policies

Business Overview

Healthcare Realty Trust Incorporated ("Company") is a real estate investment trust ("REIT") that owns, leases, manages, acquires, finances, develops and redevelops income-producing real estate properties associated primarily with the delivery of outpatient healthcare services throughout the United States. As of March 31, 2024, the Company had gross investments of approximately $13.4 billion in 654 consolidated real estate properties, construction in progress, redevelopments, financing receivables, financing lease right-of-use assets, land held for development and corporate property, excluding held for sale assets. The Company's real estate properties are located in 35 states and total approximately 38.4 million square feet. The Company provided leasing and property management services to 92% of its portfolio nationwide as of March 31, 2024.

On July 20, 2022, pursuant to that certain Agreement and Plan of Merger dated as of February 28, 2022, by and among Healthcare Realty Trust Incorporated, a Maryland corporation (now known as HRTI, LLC, a Maryland limited liability company) (“Legacy HR”), Healthcare Trust of America, Inc., a Maryland corporation (now known as Healthcare Realty Trust Incorporated) (“Legacy HTA”), Healthcare Trust of America Holdings, LP, a Delaware limited partnership (now known as Healthcare Realty Holdings, L.P.) (the “OP”), and HR Acquisition 2, LLC, a Maryland limited liability company (“Merger Sub”), Merger Sub merged with and into Legacy HR, with Legacy HR continuing as the surviving entity and a wholly-owned subsidiary of Legacy HTA (the “Merger”). The combined company operates under the name “Healthcare Realty Trust Incorporated” and its shares of class A common stock, $0.01 par value per share, trade on the New York Stock Exchange under the ticker symbol “HR”.

The Company is structured as an umbrella partnership REIT under which substantially all of its business is conducted through the OP, the day-to-day management of which is exclusively controlled by the Company. As of March 31, 2024, the Company owned 98.6% of the issued and outstanding units of the OP, with other investors owning the remaining 1.4% of outstanding units.

In addition, as of March 31, 2024, the Company had a weighted average ownership interest of approximately 43% in 33 real estate properties held in unconsolidated joint ventures. See Note 2 below for more details regarding the Company's unconsolidated joint ventures.

Any references to square footage or occupancy percentage, and any amounts derived from these values in these notes to the Company's Condensed Consolidated Financial Statements, are outside the scope of our independent registered public accounting firm’s review.

Basis of Presentation

The Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. They do not include all of the information and footnotes required by GAAP for complete financial statements. All material intercompany transactions and balances have been eliminated in consolidation.

This interim financial information should be read in conjunction with the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. Management believes that all adjustments of a normal, recurring nature considered necessary for a fair presentation have been included. In addition, the interim financial information does not necessarily represent or indicate what the operating results will be for the year ending December 31, 2024 for many reasons including, but not limited to, acquisitions, dispositions, capital financing transactions, changes in interest rates and the effects of other trends, risks and uncertainties.

Principles of Consolidation

The Company’s Condensed Consolidated Financial Statements include the accounts of the Company, its wholly owned subsidiaries, and joint ventures and partnerships where the Company controls the operating activities. GAAP requires us to identify entities for which control is achieved through means other than voting rights and to determine which business enterprise is the primary beneficiary of variable interest entities (“VIEs”). Accounting Standards Codification (“ASC”) Topic 810, Consolidation broadly defines a VIE as an entity in which either (i) the equity investors as a group, if any, lack the power through voting or similar rights to direct the activities of such entity that most significantly impact such entity’s economic performance or (ii) the equity investment at risk is insufficient to

Table of Contents

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS, cont.

finance that entity’s activities without additional subordinated financial support. The Company identifies the primary beneficiary of a VIE as the enterprise that has both of the following characteristics: (i) the power to direct the activities of the VIE that most significantly impact the entity’s economic performance and (ii) the obligation to absorb losses or receive benefits of the VIE that could potentially be significant to the entity. The Company consolidates its investment in a VIE when it determines that it is the VIE’s primary beneficiary, with any minority interests reflected as non-controlling interests or redeemable non-controlling interests in the accompanying Condensed Consolidated Financial Statements.

The Company may change its original assessment of a VIE upon subsequent events, such as the modification of contractual arrangements that affect the characteristics or adequacy of the entity’s equity investments at risk, the disposition of all or a portion of an interest held by the primary beneficiary, or changes in facts and circumstances that impact the power to direct activities of the VIE that most significantly impacts economic performance. The Company performs this analysis on an ongoing basis.

For property holding entities not determined to be VIEs, the Company consolidates such entities in which it owns 100% of the equity or has a controlling financial interest evidenced by ownership of a majority voting interest. All intercompany balances and transactions are eliminated in consolidation. For entities in which the Company owns less than 100% of the equity interest, the Company consolidates the entity if it has the direct or indirect ability to control the entities’ activities based upon the terms of the respective entities’ ownership agreements.

The OP is 98.6% owned by the Company. Holders of operating partnership units (“OP Units”) are considered to be non-controlling interest holders in the OP and their ownership interests are reflected as equity on the accompanying Condensed Consolidated Balance Sheets. Further, a portion of the earnings and losses of the OP are allocated to non-controlling interest holders based on their respective ownership percentages. Upon conversion of OP Units to common stock, any difference between the fair value of the common stock issued and the carrying value of the OP Units converted to common stock is recorded as a component of equity. As of March 31, 2024, there were approximately 5.2 million OP Units, or 1.4% of OP Units issued and outstanding, held by non-controlling interest holders. Additionally, the Company is the primary beneficiary of this VIE. Accordingly, the Company consolidates its interests in the OP.

As of March 31, 2024, the Company had four consolidated VIEs, in addition to the OP, consisting of joint venture investments in which the Company is the primary beneficiary of the VIE based on the combination of operational control and the rights to receive residual returns or the obligation to absorb losses arising from the joint ventures. Accordingly, such joint ventures have been consolidated, and the table below summarizes the balance sheets of consolidated VIEs, excluding the OP, in the aggregate:


(dollars in thousands)	MARCH 31, 2024
Assets:
Net real estate investments	$	92,028
Cash and cash equivalents	2,548
Receivables and other assets	2,687
Total assets	$	97,263
Liabilities:
Accrued expenses and other liabilities	$	5,681
Total equity	91,582
Total liabilities and equity	$	97,263

As of March 31, 2024, the Company had three unconsolidated VIEs consisting of two notes receivables and one joint venture. The Company does not have the power or economic interests to direct the activities of the VIEs on a stand-alone basis, and therefore it was determined that the Company was not the primary beneficiary. As a result, the Company accounts for the two notes receivables as amortized cost and a joint venture arrangement under the equity method. See below for additional information regarding the Company's unconsolidated VIEs.

Table of Contents

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS, cont.


(dollars in thousands) ORIGINATION DATE	LOCATION	SOURCE	CARRYING AMOUNT		MAXIMUM EXPOSURE TO LOSS
2021	Houston, TX 1	Note receivable	$	31,150	$	31,150
2021	Charlotte, NC 1	Note receivable	5,848		6,000
2022	Texas 2	Joint venture	60,476		60,476

1Assumed mortgage note receivable in connection with the Merger.

2Includes investments in seven properties.

As of March 31, 2024, the Company's unconsolidated joint venture arrangements were accounted for using the equity method of accounting as the Company exercised significant influence over but did not control these entities. See Note 2 below for more details regarding the Company's unconsolidated joint ventures.

Use of Estimates in the Condensed Consolidated Financial Statements

Preparation of the Condensed Consolidated Financial Statements in accordance with GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Actual results may differ from those estimates.

Redeemable Non-Controlling Interests

The Company accounts for redeemable equity securities in accordance with ASC Topic 480: Accounting for Redeemable Equity Instruments, which requires that equity securities redeemable at the option of the holder, not solely within our control, be classified outside permanent stockholders’ equity. The Company classifies redeemable equity securities as redeemable non-controlling interests in the accompanying Condensed Consolidated Balance Sheets. Accordingly, the Company records the carrying amount at the greater of the initial carrying amount (increased or decreased for the non-controlling interest’s share of net income or loss and distributions) or the redemption value. We measure the redemption value and record an adjustment to the carrying value of the equity securities as a component of redeemable non-controlling interest. As of March 31, 2024, the Company had redeemable non-controlling interests of $3.9 million.

Asset Impairment

The Company assesses the potential for impairment of identifiable, definite-lived, intangible assets and long-lived assets, including real estate properties, whenever the occurrence of an event or a change in circumstances indicates that the carrying value might not be fully recoverable. Indicators of impairment may include significant underperformance of an asset relative to historical or expected operating results; significant changes in the Company’s use of assets or the strategy for its overall business; plans to sell an asset before its depreciable life has ended; the expiration of a significant portion of leases in a property; or significant negative economic trends or negative industry trends for the Company or its tenants. During the three months ended March 31, 2024, the Company recognized real estate impairments totaling $15.9 million as a result of planned disposition activity.

As of March 31, 2024, three properties totaling $2.9 million were measured at fair value using level 3 fair value hierarchy. The level 3 fair value techniques included brokerage estimates and unexecuted purchase and sale agreements, less estimated closing costs.

Goodwill Impairment

During the first quarter of 2024, the Company experienced a sustained decline in the price per share of its common stock, which was identified as an indicator of goodwill impairment. As a result, a goodwill evaluation was performed. The Company's current operations are carried out through a single reporting unit with a carrying value of approximately $12.0 billion. The Company determined that the carrying value exceeded estimated fair value and therefore an impairment of goodwill was recorded. The Company recorded a $250.5 million full impairment of its goodwill, which is recorded as a non-cash charge in “Impairment of goodwill” in the Condensed Consolidated Statements of Operations.

Investments in Leases - Financing Receivables, Net

In accordance with ASC Topic 842: Leases, for transactions in which the Company enters into a contract to acquire an asset and leases it back to the seller (i.e., a sale leaseback transaction), control of the asset is not considered to have transferred when the seller-lessee has a purchase option. As a result, the Company does not recognize the underlying real estate asset but instead recognizes a financial asset in accordance with ASC Topic 310: Receivables. See below for additional information regarding the Company's financing receivables.

Table of Contents

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS, cont.


(dollars in thousands) ORIGINATION DATE	LOCATION	INTEREST RATE	CARRYING VALUE as of MARCH 31, 2024
May 2021	Poway, CA	5.73%	$	114,643
November 2021	Columbus, OH	6.48%	7,358
			$	122,001

Real Estate Notes Receivable

Real estate notes receivable consists of mezzanine and other real estate loans, which are generally collateralized by a pledge of the borrower’s ownership interest in the respective real estate owner, a mortgage or deed of trust, and/or corporate guarantees. Real estate notes receivable are intended to be held-to-maturity and are recorded at amortized cost, net of unamortized loan origination costs and fees and allowance for credit losses. As of March 31, 2024, real estate notes receivable, net, which are included in Other assets on the Company's Condensed Consolidated Balance Sheets, totaled $174.4 million.


(dollars in thousands)	ORIGINATION	MATURITY	STATED INTEREST RATE		MAXIMUM LOAN COMMITMENT		OUTSTANDING as of MAR 31, 2024		ALLOWANCE FOR CREDIT LOSSES		FAIR VALUE DISCOUNT AND FEES		CARRYING VALUE as of MAR 31, 2024
Mezzanine loans
Texas	6/24/2021	6/24/2024	8.00	%	$	54,119	$	54,119	$	(5,196)	$	(3,067)	$	45,856
Arizona	12/21/2023	12/20/2026	9.00	%	6,000		6,000		—		—		6,000
					60,119		60,119		(5,196)		(3,067)		51,856
Mortgage loans
Texas	6/30/2021	7/01/2024	7.00	%	31,150		31,150		—		—		31,150
North Carolina	12/22/2021	12/22/2024	8.00	%	6,000		6,000		—		(152)		5,848
Florida	5/17/2022	2/27/2026	6.00	%	65,000		33,209		—		(39)		33,170
California	3/30/2023	3/29/2026	6.00	%	45,000		45,000		—		—		45,000
Florida	12/28/2023	12/28/2026	9.00	%	7,700		7,423		—		—		7,423
					154,850		122,782		—		(191)		122,591

					$	214,969	$	182,901	$	(5,196)	$	(3,258)	$	174,447

Allowance for Credit Losses

Pursuant to ASC Topic 326, Financial Instruments - Credit Losses, the Company adopted a policy to evaluate current expected credit losses at the inception of loans qualifying for treatment under ASC Topic 326. The Company utilizes a probability of default method approach for estimating current expected credit losses and evaluates the liquidity and creditworthiness of its borrowers on a quarterly basis to determine whether any updates to the future expected losses recognized upon inception are necessary. The Company’s evaluation considers industry and economic conditions, credit enhancements, liquidity, and other factors. The determination of the credit allowance is based on a quarterly evaluation of all outstanding loans, including general economic conditions and estimated collectability of loan payments. The Company evaluates the collectability of loan receivables based on a combination of credit quality indicators, including, but not limited to, payment status, historical loan charge-offs, financial strength of the borrower and guarantors, and nature, extent, and value of the underlying collateral. A loan is considered to have deteriorated credit quality when, based on current information and events, it is probable that the Company will be unable to collect all amounts due as scheduled according to the contractual terms of the loan agreement. For those loans identified as having deteriorated credit quality, the amount of credit loss is determined on an individual basis. Placement on non-accrual status may be required. Consistent with this definition, all loans on non-accrual status are deemed to have deteriorated credit quality. To the extent circumstances improve and the risk of collectability is diminished, the loan may return to income accrual status. While a loan is on non-accrual status, any cash receipts are applied against the outstanding principal balance.

During the first quarter of 2023, the Company determined that the risk of credit loss on a few of its mezzanine loans were no longer remote and recorded a credit loss reserve of $5.2 million. During the three months ended March 31, 2024, the Company determined that no additional credit loss reserve was needed for its real estate notes receivable.

Table of Contents

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS, cont.

The following table summarizes the Company's allowance for credit losses on real estate notes receivable:


Dollars in thousands	THREE MONTHS ENDED MARCH 31, 2024		TWELVE MONTHS ENDED DECEMBER 31, 2023
Allowance for credit losses, beginning of period	$	5,196	$	—
Credit loss reserves	—		5,196
Allowance for credit losses, end of period	$	5,196	$	5,196

Interest Income

Income from Lease Financing Receivables

The Company recognized the related income from two financing receivables totaling $2.1 million for each of the three months ended March 31, 2024 and 2023, based on an imputed interest rate over the terms of the applicable lease. As a result, the interest recognized from the financing receivable in any particular period will not equal the cash payments from the lease agreement in that period.

Acquisition costs incurred in connection with entering into the financing receivable are treated as loan origination fees. These costs are classified with the financing receivable and are included in the balance of the net investment. Amortization of these amounts will be recognized as a reduction to Interest income over the life of the lease.

Income from Real Estate Notes Receivable

During the three months ended March 31, 2024 and 2023, the Company recognized interest income of $2.4 million and $2.1 million, respectively, related to real estate notes receivable. The Company recognizes interest income on an accrual basis unless the Company has determined that collectability of contractual amounts is not reasonably assured, at which point the note is placed on non-accrual status and interest income is recognized on a cash basis. In 2023, the Company placed two of its real estate notes receivable with principal balances, net of credit loss, of $48.9 million on non-accrual status and accordingly did not recognize any interest income for the three months ended March 31, 2024.

Revenue from Contracts with Customers (ASC Topic 606)

The Company recognizes certain revenue under the core principle of ASC Topic 606. This topic requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Lease revenue is not within the scope of ASC Topic 606. To achieve the core principle, the Company applies the five-step model specified in the guidance.

Revenue that is accounted for under ASC Topic 606 is segregated on the Company’s Condensed Consolidated Statements of Operations in the Other operating line item. This line item includes parking income, management fee income and other miscellaneous income. Below is a detail of the amounts by category:


	THREE MONTHS ENDED March 31,
in thousands	2024		2023
Type of Revenue
Parking income	$	2,545	$	2,391
Management fee income/other 1	1,646		2,227
	$	4,191	$	4,618

1 Includes the recovery of certain expenses under the financing receivable as outlined in the management agreement.

The Company’s major types of revenue that are accounted for under Topic 606 that are listed above are all accounted for as the performance obligation is satisfied. The performance obligations that are identified for each of these items are satisfied over time, and the Company recognizes revenue monthly based on this principle.

New Accounting Pronouncements

On November 27, 2023, the Financial Accounting Standards Board ("FASB") issued ASU 2023-07, Segment Reporting (Topic 280). Some of the main provisions of this update to segment reporting include; (i) a requirement to disclose significant segment expenses, on an annual and interim basis, that are regularly provided to the chief operating decision maker ("CODM") and included within each reported measure of segment profit or loss; (ii) a requirement to

Table of Contents

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS, cont.

disclose the title and position of the CODM and an explanation of how the CODM uses the reported measures of segment profit or loss in assessing segment performance and deciding how to allocate resources, and (iii) a requirement that an entity that has a single reportable segment provide all the disclosures required by the amendments in this update.

The update is effective for annual reporting periods beginning after December 15, 2023, and interim periods beginning after December 15, 2024. Early adoption is permitted. At this time, the Company does not expect that the adoption of this ASU will have a material impact on its consolidated financial statements and compliance of these new disclosure requirements will begin with the Company's Annual Report on Form 10-K for the year ending December 31, 2024.

Note 2. Real Estate Investments

2024 Acquisition Activity

The Company had no real estate acquisition activity for the three months ended March 31, 2024.

Unconsolidated Joint Ventures

The Company's investment in and loss recognized for the three months ended March 31, 2024 and 2023 related to its unconsolidated joint ventures accounted for under the equity method are shown in the table below:


	THREE MONTHS ENDED March 31,
Dollars in thousands	2024		2023

Investments in unconsolidated joint ventures, beginning of period	$	311,511	$	327,248
New investment during the period 1	—		3,824
Equity loss recognized during the period	(422)		(780)

Owner distributions	(1,335)		(2,546)
Investments in unconsolidated joint ventures, end of period	$	309,754	$	327,746

1In 2023, this was an additional investment in an existing joint venture in which the Company retained a 40% ownership interest. The investment consisted of the Company's sale of a property in Dallas, Texas to the joint venture.

2024 Real Estate Asset Dispositions

The Company had no real estate dispositions for the three months ended March 31, 2024.

Subsequent to March 31, 2024, the Company disposed of two medical outpatient buildings totaling 39,000 square feet for an aggregate of $5.8 million. The two properties were classified as held for sale as of March 31, 2024.

Table of Contents

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS, cont.

Assets Held for Sale

The table below reflects the assets and liabilities classified as held for sale as of March 31, 2024 and December 31, 2023:


Dollars in thousands	March 31, 2024		December 31, 2023
Balance Sheet data:
Land	$	2,023	$	1,850
Building and improvements	12,440		6,779
Lease intangibles	2,001		1,017




	16,464		9,646
Accumulated depreciation	(2,050)		(913)
Real estate assets held for sale, net 1	14,414		8,733
Cash and cash equivalents	260		—
Operating lease right-of-use assets	193		—
Other assets, net	16,101		101
Assets held for sale, net	$	30,968	$	8,834

Accounts payable and accrued liabilities	$	135	$	23
Operating lease liabilities	211		—

Other liabilities	354		272
Liabilities of assets held for sale	$	700	$	295

1 Net real estate assets held for sale includes the impact of $1.5 million of impairment charges for the three months ended March 31, 2024.

Note 3. Leases

Lessor Accounting

The Company’s properties generally are leased pursuant to non-cancelable, fixed-term operating leases with expiration dates through 2052. Some leases provide tenants with fixed rent renewal terms while others have market rent renewal terms. Some leases provide the lessee, during the term of the lease, with an option or right of first refusal to purchase the leased property. The Company’s single-tenant net leases generally require the lessee to pay minimum rent and all taxes (including property tax), insurance, maintenance and other operating costs associated with the leased property.

The Company's leases typically have escalators that are either based on a stated percentage or an index such as the consumer price index ("CPI"). In addition, most of the Company's leases include nonlease components, such as reimbursement of operating expenses as additional rent, or include the reimbursement of expected operating expenses as part of the lease payment. The Company adopted an accounting policy to combine lease and nonlease components. Rent escalators based on indices and reimbursements of operating expenses that are not included in the lease rate are considered variable lease payments. Variable payments are recognized in the period earned. Lease income for the Company's operating leases recognized for the three months ended March 31, 2024 was $318.1 million. Lease income for the Company's operating leases recognized for the three months ended March 31, 2023 was $324.1 million.

Future lease payments under the non-cancelable operating leases, excluding any reimbursements and one sale-type lease, as of March 31, 2024 were as follows:


Dollars in thousands	OPERATING
2024	$	680,129
2025	831,775
2026	734,080
2027	611,277
2028	497,470
2029 and thereafter	1,665,663
	$	5,020,394

Table of Contents

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS, cont.

Lessee Accounting

As of March 31, 2024, the Company was obligated, as the lessee, under operating lease agreements consisting primarily of the Company’s ground leases. As of March 31, 2024, the Company had 231 properties totaling 16.9 million square feet that were held under ground leases. Some of the ground lease renewal terms are based on fixed rent renewal terms and others have market rent renewal terms. These ground leases typically have initial terms of 40 to 99 years with expiration dates through 2119. Any rental increases related to the Company’s ground leases are generally either stated or based on CPI. The Company had 75 prepaid ground leases as of March 31, 2024. The amortization of the prepaid rent, included in the operating lease right-of-use asset, represented approximately $0.3 million of the Company’s rental expense for the three months ended March 31, 2024 and March 31, 2023.

The Company’s future lease payments (primarily for its 156 non-prepaid ground leases) as of March 31, 2024 were as follows:


Dollars in thousands	OPERATING		FINANCING
2024	$	8,760	$	1,523
2025	12,415		2,218
2026	12,503		2,255
2027	12,689		2,294
2028	12,809		2,326
2029 and thereafter	698,464		394,072
Total undiscounted lease payments	757,640		404,688
Discount	(528,417)		(329,919)
Lease liabilities	$	229,223	$	74,769

The following table provides details of the Company's total lease expense for the three months ended March 31, 2024 and 2023:


	THREE MONTHS ENDED March 31,
Dollars in thousands	2024			2023
Operating lease cost
Operating lease expense	$	4,465		$	5,107
Variable lease expense	1,228			2,136

Finance lease cost
Amortization of right-of-use assets	387			388
Interest on lease liabilities	937			918
Total lease expense	$	7,017		$	8,549

Other information
Operating cash flows outflows related to operating leases	$	4,040		$	5,960
Operating cash flows outflows related to financing leases	$	563		$	553
Financing cash flows outflows related to financing leases	$	110		$	101



Weighted-average years remaining lease term (excluding renewal options) - operating leases	45.8			47.4
Weighted-average years remaining lease term (excluding renewal options) - finance leases	57.7			58.7
Weighted-average discount rate - operating leases	5.7		%	5.8		%
Weighted-average discount rate - finance leases	5.0		%	5.0		%

Table of Contents

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS, cont.

Note 4. Notes and Bonds Payable

The table below details the Company’s notes and bonds payable as of March 31, 2024 and December 31, 2023.


	MATURITY DATES	BALANCE 1 AS OF				EFFECTIVE INTEREST RATE as of 3/31/2024
Dollars in thousands		3/31/2024		12/31/2023
$1.5 billion Unsecured Credit Facility	10/25	$	120,000	$	—	6.27	%


$200 million Unsecured Term Loan 2	5/24	199,961		199,903		6.36	%
$350 million Unsecured Term Loan	7/24	349,885		349,798		6.36	%
$300 million Unsecured Term Loan	10/25	299,964		299,958		6.36	%
$150 million Unsecured Term Loan	6/26	149,679		149,643		6.36	%
$200 million Unsecured Term Loan	7/27	199,536		199,502		6.36	%
$300 million Unsecured Term Loan	1/28	298,393		298,288		6.36	%
Senior Notes due 2025	5/25	249,579		249,484		4.12	%
Senior Notes due 2026	8/26	580,933		579,017		4.94	%
Senior Notes due 2027	7/27	484,802		483,727		4.76	%
Senior Notes due 2028	1/28	297,577		297,429		3.85	%
Senior Notes due 2030	2/30	578,038		575,443		5.30	%
Senior Notes due 2030	3/30	296,881		296,780		2.72	%
Senior Notes due 2031	3/31	295,958		295,832		2.25	%
Senior Notes due 2031	3/31	653,864		649,521		5.13	%
Mortgage notes payable	9/24-12/26	53,229		70,534		3.57%-6.88%
		$	5,108,279	$	4,994,859

1Balance is presented net of discounts and issuance costs and inclusive of premiums, where applicable.

2In April 2024, the Company exercised its option to extend the maturity date for one year to May 2025 for a fee of approximately $0.3 million.

Changes in Mortgage Notes Payable

On January 6, 2024, the Company repaid in full at maturity a mortgage note payable bearing interest at a rate of 4.77% per annum with an outstanding principal balance of $11.3 million. The mortgage note encumbered a 63,012 square foot property in California.

On February 1, 2024, the Company repaid in full at maturity a mortgage note payable bearing interest at a rate of 4.12% per annum with an outstanding principal balance of $5.6 million. The mortgage note encumbered a 40,324 square foot property in Georgia.

Note 5. Derivative Financial Instruments

Risk Management Objective of Using Derivatives

The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest rate, liquidity, and credit risk, primarily by managing the amount, sources, and duration of its assets and liabilities and the use of derivative financial instruments. Specifically, the Company enters into derivative financial instruments to manage exposures that arise from business activities that result in the receipt or payment of future known and uncertain cash amounts, the value of which are determined by interest rates. The Company’s derivative financial instruments are used to manage differences in the amount, timing, and duration of the Company’s known or expected cash receipts and its known or expected cash payments principally related to the Company’s borrowings.

Cash Flow Hedges of Interest Rate Risk

The Company’s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish this objective, the Company primarily uses interest rate swaps as part of its interest rate risk management strategy. Interest rate swaps designated as cash flow hedges involve the receipt of variable amounts from a counterparty in exchange for the Company making fixed-rate payments over the

Table of Contents

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS, cont.

life of the agreements without exchange of the underlying notional amount. Such derivatives were used to hedge the variable cash flows associated with existing variable-rate debt.

For derivatives designated, and that qualify, as cash flow hedges of interest rate risk, the gain or loss on the derivative is recorded in Accumulated Other Comprehensive Income (Loss) ("AOCI") and subsequently reclassified into interest expense in the same period(s) during which the hedged transaction affects earnings. Amounts reported in AOCI related to derivatives will be reclassified to interest expense as interest payments are made on the Company’s variable-rate debt.

As of March 31, 2024, the Company had 15 outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk:


	AMOUNT		WEIGHTED AVERAGE RATE
May 2026	275,000		3.74	%
June 2026	150,000		3.83	%
December 2026	150,000		3.84	%
June 2027	200,000		4.27	%
December 2027	300,000		3.93	%
	$	1,075,000	3.92	%

Tabular Disclosure of Fair Values of Derivative Instruments on the Balance Sheet

The table below presents the fair value of the Company's derivative financial instruments, as well as their classification on the Condensed Consolidated Balance Sheet as of March 31, 2024.


	BALANCE AT MARCH 31, 2024
In thousands	BALANCE SHEET LOCATION	FAIR VALUE
Derivatives designated as hedging instruments
Interest rate swaps	Other liabilities	$	(2,973)
Interest rate swaps	Other assets	$	10,603
Total derivatives designated as hedging instruments		$	7,630

Tabular Disclosure of the Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Income (Loss)

The table below presents the effect of cash flow hedge accounting on AOCI during the three months ended March 31, 2024 and 2023 related to the Company's outstanding interest rate swaps.


	(GAIN)/LOSS RECOGNIZED IN AOCI ON DERIVATIVE three months ended March 31,					(GAIN)/LOSS RECLASSIFIED FROM AOCI INTO INCOME three months ended March 31,
In thousands	2024		2023			2024		2023
Interest rate swaps	$	(19,611)	$	8,541	Interest expense	$	(4,014)	$	(2,433)
Settled treasury hedges	—		—		Interest expense	107		107
Settled interest rate swaps	—		—		Interest expense	42		42
	$	(19,611)	$	8,541	Total interest expense	$	(3,865)	$	(2,284)

The Company estimates that an additional $10.5 million related to active interest rate swaps will be reclassified from AOCI as a decrease to interest expense over the next 12 months, and that an additional $0.6 million related to settled interest rate swaps will be amortized from AOCI as an increase to interest expense over the next 12 months.

Credit-risk-related Contingent Features

The Company's agreements with each of its derivative counterparties contain a cross-default provision under which the Company could be declared in default of its derivative obligations if repayment of the underlying indebtedness is accelerated by the lender due to the Company's default on the indebtedness.

As of March 31, 2024, the fair value of derivatives in a net asset position including accrued interest but excluding any adjustment for nonperformance risk related to these agreements was $7.6 million. As of March 31, 2024, the Company had not posted any collateral related to these agreements and was not in breach of any agreement.

Table of Contents

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS, cont.

Note 6. Commitments and Contingencies

Legal Proceedings

The Company is, from time to time, involved in litigation arising in the ordinary course of business. The Company is not aware of any pending or threatened litigation that, if resolved against the Company, would have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows.

Development and Redevelopment Activity

For the three months ended March 31, 2024, the Company invested $7.7 million and $2.8 million toward active development and redevelopment of properties, respectively, and $11.1 million toward recently completed development and redevelopment projects.

Note 7. Stockholders' Equity

Common Stock

The following table provides a reconciliation of the beginning and ending shares of common stock outstanding for the three months ended March 31, 2024 and the twelve months ended December 31, 2023:


	THREE MONTHS ENDED MARCH 31, 2024	TWELVE MONTHS ENDED DECEMBER 31, 2023
Balance, beginning of period	380,964,433	380,589,894
Issuance of common stock	8,623	8,627
Conversion of OP unit to Common stock	194,767	190,544
Non-vested share-based awards, net of withheld shares and forfeitures	333,679	175,368
Balance, end of period	381,501,502	380,964,433

Common Stock Dividends

During the three months ended March 31, 2024, the Company declared and paid common stock dividends totaling $0.31 per share. On April 30, 2024, the Company declared a quarterly common stock dividend in the amount of $0.31 per share payable on May 23, 2024 to stockholders of record on May 13, 2024.

Authorization to Repurchase Common Stock

On May 31, 2023, the Company’s Board of Directors authorized the repurchase of up to $500.0 million of outstanding shares of the Company’s common stock either in the open market or through privately negotiated transactions, subject to market conditions, regulatory constraints, and other customary conditions. The Company is not obligated under this authorization to repurchase any specific number of shares. This authorization supersedes all previous stock repurchase authorizations. In April 2024, the Company repurchased 2,966,764 shares of its common stock at a weighted average price of $14.07 for a total of $41.7 million under this authorization.

On April 30, 2024, the Company's Board of directors authorized the repurchase of up to $500.0 million of outstanding shares of the Company's common stock, superseding the previous stock repurchase authorization.

Table of Contents

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS, cont.

Earnings Per Common Share

The Company uses the two-class method of computing net earnings per common shares. The Company's non-vested share-based awards are considered participating securities pursuant to the two-class method.

The following table sets forth the computation of basic and diluted earnings per common share for the three months ended March 31, 2024 and 2023.


	THREE MONTHS ENDED MARCH 31,
Dollars in thousands, except per share data	2024		2023
Weighted average common shares outstanding
Weighted average common shares outstanding	381,335,208		380,796,773
Non-vested shares	(1,880,401)		(1,956,353)
Weighted average common shares outstanding - basic	379,454,807		378,840,420

Weighted average common shares outstanding - basic	379,454,807		378,840,420
Dilutive effect of forward equity shares	—		—
Dilutive effect of OP Units	—		—
Dilutive effect of employee stock purchase plan	—		—
Weighted average common shares outstanding - diluted	379,454,807		378,840,420

Net loss	$	(315,220)	$	(88,078)
Income allocated to participating securities	(693)		(625)

Loss attributable to non-controlling interest	4,384		953
Adjustment to loss attributable to non-controlling interest for legally outstanding restricted units	(1,341)		(16)
Net loss applicable to common stockholders - basic	$	(312,870)	$	(87,766)





Basic earnings per common share - net loss	$	(0.82)	$	(0.23)


Diluted earnings per common share - net loss	$	(0.82)	$	(0.23)

The effect of OP Units redeemable for 3,681,225 shares and options under the Company's Employee Stock Purchase Plan (the "ESPP") to purchase 23,140 shares of the Company's common stock for the three months ended March 31, 2024 were excluded from the calculation of diluted loss per common share because the effect was anti-dilutive due to the loss from continuing operations incurred during that period.

Stock Incentive Plan

The Company's stock incentive plan ("Incentive Plan") permits the grant of incentive awards to its employees and directors in any of the following forms: options, stock appreciation rights, restricted stock, restricted or deferred stock units, performance awards, dividend equivalents, or other stock-based awards, including units in the OP.

Equity Incentive Plans

During the three months ended March 31, 2024, the Company made the following equity awards:

•Restricted Stock

During the first quarter of 2024, the Company granted non-vested stock awards to its named executive officers and other members of senior management and employees with an aggregate grant date fair value of $5.6 million, which consisted of an aggregate of 361,712 non-vested shares with vesting periods ranging from three to eight years.

•Restricted Stock Units ("RSUs")

On February 13, 2024, the Company granted an aggregate of 208,055 RSUs to members of senior management, with an aggregate grant date fair value of $3.5 million and a five-year vesting period.

Approximately 36% of the RSUs vest based on relative total shareholder return ("TSR") and were valued using independent specialists. The Company utilized a Monte Carlo simulation to calculate the weighted

Table of Contents

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS, cont.

average grant date fair value of $19.10 for the relative TSR component for the February 2024 grant using the following assumptions:


	THREE MONTHS ENDED MARCH 31,
Volatility		28.0	%
Dividend assumption		Accrued
Expected term		3 years
Risk-free rate		4.44	%
Stock price (per share)		$15.22

The remaining 64% of the RSUs vest based upon certain operating performance conditions. With respect to the operating performance conditions of the February 13, 2024 grant, the grant date fair value was $15.22 based on the Company's share price on the date of grant.

•LTIP Series C Units

On February 13, 2024, the Company granted an aggregate of 906,044 LTIP Series C units ("LTIP-C units) in the OP with three-year forward-looking performance targets, a five-year vesting period and an aggregate grant date fair value of $7.5 million.

Approximately 36% of the LTIP-C units vest based on relative TSR and were valued using independent specialists. The Company utilized a Monte Carlo simulation to calculate the weighted average grant date fair value of $9.62 for the relative TSR component for the February 2024 grant using the following assumptions:


	THREE MONTHS ENDED MARCH 31,
Volatility		28.0	%
Dividend assumption		Accrued
Expected term		3 years
Risk-free rate		4.44	%
Stock price (per share)		$15.22

The remaining 64% of the LTIP-C units vest based upon certain operating performance conditions. With respect to the operating performance conditions of the February 13, 2024 grant, the grant date fair value was $15.22 based on the Company's share price on the date of grant. The Company records amortization expense based on the probability of achieving certain operating performance conditions, which is evaluated throughout the performance period.

The following table represents the summary of non-vested share-based awards under the Incentive Plans for the three months ended March 31, 2024 and 2023:


	THREE MONTHS ENDED MARCH 31,
	2024	2023
Share-based awards, beginning of period	2,615,562	2,090,060
Granted 1	1,475,811	1,075,261
Vested	(28,414)	(113,766)
Forfeited	(19,805)	(26,063)
Share-based awards, end of period	4,043,154	3,025,492

1.LTIP-C units are issued at the maximum possible value of the award and are reflected as such in this table until the performance period has been satisfied and the exact number of awards are determinable.

During the three months ended March 31, 2024 and 2023, the Company withheld 8,228 and 38,632 shares of common stock, respectively, from participants to pay estimated withholding taxes related to shares that vested.

Table of Contents

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS, cont.

The following table represents expected amortization of the Company's non-vested shares issued as of March 31, 2024:


Dollars in millions	FUTURE AMORTIZATION of non-vested shares
2024	$	11.5
2025	13.3
2026	10.6
2027	5.7
2028 and thereafter	2.8
Total	$	43.9

Note 8. Fair Value of Financial Instruments

The following methods and assumptions were used to estimate the fair value of each class of financial instrument for which it is practical to estimate that value.

•Cash and cash equivalents - The carrying amount approximates fair value (level 1 inputs) due to the short-term maturity of these investments.

•Real estate notes receivable - Real estate notes receivable are recorded in other assets on the Company's Condensed Consolidated Balance Sheets. Fair value is estimated using cash flow analyses, based on current interest rates for similar types of arrangements.

•Borrowings under the Unsecured Credit Facility and the Term Loans Due 2024 and 2026 - The carrying amount approximates fair value because the borrowings are based on variable market interest rates.

•Senior Notes and Mortgage Notes payable - The fair value of notes and bonds payable is estimated using cash flow analyses, based on the Company’s current interest rates for similar types of borrowing arrangements.

•Interest rate swap agreements - Interest rate swap agreements are recorded in other liabilities on the Company's Condensed Consolidated Balance Sheets at fair value. Fair value is estimated by utilizing pricing models, level 2 inputs, which consider forward yield curves and discount rates. See Note 5 for additional information.

The table below details the fair values and carrying values for notes and bonds payable and real estate notes receivable at March 31, 2024 and December 31, 2023.


	March 31, 2024				December 31, 2023
Dollars in millions	CARRYING VALUE		FAIR VALUE		CARRYING VALUE		FAIR VALUE
Notes and bonds payable 1	$	5,108.3	$	4,931.9	$	4,994.9	$	4,872.7
Real estate notes receivable 1	$	174.4	$	172.8	$	173.6	$	172.5

1Level 2 – model-derived valuations in which significant inputs and significant value drivers are observable in active markets.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis should be read together with the Consolidated Financial Statements and related Notes thereto included in Item 1 of this Quarterly Report on Form 10-Q. Other important factors are identified in our Annual Report on Form 10-K for the year ended December 31, 2023, including factors identified under the headings “Business,” “Risk Factors,” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations."

Unless stated otherwise or the context otherwise requires, references to "Healthcare Realty Trust" are to Legacy HTA after giving effect to the Merger and references to the "Company," "we," "us," and "our" are to Healthcare Realty Trust and, unless the context requires otherwise, its consolidated subsidiaries, including the OP.

Disclosure Regarding Forward-Looking Statements

This report and other materials the Company has filed or may file with the SEC, as well as information included in oral statements or other written statements made, or to be made, by management of the Company, contain, or will contain, disclosures that are “forward-looking statements.” Forward-looking statements include all statements that do not relate solely to historical or current facts and can be identified by the use of words such as “may,” “will,” “expect,” “believe,” “anticipate,” “target,” “intend,” “plan,” “estimate,” “project,” “continue,” “should,” “could," "budget" and other comparable terms. These forward-looking statements are based on the Company's current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties. Such risks and uncertainties include, among other things, the following: the Company’s expected results may not be achieved; failure to realize the expected benefits of the Merger; risks related to future opportunities and plans for the Company, including the uncertainty of expected future financial performance and results of the Company; the possibility that, if the Company does not achieve the perceived benefits of the Merger as rapidly or to the extent anticipated by financial analysts or investors, the market price of the Company’s common stock could decline; pandemics or other health crises, such as COVID-19; increases in interest rates; the availability and cost of capital at expected rates; competition for quality assets; negative developments in the operating results or financial condition of the Company's tenants, including, but not limited to, their ability to pay rent; the Company's ability to reposition or sell facilities with profitable results; the Company's ability to release space at similar rates as vacancies occur; the Company's ability to renew expiring leases; government regulations affecting tenants' Medicare and Medicaid reimbursement rates and operational requirements; unanticipated difficulties and/or expenditures relating to future acquisitions and developments; changes in rules or practices governing the Company's financial reporting; the Company may be required under purchase options to sell properties and may not be able to reinvest the proceeds from such sales at rates of return equal to the return received on the properties sold; uninsured or underinsured losses related to casualty or liability; the incurrence of impairment charges on its real estate properties or other assets; other legal and operational matters; and other risks and uncertainties affecting the Company, including those described from time to time under the caption “Risk Factors” and elsewhere in the Company’s filings and reports with the SEC, including the Company's Annual Report on Form 10-K for the year ended December 31, 2023. Moreover, other risks and uncertainties of which the Company is not currently aware may also affect the Company's forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements made in this communication are made only as of the date hereof or as of the dates indicated in the forward-looking statements, even if they are subsequently made available by the Company on its website or otherwise. The Company undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made, except as required by law.

Stockholders and investors are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in the Company’s filings and reports, including, without limitation, estimates and projections regarding the performance of development projects the Company is pursuing.

For a detailed discussion of the Company’s risk factors, please refer to the Company's filings with the SEC, including this report and the Company’s Annual Report on Form 10-K for the year ended December 31, 2023.

Liquidity and Capital Resources

Sources and Uses of Cash

The Company’s primary sources of cash include rent receipts from its real estate portfolio based on contractual arrangements with its tenants, proceeds from the sales of real estate properties, joint ventures, and proceeds from public or private debt or equity offerings. As of March 31, 2024, the Company had $1.4 billion available to be drawn on its unsecured credit facility ("Unsecured Credit Facility") and available cash.

The Company expects to continue to meet its liquidity needs, including funding additional investments, paying dividends, and funding debt service, through cash flows from operations and liquidity sources, including the

Table of Contents

Unsecured Credit Facility. Management believes that the Company's liquidity and sources of capital are adequate to satisfy its cash requirements. The Company cannot, however, be certain that these sources of funds will be available at a time and upon terms acceptable to the Company in sufficient amounts to meet its liquidity needs.

Dividends paid by the Company for the three months ended March 31, 2024 were funded from cash flows from operations and the Unsecured Credit Facility, as cash flows from operations were not adequate to fully fund dividends, primarily as a result of the timing of interest payments. The Company expects that cash flows from property operations will generate sufficient cash flows such that dividends for the full year 2024 can be funded by cash flows from operations or other sources of liquidity described above.

Investing Activities

Cash flows used in investing activities for the three months ended March 31, 2024 were approximately $58.6 million. Below is a summary of the investing activities.

Acquisitions

The Company had no acquisitions for the three months ended March 31, 2024.

Dispositions

The Company had no real estate dispositions during the three months ended March 31, 2024.

Subsequent to March 31, 2024, the Company disposed of two medical outpatient buildings totaling 39,000 square feet for $5.8 million. The two properties were held for sale as of March 31, 2024.

Capital Expenditures

During the three months ended March 31, 2024, the Company incurred capital expenditures totaling $58.6 million for the following:

•$10.5 million toward active development and redevelopment of properties;

•$11.1 million toward completed development and redevelopment of properties;

•$11.8 million toward first generation tenant improvements and planned capital expenditures for acquisitions;

•$19.9 million toward second generation tenant improvements; and

•$5.3 million toward capital expenditures.

Financing Activities

Cash flows used in financing activities for the three months ended March 31, 2024 were approximately $17.1 million. See Notes 4 and 7 to the Condensed Consolidated Financial Statements accompanying this report for more information about capital markets and financing activities.

Debt Activity

As of March 31, 2024, the Company had outstanding interest rate derivatives totaling $1.1 billion to hedge one-month Term SOFR. The following details the amount and rate of each swap (dollars in thousands):


EXPIRATION DATE	AMOUNT		WEIGHTED AVERAGE RATE
May 2026	$	275,000	3.74	%
June 2026	150,000		3.83	%
December 2026	150,000		3.84	%
June 2027	200,000		4.27	%
December 2027	300,000		3.93	%
	$	1,075,000	3.92	%

Table of Contents

Changes in Mortgage Notes Payable

During the first quarter of 2024, the Company repaid in full at maturity a mortgage note payable bearing interest at a rate of 4.77% per annum with an outstanding principal balance of $11.3 million. The mortgage note encumbered a 63,012 square foot property in California. Additionally, the Company repaid in full at maturity a mortgage note payable bearing interest at a rate of 4.12% per annum with an outstanding principal balance of $5.6 million. The mortgage note encumbered a 40,324 square foot property in Georgia.

Supplemental Guarantor Information

The OP has issued unsecured notes described in Note 4 to the Company's Condensed Consolidated Financial Statements included in this report. All unsecured notes are fully and unconditionally guaranteed by the Company, and the OP is 98.6% owned by the Company. Effective January 4, 2021, the Securities and Exchange Commission (the “SEC”) adopted amendments to the financial disclosure requirements which permit subsidiary issuers of obligations guaranteed by the parent to omit separate financial statements if the consolidated financial statements of the parent company have been filed, the subsidiary obligor is a consolidated subsidiary of the parent company, the guaranteed security is debt or debt-like, and the security is guaranteed fully and unconditionally by the parent.

Accordingly, as permitted under Rule 13-01(a)(4)(vi) of Regulation S-X, the Company has excluded the summarized financial information for the OP because the assets, liabilities, and results of operations of the OP are not materially different than the corresponding amounts in the Company's consolidated financial statements and management believes such summarized financial information would be repetitive and would not provide incremental value to investors.

Operating Activities

Cash flows provided by operating activities increased from $69.2 million for the three months ended March 31, 2023 to $76.2 million for the three months ended March 31, 2024. Items impacting cash flows from operations include, but are not limited to, cash generated from property operations, interest payments and the timing related to the payment of invoices and other expenses.

The Company may, from time to time, sell properties and redeploy cash from property sales into new investments or to repay indebtedness. The income from the new investments or reduction in interest expense could be less than the income from properties sold which would adversely affect the Company's results of operations and cash flows.

Trends and Matters Impacting Operating Results

Management monitors factors and trends important to the Company and the REIT industry to gauge the potential impact on the operations of the Company. In addition to the matters discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, below are some of the factors and trends that management believes may impact future operations of the Company.

Economic and Market Conditions

Rising interest rates and increased volatility in the capital markets have increased the Company’s cost and availability of debt and equity capital. Limited availability and increases in the cost of capital could adversely impact the Company’s ability to finance operations and acquire and develop properties. To the extent the Company’s tenants experience increased costs or financing difficulties due to the economic and market conditions, they may be unable or unwilling to make payments or perform their obligations when due. Additionally, increased interest rates may also result in less liquid property markets, limiting the Company’s ability to sell existing assets or obtain joint venture capital.

Expiring Leases

The Company expects that approximately 15% of its leases will expire each year in the ordinary course of business. There are 1,146 leases totaling 3.5 million square feet that will expire during the remainder of 2024. Approximately 75% of the leases expiring during the remainder of 2024 are for space in buildings located on or adjacent to hospital campuses, are distributed throughout the portfolio, and are not concentrated with any one tenant, health system or market area. The Company typically expects to retain 75% to 90% of tenants upon expiration, and the retention ratio for the first three months of the year was within this range.

Table of Contents

Operating Expenses

The Company historically has experienced increases in property taxes throughout its portfolio as a result of increasing assessments and tax rates levied across the country. The Company continues its efforts to appeal property tax increases and manage the impact of the increases. In addition, the Company historically has incurred variability in portfolio utilities expense based on seasonality, with the first and third quarters usually reflecting greater amounts. The effects of these operating expense increases are mitigated in leases that have provisions for operating expense reimbursement. As of March 31, 2024, leases for approximately 92% of the Company's total leased square footage allow for some recovery of operating expenses, with approximately 28% having modified gross lease structures and approximately 64% having net lease structures.

Purchase Options

Information about the Company's unexercised purchase options and the amount and basis for determination of the purchase price is detailed in the table below (dollars in thousands):


YEAR EXERCISABLE	NUMBER OF PROPERTIES	GROSS REAL ESTATE INVESTMENT AS OF MARCH 31, 2024 1
Current 2	6	$	110,891
2025	5	93,860
2026	6	181,744
2027	4	110,574
2028	5	134,893
2029	3	81,846
2030	—	—
2031	4	106,016
2032	2	23,415
2033	—	—
2034 and thereafter 3	9	319,710
Total	44	$	1,162,949

1Includes three properties totaling $45.4 million with stated purchase prices or prices based on fixed capitalization rates.

2These purchase options have been exercisable for an average of 14.1 years.

3Includes two medical office buildings that are recorded in the line item Investment in financing receivable, net on the Company's Condensed Consolidated Balance Sheet.

Non-GAAP Financial Measures and Key Performance Indicators

Management considers certain non-GAAP financial measures and key performance indicators to be useful supplemental measures of the Company's operating performance. A non-GAAP financial measure is generally defined as one that purports to measure financial performance, financial position or cash flows, but excludes or includes amounts that would not be so adjusted in the most comparable measure determined in accordance with GAAP. Set forth below are descriptions of the non-GAAP financial measures management considers relevant to the Company's business and useful to investors, as well as reconciliations of these measures to the most directly comparable GAAP financial measures.

The non-GAAP financial measures and key performance indicators presented herein are not necessarily identical to those presented by other real estate companies due to the fact that not all real estate companies use the same definitions. These measures should not be considered as alternatives to net income, as indicators of the Company's financial performance, or as alternatives to cash flow from operating activities as measures of the Company's liquidity, nor are these measures necessarily indicative of sufficient cash flow to fund all of the Company's needs. Management believes that in order to facilitate a clear understanding of the Company's historical consolidated operating results, these measures should be examined in conjunction with net income and cash flows from operations as presented in the Condensed Consolidated Financial Statements and other financial data included elsewhere in this Quarterly Report on Form 10-Q.

Table of Contents

Funds from Operations ("FFO"), Normalized FFO and Funds Available for Distribution ("FAD")

FFO and FFO per share are operating performance measures adopted by the National Association of Real Estate Investment Trusts (“NAREIT”). NAREIT defines FFO as the most commonly accepted and reported measure of a REIT’s operating performance equal to “net income (computed in accordance with GAAP), excluding gains (or losses) from sales of property, plus depreciation and amortization, impairment, and after adjustments for unconsolidated partnerships and joint ventures.”

In addition to FFO, the Company presents Normalized FFO and FAD. Normalized FFO is presented by adding to FFO acquisition-related costs, acceleration of debt issuance costs, debt extinguishment costs and other Company-defined normalizing items to evaluate operating performance. FAD is presented by adding to Normalized FFO non-real estate depreciation and amortization, non-cash financing receivable amortization, loan origination cost amortization, deferred financing fees amortization, stock-based compensation expense and rent reserves, net; and subtracting maintenance capital expenditures, including second generation tenant improvements and leasing commissions paid and straight-line rent income, net of expense. The Company's definition of these terms may not be comparable to that of other real estate companies as they may have different methodologies for computing these amounts. FFO, Normalized FFO and FAD should not be considered as an alternative to net income as an indicator of the Company's financial performance or to cash flow from operating activities as an indicator of the Company's liquidity. FFO, Normalized FFO and FAD should be reviewed in connection with GAAP financial measures.

Management believes FFO, Normalized FFO, FFO per common share, Normalized FFO per share and FAD ("Non-GAAP Measures") provide an understanding of the operating performance of the Company’s properties without giving effect to certain significant non-cash items, primarily depreciation and amortization expense. Historical cost accounting for real estate assets in accordance with GAAP assumes that the value of real estate assets diminishes predictably over time. However, real estate values instead have historically risen or fallen with market conditions. The Company believes that by excluding the effect of depreciation, amortization, impairments and gains or losses from sales of real estate, all of which are based on historical costs, and which may be of limited relevance in evaluating current performance, Non-GAAP Measures can facilitate comparisons of operating performance between periods. The Company reports Non-GAAP Measures because these measures are observed by management to also be the predominant measures used by the REIT industry and by industry analysts to evaluate REITs. For these reasons, management deems it appropriate to disclose and discuss these Non-GAAP Measures. However, none of these measures represent cash generated from operating activities determined in accordance with GAAP and are not necessarily indicative of cash available to fund cash needs. Further, these measures should not be considered as an alternative to net income as an indicator of the Company’s operating performance or as an alternative to cash flow from operating activities as a measure of liquidity.

Table of Contents

The table below reconciles net income to FFO, Normalized FFO and FAD for the three months ended March 31, 2024 and 2023.


	THREE MONTHS ENDED MARCH 31,
Amounts in thousands, except per share data	2024		2023
Net loss attributable to common stockholders	$	(310,836)	$	(87,125)
Net loss attributable to common stockholders per diluted share 1	$	(0.82)	$	(0.23)

Gain on sales of real estate properties	(22)		(1,007)
Impairment of real estate properties	15,937		26,227
Real estate depreciation and amortization	181,161		186,109
Non-controlling loss from operating partnership units	(4,278)		(1,067)
Proportionate share of unconsolidated joint ventures	4,568		4,841
FFO adjustments	$	197,366	$	215,103
FFO adjustments per common share - diluted	$	0.51	$	0.56

FFO attributable to common stockholders	$	(113,470)	$	127,978
FFO attributable to common stockholders per common share - diluted 2	$	(0.30)	$	0.33

Transaction costs	395		287
Merger-related costs 3	—		4,855
Merger-related fair value of debt instruments	10,105		10,864
Lease intangible amortization	175		146

Allowance for credit losses 4	—		8,599
Impairment of goodwill	250,530		—

Unconsolidated JV normalizing items 5	87		117
Normalized FFO adjustments	$	261,292	$	24,868
Normalized FFO adjustments per common share - diluted	$	0.68	$	0.06

Normalized FFO attributable to common stockholders	$	147,822	$	152,846
Normalized FFO attributable to common stockholders per common share - diluted	$	0.39	$	0.40

Non-real estate depreciation and amortization	485		604
Non-cash interest amortization 6	1,277		682
Rent reserves, net	(151)		1,371
Straight-line rent, net	(7,633)		(8,246)
Share-based compensation	3,562		3,745
Unconsolidated JV non-cash items 7	(122)		(227)
Normalized FFO adjusted for non-cash items	$	145,240	$	150,775
2nd generation TI	(20,204)		(8,882)
Leasing commissions paid	(15,215)		(7,013)
Capital additions	(5,363)		(8,946)
FAD	$	104,458	$	125,934


FFO weighted average common shares outstanding - diluted 8	383,413		383,335

1Potential common shares are not included in the computation of diluted earnings per share when a loss exists as the effect would be an antidilutive per share amount.

2For the three months ended March 31, 2024, basic weighted average common shares outstanding was the denominator used in the per share calculation.

3Includes costs incurred related to the Merger.

4For the three months ended March 31, 2023, includes a $5.2 million credit allowance for a mezzanine loan included in "Impairment of real estate and credit loss reserves" on the Statement of Operations and $3.4 million reserve included in “Rental Income” on the Statement of Operations for previously deferred rent and straight line rent for three skilled nursing facilities.

5Includes the Company's proportionate share of acquisition and pursuit costs related to unconsolidated joint ventures.

6Includes the amortization of deferred financing costs, discounts and premiums, and non-cash financing receivable amortization.

7Includes the Company's proportionate share of straight-line rent, net related to unconsolidated joint ventures.

8The Company utilizes the treasury stock method which includes the dilutive effect of nonvested share-based awards outstanding of 254,261 and 401,937, respectively, for the three months ended March 31, 2024 and 2023, and the diluted impact of 3,681,225 OP Units outstanding for the three months ended March 31, 2024.

Table of Contents

Cash Net Operating Income ("NOI") and Same Store Cash NOI

Cash NOI and Same Store Cash NOI are key performance indicators. Management considers these to be supplemental measures that allow investors, analysts and Company management to measure unlevered property-level operating results. The Company defines Cash NOI as rental income, interest from financing receivables less property operating expenses. Cash NOI excludes non-cash items such as above and below market lease intangibles, straight-line rent, lease inducements, financing receivable amortization, tenant improvement amortization and leasing commission amortization. The Company also excludes cash lease termination fees. Cash NOI is historical and not necessarily indicative of future results.

Same Store Cash NOI compares Cash NOI for stabilized properties. Stabilized properties are properties that have been included in operations for the duration of the year-over-year comparison period presented. Accordingly, stabilized properties exclude properties that were recently acquired or disposed of, properties classified as held for sale or intended for sale, properties undergoing redevelopment, and newly redeveloped or developed properties.

The Company utilizes the redevelopment classification for properties where management has approved a change in strategic direction for such properties through the application of additional resources including an amount of capital expenditures significantly above routine maintenance and capital improvement expenditures.

Any recently acquired property will be included in the same store pool once the Company has owned the property for five full quarters. Newly developed or redeveloped properties will be included in the same store pool five full quarters after substantial completion.

The following table reflects the Company's Same Store Cash NOI for the three months ended March 31, 2024 and 2023.


	NUMBER OF PROPERTIES	GROSS INVESTMENT at March 31, 2024		SAME STORE CASH NOI for the three months ended March 31,
Dollars in thousands				2024		2023
Same store properties	624	$	12,512,764	$	191,222	$	185,796
Joint venture same store properties	33	352,845		$	4,833	$	4,563

The following tables reconcile net income to Same Store NOI and the same store property metrics to the total owned real estate portfolio for the three months ended March 31, 2024 and 2023:

Reconciliation of Same Store Cash NOI


SAME STORE RECONCILIATION
	THREE MONTHS ENDED MARCH 31,
Dollars in thousands	2024		2023
Net loss	$	(315,220)	$	(88,078)


Other expense	327,646		94,407
General and administrative expense	14,787		14,935
Depreciation and amortization expense	178,119		184,479
Other expenses 1	4,727		7,940
Straight-line rent, net	(7,633)		(8,245)
Joint venture properties	4,958		4,769
Other revenue 2	(7,006)		(733)
Cash NOI	200,378		209,474
Cash NOI not included in same store	(4,323)		(19,115)
Same store cash NOI	196,055		190,359
Same store joint venture properties	(4,833)		(4,563)
Same store cash NOI (excluding JVs)	$	191,222	$	185,796

1.Includes transaction costs, Merger-related costs, rent reserves, above and below market ground lease intangible amortization, leasing commission amortization and ground lease straight-line rent expense.

2.Includes management fee income, interest, above and below market lease intangible amortization, lease inducement amortization, lease terminations and tenant improvement overage amortization.

Table of Contents

Reconciliation of Same Store Properties


	AS OF MARCH 31, 2024
Dollars and square feet in thousands	PROPERTY COUNT	GROSS INVESTMENT 1		SQUARE FEET	OCCUPANCY
Same store properties	624	$	12,512,764	36,101	89.5	%
Joint venture same store properties	33	352,845		1,913	86.2	%
Wholly owned and joint venture acquisitions	3	50,838		195	97.8	%
Development completions	4	95,195		335	64.5	%
Redevelopments	18	440,632		1,503	51.7	%
Planned Dispositions	5	61,505		228	25.9	%
Total	687	$	13,513,779	40,275	87.4	%
Joint venture properties	34	360,501		1,949	86.5	%
Total owned real estate properties	653	$	13,153,278	38,326	87.5	%

1Excludes assets held for sale, construction in progress, land held for development, corporate property and financing lease right-of-use assets unrelated to an imputed lease arrangement as a result of a sale leaseback transaction.

Results of Operations

Three Months Ended March 31, 2024 Compared to Three Months Ended March 31, 2023

The Company’s results of operations for the three months ended March 31, 2024 compared to the same period in 2023 were impacted by acquisitions, developments, dispositions, gains on sale, and capital markets transactions.

Revenues

Rental income decreased $6.0 million, or 1.9%, for the three months ended March 31, 2024 compared to the prior year period. This decrease is primarily comprised of the following:

•Acquisitions in 2023 contributed $1.1 million.

•Leasing activity, including contractual rent increases, contributed $8.3 million.

•Dispositions in 2023 resulted in a decrease of $15.4 million.

Other operating income decreased $0.4 million, or 9.2%, for the three months ended March 31, 2024 compared to the prior year period primarily as a result of variable parking and management fees.

Expenses

Property operating expenses decreased $1.0 million, or 0.8%, for the three months ended March 31, 2024 compared to the prior year period primarily as a result of the following activity:

•Acquisitions in 2023 resulted in an increase of $0.5 million.

•Increases in portfolio operating expenses as follows:

◦Utilities expense of $2.0 million;

◦Administrative, leasing commissions, and other legal expense of $3.0 million;

◦Maintenance and repair expense of $2.2 million;

◦Property taxes of $0.3 million;

◦Janitorial expense of $0.7 million; and

◦Insurance expense of $0.2 million.

•Decrease in compensation expense of $1.5 million.

•Dispositions in 2023 resulted in a decrease of $8.4 million.

General and administrative expenses decreased approximately $0.1 million, or 1.0%, for the three months ended March 31, 2024 compared to the prior year period primarily as a result of the following activity:

•Decrease in payroll and payroll related expenses of approximately $0.9 million.

Table of Contents

•Increase in cash compensation incentive expense of $0.7 million.

•Increase in non-cash compensation incentive expense of $0.5 million.

•Other decreases included legal and other administrative costs of $0.4 million.

Merger-related costs decreased $4.9 million for the three months ended March 31, 2024 compared to the prior year period primarily due to 2023 legal and consulting services in connection with the Merger.

Depreciation and amortization expense decreased $6.4 million, or 3.4%, for the three months ended March 31, 2024 compared to the prior year period primarily as a result of the following activity:

•Acquisitions in 2023 resulted in an increase of $0.7 million.

•Various building and tenant improvement expenditures resulted in an increase of $13.0 million.

•Dispositions in 2023 resulted in a decrease of $11.5 million.

•Assets that became fully depreciated resulted in a decrease of $8.6 million.

Other Income (Expense)

Gains on sale of real estate properties.

The Company had no real estate dispositions in the first quarter of 2024. In the first quarter of 2023, the Company recognized gains of approximately $1.0 million primarily on the disposition of one property.

Interest expense

Interest expense decreased $2.7 million, or 4.2%, for the three months ended March 31, 2024 compared to the prior year period. The components of interest expense are as follows:


	THREE MONTHS ENDED MARCH 31,				CHANGE
Dollars in thousands	2024		2023		$		%
Contractual interest	$	49,458	$	50,766	$	(1,308)	(2.6)	%
Net discount/premium accretion	10,067		9,591		476		5.0	%
Debt issuance costs amortization	1,207		1,476		(269)		(18.2)	%
Amortization of interest rate swap settlement	42		42		—		—	%
Amortization of treasury hedge settlement	107		107		—		—	%
Fair value derivative	177		1,429		(1,252)		(87.6)	%
Interest cost capitalization	(942)		(570)		(372)		65.3	%
Interest on lease liabilities	938		918		20		2.2	%
Total interest expense	$	61,054	$	63,759	$	(2,705)	(4.2)	%

Contractual interest expense decreased $1.3 million, or 2.6%, for the three months ended March 31, 2024 compared to the prior year period primarily as a result of the following activity:

•The Unsecured Term Loans accounted for an increase of approximately $3.3 million.

•The Unsecured Credit Facility accounted for a decrease of approximately $4.0 million due to a decreased weighted average balance outstanding.

•Active interest rate derivatives accounted for a decrease of $0.3 million.

•Mortgage note repayments, net of assumptions, accounted for a decrease of approximately $0.3 million.

Impairment of Real Estate Properties

In the first quarter of 2024, the Company recognized impairments totaling $15.9 million on four properties with changes in the expected holding periods, including one property reclassified to held for sale.

Impairment of Goodwill

The Company determined that the carrying value if its single reporting unit exceeded estimated fair value and therefore recorded a $250.5 million full impairment of its goodwill, which is recorded as a non-cash charge in “Impairment of goodwill” in the consolidated statements of operations. See Note 1 to the Condensed Consolidated Financial Statements accompanying this report for more details.

Table of Contents

Equity loss from unconsolidated joint ventures

The Company recognized its proportionate share of losses from its unconsolidated joint ventures. These losses are primarily attributable to non-cash depreciation expense. See Note 2 to the Condensed Consolidated Financial Statements accompanying this report for more details regarding the Company's unconsolidated joint ventures.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

The Company is exposed to market risk in the form of changing interest rates on its debt and mortgage notes. Management uses regular monitoring of market conditions and analysis techniques to manage this risk. During the three months ended March 31, 2024, there were no material changes in the quantitative and qualitative disclosures about market risks presented in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

The Company’s management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), as of the end of the period covered by this report. Based on this evaluation, the Company’s Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of such period, the Company’s disclosure controls and procedures were effective in recording, processing, summarizing and reporting, on a timely basis, information required to be disclosed by the Company in the reports it files or submits under the Exchange Act.

Changes in Internal Control over Financial Reporting

There have not been any changes in the Company’s internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the fiscal quarter to which this report relates that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

Item 1A. Risk Factors

In addition to the other information set forth in this report and the risk factor discussed below, an investor should carefully consider the factors discussed in Part I, “Item 1A. Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, which could materially affect the Company’s business, financial condition or future results. The risks, as described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, are not the only risks facing the Company. Additional risks and uncertainties not currently known to management or that management currently deems immaterial also may materially, adversely affect the Company’s business, financial condition, operating results or cash flows.

Risk Factors Relating to the Company

Operational Risks

The Company's revenues depend on the ability of its tenants under its leases to generate sufficient income from their operations to make rental payments to the Company.

The Company’s revenues are subject to the financial strength of its tenants and associated health systems. The Company has no operational control over the business of these tenants and associated health systems who face a wide range of economic, competitive, government reimbursement and regulatory pressures and constraints, including the

Table of Contents

loss of licensure or certification. Any slowdown in the economy, decline in the availability of financing from the capital markets, and changes in healthcare regulations may adversely affect the businesses of the Company’s tenants to varying degrees. Such conditions may further impact such tenants’ abilities to meet their obligations to the Company and, in certain cases, could lead to restructurings, disruptions, or bankruptcies of such tenants. The Company leases to government tenants from time to time that may be subject to annual budget appropriations. If a government tenant fails to receive its annual budget appropriation, it might not be able to make its lease payments to the Company. In addition, defaults under leases with federal government tenants are governed by federal statute and not by state eviction or rent deficiency laws. These conditions could adversely affect the Company’s revenues and could increase allowances for losses and result in impairment charges, which could decrease net income attributable to common stockholders and equity and reduce cash flows from operations. For example, Steward Health Care System LLC (“Steward”), leases approximately 580,000 square feet of space from the Company, accounting for approximately 1.6% of the Company’s total in-place annualized base rent at March 31, 2024. On May 6, 2024, Steward announced that it had filed petitions for relief under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the Southern District of Texas. The bankruptcy filing by Steward could delay the Company’s efforts to collect past due balances under the leases or ultimately preclude collection of these amounts. As of April 30, 2024, Steward owes the Company approximately $2.6 million in rent. There can be no assurance that Steward will meet its financial obligations to the Company.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

During the three months ended March 31, 2024, the Company withheld and canceled shares of Company common stock to satisfy employee tax withholding obligations payable upon the vesting of non-vested shares, as follows:


PERIOD	TOTAL NUMBER OF SHARES PURCHASED	AVERAGE PRICE PAID per share		TOTAL NUMBER OF SHARES purchased as part of publicly announced plans or programs	MAXIMUM NUMBER OF SHARES that may yet be purchased under the plans or programs
January 1 - January 31	—	$	—	—	—
February 1 - February 29	8,228	16.31		—	—
March 1 - March 31	—	—		—	—
Total	8,228	$	16.31

In April 2024, the Company repurchased 2,966,764 shares of its common stock at a weighted-average price of $14.07 for a total of $41.7 million.

Item 5. Other Information

During the three months ended March 31, 2024, no director or officer of the Company adopted or terminated a "Rule 10b5-1 trading agreement" or "non-Rule 10b5-1 trading agreement," as each term is defined in Item 408(a) of Regulation S-K.

Item 6. Exhibits


EXHIBIT			DESCRIPTION
Exhibit 3.1			Fifth Articles of Amendment and Restatement of the Company, as amended.1
Exhibit 3.2			Fourth Amended and Restated Bylaws of the Company.2
Exhibit 3.4			Certificate of Limited Partnership of Healthcare Realty Holdings, L.P.3
Exhibit 3.5			Second Amended and Restated Agreement of Limited Partnership of Healthcare Realty Holdings, L.P.3
Exhibit 4.1			Description of the Registrant's securities registered pursuant to Section 12 of the Securities and Exchange Act of 1934.

Table of Contents


Exhibit 22			Subsidiary Issuers of Guaranteed Securities (filed herewith).
Exhibit 31.1			Certification of the Chief Executive Officer of Healthcare Realty Trust Incorporated pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).
Exhibit 31.2			Certification of the Chief Financial Officer of Healthcare Realty Trust Incorporated pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).
Exhibit 32			Certifications pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).
Exhibit 101.INS			The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.
Exhibit 101.SCH			XBRL Taxonomy Extension Schema Document (furnished electronically herewith)
Exhibit 101.CAL			XBRL Taxonomy Extension Calculation Linkbase Document (furnished electronically herewith)
Exhibit 101.LAB			XBRL Taxonomy Extension Labels Linkbase Document (furnished electronically herewith)
Exhibit 101.DEF			XBRL Taxonomy Extension Definition Linkbase Document (furnished electronically herewith)
Exhibit 101.PRE			XBRL Taxonomy Extension Presentation Linkbase Document (furnished electronically herewith)

1 Filed as an exhibit to the Company's (File No. 001-35568) Form 10-Q filed with the SEC on August 8, 2023 and hereby incorporated by reference.

2 Filed as an exhibit to Legacy HTA's (File No. 001-35568) Form 8-K filed with the SEC on April 29, 2020 and hereby incorporated by reference.

3 Filed as an exhibit to the Company's (File No. 001-35568) Form 8-K filed with the SEC on July 26, 2022 and hereby incorporated by reference.

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	HEALTHCARE REALTY TRUST INCORPORATED

	By:	/s/ J. CHRISTOPHER DOUGLAS
		J. Christopher Douglas
		Executive Vice President and Chief Financial Officer
May 7, 2024

EX-22 2 hr-2024331xex22.htm EX-22 Document

Exhibit 22

LIST OF SUBSIDIARY ISSUERS OF GUARANTEED SECURITIES

As of March 31, 2024, Healthcare Realty Trust Incorporated is the guarantor of the outstanding debt securities of its subsidiaries, as listed below.


Debt Instrument			Issuer
3.88% Senior Notes due 2025			Healthcare Realty Holdings, L.P.
3.50% Senior Notes due 2026			Healthcare Realty Holdings, L.P.
3.75% Senior Notes due 2027			Healthcare Realty Holdings, L.P.
3.63% Senior Notes due 2028			Healthcare Realty Holdings, L.P.
3.10% Senior Notes due 2030			Healthcare Realty Holdings, L.P.
2.40% Senior Notes due 2030			Healthcare Realty Holdings, L.P.
2.05% Senior Notes due 2031			Healthcare Realty Holdings, L.P.
2.00% Senior Notes due 2031			Healthcare Realty Holdings, L.P.

EX-31.1 3 hr-2024331xex311.htm EX-31.1 Document

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302

Exhibit 31.1

Healthcare Realty Trust Incorporated

Certification

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Todd J. Meredith, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Healthcare Realty Trust Incorporated;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date:	May 7, 2024
		/s/ TODD J. MEREDITH
		Todd J. Meredith
		President and Chief Executive Officer

EX-31.2 4 hr-2024331xex312.htm EX-31.2 Document

CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302

Exhibit 31.2

Healthcare Realty Trust Incorporated

Certification

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, J. Christopher Douglas, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Healthcare Realty Trust Incorporated;

b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date:	May 7, 2024
		/s/ J. CHRISTOPHER DOUGLAS
		J. Christopher Douglas
		Executive Vice President and Chief Financial Officer

EX-32 5 hr-2024331xex32.htm EX-32 Document

CERTIFICATIONS PURSUANT TO 18 U.S.C. SECTION 1350 SECTION 906

Exhibit 32

Healthcare Realty Trust Incorporated

Certification Pursuant to

18 U.S.C. Section 1350,

as Adopted Pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report of Healthcare Realty Trust Incorporated (the “Company”) on Form 10-Q for the quarter ended March 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Todd J. Meredith, President and Chief Executive Officer of the Company, and I, J. Christopher Douglas, Executive Vice President and Chief Financial Officer of the Company, each certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1.The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.Information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date:	May 7, 2024
		/s/ TODD J. MEREDITH
		Todd J. Meredith
		President and Chief Executive Officer

		/s/ J. CHRISTOPHER DOUGLAS
		J. Christopher Douglas
		Executive Vice President and Chief Financial Officer

EX-101.SCH 6 hr-20240331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Condensed Consolidated Statements of Equity and Redeemable Non-Controlling Interests link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Condensed Consolidated Statements of Equity and Redeemable Non-Controlling Interests (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Real Estate Investments link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Notes and Bonds Payable link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Derivative Financial Instruments link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Real Estate Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Notes and Bonds Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Derivative Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Fair Value of Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Summary of Significant Accounting Policies - Consolidated balance sheets (Details) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Summary of Significant Accounting Policies - Variable interest entity (Details) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Summary of Significant Accounting Policies - Schedule of Notes Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Summary of Significant Accounting Policies - Schedule of Company's Allowance For Credit Losses (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Summary of Significant Accounting Policies - Revenue Recognition (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Real Estate Investments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Real Estate Investments - Unconsolidated Joint Venture Acquisitions (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Real Estate Investments - Assets Held for Sale (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Leases - Lease Income (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Leases - Lessor Accounting (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Leases - Ground Leases (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Leases - Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Leases - Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Leases - Lease Cost (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Notes and Bonds Payable (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Notes and Bonds Payable - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Derivative Financial Instruments - Cash Flow Hedges of Interest Rate Risk (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Derivative Financial Instruments - Fair Value of Derivative Instruments on the Balance Sheet (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Derivative Financial Instruments - Effect of Cash Flow Hedging on AOCI (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Derivative Financial Instruments - Derivative Instruments Designated as Cash Flow Hedges (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Commitment and Contingencies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Stockholders' Equity - Reconciliation of Beginning and Ending Common Stock Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Stockholders' Equity - Stock Transactions - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Stockholders' Equity - Computation of Basic and Diluted Earnings (Loss) Per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Stockholders' Equity - Schedule of Stock Options, Valuation Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Stockholders' Equity - Summary of the Activity Under the Incentive Plan and RSU Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Stockholders' Equity - Amortization of Compensation for Nonvested Shares (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Fair Value of Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 hr-20240331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 hr-20240331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 hr-20240331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Consolidated Entities [Axis] Consolidated Entities [Axis] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Net loss attributable to non-controlling interests Loss attributable to non-controlling interest Net Income (Loss) Attributable to Noncontrolling Interest Share-Based Payment Arrangement, Nonemployee Share-Based Payment Arrangement, Nonemployee [Member] Pay vs Performance Disclosure [Line Items] Financing Receivable, Allowance for Credit Loss [Roll Forward] Financing Receivable, Allowance for Credit Loss [Roll Forward] Statistical Measurement [Domain] Statistical Measurement [Domain] Credit facility Line of Credit Facility, Maximum Borrowing Capacity Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Receivables and other assets Receivables And Other Assets Receivables And Other Assets Award Type [Domain] Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Investment, Name [Domain] Investment, Name [Domain] Share-based awards, beginning of period (in shares) Share-based awards, ending of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Number of prepaid ground leases Number of Ground Leases Prepaid Number of Ground Leases Prepaid Notes and Bonds Payable Debt Disclosure [Text Block] Dilutive effect of forward equity shares (in shares) Incremental Common Shares Attributable to Dilutive Effect of Equity Forward Agreements Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Dilutive effect of employee stock purchase plan (in shares) Incremental Common Shares Attributable to Dilutive Effect of Employee Stock Purchase Plan Incremental common shares attributable to dilutive effect of employee stock purchase plan. Variable interest entity Variable Interest Entity, Primary Beneficiary [Member] Accumulated other comprehensive income (loss) Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Restatement Determination Date: Restatement Determination Date [Axis] Investment, Name [Axis] Investment, Name [Axis] Total other income (expense) Nonoperating Income (Expense) Commitments and contingencies Commitments and Contingencies OPERATING Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Insider Trading Policies and Procedures [Line Items] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Weighted average grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Stockholders' Equity Equity [Text Block] Net proceeds from issuance of common stock Proceeds from Issuance of Common Stock Geographical [Axis] Geographical [Axis] Total real estate properties Real Estate Investment Property, at Cost Variable Interest Entity [Line Items] Variable Interest Entity [Line Items] Ownership [Axis] Ownership [Axis] Net borrowings on unsecured credit facility Proceeds from (Repayments of) Lines of Credit Non-vested share-based awards, net of withheld shares and forfeitures (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Redevelopment Properties Redevelopment Properties [Member] Redevelopment Properties 2029 and thereafter Finance Lease, Liability, to be Paid, after Year Four Finance Lease, Liability, to be Paid, after Year Four Reporting Unit [Domain] Reporting Unit [Domain] Number of instruments Number of Interest Rate Derivatives Held Contributions from redeemable non-controlling interests Temporary Equity, Carrying Amount, Period Increase (Decrease) Contributions from redeemable non-controlling interests Proceeds from Contributions from Redeemable Noncontrolling Interests Proceeds from Contributions from Redeemable Noncontrolling Interests Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, $.01 par value per share; 200,000 shares authorized; none issued and outstanding Preferred Stock, Value, Issued Subsequent Event Type [Domain] Subsequent Event Type [Domain] Funding of mortgages and notes receivable Payments to Acquire Notes Receivable Nationwide portfolio (percent) Leasing and Property Management Services Provided as Percentage of Nationwide Portfolio Leasing and Property Management Services Provided as Percentage of Nationwide Portfolio Dividends paid Payments of Ordinary Dividends, Common Stock Diluted earnings per common share (in dollars per share) Diluted earnings per common share- net loss (in dollars per share) Earnings Per Share, Diluted Investment in financing receivable, net Financing Receivable, Excluding Accrued Interest, after Allowance for Credit Loss Liability derivatives Derivative Liability, Subject to Master Netting Arrangement, before Offset Interest Rate Swap, Expiring May 1, 2026 Interest Rate Swap, Expiring May 1, 2026 [Member] Interest Rate Swap, Expiring May 1, 2026 PEO Total Compensation Amount PEO Total Compensation Amount Senior Notes due 2028 Senior Notes due 2028 [Member] Senior Notes due 2028 [Member] Variable Interest Entity Variable Interest Entity [Member] Variable Interest Entity Interest income Interest Income, Financing Receivable, before Allowance for Credit Loss Hedging Relationship [Axis] Hedging Relationship [Axis] Number of owned real estate properties Number of Properties Classified as Held for Sale Number of Properties Classified as Held for Sale OPERATING Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Abstract] Land Land Land Reclassification adjustments for gains included in interest expense Reclassification adjustments for gains included in net income (interest expense) (Gain) Loss, Reclassified from AOCI into income Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Texas Texas TEXAS Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Outstanding principal repaid Extinguishment of Debt, Amount Fair Value, Inputs, Level 3 Fair Value, Inputs, Level 3 [Member] Line of credit Line of Credit [Member] Stock price (in dollar per share) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Stock Price Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Stock Price Investment in financing receivable Payments to Acquire Finance Receivables Trading Symbol Trading Symbol Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Schedule of Company's Allowance For Credit Losses Financing Receivable, Allowance for Credit Loss [Table Text Block] Extinguishment of Debt, Type [Domain] Extinguishment of Debt, Type [Domain] Net loss attributable to common stockholders Net income (loss) Net Income (Loss) Goodwill Impairment Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Derivative Contract [Domain] Derivative Contract [Domain] 2026 Finance Lease, Liability, to be Paid, Year Two Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Leases Lessee, Operating Leases [Text Block] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities: Liabilities and Equity [Abstract] Total Lessor, Operating Lease, Payment to be Received Cumulative net income attributable to common stockholders Cumulative Net Income Attributable to Common Stockholders Cumulative net income attributable to common stockholders. (Gain)/loss recognized in AOCI on derivative Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Schedule of Earnings (Loss) per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Encumbered square footage Extinguishment of Debt, Encumbered Square Footage Extinguishment of Debt, Encumbered Square Footage Transaction costs Acquisition Costs, Period Cost Award vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Executive Category: Executive Category [Axis] Summary of the Activity Under the Incentive Plan and RSU Activity Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block] 2028 Lessor, Operating Lease, Payment to be Received, Year Four Summary of the activity under the incentive plans Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Other Commitments [Table] Other Commitments [Table] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Proceeds from sales of real estate properties and additional long-lived assets Proceeds from Sale, Property, Held-for-Sale Name Measure Name Name Forgone Recovery, Individual Name CARRYING VALUE Reported Value Measurement [Member] FAIR VALUE DISCOUNT AND FEES Financing Receivable, Covered and Not Covered, after Allowance for Credit Loss, Fee, Premium, and Discount Goodwill Goodwill Equity Components [Axis] Equity Components [Axis] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Net loss applicable to common stockholders - basic Net Income (Loss) from Continuing Operations Available to Common Stockholders, Basic Net Income (Loss) from Continuing Operations Available to Common Stockholders, Basic Hedging Relationship [Domain] Hedging Relationship [Domain] Owner distributions Distribution Made to Limited Liability Company (LLC) Member, Cash Distributions Declared Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Measurement Basis [Axis] Measurement Basis [Axis] ALLOWANCE FOR CREDIT LOSSES Allowance for credit losses, beginning of period Allowance for credit losses, end of period Financing Receivable, Allowance for Credit Loss, Excluding Accrued Interest Underlying Securities Award Underlying Securities Amount Entity Small Business Entity Small Business Real Estate Investments Acquisitions and Dispositions [Text Block] Acquisitions and dispositions. Local Phone Number Local Phone Number Fair Value Measurement [Domain] Fair Value Measurement [Domain] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Dividends declared per common share, during the period (in dollars per share) Common Stock, Dividends, Per Share, Declared Settled Interest Rate Swaps Settled Interest Rate Swaps [Member] Settled Interest Rate Swaps AMOUNT Derivative, Notional Amount Capitalized interest Interest Paid, Capitalized, Investing Activities Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Other information Leases, Operating [Abstract] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Non-cash interest from financing and notes receivable Interest Income, Financing Receivable, Noncash Interest Income, Financing Receivable, Noncash Amortization of prepaid rent Amortization of Prepaid Rent Amortization of Prepaid Rent Acquisitions of real estate Payments to Acquire Real Estate Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Income Statement Location [Axis] Income Statement Location [Axis] Conversion of OP Units to common stock Stock Issued During Period, Value, Conversion of Units Schedule of Real Estate Properties [Table] Schedule of Real Estate Properties [Table] Amortization of straight-line rent on operating leases (lessee) Straight-line Rent Liability Straight-line rent liability. Schedule of Future Minimum Operating Lease Payments Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Schedule of Equity Method Investments Equity Method Investments [Table Text Block] Amortization of straight-line rent receivable (lessor) Straight-line Rent Receivable Straight-line rent receivable. Mortgages Mortgages [Member] Reporting unit, carrying value Reporting Unit, Carrying Value Reporting Unit, Carrying Value Variable Interest Entities Consolidation, Variable Interest Entity, Policy [Policy Text Block] Revenues Revenues Schedule of Fair Value And Carrying Values For Notes And Bonds Payable, Real Estate Notes Receivable, And Notes Receivable Fair Value, by Balance Sheet Grouping [Table Text Block] Property Entities Not Determined to be VIEs Property Entities Not Determined to be VIEs [Member] Property Entities Not Determined to be VIEs 2028 and thereafter Employee Service Share-based Compensation, Non Vested Awards, Compensation Cost Not yet Recognized, after Year Four Employee Service Share-based Compensation, Non Vested Awards, Compensation Cost Not yet Recognized, After Year Four Product and Service [Domain] Product and Service [Domain] Other Performance Measure, Amount Other Performance Measure, Amount Grantee Status [Axis] Grantee Status [Axis] Operating Partnership Performance Units Operating Partnership Performance Units [Member] Operating Partnership Performance Units Real estate properties Real Estate Investment Property, Net [Abstract] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Asset Impairment: Asset Impairment Charges [Abstract] Schedule of Lease Cost Lease, Cost [Table Text Block] INVESTING ACTIVITIES Net Cash Provided by (Used in) Investing Activities [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Houston, TX Houston, Texas [Member] Houston, Texas [Member] Grant date fair value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value Weighted-average incremental shares of common stock excluded from the computation (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Award Type [Axis] Award Type [Axis] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Plan Name [Domain] Plan Name [Domain] Document Quarterly Report Document Quarterly Report Impairment of real estate properties and credit loss reserves Impairment of Real Estate and Credit Loss Reserves Impairment of Real Estate and Credit Loss Reserves Interest expense Interest Expense HealthCare Realty Trust Incorporated HealthCare Realty Trust Incorporated [Member] HealthCare Realty Trust Incorporated Invoices accrued for construction, tenant improvements and other capitalized costs Capital Expenditures Incurred but Not yet Paid Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Hedging Designation [Axis] Hedging Designation [Axis] Trading Arrangement: Trading Arrangement [Axis] Discount Lessee, Operating Lease, Liability, Undiscounted Excess Amount Use of Estimates in the Condensed Consolidated Financial Statements Use of Estimates, Policy [Policy Text Block] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Leases Lessee, Finance Leases [Text Block] $150 million Unsecured Term Loan Term Loan due 2026 [Member] Term Loan due 2026 [Member] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity File Number Entity File Number Cumulative Dividends Cumulative Dividends [Member] Cumulative Dividends [Member]. Property operating Direct Costs of Leased and Rented Property or Equipment Interest on lease liabilities Finance Lease, Interest Expense Real Estate Notes Receivable: Real Estate [Abstract] Real Estate [Domain] Real Estate [Domain] Entity Shell Company Entity Shell Company 2027 Lessee, Operating Lease, Liability, to be Paid, Year Three $350 million Unsecured Term Loan Term Loan due July 2024 [Member] Term Loan due July 2024 Properties measured at fair value Long-Lived Asset, Held-for-Sale, Fair Value Disclosure Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Los Angeles, California [Member] Los Angeles, California [Member] Los Angeles, California [Member] New Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Restatement Determination Date Restatement Determination Date Shares acquired, average cost per share (in dollars per shares) Shares Acquired, Average Cost Per Share Adjustment to loss attributable to non-controlling interest for legally outstanding restricted units Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities EX-101.PRE 10 hr-20240331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R1.htm IDEA: XBRL DOCUMENT

Cover Page - shares	3 Months Ended
Cover Page - shares	Mar. 31, 2024	May 03, 2024
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2024
Document Transition Report	false
Entity File Number	001-35568
Entity Registrant Name	HEALTHCARE REALTY TRUST INCORPORATED
Entity Incorporation, State or Country Code	MD
Entity Tax Identification Number	20-4738467
Entity Address, Address Line One	3310 West End Avenue
Entity Address, Address Line Two	Suite 700
Entity Address, City or Town	Nashville
Entity Address, State or Province	TN
Entity Address, Postal Zip Code	37203
City Area Code	615
Local Phone Number	269-8175
Title of 12(b) Security	Class A Common Stock, $0.01 par value per share
Trading Symbol	HR
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		378,544,088
Entity Central Index Key	0001360604
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q1
Amendment Flag	false

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Real estate properties
Land	$ 1,342,895	$ 1,343,265
Buildings and improvements	10,902,835	10,881,373
Lease intangibles	816,303	836,302
Personal property	12,720	12,718
Investment in financing receivable, net	122,001	122,602
Financing lease right-of-use assets	81,805	82,209
Construction in progress	70,651	60,727
Land held for development	59,871	59,871
Total real estate properties	13,409,081	13,399,067
Less accumulated depreciation and amortization	(2,374,047)	(2,226,853)
Total real estate properties, net	11,035,034	11,172,214
Cash and cash equivalents	26,172	25,699
Assets held for sale, net	30,968	8,834
Operating lease right-of-use assets	273,949	275,975
Investments in unconsolidated joint ventures	309,754	311,511
Goodwill	0	250,530
Other assets, net	605,047	592,368
Total assets	12,280,924	12,637,131
Liabilities
Notes and bonds payable	5,108,279	4,994,859
Accounts payable and accrued liabilities	163,172	211,994
Liabilities of assets held for sale	700	295
Operating lease liabilities	229,223	229,714
Financing lease liabilities	74,769	74,503
Other liabilities	197,763	202,984
Total liabilities	5,773,906	5,714,349
Commitments and contingencies
Redeemable non-controlling interests	3,880	3,868
Stockholders' equity
Preferred stock, $.01 par value per share; 200,000 shares authorized; none issued and outstanding	0	0
Class A Common stock, $.01 par value per share; 1,000,000 shares authorized; 381,502 and 380,964 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	3,815	3,810
Additional paid-in capital	9,609,530	9,602,592
Accumulated other comprehensive income (loss)	4,791	(10,741)
Cumulative net income attributable to common stockholders	717,958	1,028,794
Cumulative dividends	(3,920,199)	(3,801,793)
Total stockholders' equity	6,415,895	6,822,662
Non-controlling interest	87,243	96,252
Total equity	6,503,138	6,918,914
Total liabilities and equity	$ 12,280,924	$ 12,637,131

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, authorized (in shares)	200,000,000	200,000,000
Preferred stock, issued (in shares)	0	0
Preferred stock, outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized (in shares)	1,000,000,000	1,000,000,000
Common stock, issued (in shares)	381,502,000	380,964,000
Common stock, outstanding (in shares)	381,502,000	380,964,000

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues
Rental income	$ 318,076	$ 324,093
Interest income	4,538	4,214
Other operating	4,191	4,618
Revenues	326,805	332,925
Expenses
Property operating	121,078	122,040
General and administrative	14,787	14,935
Transaction costs	395	287
Merger-related costs	0	4,855
Depreciation and amortization	178,119	184,479
Expenses	314,379	326,596
Other income (expense)
Gain on sales of real estate properties	22	1,007
Interest expense	(61,054)	(63,759)
Impairment of real estate properties and credit loss reserves	(15,937)	(31,422)
Impairment of goodwill	(250,530)	0
Equity loss from unconsolidated joint ventures	(422)	(780)
Interest and other income, net	275	547
Total other income (expense)	(327,646)	(94,407)
Net loss	(315,220)	(88,078)
Net loss attributable to non-controlling interests	4,384	953
Net loss attributable to common stockholders	$ (310,836)	$ (87,125)
Basic earnings per common share (in dollars per share)	$ (0.82)	$ (0.23)
Diluted earnings per common share (in dollars per share)	$ (0.82)	$ (0.23)
Weighted average common shares outstanding - basic (in shares)	379,454,807	378,840,420
Weighted average common shares outstanding - diluted (in shares)	379,454,807	378,840,420
Revenue, Product and Service [Extensible List]	Service [Member]	Service [Member]

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Net loss	$ (315,220)	$ (88,078)
Interest rate derivatives
Reclassification adjustments for gains included in interest expense	(3,865)	(2,284)
Gains (losses) arising during the period on interest rate swaps	19,611	(8,541)
Other comprehensive income	15,746	(10,825)
Comprehensive loss	(299,474)	(98,903)
Less: comprehensive loss attributable to non-controlling interests	4,170	1,084
Comprehensive loss attributable to common stockholders	(295,304)	(97,819)
Interest Rate Swaps
Interest rate derivatives
Gains (losses) arising during the period on interest rate swaps	$ 19,611	$ (8,541)

- Definition

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References + Details

- Definition

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References + Details

- Definition

Amount after tax and reclassification adjustments of other comprehensive income (loss).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-SubTopic 10
-Topic 505
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481674/830-30-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481694/830-30-45-17

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-4

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-5

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481694/830-30-45-20

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-SubTopic 10
-Topic 220
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482739/220-10-55-15

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A

+ Details

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-11

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 205
-Name Accounting Standards Codification
-Section 45
-Paragraph 3
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480767/946-205-45-3

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483581/946-220-45-7

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(16))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 19
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481231/810-10-45-19

Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-6

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 29: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7

Reference 33: http://www.xbrl.org/2003/role/exampleRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 4J
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J

Reference 34: http://www.xbrl.org/2003/role/exampleRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 4K
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-2

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A

Reference 39: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A

+ Details

XML 17 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Equity and Redeemable Non-Controlling Interests - USD ($) $ in Thousands	Total	Total Stockholders’ Equity	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Cumulative Net Income	Cumulative Dividends	Non-controlling Interests
Beginning balance at Dec. 31, 2022	$ 7,679,818	$ 7,571,076	$ 3,806	$ 9,587,637	$ 2,140	$ 1,307,055	$ (3,329,562)	$ 108,742
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock, net of issuance costs	51	51		51
Common stock redemptions	(1,484)	(1,484)	(1)	(1,483)
Share-based compensation	4,992	4,992	3	4,989
Net loss	(88,078)	(87,125)				(87,125)		(953)
Reclassification adjustments for gains included in net income (interest expense)	(2,284)	(2,256)			(2,256)			(28)
Gains (losses) arising during the period on interest rate swaps	(8,541)	(8,438)			(8,438)			(103)
Dividends to common stockholders and distributions to non-controlling interest holders	(119,635)	(118,188)					(118,188)	(1,447)
Ending balance at Mar. 31, 2023	7,464,839	7,358,628	3,808	9,591,194	(8,554)	1,219,930	(3,447,750)	106,211
Redeemable Non-controlling Interests, beginning balance at Dec. 31, 2022	2,014
Redeemable Non-controlling Interests
Adjustments to redemption value of redeemable non-controlling interests	(14)
Redeemable Non-controlling Interests, ending balance at Mar. 31, 2023	2,000
Beginning balance at Dec. 31, 2023	6,918,914	6,822,662	3,810	9,602,592	(10,741)	1,028,794	(3,801,793)	96,252
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock, net of issuance costs	104	104		104
Common stock redemptions	(135)	(135)		(135)
Conversion of OP Units to common stock	0	3,412	2	3,410				(3,412)
Share-based compensation	3,562	3,562	3	3,559
Net loss	(315,220)	(310,836)				(310,836)		(4,384)
Reclassification adjustments for gains included in net income (interest expense)	(3,865)	(3,813)			(3,813)			(52)
Gains (losses) arising during the period on interest rate swaps	19,611	19,345			19,345			266
Dividends to common stockholders and distributions to non-controlling interest holders	(119,833)	(118,406)					(118,406)	(1,427)
Ending balance at Mar. 31, 2024	6,503,138	$ 6,415,895	$ 3,815	$ 9,609,530	$ 4,791	$ 717,958	$ (3,920,199)	$ 87,243
Redeemable Non-controlling Interests, beginning balance at Dec. 31, 2023	3,868
Redeemable Non-controlling Interests
Contributions from redeemable non-controlling interests	13
Adjustments to redemption value of redeemable non-controlling interests	(1)
Redeemable Non-controlling Interests, ending balance at Mar. 31, 2024	$ 3,880

XML 18 R7.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Equity and Redeemable Non-Controlling Interests (Parenthetical) - $ / shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Statement of Stockholders' Equity [Abstract]
Dividends to common stockholders and distributions to non-controlling interest holders (in dollars per share)	$ 0.31	$ 0.31

XML 19 R8.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
OPERATING ACTIVITIES
Net loss	$ (315,220)	$ (88,078)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	178,119	184,479
Other amortization	11,829	11,104
Share-based compensation	3,562	4,992
Amortization of straight-line rent receivable (lessor)	(8,568)	(9,783)
Amortization of straight-line rent on operating leases (lessee)	935	1,537
Gain on sales of real estate properties	(22)	(1,007)
Impairment of real estate properties and credit loss reserves	15,937	31,422
Impairment of goodwill	250,530	0
Equity loss from unconsolidated joint ventures	422	780
Distributions from unconsolidated joint ventures	1,335	2,542
Non-cash interest from financing and notes receivable	(242)	(1,385)
Changes in operating assets and liabilities:
Other assets, including right-of-use-assets	(14,989)	(8,360)
Accounts payable and accrued liabilities	(52,163)	(66,954)
Other liabilities	4,687	7,901
Net cash provided by operating activities	76,152	69,190
INVESTING ACTIVITIES
Acquisitions of real estate	0	(30,725)
Development of real estate	(8,383)	(6,707)
Additional long-lived assets	(50,388)	(60,159)
Funding of mortgages and notes receivable	(1,052)	(6,230)
Investments in unconsolidated joint ventures	0	(3,824)
Investment in financing receivable	746
Investment in financing receivable		(302)
Contributions from redeemable non-controlling interests	13	0
Proceeds from sales of real estate properties and additional long-lived assets	226	149,171
Proceeds from notes receivable repayments	277	336
Net cash (used in) provided by investing activities	(58,561)	41,560
FINANCING ACTIVITIES
Net borrowings on unsecured credit facility	120,000
Repayments of notes and bonds payable	(17,326)	(667)
Dividends paid	(118,269)	(118,052)
Net proceeds from issuance of common stock	104	51
Common stock redemptions	(318)	(1,729)
Distributions to non-controlling interest holders	(1,199)	(1,272)
Payments made on finance leases	(110)	(101)
Net cash used in financing activities	(17,118)	(121,770)
Increase (decrease) in cash and cash equivalents	473	(11,020)
Cash and cash equivalents at beginning of period	25,699	60,961
Cash and cash equivalents at end of period	26,172	49,941
Supplemental Cash Flow Information
Interest paid	73,518	75,082
Mortgage note receivables taken in connection with sale of real estate	0	45,000
Invoices accrued for construction, tenant improvements and other capitalized costs	35,777	28,138
Capitalized interest	$ 942	$ 570

XML 20 R9.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2024

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Business Overview

Basis of Presentation

Principles of Consolidation


(dollars in thousands)	MARCH 31, 2024
Assets:
Net real estate investments	$	92,028
Cash and cash equivalents	2,548
Receivables and other assets	2,687
Total assets	$	97,263
Liabilities:
Accrued expenses and other liabilities	$	5,681
Total equity	91,582
Total liabilities and equity	$	97,263


(dollars in thousands) ORIGINATION DATE	LOCATION	SOURCE	CARRYING AMOUNT		MAXIMUM EXPOSURE TO LOSS
2021	Houston, TX 1	Note receivable	$	31,150	$	31,150
2021	Charlotte, NC 1	Note receivable	5,848		6,000
2022	Texas 2	Joint venture	60,476		60,476

1Assumed mortgage note receivable in connection with the Merger.

2Includes investments in seven properties.

Use of Estimates in the Condensed Consolidated Financial Statements

Redeemable Non-Controlling Interests

Asset Impairment

Goodwill Impairment

Investments in Leases - Financing Receivables, Net


(dollars in thousands) ORIGINATION DATE	LOCATION	INTEREST RATE	CARRYING VALUE as of MARCH 31, 2024
May 2021	Poway, CA	5.73%	$	114,643
November 2021	Columbus, OH	6.48%	7,358
			$	122,001

Real Estate Notes Receivable


(dollars in thousands)	ORIGINATION	MATURITY	STATED INTEREST RATE		MAXIMUM LOAN COMMITMENT		OUTSTANDING as of MAR 31, 2024		ALLOWANCE FOR CREDIT LOSSES		FAIR VALUE DISCOUNT AND FEES		CARRYING VALUE as of MAR 31, 2024
Mezzanine loans
Texas	6/24/2021	6/24/2024	8.00	%	$	54,119	$	54,119	$	(5,196)	$	(3,067)	$	45,856
Arizona	12/21/2023	12/20/2026	9.00	%	6,000		6,000		—		—		6,000
					60,119		60,119		(5,196)		(3,067)		51,856
Mortgage loans
Texas	6/30/2021	7/01/2024	7.00	%	31,150		31,150		—		—		31,150
North Carolina	12/22/2021	12/22/2024	8.00	%	6,000		6,000		—		(152)		5,848
Florida	5/17/2022	2/27/2026	6.00	%	65,000		33,209		—		(39)		33,170
California	3/30/2023	3/29/2026	6.00	%	45,000		45,000		—		—		45,000
Florida	12/28/2023	12/28/2026	9.00	%	7,700		7,423		—		—		7,423
					154,850		122,782		—		(191)		122,591

					$	214,969	$	182,901	$	(5,196)	$	(3,258)	$	174,447

Allowance for Credit Losses

The following table summarizes the Company's allowance for credit losses on real estate notes receivable:


Dollars in thousands	THREE MONTHS ENDED MARCH 31, 2024		TWELVE MONTHS ENDED DECEMBER 31, 2023
Allowance for credit losses, beginning of period	$	5,196	$	—
Credit loss reserves	—		5,196
Allowance for credit losses, end of period	$	5,196	$	5,196

Interest Income

Income from Lease Financing Receivables

Income from Real Estate Notes Receivable

Revenue from Contracts with Customers (ASC Topic 606)


	THREE MONTHS ENDED March 31,
in thousands	2024		2023
Type of Revenue
Parking income	$	2,545	$	2,391
Management fee income/other 1	1,646		2,227
	$	4,191	$	4,618

1 Includes the recovery of certain expenses under the financing receivable as outlined in the management agreement.

New Accounting Pronouncements

XML 21 R10.htm IDEA: XBRL DOCUMENT

Real Estate Investments

3 Months Ended

Mar. 31, 2024

Business Combination and Asset Acquisition [Abstract]

Real Estate Investments

2024 Acquisition Activity

The Company had no real estate acquisition activity for the three months ended March 31, 2024.

Unconsolidated Joint Ventures


	THREE MONTHS ENDED March 31,
Dollars in thousands	2024		2023

Investments in unconsolidated joint ventures, beginning of period	$	311,511	$	327,248
New investment during the period 1	—		3,824
Equity loss recognized during the period	(422)		(780)

Owner distributions	(1,335)		(2,546)
Investments in unconsolidated joint ventures, end of period	$	309,754	$	327,746

2024 Real Estate Asset Dispositions

The Company had no real estate dispositions for the three months ended March 31, 2024.

Assets Held for Sale

The table below reflects the assets and liabilities classified as held for sale as of March 31, 2024 and December 31, 2023:


Dollars in thousands	March 31, 2024		December 31, 2023
Balance Sheet data:
Land	$	2,023	$	1,850
Building and improvements	12,440		6,779
Lease intangibles	2,001		1,017




	16,464		9,646
Accumulated depreciation	(2,050)		(913)
Real estate assets held for sale, net 1	14,414		8,733
Cash and cash equivalents	260		—
Operating lease right-of-use assets	193		—
Other assets, net	16,101		101
Assets held for sale, net	$	30,968	$	8,834

Accounts payable and accrued liabilities	$	135	$	23
Operating lease liabilities	211		—

Other liabilities	354		272
Liabilities of assets held for sale	$	700	$	295

1 Net real estate assets held for sale includes the impact of $1.5 million of impairment charges for the three months ended March 31, 2024.

XML 22 R11.htm IDEA: XBRL DOCUMENT

Leases

3 Months Ended

Mar. 31, 2024

Leases [Abstract]

Leases

Lessor Accounting

Future lease payments under the non-cancelable operating leases, excluding any reimbursements and one sale-type lease, as of March 31, 2024 were as follows:


Dollars in thousands	OPERATING
2024	$	680,129
2025	831,775
2026	734,080
2027	611,277
2028	497,470
2029 and thereafter	1,665,663
	$	5,020,394

Lessee Accounting

The Company’s future lease payments (primarily for its 156 non-prepaid ground leases) as of March 31, 2024 were as follows:


Dollars in thousands	OPERATING		FINANCING
2024	$	8,760	$	1,523
2025	12,415		2,218
2026	12,503		2,255
2027	12,689		2,294
2028	12,809		2,326
2029 and thereafter	698,464		394,072
Total undiscounted lease payments	757,640		404,688
Discount	(528,417)		(329,919)
Lease liabilities	$	229,223	$	74,769

The following table provides details of the Company's total lease expense for the three months ended March 31, 2024 and 2023:


	THREE MONTHS ENDED March 31,
Dollars in thousands	2024			2023
Operating lease cost
Operating lease expense	$	4,465		$	5,107
Variable lease expense	1,228			2,136

Finance lease cost
Amortization of right-of-use assets	387			388
Interest on lease liabilities	937			918
Total lease expense	$	7,017		$	8,549

Other information
Operating cash flows outflows related to operating leases	$	4,040		$	5,960
Operating cash flows outflows related to financing leases	$	563		$	553
Financing cash flows outflows related to financing leases	$	110		$	101



Weighted-average years remaining lease term (excluding renewal options) - operating leases	45.8			47.4
Weighted-average years remaining lease term (excluding renewal options) - finance leases	57.7			58.7
Weighted-average discount rate - operating leases	5.7		%	5.8		%
Weighted-average discount rate - finance leases	5.0		%	5.0		%

Leases

Lessor Accounting

Future lease payments under the non-cancelable operating leases, excluding any reimbursements and one sale-type lease, as of March 31, 2024 were as follows:


Dollars in thousands	OPERATING
2024	$	680,129
2025	831,775
2026	734,080
2027	611,277
2028	497,470
2029 and thereafter	1,665,663
	$	5,020,394

Lessee Accounting

The Company’s future lease payments (primarily for its 156 non-prepaid ground leases) as of March 31, 2024 were as follows:


Dollars in thousands	OPERATING		FINANCING
2024	$	8,760	$	1,523
2025	12,415		2,218
2026	12,503		2,255
2027	12,689		2,294
2028	12,809		2,326
2029 and thereafter	698,464		394,072
Total undiscounted lease payments	757,640		404,688
Discount	(528,417)		(329,919)
Lease liabilities	$	229,223	$	74,769

The following table provides details of the Company's total lease expense for the three months ended March 31, 2024 and 2023:


	THREE MONTHS ENDED March 31,
Dollars in thousands	2024			2023
Operating lease cost
Operating lease expense	$	4,465		$	5,107
Variable lease expense	1,228			2,136

Finance lease cost
Amortization of right-of-use assets	387			388
Interest on lease liabilities	937			918
Total lease expense	$	7,017		$	8,549

Other information
Operating cash flows outflows related to operating leases	$	4,040		$	5,960
Operating cash flows outflows related to financing leases	$	563		$	553
Financing cash flows outflows related to financing leases	$	110		$	101



Weighted-average years remaining lease term (excluding renewal options) - operating leases	45.8			47.4
Weighted-average years remaining lease term (excluding renewal options) - finance leases	57.7			58.7
Weighted-average discount rate - operating leases	5.7		%	5.8		%
Weighted-average discount rate - finance leases	5.0		%	5.0		%

XML 23 R12.htm IDEA: XBRL DOCUMENT

Notes and Bonds Payable

3 Months Ended

Mar. 31, 2024

Debt Disclosure [Abstract]

Notes and Bonds Payable

The table below details the Company’s notes and bonds payable as of March 31, 2024 and December 31, 2023.


	MATURITY DATES	BALANCE 1 AS OF				EFFECTIVE INTEREST RATE as of 3/31/2024
Dollars in thousands		3/31/2024		12/31/2023
$1.5 billion Unsecured Credit Facility	10/25	$	120,000	$	—	6.27	%


$200 million Unsecured Term Loan 2	5/24	199,961		199,903		6.36	%
$350 million Unsecured Term Loan	7/24	349,885		349,798		6.36	%
$300 million Unsecured Term Loan	10/25	299,964		299,958		6.36	%
$150 million Unsecured Term Loan	6/26	149,679		149,643		6.36	%
$200 million Unsecured Term Loan	7/27	199,536		199,502		6.36	%
$300 million Unsecured Term Loan	1/28	298,393		298,288		6.36	%
Senior Notes due 2025	5/25	249,579		249,484		4.12	%
Senior Notes due 2026	8/26	580,933		579,017		4.94	%
Senior Notes due 2027	7/27	484,802		483,727		4.76	%
Senior Notes due 2028	1/28	297,577		297,429		3.85	%
Senior Notes due 2030	2/30	578,038		575,443		5.30	%
Senior Notes due 2030	3/30	296,881		296,780		2.72	%
Senior Notes due 2031	3/31	295,958		295,832		2.25	%
Senior Notes due 2031	3/31	653,864		649,521		5.13	%
Mortgage notes payable	9/24-12/26	53,229		70,534		3.57%-6.88%
		$	5,108,279	$	4,994,859

1Balance is presented net of discounts and issuance costs and inclusive of premiums, where applicable.

2In April 2024, the Company exercised its option to extend the maturity date for one year to May 2025 for a fee of approximately $0.3 million.

Changes in Mortgage Notes Payable

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//470/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

+ Details

XML 24 R13.htm IDEA: XBRL DOCUMENT

Derivative Financial Instruments

3 Months Ended

Mar. 31, 2024

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Financial Instruments

Risk Management Objective of Using Derivatives

Cash Flow Hedges of Interest Rate Risk

life of the agreements without exchange of the underlying notional amount. Such derivatives were used to hedge the variable cash flows associated with existing variable-rate debt.

As of March 31, 2024, the Company had 15 outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk:


	AMOUNT		WEIGHTED AVERAGE RATE
May 2026	275,000		3.74	%
June 2026	150,000		3.83	%
December 2026	150,000		3.84	%
June 2027	200,000		4.27	%
December 2027	300,000		3.93	%
	$	1,075,000	3.92	%

Tabular Disclosure of Fair Values of Derivative Instruments on the Balance Sheet

The table below presents the fair value of the Company's derivative financial instruments, as well as their classification on the Condensed Consolidated Balance Sheet as of March 31, 2024.


	BALANCE AT MARCH 31, 2024
In thousands	BALANCE SHEET LOCATION	FAIR VALUE
Derivatives designated as hedging instruments
Interest rate swaps	Other liabilities	$	(2,973)
Interest rate swaps	Other assets	$	10,603
Total derivatives designated as hedging instruments		$	7,630

Tabular Disclosure of the Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Income (Loss)

The table below presents the effect of cash flow hedge accounting on AOCI during the three months ended March 31, 2024 and 2023 related to the Company's outstanding interest rate swaps.


	(GAIN)/LOSS RECOGNIZED IN AOCI ON DERIVATIVE three months ended March 31,					(GAIN)/LOSS RECLASSIFIED FROM AOCI INTO INCOME three months ended March 31,
In thousands	2024		2023			2024		2023
Interest rate swaps	$	(19,611)	$	8,541	Interest expense	$	(4,014)	$	(2,433)
Settled treasury hedges	—		—		Interest expense	107		107
Settled interest rate swaps	—		—		Interest expense	42		42
	$	(19,611)	$	8,541	Total interest expense	$	(3,865)	$	(2,284)

Credit-risk-related Contingent Features

XML 25 R14.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies	3 Months Ended
Commitments and Contingencies	Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Legal Proceedings The Company is, from time to time, involved in litigation arising in the ordinary course of business. The Company is not aware of any pending or threatened litigation that, if resolved against the Company, would have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows. Development and Redevelopment Activity For the three months ended March 31, 2024, the Company invested $7.7 million and $2.8 million toward active development and redevelopment of properties, respectively, and $11.1 million toward recently completed development and redevelopment projects.

XML 26 R15.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

3 Months Ended

Mar. 31, 2024

Equity [Abstract]

Stockholders' Equity

Common Stock

The following table provides a reconciliation of the beginning and ending shares of common stock outstanding for the three months ended March 31, 2024 and the twelve months ended December 31, 2023:


	THREE MONTHS ENDED MARCH 31, 2024	TWELVE MONTHS ENDED DECEMBER 31, 2023
Balance, beginning of period	380,964,433	380,589,894
Issuance of common stock	8,623	8,627
Conversion of OP unit to Common stock	194,767	190,544
Non-vested share-based awards, net of withheld shares and forfeitures	333,679	175,368
Balance, end of period	381,501,502	380,964,433

Common Stock Dividends

Authorization to Repurchase Common Stock

Earnings Per Common Share

The following table sets forth the computation of basic and diluted earnings per common share for the three months ended March 31, 2024 and 2023.


	THREE MONTHS ENDED MARCH 31,
Dollars in thousands, except per share data	2024		2023
Weighted average common shares outstanding
Weighted average common shares outstanding	381,335,208		380,796,773
Non-vested shares	(1,880,401)		(1,956,353)
Weighted average common shares outstanding - basic	379,454,807		378,840,420

Weighted average common shares outstanding - basic	379,454,807		378,840,420
Dilutive effect of forward equity shares	—		—
Dilutive effect of OP Units	—		—
Dilutive effect of employee stock purchase plan	—		—
Weighted average common shares outstanding - diluted	379,454,807		378,840,420

Net loss	$	(315,220)	$	(88,078)
Income allocated to participating securities	(693)		(625)

Loss attributable to non-controlling interest	4,384		953
Adjustment to loss attributable to non-controlling interest for legally outstanding restricted units	(1,341)		(16)
Net loss applicable to common stockholders - basic	$	(312,870)	$	(87,766)





Basic earnings per common share - net loss	$	(0.82)	$	(0.23)


Diluted earnings per common share - net loss	$	(0.82)	$	(0.23)

Stock Incentive Plan

Equity Incentive Plans

During the three months ended March 31, 2024, the Company made the following equity awards:

•Restricted Stock

•Restricted Stock Units ("RSUs")

On February 13, 2024, the Company granted an aggregate of 208,055 RSUs to members of senior management, with an aggregate grant date fair value of $3.5 million and a five-year vesting period.

average grant date fair value of $19.10 for the relative TSR component for the February 2024 grant using the following assumptions:


	THREE MONTHS ENDED MARCH 31,
Volatility		28.0	%
Dividend assumption		Accrued
Expected term		3 years
Risk-free rate		4.44	%
Stock price (per share)		$15.22

•LTIP Series C Units


	THREE MONTHS ENDED MARCH 31,
Volatility		28.0	%
Dividend assumption		Accrued
Expected term		3 years
Risk-free rate		4.44	%
Stock price (per share)		$15.22

The following table represents the summary of non-vested share-based awards under the Incentive Plans for the three months ended March 31, 2024 and 2023:


	THREE MONTHS ENDED MARCH 31,
	2024	2023
Share-based awards, beginning of period	2,615,562	2,090,060
Granted 1	1,475,811	1,075,261
Vested	(28,414)	(113,766)
Forfeited	(19,805)	(26,063)
Share-based awards, end of period	4,043,154	3,025,492

The following table represents expected amortization of the Company's non-vested shares issued as of March 31, 2024:


Dollars in millions	FUTURE AMORTIZATION of non-vested shares
2024	$	11.5
2025	13.3
2026	10.6
2027	5.7
2028 and thereafter	2.8
Total	$	43.9

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481004/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

+ Details

XML 27 R16.htm IDEA: XBRL DOCUMENT

Fair Value of Financial Instruments

3 Months Ended

Mar. 31, 2024

Fair Value Disclosures [Abstract]

Fair Value of Financial Instruments

The following methods and assumptions were used to estimate the fair value of each class of financial instrument for which it is practical to estimate that value.

•Cash and cash equivalents - The carrying amount approximates fair value (level 1 inputs) due to the short-term maturity of these investments.

The table below details the fair values and carrying values for notes and bonds payable and real estate notes receivable at March 31, 2024 and December 31, 2023.


	March 31, 2024				December 31, 2023
Dollars in millions	CARRYING VALUE		FAIR VALUE		CARRYING VALUE		FAIR VALUE
Notes and bonds payable 1	$	5,108.3	$	4,931.9	$	4,994.9	$	4,872.7
Real estate notes receivable 1	$	174.4	$	172.8	$	173.6	$	172.5

1Level 2 – model-derived valuations in which significant inputs and significant value drivers are observable in active markets.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 28 R17.htm IDEA: XBRL DOCUMENT

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Mar. 31, 2024	Mar. 31, 2023
Pay vs Performance Disclosure
Net income (loss)	$ (310,836)	$ (87,125)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-10

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483581/946-220-45-7

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7

Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B

Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

+ Details

XML 29 R18.htm IDEA: XBRL DOCUMENT

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Mar. 31, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

XML 30 R19.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)	3 Months Ended
Summary of Significant Accounting Policies (Policies)	Mar. 31, 2024
Accounting Policies [Abstract]
Business Overview	Business Overview Healthcare Realty Trust Incorporated ("Company") is a real estate investment trust ("REIT") that owns, leases, manages, acquires, finances, develops and redevelops income-producing real estate properties associated primarily with the delivery of outpatient healthcare services throughout the United States. As of March 31, 2024, the Company had gross investments of approximately $13.4 billion in 654 consolidated real estate properties, construction in progress, redevelopments, financing receivables, financing lease right-of-use assets, land held for development and corporate property, excluding held for sale assets. The Company's real estate properties are located in 35 states and total approximately 38.4 million square feet. The Company provided leasing and property management services to 92% of its portfolio nationwide as of March 31, 2024. On July 20, 2022, pursuant to that certain Agreement and Plan of Merger dated as of February 28, 2022, by and among Healthcare Realty Trust Incorporated, a Maryland corporation (now known as HRTI, LLC, a Maryland limited liability company) (“Legacy HR”), Healthcare Trust of America, Inc., a Maryland corporation (now known as Healthcare Realty Trust Incorporated) (“Legacy HTA”), Healthcare Trust of America Holdings, LP, a Delaware limited partnership (now known as Healthcare Realty Holdings, L.P.) (the “OP”), and HR Acquisition 2, LLC, a Maryland limited liability company (“Merger Sub”), Merger Sub merged with and into Legacy HR, with Legacy HR continuing as the surviving entity and a wholly-owned subsidiary of Legacy HTA (the “Merger”). The combined company operates under the name “Healthcare Realty Trust Incorporated” and its shares of class A common stock, $0.01 par value per share, trade on the New York Stock Exchange under the ticker symbol “HR”. The Company is structured as an umbrella partnership REIT under which substantially all of its business is conducted through the OP, the day-to-day management of which is exclusively controlled by the Company. As of March 31, 2024, the Company owned 98.6% of the issued and outstanding units of the OP, with other investors owning the remaining 1.4% of outstanding units. In addition, as of March 31, 2024, the Company had a weighted average ownership interest of approximately 43% in 33 real estate properties held in unconsolidated joint ventures. See Note 2 below for more details regarding the Company's unconsolidated joint ventures. Any references to square footage or occupancy percentage, and any amounts derived from these values in these notes to the Company's Condensed Consolidated Financial Statements, are outside the scope of our independent registered public accounting firm’s review.
Basis of Presentation	Basis of Presentation The Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. They do not include all of the information and footnotes required by GAAP for complete financial statements. All material intercompany transactions and balances have been eliminated in consolidation. This interim financial information should be read in conjunction with the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. Management believes that all adjustments of a normal, recurring nature considered necessary for a fair presentation have been included. In addition, the interim financial information does not necessarily represent or indicate what the operating results will be for the year ending December 31, 2024 for many reasons including, but not limited to, acquisitions, dispositions, capital financing transactions, changes in interest rates and the effects of other trends, risks and uncertainties.
Principles of Consolidation	Principles of Consolidation The Company’s Condensed Consolidated Financial Statements include the accounts of the Company, its wholly owned subsidiaries, and joint ventures and partnerships where the Company controls the operating activities. GAAP requires us to identify entities for which control is achieved through means other than voting rights and to determine which business enterprise is the primary beneficiary of variable interest entities (“VIEs”). Accounting Standards Codification (“ASC”) Topic 810, Consolidation broadly defines a VIE as an entity in which either (i) the equity investors as a group, if any, lack the power through voting or similar rights to direct the activities of such entity that most significantly impact such entity’s economic performance or (ii) the equity investment at risk is insufficient to finance that entity’s activities without additional subordinated financial support. The Company identifies the primary beneficiary of a VIE as the enterprise that has both of the following characteristics: (i) the power to direct the activities of the VIE that most significantly impact the entity’s economic performance and (ii) the obligation to absorb losses or receive benefits of the VIE that could potentially be significant to the entity. The Company consolidates its investment in a VIE when it determines that it is the VIE’s primary beneficiary, with any minority interests reflected as non-controlling interests or redeemable non-controlling interests in the accompanying Condensed Consolidated Financial Statements. The Company may change its original assessment of a VIE upon subsequent events, such as the modification of contractual arrangements that affect the characteristics or adequacy of the entity’s equity investments at risk, the disposition of all or a portion of an interest held by the primary beneficiary, or changes in facts and circumstances that impact the power to direct activities of the VIE that most significantly impacts economic performance. The Company performs this analysis on an ongoing basis. For property holding entities not determined to be VIEs, the Company consolidates such entities in which it owns 100% of the equity or has a controlling financial interest evidenced by ownership of a majority voting interest. All intercompany balances and transactions are eliminated in consolidation. For entities in which the Company owns less than 100% of the equity interest, the Company consolidates the entity if it has the direct or indirect ability to control the entities’ activities based upon the terms of the respective entities’ ownership agreements. The OP is 98.6% owned by the Company. Holders of operating partnership units (“OP Units”) are considered to be non-controlling interest holders in the OP and their ownership interests are reflected as equity on the accompanying Condensed Consolidated Balance Sheets. Further, a portion of the earnings and losses of the OP are allocated to non-controlling interest holders based on their respective ownership percentages. Upon conversion of OP Units to common stock, any difference between the fair value of the common stock issued and the carrying value of the OP Units converted to common stock is recorded as a component of equity. As of March 31, 2024, there were approximately 5.2 million OP Units, or 1.4% of OP Units issued and outstanding, held by non-controlling interest holders. Additionally, the Company is the primary beneficiary of this VIE. Accordingly, the Company consolidates its interests in the OP.
Variable Interest Entities	As of March 31, 2024, the Company's unconsolidated joint venture arrangements were accounted for using the equity method of accounting as the Company exercised significant influence over but did not control these entities.
Use of Estimates in the Condensed Consolidated Financial Statements	Use of Estimates in the Condensed Consolidated Financial Statements Preparation of the Condensed Consolidated Financial Statements in accordance with GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Actual results may differ from those estimates.
Redeemable Non-Controlling Interests	Redeemable Non-Controlling Interests The Company accounts for redeemable equity securities in accordance with ASC Topic 480: Accounting for Redeemable Equity Instruments, which requires that equity securities redeemable at the option of the holder, not solely within our control, be classified outside permanent stockholders’ equity. The Company classifies redeemable equity securities as redeemable non-controlling interests in the accompanying Condensed Consolidated Balance Sheets. Accordingly, the Company records the carrying amount at the greater of the initial carrying amount (increased or decreased for the non-controlling interest’s share of net income or loss and distributions) or the redemption value. We measure the redemption value and record an adjustment to the carrying value of the equity securities as a component of redeemable non-controlling interest.
Asset Impairment	Asset Impairment The Company assesses the potential for impairment of identifiable, definite-lived, intangible assets and long-lived assets, including real estate properties, whenever the occurrence of an event or a change in circumstances indicates that the carrying value might not be fully recoverable. Indicators of impairment may include significant underperformance of an asset relative to historical or expected operating results; significant changes in the Company’s use of assets or the strategy for its overall business; plans to sell an asset before its depreciable life has ended; the expiration of a significant portion of leases in a property; or significant negative economic trends or negative industry trends for the Company or its tenants.
Goodwill Impairment	Goodwill Impairment During the first quarter of 2024, the Company experienced a sustained decline in the price per share of its common stock, which was identified as an indicator of goodwill impairment. As a result, a goodwill evaluation was performed. The Company's current operations are carried out through a single reporting unit with a carrying value of approximately $12.0 billion. The Company determined that the carrying value exceeded estimated fair value and therefore an impairment of goodwill was recorded. The Company recorded a $250.5 million full impairment of its goodwill, which is recorded as a non-cash charge in “Impairment of goodwill” in the Condensed Consolidated Statements of Operations.
Investments in Leases - Financing Receivables, Net and Real Estate Notes Receivable and Interest Income	Investments in Leases - Financing Receivables, Net In accordance with ASC Topic 842: Leases, for transactions in which the Company enters into a contract to acquire an asset and leases it back to the seller (i.e., a sale leaseback transaction), control of the asset is not considered to have transferred when the seller-lessee has a purchase option. As a result, the Company does not recognize the underlying real estate asset but instead recognizes a financial asset in accordance with ASC Topic 310: Receivables. Real Estate Notes Receivable Real estate notes receivable consists of mezzanine and other real estate loans, which are generally collateralized by a pledge of the borrower’s ownership interest in the respective real estate owner, a mortgage or deed of trust, and/or corporate guarantees. Real estate notes receivable are intended to be held-to-maturity and are recorded at amortized cost, net of unamortized loan origination costs and fees and allowance for credit losses. Allowance for Credit Losses Pursuant to ASC Topic 326, Financial Instruments - Credit Losses, the Company adopted a policy to evaluate current expected credit losses at the inception of loans qualifying for treatment under ASC Topic 326. The Company utilizes a probability of default method approach for estimating current expected credit losses and evaluates the liquidity and creditworthiness of its borrowers on a quarterly basis to determine whether any updates to the future expected losses recognized upon inception are necessary. The Company’s evaluation considers industry and economic conditions, credit enhancements, liquidity, and other factors. The determination of the credit allowance is based on a quarterly evaluation of all outstanding loans, including general economic conditions and estimated collectability of loan payments. The Company evaluates the collectability of loan receivables based on a combination of credit quality indicators, including, but not limited to, payment status, historical loan charge-offs, financial strength of the borrower and guarantors, and nature, extent, and value of the underlying collateral. A loan is considered to have deteriorated credit quality when, based on current information and events, it is probable that the Company will be unable to collect all amounts due as scheduled according to the contractual terms of the loan agreement. For those loans identified as having deteriorated credit quality, the amount of credit loss is determined on an individual basis. Placement on non-accrual status may be required. Consistent with this definition, all loans on non-accrual status are deemed to have deteriorated credit quality. To the extent circumstances improve and the risk of collectability is diminished, the loan may return to income accrual status. While a loan is on non-accrual status, any cash receipts are applied against the outstanding principal balance. Interest Income Income from Lease Financing Receivables The Company recognized the related income from two financing receivables totaling $2.1 million for each of the three months ended March 31, 2024 and 2023, based on an imputed interest rate over the terms of the applicable lease. As a result, the interest recognized from the financing receivable in any particular period will not equal the cash payments from the lease agreement in that period. Acquisition costs incurred in connection with entering into the financing receivable are treated as loan origination fees. These costs are classified with the financing receivable and are included in the balance of the net investment. Amortization of these amounts will be recognized as a reduction to Interest income over the life of the lease.
Revenue from Contracts with Customers (ASC Topic 606)	Revenue from Contracts with Customers (ASC Topic 606) The Company recognizes certain revenue under the core principle of ASC Topic 606. This topic requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Lease revenue is not within the scope of ASC Topic 606. To achieve the core principle, the Company applies the five-step model specified in the guidance. Revenue that is accounted for under ASC Topic 606 is segregated on the Company’s Condensed Consolidated Statements of Operations in the Other operating line item. This line item includes parking income, management fee income and other miscellaneous income. The Company’s major types of revenue that are accounted for under Topic 606 that are listed above are all accounted for as the performance obligation is satisfied. The performance obligations that are identified for each of these items are satisfied over time, and the Company recognizes revenue monthly based on this principle.
New Accounting Pronouncements	New Accounting Pronouncements On November 27, 2023, the Financial Accounting Standards Board ("FASB") issued ASU 2023-07, Segment Reporting (Topic 280). Some of the main provisions of this update to segment reporting include; (i) a requirement to disclose significant segment expenses, on an annual and interim basis, that are regularly provided to the chief operating decision maker ("CODM") and included within each reported measure of segment profit or loss; (ii) a requirement to disclose the title and position of the CODM and an explanation of how the CODM uses the reported measures of segment profit or loss in assessing segment performance and deciding how to allocate resources, and (iii) a requirement that an entity that has a single reportable segment provide all the disclosures required by the amendments in this update. The update is effective for annual reporting periods beginning after December 15, 2023, and interim periods beginning after December 15, 2024. Early adoption is permitted. At this time, the Company does not expect that the adoption of this ASU will have a material impact on its consolidated financial statements and compliance of these new disclosure requirements will begin with the Company's Annual Report on Form 10-K for the year ending December 31, 2024.

XML 31 R20.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2024

Accounting Policies [Abstract]

Schedule of Condensed Balance Sheet

Accordingly, such joint ventures have been consolidated, and the table below summarizes the balance sheets of consolidated VIEs, excluding the OP, in the aggregate:


(dollars in thousands)	MARCH 31, 2024
Assets:
Net real estate investments	$	92,028
Cash and cash equivalents	2,548
Receivables and other assets	2,687
Total assets	$	97,263
Liabilities:
Accrued expenses and other liabilities	$	5,681
Total equity	91,582
Total liabilities and equity	$	97,263

Schedule of Variable Interest Entities

As a result, the Company accounts for the two notes receivables as amortized cost and a joint venture arrangement under the equity method. See below for additional information regarding the Company's unconsolidated VIEs.


(dollars in thousands) ORIGINATION DATE	LOCATION	SOURCE	CARRYING AMOUNT		MAXIMUM EXPOSURE TO LOSS
2021	Houston, TX 1	Note receivable	$	31,150	$	31,150
2021	Charlotte, NC 1	Note receivable	5,848		6,000
2022	Texas 2	Joint venture	60,476		60,476

1Assumed mortgage note receivable in connection with the Merger.

2Includes investments in seven properties.

Schedule of Accounts, Notes, Loans and Financing Receivable

See below for additional information regarding the Company's financing receivables.


(dollars in thousands) ORIGINATION DATE	LOCATION	INTEREST RATE	CARRYING VALUE as of MARCH 31, 2024
May 2021	Poway, CA	5.73%	$	114,643
November 2021	Columbus, OH	6.48%	7,358
			$	122,001


(dollars in thousands)	ORIGINATION	MATURITY	STATED INTEREST RATE		MAXIMUM LOAN COMMITMENT		OUTSTANDING as of MAR 31, 2024		ALLOWANCE FOR CREDIT LOSSES		FAIR VALUE DISCOUNT AND FEES		CARRYING VALUE as of MAR 31, 2024
Mezzanine loans
Texas	6/24/2021	6/24/2024	8.00	%	$	54,119	$	54,119	$	(5,196)	$	(3,067)	$	45,856
Arizona	12/21/2023	12/20/2026	9.00	%	6,000		6,000		—		—		6,000
					60,119		60,119		(5,196)		(3,067)		51,856
Mortgage loans
Texas	6/30/2021	7/01/2024	7.00	%	31,150		31,150		—		—		31,150
North Carolina	12/22/2021	12/22/2024	8.00	%	6,000		6,000		—		(152)		5,848
Florida	5/17/2022	2/27/2026	6.00	%	65,000		33,209		—		(39)		33,170
California	3/30/2023	3/29/2026	6.00	%	45,000		45,000		—		—		45,000
Florida	12/28/2023	12/28/2026	9.00	%	7,700		7,423		—		—		7,423
					154,850		122,782		—		(191)		122,591

					$	214,969	$	182,901	$	(5,196)	$	(3,258)	$	174,447

Schedule of Company's Allowance For Credit Losses

The following table summarizes the Company's allowance for credit losses on real estate notes receivable:


Dollars in thousands	THREE MONTHS ENDED MARCH 31, 2024		TWELVE MONTHS ENDED DECEMBER 31, 2023
Allowance for credit losses, beginning of period	$	5,196	$	—
Credit loss reserves	—		5,196
Allowance for credit losses, end of period	$	5,196	$	5,196

Schedule of Disaggregation of revenue

Below is a detail of the amounts by category:


	THREE MONTHS ENDED March 31,
in thousands	2024		2023
Type of Revenue
Parking income	$	2,545	$	2,391
Management fee income/other 1	1,646		2,227
	$	4,191	$	4,618

1 Includes the recovery of certain expenses under the financing receivable as outlined in the management agreement.

- Definition

Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.

+ References + Details

XML 32 R21.htm IDEA: XBRL DOCUMENT

Real Estate Investments (Tables)

3 Months Ended

Mar. 31, 2024

Business Combination and Asset Acquisition [Abstract]

Schedule of Equity Method Investments


	THREE MONTHS ENDED March 31,
Dollars in thousands	2024		2023

Investments in unconsolidated joint ventures, beginning of period	$	311,511	$	327,248
New investment during the period 1	—		3,824
Equity loss recognized during the period	(422)		(780)

Owner distributions	(1,335)		(2,546)
Investments in unconsolidated joint ventures, end of period	$	309,754	$	327,746

Schedule of Assets and Liabilities Held for Sale

The table below reflects the assets and liabilities classified as held for sale as of March 31, 2024 and December 31, 2023:


Dollars in thousands	March 31, 2024		December 31, 2023
Balance Sheet data:
Land	$	2,023	$	1,850
Building and improvements	12,440		6,779
Lease intangibles	2,001		1,017




	16,464		9,646
Accumulated depreciation	(2,050)		(913)
Real estate assets held for sale, net 1	14,414		8,733
Cash and cash equivalents	260		—
Operating lease right-of-use assets	193		—
Other assets, net	16,101		101
Assets held for sale, net	$	30,968	$	8,834

Accounts payable and accrued liabilities	$	135	$	23
Operating lease liabilities	211		—

Other liabilities	354		272
Liabilities of assets held for sale	$	700	$	295

1 Net real estate assets held for sale includes the impact of $1.5 million of impairment charges for the three months ended March 31, 2024.

XML 33 R22.htm IDEA: XBRL DOCUMENT

Leases (Tables)

3 Months Ended

Mar. 31, 2024

Leases [Abstract]

Schedule of Future Minimum Operating Lease Payments Receivable

Future lease payments under the non-cancelable operating leases, excluding any reimbursements and one sale-type lease, as of March 31, 2024 were as follows:


Dollars in thousands	OPERATING
2024	$	680,129
2025	831,775
2026	734,080
2027	611,277
2028	497,470
2029 and thereafter	1,665,663
	$	5,020,394

Schedule of Future Minimum Operating Lease Payments

The Company’s future lease payments (primarily for its 156 non-prepaid ground leases) as of March 31, 2024 were as follows:


Dollars in thousands	OPERATING		FINANCING
2024	$	8,760	$	1,523
2025	12,415		2,218
2026	12,503		2,255
2027	12,689		2,294
2028	12,809		2,326
2029 and thereafter	698,464		394,072
Total undiscounted lease payments	757,640		404,688
Discount	(528,417)		(329,919)
Lease liabilities	$	229,223	$	74,769

Schedule of Future Minimum Financing Lease Payments

The Company’s future lease payments (primarily for its 156 non-prepaid ground leases) as of March 31, 2024 were as follows:


Dollars in thousands	OPERATING		FINANCING
2024	$	8,760	$	1,523
2025	12,415		2,218
2026	12,503		2,255
2027	12,689		2,294
2028	12,809		2,326
2029 and thereafter	698,464		394,072
Total undiscounted lease payments	757,640		404,688
Discount	(528,417)		(329,919)
Lease liabilities	$	229,223	$	74,769

Schedule of Lease Cost

The following table provides details of the Company's total lease expense for the three months ended March 31, 2024 and 2023:


	THREE MONTHS ENDED March 31,
Dollars in thousands	2024			2023
Operating lease cost
Operating lease expense	$	4,465		$	5,107
Variable lease expense	1,228			2,136

Finance lease cost
Amortization of right-of-use assets	387			388
Interest on lease liabilities	937			918
Total lease expense	$	7,017		$	8,549

Other information
Operating cash flows outflows related to operating leases	$	4,040		$	5,960
Operating cash flows outflows related to financing leases	$	563		$	553
Financing cash flows outflows related to financing leases	$	110		$	101



Weighted-average years remaining lease term (excluding renewal options) - operating leases	45.8			47.4
Weighted-average years remaining lease term (excluding renewal options) - finance leases	57.7			58.7
Weighted-average discount rate - operating leases	5.7		%	5.8		%
Weighted-average discount rate - finance leases	5.0		%	5.0		%

XML 34 R23.htm IDEA: XBRL DOCUMENT

Notes and Bonds Payable (Tables)

3 Months Ended

Mar. 31, 2024

Debt Disclosure [Abstract]

Schedule of Debt

The table below details the Company’s notes and bonds payable as of March 31, 2024 and December 31, 2023.


	MATURITY DATES	BALANCE 1 AS OF				EFFECTIVE INTEREST RATE as of 3/31/2024
Dollars in thousands		3/31/2024		12/31/2023
$1.5 billion Unsecured Credit Facility	10/25	$	120,000	$	—	6.27	%


$200 million Unsecured Term Loan 2	5/24	199,961		199,903		6.36	%
$350 million Unsecured Term Loan	7/24	349,885		349,798		6.36	%
$300 million Unsecured Term Loan	10/25	299,964		299,958		6.36	%
$150 million Unsecured Term Loan	6/26	149,679		149,643		6.36	%
$200 million Unsecured Term Loan	7/27	199,536		199,502		6.36	%
$300 million Unsecured Term Loan	1/28	298,393		298,288		6.36	%
Senior Notes due 2025	5/25	249,579		249,484		4.12	%
Senior Notes due 2026	8/26	580,933		579,017		4.94	%
Senior Notes due 2027	7/27	484,802		483,727		4.76	%
Senior Notes due 2028	1/28	297,577		297,429		3.85	%
Senior Notes due 2030	2/30	578,038		575,443		5.30	%
Senior Notes due 2030	3/30	296,881		296,780		2.72	%
Senior Notes due 2031	3/31	295,958		295,832		2.25	%
Senior Notes due 2031	3/31	653,864		649,521		5.13	%
Mortgage notes payable	9/24-12/26	53,229		70,534		3.57%-6.88%
		$	5,108,279	$	4,994,859

1Balance is presented net of discounts and issuance costs and inclusive of premiums, where applicable.

2In April 2024, the Company exercised its option to extend the maturity date for one year to May 2025 for a fee of approximately $0.3 million.

XML 35 R24.htm IDEA: XBRL DOCUMENT

Derivative Financial Instruments (Tables)

3 Months Ended

Mar. 31, 2024

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss)

As of March 31, 2024, the Company had 15 outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk:


	AMOUNT		WEIGHTED AVERAGE RATE
May 2026	275,000		3.74	%
June 2026	150,000		3.83	%
December 2026	150,000		3.84	%
June 2027	200,000		4.27	%
December 2027	300,000		3.93	%
	$	1,075,000	3.92	%

The table below presents the effect of cash flow hedge accounting on AOCI during the three months ended March 31, 2024 and 2023 related to the Company's outstanding interest rate swaps.


	(GAIN)/LOSS RECOGNIZED IN AOCI ON DERIVATIVE three months ended March 31,					(GAIN)/LOSS RECLASSIFIED FROM AOCI INTO INCOME three months ended March 31,
In thousands	2024		2023			2024		2023
Interest rate swaps	$	(19,611)	$	8,541	Interest expense	$	(4,014)	$	(2,433)
Settled treasury hedges	—		—		Interest expense	107		107
Settled interest rate swaps	—		—		Interest expense	42		42
	$	(19,611)	$	8,541	Total interest expense	$	(3,865)	$	(2,284)

Schedule of Derivative Instruments in Statement of Financial Position, Fair Value

The table below presents the fair value of the Company's derivative financial instruments, as well as their classification on the Condensed Consolidated Balance Sheet as of March 31, 2024.


	BALANCE AT MARCH 31, 2024
In thousands	BALANCE SHEET LOCATION	FAIR VALUE
Derivatives designated as hedging instruments
Interest rate swaps	Other liabilities	$	(2,973)
Interest rate swaps	Other assets	$	10,603
Total derivatives designated as hedging instruments		$	7,630

XML 36 R25.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Tables)

3 Months Ended

Mar. 31, 2024

Equity [Abstract]

Schedule of Reconciliation of Common Stock Outstanding

The following table provides a reconciliation of the beginning and ending shares of common stock outstanding for the three months ended March 31, 2024 and the twelve months ended December 31, 2023:


	THREE MONTHS ENDED MARCH 31, 2024	TWELVE MONTHS ENDED DECEMBER 31, 2023
Balance, beginning of period	380,964,433	380,589,894
Issuance of common stock	8,623	8,627
Conversion of OP unit to Common stock	194,767	190,544
Non-vested share-based awards, net of withheld shares and forfeitures	333,679	175,368
Balance, end of period	381,501,502	380,964,433

Schedule of Earnings (Loss) per Share

The following table sets forth the computation of basic and diluted earnings per common share for the three months ended March 31, 2024 and 2023.


	THREE MONTHS ENDED MARCH 31,
Dollars in thousands, except per share data	2024		2023
Weighted average common shares outstanding
Weighted average common shares outstanding	381,335,208		380,796,773
Non-vested shares	(1,880,401)		(1,956,353)
Weighted average common shares outstanding - basic	379,454,807		378,840,420

Weighted average common shares outstanding - basic	379,454,807		378,840,420
Dilutive effect of forward equity shares	—		—
Dilutive effect of OP Units	—		—
Dilutive effect of employee stock purchase plan	—		—
Weighted average common shares outstanding - diluted	379,454,807		378,840,420

Net loss	$	(315,220)	$	(88,078)
Income allocated to participating securities	(693)		(625)

Loss attributable to non-controlling interest	4,384		953
Adjustment to loss attributable to non-controlling interest for legally outstanding restricted units	(1,341)		(16)
Net loss applicable to common stockholders - basic	$	(312,870)	$	(87,766)





Basic earnings per common share - net loss	$	(0.82)	$	(0.23)


Diluted earnings per common share - net loss	$	(0.82)	$	(0.23)

Schedule of Stock Options, Valuation Assumptions


	THREE MONTHS ENDED MARCH 31,
Volatility		28.0	%
Dividend assumption		Accrued
Expected term		3 years
Risk-free rate		4.44	%
Stock price (per share)		$15.22


	THREE MONTHS ENDED MARCH 31,
Volatility		28.0	%
Dividend assumption		Accrued
Expected term		3 years
Risk-free rate		4.44	%
Stock price (per share)		$15.22

Summary of the Activity Under the Incentive Plan and RSU Activity

The following table represents the summary of non-vested share-based awards under the Incentive Plans for the three months ended March 31, 2024 and 2023:


	THREE MONTHS ENDED MARCH 31,
	2024	2023
Share-based awards, beginning of period	2,615,562	2,090,060
Granted 1	1,475,811	1,075,261
Vested	(28,414)	(113,766)
Forfeited	(19,805)	(26,063)
Share-based awards, end of period	4,043,154	3,025,492

Schedule of Unrecognized Compensation Cost, Nonvested Awards

The following table represents expected amortization of the Company's non-vested shares issued as of March 31, 2024:


Dollars in millions	FUTURE AMORTIZATION of non-vested shares
2024	$	11.5
2025	13.3
2026	10.6
2027	5.7
2028 and thereafter	2.8
Total	$	43.9

XML 37 R26.htm IDEA: XBRL DOCUMENT

Fair Value of Financial Instruments (Tables)

3 Months Ended

Mar. 31, 2024

Fair Value Disclosures [Abstract]

Schedule of Fair Value And Carrying Values For Notes And Bonds Payable, Real Estate Notes Receivable, And Notes Receivable

The table below details the fair values and carrying values for notes and bonds payable and real estate notes receivable at March 31, 2024 and December 31, 2023.


	March 31, 2024				December 31, 2023
Dollars in millions	CARRYING VALUE		FAIR VALUE		CARRYING VALUE		FAIR VALUE
Notes and bonds payable 1	$	5,108.3	$	4,931.9	$	4,994.9	$	4,872.7
Real estate notes receivable 1	$	174.4	$	172.8	$	173.6	$	172.5

1Level 2 – model-derived valuations in which significant inputs and significant value drivers are observable in active markets.

XML 38 R27.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details) $ / shares in Units, $ in Thousands, shares in Millions, ft² in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2024 USD ($) ft² property variable_interest_entity note_receivable financing_receivable state joint_venture $ / shares shares	Mar. 31, 2023 USD ($)	Dec. 31, 2023 USD ($) financing_receivable $ / shares	Dec. 31, 2022 USD ($)	Jul. 20, 2021 $ / shares
Business Overview:
Gross investment amount, total	$ 13,400,000
Number of real estate properties \| property	654
Number of states that the company owns real estate in, whole units \| state	35
Approximate square feet invested in by company \| ft²	38.4
Nationwide portfolio (percent)	92.00%
Common stock, par value (in dollars per share) \| $ / shares	$ 0.01		$ 0.01
Number of properties held in unconsolidated joint ventures \| property	33
Principles of Consolidation:
Equity ownership for consolidation (percent)	100.00%
Number of variable interest entities \| variable_interest_entity	4
Redeemable Non-Controlling Interests:
Redeemable non-controlling interests	$ 3,880	$ 2,000	$ 3,868	$ 2,014
Asset Impairment:
Impairment of real estate assets	15,900
Goodwill Impairment
Impairment of goodwill	250,530	0
Real Estate Notes Receivable:
Investment in financing receivable, net	174,400
Allowance for Credit Losses, Interest Income, Income from Real Estate Notes Receivable:
Credit loss reserves	$ 0	5,200	$ 5,196
Number of recognized lease financial receivables \| financing_receivable	2
Income from financing receivables	$ 2,100
Number of real estate notes receivable \| financing_receivable			2
Financing receivable, nonaccrual			$ 48,900
Fair Value, Inputs, Level 3
Asset Impairment:
Number of properties measured at fair value \| property	3
Properties measured at fair value	$ 2,900
One
Goodwill Impairment
Reporting unit, carrying value	12,000,000
Notes Receivable
Allowance for Credit Losses, Interest Income, Income from Real Estate Notes Receivable:
Interest income	$ 2,400	$ 2,100
Variable Interest Entity
Principles of Consolidation:
Number of variable interest entities \| variable_interest_entity	3
Number of notes receivable \| note_receivable	2
Number of joint ventures \| joint_venture	1
HealthCare Realty Trust Incorporated
Business Overview:
Common stock, par value (in dollars per share) \| $ / shares					$ 0.01
Non-Controlling Interest Holders \| Healthcare Trust of America Holdings L P
Principles of Consolidation:
Limited partner's capital, units outstanding (in shares) \| shares	5.2
Limited partners ownership interest (in percent)	1.40%
HealthCare Realty Trust Incorporated \| Other Investors
Business Overview:
Subsidiary, ownership percentage, noncontrolling owner	1.40%
Property Entities Not Determined to be VIEs
Principles of Consolidation:
Equity interest owned (percent)	100.00%
Healthcare Trust of America Holdings L P
Principles of Consolidation:
Equity interest owned (percent)	98.60%
Real Estate Properties Held in Joint Ventures
Business Overview:
Joint venture ownership (percent)	43.00%

XML 39 R28.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Consolidated balance sheets (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Assets:
Net real estate investments	$ 11,035,034	$ 11,172,214
Cash and cash equivalents	26,172	25,699
Total assets	12,280,924	12,637,131
Liabilities:
Total equity	6,415,895	6,822,662
Total liabilities and equity	12,280,924	$ 12,637,131
Variable interest entity
Assets:
Net real estate investments	92,028
Cash and cash equivalents	2,548
Receivables and other assets	2,687
Total assets	97,263
Liabilities:
Accrued expenses and other liabilities	5,681
Total equity	91,582
Total liabilities and equity	$ 97,263

XML 40 R29.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Variable interest entity (Details) $ in Thousands	Mar. 31, 2024 USD ($) note_receivable property
Variable Interest Entity
Variable Interest Entity [Line Items]
Number of notes receivable \| note_receivable	2
Houston, TX \| Variable Interest Entity, Not Primary Beneficiary
Variable Interest Entity [Line Items]
Notes receivable, carrying amount	$ 31,150
MAXIMUM EXPOSURE TO LOSS	31,150
North Carolina \| Variable Interest Entity, Not Primary Beneficiary
Variable Interest Entity [Line Items]
Notes receivable, carrying amount	5,848
MAXIMUM EXPOSURE TO LOSS	6,000
Texas \| Variable Interest Entity, Not Primary Beneficiary
Variable Interest Entity [Line Items]
Joint venture, carrying amount	60,476
MAXIMUM EXPOSURE TO LOSS	$ 60,476
Number of owned real estate properties \| property	7

XML 41 R30.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Schedule of Notes Receivable (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Accounts, Notes, Loans and Financing Receivable [Line Items]
Financing receivable, carrying value	$ 122,001
MAXIMUM LOAN COMMITMENT	214,969
REAL ESTATE NOTES RECEIVABLE, GROSS	182,901
ALLOWANCE FOR CREDIT LOSSES	(5,196)	$ (5,196)	$ 0
FAIR VALUE DISCOUNT AND FEES	(3,258)
CARRYING VALUE	174,447
Mezzanine loans
Accounts, Notes, Loans and Financing Receivable [Line Items]
MAXIMUM LOAN COMMITMENT	60,119
REAL ESTATE NOTES RECEIVABLE, GROSS	60,119
ALLOWANCE FOR CREDIT LOSSES	(5,196)
FAIR VALUE DISCOUNT AND FEES	(3,067)
CARRYING VALUE	51,856
Mortgage loans
Accounts, Notes, Loans and Financing Receivable [Line Items]
MAXIMUM LOAN COMMITMENT	154,850
REAL ESTATE NOTES RECEIVABLE, GROSS	122,782
ALLOWANCE FOR CREDIT LOSSES	0
FAIR VALUE DISCOUNT AND FEES	(191)
CARRYING VALUE	$ 122,591
Poway, CA
Accounts, Notes, Loans and Financing Receivable [Line Items]
INTEREST RATE	5.73%
Financing receivable, carrying value	$ 114,643
Columbus, OH
Accounts, Notes, Loans and Financing Receivable [Line Items]
INTEREST RATE	6.48%
Financing receivable, carrying value	$ 7,358
Texas \| Mezzanine loans
Accounts, Notes, Loans and Financing Receivable [Line Items]
INTEREST RATE	8.00%
MAXIMUM LOAN COMMITMENT	$ 54,119
REAL ESTATE NOTES RECEIVABLE, GROSS	54,119
ALLOWANCE FOR CREDIT LOSSES	(5,196)
FAIR VALUE DISCOUNT AND FEES	(3,067)
CARRYING VALUE	$ 45,856
Texas \| Mortgage loans
Accounts, Notes, Loans and Financing Receivable [Line Items]
INTEREST RATE	7.00%
MAXIMUM LOAN COMMITMENT	$ 31,150
REAL ESTATE NOTES RECEIVABLE, GROSS	31,150
ALLOWANCE FOR CREDIT LOSSES	0
FAIR VALUE DISCOUNT AND FEES	0
CARRYING VALUE	$ 31,150
Arizona \| Mezzanine loans
Accounts, Notes, Loans and Financing Receivable [Line Items]
INTEREST RATE	9.00%
MAXIMUM LOAN COMMITMENT	$ 6,000
REAL ESTATE NOTES RECEIVABLE, GROSS	6,000
ALLOWANCE FOR CREDIT LOSSES	0
FAIR VALUE DISCOUNT AND FEES	0
CARRYING VALUE	$ 6,000
North Carolina \| Mortgage loans
Accounts, Notes, Loans and Financing Receivable [Line Items]
INTEREST RATE	8.00%
MAXIMUM LOAN COMMITMENT	$ 6,000
REAL ESTATE NOTES RECEIVABLE, GROSS	6,000
ALLOWANCE FOR CREDIT LOSSES	0
FAIR VALUE DISCOUNT AND FEES	(152)
CARRYING VALUE	$ 5,848
Florida \| Mortgage loans
Accounts, Notes, Loans and Financing Receivable [Line Items]
INTEREST RATE	6.00%
MAXIMUM LOAN COMMITMENT	$ 65,000
REAL ESTATE NOTES RECEIVABLE, GROSS	33,209
ALLOWANCE FOR CREDIT LOSSES	0
FAIR VALUE DISCOUNT AND FEES	(39)
CARRYING VALUE	$ 33,170
California \| Mortgage loans
Accounts, Notes, Loans and Financing Receivable [Line Items]
INTEREST RATE	6.00%
MAXIMUM LOAN COMMITMENT	$ 45,000
REAL ESTATE NOTES RECEIVABLE, GROSS	45,000
ALLOWANCE FOR CREDIT LOSSES	0
FAIR VALUE DISCOUNT AND FEES	0
CARRYING VALUE	$ 45,000
Florida 1 \| Mortgage loans
Accounts, Notes, Loans and Financing Receivable [Line Items]
INTEREST RATE	9.00%
MAXIMUM LOAN COMMITMENT	$ 7,700
REAL ESTATE NOTES RECEIVABLE, GROSS	7,423
ALLOWANCE FOR CREDIT LOSSES	0
FAIR VALUE DISCOUNT AND FEES	0
CARRYING VALUE	$ 7,423

XML 42 R31.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Schedule of Company's Allowance For Credit Losses (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Financing Receivable, Allowance for Credit Loss [Roll Forward]
Allowance for credit losses, beginning of period	$ 5,196	$ 0	$ 0
Credit loss reserves	0	$ 5,200	5,196
Allowance for credit losses, end of period	$ 5,196		$ 5,196

XML 43 R32.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Revenue Recognition (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Disaggregation of Revenue [Line Items]
Type of Revenue	$ 4,191	$ 4,618
Parking income
Disaggregation of Revenue [Line Items]
Type of Revenue	2,545	2,391
Management fee income/other
Disaggregation of Revenue [Line Items]
Type of Revenue	$ 1,646	$ 2,227

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-4

+ Details

XML 44 R33.htm IDEA: XBRL DOCUMENT

Real Estate Investments - Narrative (Details) ft² in Thousands, $ in Millions	1 Months Ended
	May 07, 2024 USD ($) ft² property	Mar. 31, 2024 property
Asset Acquisition [Line Items]
Number of owned real estate properties		2
Subsequent event
Asset Acquisition [Line Items]
Number of property dispositions	2
Real Estate Dispositions \| Subsequent event
Asset Acquisition [Line Items]
Area covered under real estate investment sold in measurement units \| ft²	39
Proceeds from sale, real estate, held-for-investment \| $	$ 5.8

XML 45 R34.htm IDEA: XBRL DOCUMENT

Real Estate Investments - Unconsolidated Joint Venture Acquisitions (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Equity Method Investments [Roll Forward]
Investments in unconsolidated joint ventures, beginning of period	$ 311,511
Equity loss recognized during the period	(422)	$ (780)
Investments in unconsolidated joint ventures, end of period	309,754
Parking Garages
Equity Method Investments [Roll Forward]
Investments in unconsolidated joint ventures, beginning of period	311,511	327,248
New investments during the period	0	3,824
Equity loss recognized during the period	(422)	(780)
Owner distributions	(1,335)	(2,546)
Investments in unconsolidated joint ventures, end of period	$ 309,754	$ 327,746
Parking Garages \| Los Angeles, California [Member] \| Limited Liability Company One
Equity Method Investments [Roll Forward]
Joint venture, ownership (in percentage)	40.00%

XML 46 R35.htm IDEA: XBRL DOCUMENT

Real Estate Investments - Assets Held for Sale (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Long Lived Assets Held-for-sale [Line Items]
Land	$ 1,342,895	$ 1,343,265
Building and improvements	10,902,835	10,881,373
Total real estate properties	13,409,081	13,399,067
Accumulated depreciation	(2,374,047)	(2,226,853)
Real estate assets held for sale, net	11,035,034	11,172,214
Cash and cash equivalents	26,172	25,699
Operating lease right-of-use assets	273,949	275,975
Assets held for sale, net	30,968	8,834
Operating lease liabilities	229,223	229,714
Liabilities of assets held for sale	700	295
Disposal Group, Held-for-sale, Not Discontinued Operations
Long Lived Assets Held-for-sale [Line Items]
Impairment charges on net real estate assets held for sale	1,500
Land	2,023	1,850
Building and improvements	12,440	6,779
Lease intangibles	2,001	1,017
Total real estate properties	16,464	9,646
Accumulated depreciation	(2,050)	(913)
Real estate assets held for sale, net	14,414	8,733
Cash and cash equivalents	260	0
Operating lease right-of-use assets	193	0
Other assets, net	16,101	101
Assets held for sale, net	30,968	8,834
Accounts payable and accrued liabilities	135	23
Operating lease liabilities	211	0
Other liabilities	354	272
Liabilities of assets held for sale	$ 700	$ 295

XML 47 R36.htm IDEA: XBRL DOCUMENT

Leases - Lease Income (Details) - USD ($) $ in Thousands	3 Months Ended
Leases - Lease Income (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Mar. 31, 2023
Leases [Abstract]
Rental income	$ 318,076	$ 324,093

XML 48 R37.htm IDEA: XBRL DOCUMENT

Leases - Lessor Accounting (Details) $ in Thousands	Mar. 31, 2024 USD ($)
OPERATING
2024	$ 680,129
2025	831,775
2026	734,080
2027	611,277
2028	497,470
2029 and thereafter	1,665,663
Total	$ 5,020,394

XML 49 R38.htm IDEA: XBRL DOCUMENT

Leases - Ground Leases (Details) ft² in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2024 USD ($) ft² lease	Mar. 31, 2023 USD ($)
Lessee, Lease, Description [Line Items]
Square feet subject to ground leases \| ft²	16.9
Number of prepaid ground leases	75
Amortization of prepaid rent \| $	$ 0.3	$ 0.3
Number of non-prepaid ground leases	156
Minimum
Lessee, Lease, Description [Line Items]
Ground lease, initial term	40 years
Maximum
Lessee, Lease, Description [Line Items]
Ground lease, initial term	99 years

XML 50 R39.htm IDEA: XBRL DOCUMENT

Leases - Future Minimum Lease Payments (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
OPERATING
2024	$ 8,760
2025	12,415
2026	12,503
2027	12,689
2028	12,809
2029 and thereafter	698,464
Total undiscounted lease payments	757,640
Discount	(528,417)
Lease liabilities	229,223	$ 229,714
FINANCING
2024	1,523
2025	2,218
2026	2,255
2027	2,294
2028	2,326
2029 and thereafter	394,072
Total undiscounted lease payments	404,688
Discount	(329,919)
Lease liabilities	$ 74,769	$ 74,503

XML 51 R40.htm IDEA: XBRL DOCUMENT

Leases - Lease Cost (Details) - USD ($) $ in Thousands	3 Months Ended
Leases - Lease Cost (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Mar. 31, 2023
Operating lease cost
Operating lease expense	$ 4,465	$ 5,107
Variable lease expense	1,228	2,136
Finance lease cost
Amortization of right-of-use assets	387	388
Interest on lease liabilities	937	918
Total lease expense	7,017	8,549
Other information
Operating cash flows outflows related to operating leases	4,040	5,960
Operating cash flows outflows related to financing leases	563	553
Financing cash flows outflows related to financing leases	$ 110	$ 101
Weighted-average years remaining lease term (excluding renewal options) - operating leases	45 years 9 months 18 days	47 years 4 months 24 days
Weighted-average years remaining lease term (excluding renewal options) - finance leases	57 years 8 months 12 days	58 years 8 months 12 days
Weighted-average discount rate - operating leases	5.70%	5.80%
Weighted-average discount rate - finance leases	5.00%	5.00%

XML 52 R41.htm IDEA: XBRL DOCUMENT

Notes and Bonds Payable (Details) - USD ($)	1 Months Ended
Notes and Bonds Payable (Details) - USD ($)	Apr. 30, 2024	Mar. 31, 2024	Dec. 31, 2023
Debt Instrument [Line Items]
Notes and bonds payable		$ 5,108,279,000	$ 4,994,859,000
Subsequent event
Debt Instrument [Line Items]
Extension period for maturity date	1 year
Debt fees	$ 300,000
Mortgage notes payable \| Minimum
Debt Instrument [Line Items]
Effective interest rate		3.57%
Mortgage notes payable \| Maximum
Debt Instrument [Line Items]
Effective interest rate		6.88%
Line of credit \| $1.5 billion Unsecured Credit Facility
Debt Instrument [Line Items]
Notes and bonds payable		$ 120,000,000	0
Effective interest rate		6.27%
Credit facility		$ 1,500,000,000
Medium-term notes \| $200 million Unsecured Term Loan
Debt Instrument [Line Items]
Notes and bonds payable		$ 199,961,000	199,903,000
Effective interest rate		6.36%
Face amount		$ 200,000,000
Medium-term notes \| $350 million Unsecured Term Loan
Debt Instrument [Line Items]
Notes and bonds payable		$ 349,885,000	349,798,000
Effective interest rate		6.36%
Face amount		$ 350,000,000
Medium-term notes \| $300 million Unsecured Term Loan
Debt Instrument [Line Items]
Notes and bonds payable		$ 299,964,000	299,958,000
Effective interest rate		6.36%
Face amount		$ 300,000,000
Medium-term notes \| $150 million Unsecured Term Loan
Debt Instrument [Line Items]
Notes and bonds payable		$ 149,679,000	149,643,000
Effective interest rate		6.36%
Face amount		$ 150,000,000
Medium-term notes \| $200 million Unsecured Term Loan
Debt Instrument [Line Items]
Notes and bonds payable		$ 199,536,000	199,502,000
Effective interest rate		6.36%
Face amount		$ 200,000,000
Medium-term notes \| $300 million Unsecured Term Loan
Debt Instrument [Line Items]
Notes and bonds payable		$ 298,393,000	298,288,000
Effective interest rate		6.36%
Face amount		$ 300,000,000
Senior notes \| Senior Notes due 2025
Debt Instrument [Line Items]
Notes and bonds payable		$ 249,579,000	249,484,000
Effective interest rate		4.12%
Senior notes \| Senior Notes due 2026
Debt Instrument [Line Items]
Notes and bonds payable		$ 580,933,000	579,017,000
Effective interest rate		4.94%
Senior notes \| Senior Notes due 2027
Debt Instrument [Line Items]
Notes and bonds payable		$ 484,802,000	483,727,000
Effective interest rate		4.76%
Senior notes \| Senior Notes due 2028
Debt Instrument [Line Items]
Notes and bonds payable		$ 297,577,000	297,429,000
Effective interest rate		3.85%
Senior notes \| Senior Notes due 2030
Debt Instrument [Line Items]
Notes and bonds payable		$ 578,038,000	575,443,000
Effective interest rate		5.30%
Senior notes \| Senior Notes due 2030
Debt Instrument [Line Items]
Notes and bonds payable		$ 296,881,000	296,780,000
Effective interest rate		2.72%
Senior notes \| Senior Notes due 2031
Debt Instrument [Line Items]
Notes and bonds payable		$ 295,958,000	295,832,000
Effective interest rate		2.25%
Senior notes \| Senior Notes due 2031
Debt Instrument [Line Items]
Notes and bonds payable		$ 653,864,000	649,521,000
Effective interest rate		5.13%
Mortgages \| Mortgage notes payable
Debt Instrument [Line Items]
Notes and bonds payable		$ 53,229,000	$ 70,534,000

XML 53 R42.htm IDEA: XBRL DOCUMENT

Notes and Bonds Payable - Narrative (Details) - Mortgages $ in Millions	Feb. 01, 2024 USD ($) ft²	Jan. 06, 2024 USD ($) ft²
Debt Instrument [Line Items]
Effective interest rate	4.12%	4.77%
Outstanding principal repaid \| $	$ 5.6	$ 11.3
California
Debt Instrument [Line Items]
Encumbered square footage		63,012
Georgia
Debt Instrument [Line Items]
Encumbered square footage	40,324

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482900/835-30-50-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(f))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69B
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69C
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69E
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69F
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

+ Details

XML 54 R43.htm IDEA: XBRL DOCUMENT

Derivative Financial Instruments - Cash Flow Hedges of Interest Rate Risk (Details) $ in Thousands	Mar. 31, 2024 USD ($) derivative
Derivative [Line Items]
Number of instruments \| derivative	15
Interest Rate Swaps \| Cash flow hedging \| Designated as hedging instrument
Derivative [Line Items]
AMOUNT	$ 1,075,000
Weighted average interest rate (percent)	3.92%
Interest Rate Swap, Expiring May 1, 2026 \| Cash flow hedging \| Designated as hedging instrument
Derivative [Line Items]
AMOUNT	$ 275,000
Weighted average interest rate (percent)	3.74%
Interest Rate Swap, Expiring June 1, 2026 \| Cash flow hedging \| Designated as hedging instrument
Derivative [Line Items]
AMOUNT	$ 150,000
Weighted average interest rate (percent)	3.83%
Interest Rate Swap, Expiring December 1, 2026 \| Cash flow hedging \| Designated as hedging instrument
Derivative [Line Items]
AMOUNT	$ 150,000
Weighted average interest rate (percent)	3.84%
Interest Rate Swap, Expiring June 1, 2027 \| Cash flow hedging \| Designated as hedging instrument
Derivative [Line Items]
AMOUNT	$ 200,000
Weighted average interest rate (percent)	4.27%
Interest Rate Swap, Expiring December 1, 2027 \| Cash flow hedging \| Designated as hedging instrument
Derivative [Line Items]
AMOUNT	$ 300,000
Weighted average interest rate (percent)	3.93%

XML 55 R44.htm IDEA: XBRL DOCUMENT

Derivative Financial Instruments - Fair Value of Derivative Instruments on the Balance Sheet (Details) - Designated as hedging instrument - Interest Rate Swaps $ in Thousands	Mar. 31, 2024 USD ($)
Derivative [Line Items]
Liability derivatives	$ 7,630
Other liabilities
Derivative [Line Items]
Liability derivatives	(2,973)
Other assets
Derivative [Line Items]
Liability derivatives	$ 10,603

XML 56 R45.htm IDEA: XBRL DOCUMENT

Derivative Financial Instruments - Effect of Cash Flow Hedging on AOCI (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Derivative [Line Items]
(Gain)/loss recognized in AOCI on derivative	$ (19,611)	$ 8,541
(Gain) Loss, Reclassified from AOCI into income	(3,865)	(2,284)
Interest expense
Derivative [Line Items]
(Gain) Loss, Reclassified from AOCI into income	(3,865)	(2,284)
Interest rate swaps
Derivative [Line Items]
(Gain)/loss recognized in AOCI on derivative	(19,611)	8,541
Interest rate swaps \| Interest expense
Derivative [Line Items]
(Gain) Loss, Reclassified from AOCI into income	(4,014)	(2,433)
Settled treasury hedges
Derivative [Line Items]
(Gain)/loss recognized in AOCI on derivative	0	0
Settled treasury hedges \| Interest expense
Derivative [Line Items]
(Gain) Loss, Reclassified from AOCI into income	107	107
Settled interest rate swaps
Derivative [Line Items]
(Gain)/loss recognized in AOCI on derivative	0	0
Settled interest rate swaps \| Interest expense
Derivative [Line Items]
(Gain) Loss, Reclassified from AOCI into income	$ 42	$ 42

XML 57 R46.htm IDEA: XBRL DOCUMENT

Derivative Financial Instruments - Derivative Instruments Designated as Cash Flow Hedges (Details) $ in Millions	Mar. 31, 2024 USD ($)
Derivative [Line Items]
Derivatives in net asset position	$ 7.6
Active Interest Rate Swap
Derivative [Line Items]
Interest rate cash flow hedge gain (loss) to be reclassified to interest expense during the next 12 months	10.5
Settled Interest Rate Swaps
Derivative [Line Items]
Interest rate cash flow hedge gain (loss) to be reclassified to interest expense during the next 12 months	$ (0.6)

XML 58 R47.htm IDEA: XBRL DOCUMENT

Commitment and Contingencies - Narrative (Details) $ in Millions	3 Months Ended
	Mar. 31, 2024 USD ($)
Active Development Properties
Other Commitments [Line Items]
Construction activity and development properties	$ 7.7
Redevelopment Properties
Other Commitments [Line Items]
Construction activity and development properties	2.8
Completed Develpoment and Redevelopment Properties
Other Commitments [Line Items]
Construction activity and development properties	$ 11.1

XML 59 R48.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Reconciliation of Beginning and Ending Common Stock Outstanding (Details) - shares	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Reconciliation of the beginning and ending common stock outstanding
Balance, beginning of period (in shares)	380,964,000
Balance, end of period (in shares)	381,502,000	380,964,000
Common Stock
Reconciliation of the beginning and ending common stock outstanding
Balance, beginning of period (in shares)	380,964,433	380,589,894
Issuance of common stock (in shares)	8,623	8,627
Stock issued during period, shares, conversion of units	194,767	190,544
Non-vested share-based awards, net of withheld shares and forfeitures (in shares)	333,679	175,368
Balance, end of period (in shares)	381,501,502	380,964,433

XML 60 R49.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Stock Transactions - Narrative (Details) - USD ($)			1 Months Ended			3 Months Ended
	Apr. 30, 2024	Feb. 13, 2024	Apr. 30, 2024	Feb. 29, 2024	Jan. 31, 2023	Mar. 31, 2024	Mar. 31, 2023	May 31, 2023
Class of Stock [Line Items]
Dividends paid per common share, during the period (in dollars per share)						$ 0.31	$ 0.31
Stock repurchase program, authorized amount								$ 500,000,000
Subsequent event
Class of Stock [Line Items]
Dividends declared per common share, during the period (in dollars per share)	$ 0.31
Stock repurchase program, authorized amount	$ 500,000,000		$ 500,000,000
Treasury stock, shares, acquired (in shares)			2,966,764
Shares acquired, average cost per share (in dollars per shares)			$ 14.07
Treasury stock, value, acquired, cost method			$ 41,700,000
Stock incentive plan
Class of Stock [Line Items]
Granted (in shares)						1,475,811	1,075,261
LTIP Series C Units \| Directors \| Share-Based Payment Arrangement, Nonemployee
Class of Stock [Line Items]
Granted (in shares)		906,044
Grant date fair value				$ 7,500,000
Operating Partnership Performance Units
Class of Stock [Line Items]
Award performance period				3 years
Operating Partnership Performance Units \| Performance conditions
Class of Stock [Line Items]
Percentage of restricted stock units					64.00%
Weighted average grant date fair value (in dollars per share)					$ 15.22
Operating Partnership Performance Units \| Relative TSR Component
Class of Stock [Line Items]
Weighted average grant date fair value (in dollars per share)				$ 9.62
Operating Partnership Performance Units \| LTIP Series C Units
Class of Stock [Line Items]
Percentage of restricted stock units				36.00%
Non-vested Stock Award \| Executive Incentive Program
Class of Stock [Line Items]
Grant date fair value						$ 5,600,000
Granted (in shares)						361,712
Non-vested Stock Award \| Executive Incentive Program \| Minimum
Class of Stock [Line Items]
Award vesting period						3 years
Non-vested Stock Award \| Executive Incentive Program \| Maximum
Class of Stock [Line Items]
Award vesting period						8 years
Restricted stock \| Stock incentive plan
Class of Stock [Line Items]
Shares withheld to pay estimated withholding taxes (in shares)						8,228	38,632
Restricted Stock Units (RSUs)
Class of Stock [Line Items]
Award vesting period		5 years
Percentage of restricted stock units		36.00%
Restricted Stock Units (RSUs) \| Performance conditions
Class of Stock [Line Items]
Percentage of restricted stock units		64.00%
Weighted average grant date fair value (in dollars per share)		$ 15.22
Restricted Stock Units (RSUs) \| Relative TSR Component
Class of Stock [Line Items]
Weighted average grant date fair value (in dollars per share)		$ 19.10
Restricted Stock Units (RSUs) \| Executive Incentive Program
Class of Stock [Line Items]
Grant date fair value		$ 3,500,000
Granted (in shares)		208,055
Options under the Employee Stock Option Plan
Class of Stock [Line Items]
Weighted-average incremental shares of common stock excluded from the computation (in shares)						23,140
Options under the Employee Stock Option Plan \| Operating Partnership Performance Units
Class of Stock [Line Items]
Nonvested shares (in shares)						3,681,225

XML 61 R50.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Computation of Basic and Diluted Earnings (Loss) Per Common Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Weighted average common shares outstanding
Weighted average common shares outstanding (in shares)	381,335,208	380,796,773
Non-vested shares (in shares)	(1,880,401)	(1,956,353)
Weighted average common shares outstanding - basic (in shares)	379,454,807	378,840,420
Dilutive effect of forward equity shares (in shares)	0	0
Dilutive effect of OP Units (in shares)	0	0
Dilutive effect of employee stock purchase plan (in shares)	0
Weighted average common shares outstanding - diluted (in shares)	379,454,807	378,840,420
Net loss	$ (315,220)	$ (88,078)
Income allocated to participating securities	(693)	(625)
Loss attributable to non-controlling interest	4,384	953
Adjustment to loss attributable to non-controlling interest for legally outstanding restricted units	(1,341)	(16)
Net loss applicable to common stockholders - basic	$ (312,870)	$ (87,766)
Basic earnings per common share - net loss (in dollars per share)	$ (0.82)	$ (0.23)
Diluted earnings per common share- net loss (in dollars per share)	$ (0.82)	$ (0.23)

XML 62 R51.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Schedule of Stock Options, Valuation Assumptions (Details) - $ / shares		1 Months Ended
	Jan. 04, 2023	Jan. 31, 2023
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Volatility	28.00%
Expected term	3 years
Risk-free rate	4.44%
Stock price (in dollar per share)	$ 15.22
Operating Partnership Performance Units
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Volatility		28.00%
Expected term		3 years
Risk-free rate		4.44%
Stock price (in dollar per share)		$ 15.22

XML 63 R52.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Summary of the Activity Under the Incentive Plan and RSU Activity (Details) - Stock incentive plan - shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Summary of the activity under the incentive plans
Share-based awards, beginning of period (in shares)	2,615,562	2,090,060
Granted (in shares)	1,475,811	1,075,261
Vested/Forfeited (in shares)	(28,414)	(113,766)
Forfeited (in shares)	(19,805)	(26,063)
Share-based awards, ending of period (in shares)	4,043,154	3,025,492

XML 64 R53.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Amortization of Compensation for Nonvested Shares (Details) $ in Millions	Mar. 31, 2024 USD ($)
Equity [Abstract]
2024	$ 11.5
2025	13.3
2026	10.6
2027	5.7
2028 and thereafter	2.8
Total	$ 43.9

XML 65 R54.htm IDEA: XBRL DOCUMENT

Fair Value of Financial Instruments (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
CARRYING VALUE
Derivative [Line Items]
Notes and bonds payable	$ 5,108.3	$ 4,994.9
Real estate notes receivable	174.4	173.6
FAIR VALUE
Derivative [Line Items]
Notes and bonds payable	4,931.9	4,872.7
Real estate notes receivable	$ 172.8	$ 172.5

EXCEL 66 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 67 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 68 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 70 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 199 343 1 false 96 0 false 13 false false R1.htm 0000001 - Document - Cover Page Sheet http://healthcarerealty.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - Condensed Consolidated Statements of Operations Sheet http://healthcarerealty.com/role/CondensedConsolidatedStatementsofOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss Sheet http://healthcarerealty.com/role/CondensedConsolidatedStatementsofComprehensiveLoss Condensed Consolidated Statements of Comprehensive Loss Statements 5 false false R6.htm 0000006 - Statement - Condensed Consolidated Statements of Equity and Redeemable Non-Controlling Interests Sheet http://healthcarerealty.com/role/CondensedConsolidatedStatementsofEquityandRedeemableNonControllingInterests Condensed Consolidated Statements of Equity and Redeemable Non-Controlling Interests Statements 6 false false R7.htm 0000007 - Statement - Condensed Consolidated Statements of Equity and Redeemable Non-Controlling Interests (Parenthetical) Sheet http://healthcarerealty.com/role/CondensedConsolidatedStatementsofEquityandRedeemableNonControllingInterestsParenthetical Condensed Consolidated Statements of Equity and Redeemable Non-Controlling Interests (Parenthetical) Statements 7 false false R8.htm 0000008 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 8 false false R9.htm 0000009 - Disclosure - Summary of Significant Accounting Policies Sheet http://healthcarerealty.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 0000010 - Disclosure - Real Estate Investments Sheet http://healthcarerealty.com/role/RealEstateInvestments Real Estate Investments Notes 10 false false R11.htm 0000011 - Disclosure - Leases Sheet http://healthcarerealty.com/role/Leases Leases Notes 11 false false R12.htm 0000012 - Disclosure - Notes and Bonds Payable Notes http://healthcarerealty.com/role/NotesandBondsPayable Notes and Bonds Payable Notes 12 false false R13.htm 0000013 - Disclosure - Derivative Financial Instruments Sheet http://healthcarerealty.com/role/DerivativeFinancialInstruments Derivative Financial Instruments Notes 13 false false R14.htm 0000014 - Disclosure - Commitments and Contingencies Sheet http://healthcarerealty.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 14 false false R15.htm 0000015 - Disclosure - Stockholders' Equity Sheet http://healthcarerealty.com/role/StockholdersEquity Stockholders' Equity Notes 15 false false R16.htm 0000016 - Disclosure - Fair Value of Financial Instruments Sheet http://healthcarerealty.com/role/FairValueofFinancialInstruments Fair Value of Financial Instruments Notes 16 false false R17.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 17 false false R18.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 18 false false R19.htm 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://healthcarerealty.com/role/SummaryofSignificantAccountingPolicies 19 false false R20.htm 9954472 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://healthcarerealty.com/role/SummaryofSignificantAccountingPolicies 20 false false R21.htm 9954473 - Disclosure - Real Estate Investments (Tables) Sheet http://healthcarerealty.com/role/RealEstateInvestmentsTables Real Estate Investments (Tables) Tables http://healthcarerealty.com/role/RealEstateInvestments 21 false false R22.htm 9954474 - Disclosure - Leases (Tables) Sheet http://healthcarerealty.com/role/LeasesTables Leases (Tables) Tables http://healthcarerealty.com/role/Leases 22 false false R23.htm 9954475 - Disclosure - Notes and Bonds Payable (Tables) Notes http://healthcarerealty.com/role/NotesandBondsPayableTables Notes and Bonds Payable (Tables) Tables http://healthcarerealty.com/role/NotesandBondsPayable 23 false false R24.htm 9954476 - Disclosure - Derivative Financial Instruments (Tables) Sheet http://healthcarerealty.com/role/DerivativeFinancialInstrumentsTables Derivative Financial Instruments (Tables) Tables http://healthcarerealty.com/role/DerivativeFinancialInstruments 24 false false R25.htm 9954477 - Disclosure - Stockholders' Equity (Tables) Sheet http://healthcarerealty.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://healthcarerealty.com/role/StockholdersEquity 25 false false R26.htm 9954478 - Disclosure - Fair Value of Financial Instruments (Tables) Sheet http://healthcarerealty.com/role/FairValueofFinancialInstrumentsTables Fair Value of Financial Instruments (Tables) Tables http://healthcarerealty.com/role/FairValueofFinancialInstruments 26 false false R27.htm 9954479 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesTables 27 false false R28.htm 9954480 - Disclosure - Summary of Significant Accounting Policies - Consolidated balance sheets (Details) Sheet http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesConsolidatedbalancesheetsDetails Summary of Significant Accounting Policies - Consolidated balance sheets (Details) Details 28 false false R29.htm 9954481 - Disclosure - Summary of Significant Accounting Policies - Variable interest entity (Details) Sheet http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesVariableinterestentityDetails Summary of Significant Accounting Policies - Variable interest entity (Details) Details 29 false false R30.htm 9954482 - Disclosure - Summary of Significant Accounting Policies - Schedule of Notes Receivable (Details) Notes http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesScheduleofNotesReceivableDetails Summary of Significant Accounting Policies - Schedule of Notes Receivable (Details) Details 30 false false R31.htm 9954483 - Disclosure - Summary of Significant Accounting Policies - Schedule of Company's Allowance For Credit Losses (Details) Sheet http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesScheduleofCompanysAllowanceForCreditLossesDetails Summary of Significant Accounting Policies - Schedule of Company's Allowance For Credit Losses (Details) Details 31 false false R32.htm 9954484 - Disclosure - Summary of Significant Accounting Policies - Revenue Recognition (Details) Sheet http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails Summary of Significant Accounting Policies - Revenue Recognition (Details) Details 32 false false R33.htm 9954485 - Disclosure - Real Estate Investments - Narrative (Details) Sheet http://healthcarerealty.com/role/RealEstateInvestmentsNarrativeDetails Real Estate Investments - Narrative (Details) Details 33 false false R34.htm 9954486 - Disclosure - Real Estate Investments - Unconsolidated Joint Venture Acquisitions (Details) Sheet http://healthcarerealty.com/role/RealEstateInvestmentsUnconsolidatedJointVentureAcquisitionsDetails Real Estate Investments - Unconsolidated Joint Venture Acquisitions (Details) Details 34 false false R35.htm 9954487 - Disclosure - Real Estate Investments - Assets Held for Sale (Details) Sheet http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails Real Estate Investments - Assets Held for Sale (Details) Details 35 false false R36.htm 9954488 - Disclosure - Leases - Lease Income (Details) Sheet http://healthcarerealty.com/role/LeasesLeaseIncomeDetails Leases - Lease Income (Details) Details 36 false false R37.htm 9954489 - Disclosure - Leases - Lessor Accounting (Details) Sheet http://healthcarerealty.com/role/LeasesLessorAccountingDetails Leases - Lessor Accounting (Details) Details 37 false false R38.htm 9954490 - Disclosure - Leases - Ground Leases (Details) Sheet http://healthcarerealty.com/role/LeasesGroundLeasesDetails Leases - Ground Leases (Details) Details 38 false false R39.htm 9954491 - Disclosure - Leases - Future Minimum Lease Payments (Details) Sheet http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails Leases - Future Minimum Lease Payments (Details) Details 39 false false R40.htm 9954492 - Disclosure - Leases - Lease Cost (Details) Sheet http://healthcarerealty.com/role/LeasesLeaseCostDetails Leases - Lease Cost (Details) Details 40 false false R41.htm 9954493 - Disclosure - Notes and Bonds Payable (Details) Notes http://healthcarerealty.com/role/NotesandBondsPayableDetails Notes and Bonds Payable (Details) Details http://healthcarerealty.com/role/NotesandBondsPayableTables 41 false false R42.htm 9954494 - Disclosure - Notes and Bonds Payable - Narrative (Details) Notes http://healthcarerealty.com/role/NotesandBondsPayableNarrativeDetails Notes and Bonds Payable - Narrative (Details) Details 42 false false R43.htm 9954495 - Disclosure - Derivative Financial Instruments - Cash Flow Hedges of Interest Rate Risk (Details) Sheet http://healthcarerealty.com/role/DerivativeFinancialInstrumentsCashFlowHedgesofInterestRateRiskDetails Derivative Financial Instruments - Cash Flow Hedges of Interest Rate Risk (Details) Details 43 false false R44.htm 9954496 - Disclosure - Derivative Financial Instruments - Fair Value of Derivative Instruments on the Balance Sheet (Details) Sheet http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueofDerivativeInstrumentsontheBalanceSheetDetails Derivative Financial Instruments - Fair Value of Derivative Instruments on the Balance Sheet (Details) Details 44 false false R45.htm 9954497 - Disclosure - Derivative Financial Instruments - Effect of Cash Flow Hedging on AOCI (Details) Sheet http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectofCashFlowHedgingonAOCIDetails Derivative Financial Instruments - Effect of Cash Flow Hedging on AOCI (Details) Details 45 false false R46.htm 9954498 - Disclosure - Derivative Financial Instruments - Derivative Instruments Designated as Cash Flow Hedges (Details) Sheet http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedasCashFlowHedgesDetails Derivative Financial Instruments - Derivative Instruments Designated as Cash Flow Hedges (Details) Details 46 false false R47.htm 9954499 - Disclosure - Commitment and Contingencies - Narrative (Details) Sheet http://healthcarerealty.com/role/CommitmentandContingenciesNarrativeDetails Commitment and Contingencies - Narrative (Details) Details 47 false false R48.htm 9954500 - Disclosure - Stockholders' Equity - Reconciliation of Beginning and Ending Common Stock Outstanding (Details) Sheet http://healthcarerealty.com/role/StockholdersEquityReconciliationofBeginningandEndingCommonStockOutstandingDetails Stockholders' Equity - Reconciliation of Beginning and Ending Common Stock Outstanding (Details) Details 48 false false R49.htm 9954501 - Disclosure - Stockholders' Equity - Stock Transactions - Narrative (Details) Sheet http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails Stockholders' Equity - Stock Transactions - Narrative (Details) Details 49 false false R50.htm 9954502 - Disclosure - Stockholders' Equity - Computation of Basic and Diluted Earnings (Loss) Per Common Share (Details) Sheet http://healthcarerealty.com/role/StockholdersEquityComputationofBasicandDilutedEarningsLossPerCommonShareDetails Stockholders' Equity - Computation of Basic and Diluted Earnings (Loss) Per Common Share (Details) Details 50 false false R51.htm 9954503 - Disclosure - Stockholders' Equity - Schedule of Stock Options, Valuation Assumptions (Details) Sheet http://healthcarerealty.com/role/StockholdersEquityScheduleofStockOptionsValuationAssumptionsDetails Stockholders' Equity - Schedule of Stock Options, Valuation Assumptions (Details) Details 51 false false R52.htm 9954504 - Disclosure - Stockholders' Equity - Summary of the Activity Under the Incentive Plan and RSU Activity (Details) Sheet http://healthcarerealty.com/role/StockholdersEquitySummaryoftheActivityUndertheIncentivePlanandRSUActivityDetails Stockholders' Equity - Summary of the Activity Under the Incentive Plan and RSU Activity (Details) Details 52 false false R53.htm 9954505 - Disclosure - Stockholders' Equity - Amortization of Compensation for Nonvested Shares (Details) Sheet http://healthcarerealty.com/role/StockholdersEquityAmortizationofCompensationforNonvestedSharesDetails Stockholders' Equity - Amortization of Compensation for Nonvested Shares (Details) Details 53 false false R54.htm 9954506 - Disclosure - Fair Value of Financial Instruments (Details) Sheet http://healthcarerealty.com/role/FairValueofFinancialInstrumentsDetails Fair Value of Financial Instruments (Details) Details http://healthcarerealty.com/role/FairValueofFinancialInstrumentsTables 54 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 - hr-20240331.htm 4 hr-20240331.htm hr-20240331.xsd hr-20240331_cal.xml hr-20240331_def.xml hr-20240331_lab.xml hr-20240331_pre.xml http://fasb.org/srt/2023 http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 73 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "hr-20240331.htm": { "nsprefix": "hr", "nsuri": "http://healthcarerealty.com/20240331", "dts": { "inline": { "local": [ "hr-20240331.htm" ] }, "schema": { "local": [ "hr-20240331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "calculationLink": { "local": [ "hr-20240331_cal.xml" ] }, "definitionLink": { "local": [ "hr-20240331_def.xml" ] }, "labelLink": { "local": [ "hr-20240331_lab.xml" ] }, "presentationLink": { "local": [ "hr-20240331_pre.xml" ] } }, "keyStandard": 276, "keyCustom": 67, "axisStandard": 30, "axisCustom": 2, "memberStandard": 38, "memberCustom": 55, "hidden": { "total": 10, "http://xbrl.sec.gov/dei/2023": 5, "http://fasb.org/us-gaap/2023": 5 }, "contextCount": 199, "entityCount": 1, "segmentCount": 96, "elementCount": 664, "unitCount": 13, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 686, "http://xbrl.sec.gov/dei/2023": 31, "http://xbrl.sec.gov/ecd/2023": 4, "http://fasb.org/srt/2023": 1 }, "report": { "R1": { "role": "http://healthcarerealty.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true } }, "R2": { "role": "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets", "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:Land", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:OtherFiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "unique": true } }, "R3": { "role": "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true } }, "R4": { "role": "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofOperations", "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations", "shortName": "Condensed Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseLeaseIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InterestIncomeFinancingReceivableBeforeAllowanceForCreditLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "unique": true } }, "R5": { "role": "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "longName": "0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss", "shortName": "Condensed Consolidated Statements of Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "unique": true } }, "R6": { "role": "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofEquityandRedeemableNonControllingInterests", "longName": "0000006 - Statement - Condensed Consolidated Statements of Equity and Redeemable Non-Controlling Interests", "shortName": "Condensed Consolidated Statements of Equity and Redeemable Non-Controlling Interests", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-36", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-36", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true } }, "R7": { "role": "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofEquityandRedeemableNonControllingInterestsParenthetical", "longName": "0000007 - Statement - Condensed Consolidated Statements of Equity and Redeemable Non-Controlling Interests (Parenthetical)", "shortName": "Condensed Consolidated Statements of Equity and Redeemable Non-Controlling Interests (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommonStockDividendsPerShareCashPaid", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true }, "uniqueAnchor": null }, "R8": { "role": "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows", "longName": "0000008 - Statement - Condensed Consolidated Statements of Cash Flows", "shortName": "Condensed Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "unique": true } }, "R9": { "role": "http://healthcarerealty.com/role/SummaryofSignificantAccountingPolicies", "longName": "0000009 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true } }, "R10": { "role": "http://healthcarerealty.com/role/RealEstateInvestments", "longName": "0000010 - Disclosure - Real Estate Investments", "shortName": "Real Estate Investments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "hr:AcquisitionsAndDispositionsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "hr:AcquisitionsAndDispositionsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true } }, "R11": { "role": "http://healthcarerealty.com/role/Leases", "longName": "0000011 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeFinanceLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeFinanceLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true } }, "R12": { "role": "http://healthcarerealty.com/role/NotesandBondsPayable", "longName": "0000012 - Disclosure - Notes and Bonds Payable", "shortName": "Notes and Bonds Payable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true } }, "R13": { "role": "http://healthcarerealty.com/role/DerivativeFinancialInstruments", "longName": "0000013 - Disclosure - Derivative Financial Instruments", "shortName": "Derivative Financial Instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true } }, "R14": { "role": "http://healthcarerealty.com/role/CommitmentsandContingencies", "longName": "0000014 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true } }, "R15": { "role": "http://healthcarerealty.com/role/StockholdersEquity", "longName": "0000015 - Disclosure - Stockholders' Equity", "shortName": "Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true } }, "R16": { "role": "http://healthcarerealty.com/role/FairValueofFinancialInstruments", "longName": "0000016 - Disclosure - Fair Value of Financial Instruments", "shortName": "Fair Value of Financial Instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true } }, "R17": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true }, "uniqueAnchor": null }, "R18": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true } }, "R19": { "role": "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "hr:NatureOfOperationsPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "hr:NatureOfOperationsPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true } }, "R20": { "role": "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesTables", "longName": "9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "srt:ScheduleOfCondensedBalanceSheetTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "srt:ScheduleOfCondensedBalanceSheetTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true } }, "R21": { "role": "http://healthcarerealty.com/role/RealEstateInvestmentsTables", "longName": "9954473 - Disclosure - Real Estate Investments (Tables)", "shortName": "Real Estate Investments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EquityMethodInvestmentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EquityMethodInvestmentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true } }, "R22": { "role": "http://healthcarerealty.com/role/LeasesTables", "longName": "9954474 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true } }, "R23": { "role": "http://healthcarerealty.com/role/NotesandBondsPayableTables", "longName": "9954475 - Disclosure - Notes and Bonds Payable (Tables)", "shortName": "Notes and Bonds Payable (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true } }, "R24": { "role": "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsTables", "longName": "9954476 - Disclosure - Derivative Financial Instruments (Tables)", "shortName": "Derivative Financial Instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true } }, "R25": { "role": "http://healthcarerealty.com/role/StockholdersEquityTables", "longName": "9954477 - Disclosure - Stockholders' Equity (Tables)", "shortName": "Stockholders' Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true } }, "R26": { "role": "http://healthcarerealty.com/role/FairValueofFinancialInstrumentsTables", "longName": "9954478 - Disclosure - Fair Value of Financial Instruments (Tables)", "shortName": "Fair Value of Financial Instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true } }, "R27": { "role": "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails", "longName": "9954479 - Disclosure - Summary of Significant Accounting Policies (Details)", "shortName": "Summary of Significant Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "c-3", "name": "hr:InvestmentInRealEstatePropertiesAndMortgageNotes", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "hr:NatureOfOperationsPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "hr:InvestmentInRealEstatePropertiesAndMortgageNotes", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "hr:NatureOfOperationsPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true } }, "R28": { "role": "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesConsolidatedbalancesheetsDetails", "longName": "9954480 - Disclosure - Summary of Significant Accounting Policies - Consolidated balance sheets (Details)", "shortName": "Summary of Significant Accounting Policies - Consolidated balance sheets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:RealEstateInvestmentPropertyNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-59", "name": "us-gaap:RealEstateInvestmentPropertyNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "unique": true } }, "R29": { "role": "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesVariableinterestentityDetails", "longName": "9954481 - Disclosure - Summary of Significant Accounting Policies - Variable interest entity (Details)", "shortName": "Summary of Significant Accounting Policies - Variable interest entity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "c-60", "name": "hr:NumberOfNotesReceivable", "unitRef": "note_receivable", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-62", "name": "hr:NotesReceivableCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "unique": true } }, "R30": { "role": "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesScheduleofNotesReceivableDetails", "longName": "9954482 - Disclosure - Summary of Significant Accounting Policies - Schedule of Notes Receivable (Details)", "shortName": "Summary of Significant Accounting Policies - Schedule of Notes Receivable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:SaleLeasebackTransactionNetBookValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:SaleLeasebackTransactionNetBookValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true } }, "R31": { "role": "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesScheduleofCompanysAllowanceForCreditLossesDetails", "longName": "9954483 - Disclosure - Summary of Significant Accounting Policies - Schedule of Company's Allowance For Credit Losses (Details)", "shortName": "Summary of Significant Accounting Policies - Schedule of Company's Allowance For Credit Losses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true }, "uniqueAnchor": null }, "R32": { "role": "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails", "longName": "9954484 - Disclosure - Summary of Significant Accounting Policies - Revenue Recognition (Details)", "shortName": "Summary of Significant Accounting Policies - Revenue Recognition (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-81", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "unique": true } }, "R33": { "role": "http://healthcarerealty.com/role/RealEstateInvestmentsNarrativeDetails", "longName": "9954485 - Disclosure - Real Estate Investments - Narrative (Details)", "shortName": "Real Estate Investments - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "c-3", "name": "hr:NumberOfPropertiesClassifiedAsHeldForSale", "unitRef": "property", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "hr:NumberOfPropertiesClassifiedAsHeldForSale", "unitRef": "property", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true } }, "R34": { "role": "http://healthcarerealty.com/role/RealEstateInvestmentsUnconsolidatedJointVentureAcquisitionsDetails", "longName": "9954486 - Disclosure - Real Estate Investments - Unconsolidated Joint Venture Acquisitions (Details)", "shortName": "Real Estate Investments - Unconsolidated Joint Venture Acquisitions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-85", "name": "us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:EquityMethodInvestmentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "unique": true } }, "R35": { "role": "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails", "longName": "9954487 - Disclosure - Real Estate Investments - Assets Held for Sale (Details)", "shortName": "Real Estate Investments - Assets Held for Sale (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:Land", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-97", "name": "hr:ImpairmentChargeOnRealEstateAssetsHeldForSale", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "hr:ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "unique": true } }, "R36": { "role": "http://healthcarerealty.com/role/LeasesLeaseIncomeDetails", "longName": "9954488 - Disclosure - Leases - Lease Income (Details)", "shortName": "Leases - Lease Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseLeaseIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true }, "uniqueAnchor": null }, "R37": { "role": "http://healthcarerealty.com/role/LeasesLessorAccountingDetails", "longName": "9954489 - Disclosure - Leases - Lessor Accounting (Details)", "shortName": "Leases - Lessor Accounting (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true } }, "R38": { "role": "http://healthcarerealty.com/role/LeasesGroundLeasesDetails", "longName": "9954490 - Disclosure - Leases - Ground Leases (Details)", "shortName": "Leases - Ground Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "hr:SquareFeetSubjecttoGroundLeases", "unitRef": "sqft", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "hr:SquareFeetSubjecttoGroundLeases", "unitRef": "sqft", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true } }, "R39": { "role": "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails", "longName": "9954491 - Disclosure - Leases - Future Minimum Lease Payments (Details)", "shortName": "Leases - Future Minimum Lease Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true } }, "R40": { "role": "http://healthcarerealty.com/role/LeasesLeaseCostDetails", "longName": "9954492 - Disclosure - Leases - Lease Cost (Details)", "shortName": "Leases - Lease Cost (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true } }, "R41": { "role": "http://healthcarerealty.com/role/NotesandBondsPayableDetails", "longName": "9954493 - Disclosure - Notes and Bonds Payable (Details)", "shortName": "Notes and Bonds Payable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LongTermDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-134", "name": "hr:DebtInstrumentExtensionPeriodForMaturityDate", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "unique": true } }, "R42": { "role": "http://healthcarerealty.com/role/NotesandBondsPayableNarrativeDetails", "longName": "9954494 - Disclosure - Notes and Bonds Payable - Narrative (Details)", "shortName": "Notes and Bonds Payable - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-139", "name": "us-gaap:DebtInstrumentInterestRateEffectivePercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-139", "name": "us-gaap:DebtInstrumentInterestRateEffectivePercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true } }, "R43": { "role": "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsCashFlowHedgesofInterestRateRiskDetails", "longName": "9954495 - Disclosure - Derivative Financial Instruments - Cash Flow Hedges of Interest Rate Risk (Details)", "shortName": "Derivative Financial Instruments - Cash Flow Hedges of Interest Rate Risk (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:NumberOfInterestRateDerivativesHeld", "unitRef": "derivative", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:NumberOfInterestRateDerivativesHeld", "unitRef": "derivative", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true } }, "R44": { "role": "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueofDerivativeInstrumentsontheBalanceSheetDetails", "longName": "9954496 - Disclosure - Derivative Financial Instruments - Fair Value of Derivative Instruments on the Balance Sheet (Details)", "shortName": "Derivative Financial Instruments - Fair Value of Derivative Instruments on the Balance Sheet (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-150", "name": "us-gaap:DerivativeFairValueOfDerivativeLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-150", "name": "us-gaap:DerivativeFairValueOfDerivativeLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true } }, "R45": { "role": "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectofCashFlowHedgingonAOCIDetails", "longName": "9954497 - Disclosure - Derivative Financial Instruments - Effect of Cash Flow Hedging on AOCI (Details)", "shortName": "Derivative Financial Instruments - Effect of Cash Flow Hedging on AOCI (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true } }, "R46": { "role": "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedasCashFlowHedgesDetails", "longName": "9954498 - Disclosure - Derivative Financial Instruments - Derivative Instruments Designated as Cash Flow Hedges (Details)", "shortName": "Derivative Financial Instruments - Derivative Instruments Designated as Cash Flow Hedges (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-3", "name": "hr:DerivativeNetAssetPositionAggregateFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "hr:DerivativeNetAssetPositionAggregateFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true } }, "R47": { "role": "http://healthcarerealty.com/role/CommitmentandContingenciesNarrativeDetails", "longName": "9954499 - Disclosure - Commitment and Contingencies - Narrative (Details)", "shortName": "Commitment and Contingencies - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-165", "name": "hr:ConstructionActivityTotalFundingDuringthePeriod", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-165", "name": "hr:ConstructionActivityTotalFundingDuringthePeriod", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true } }, "R48": { "role": "http://healthcarerealty.com/role/StockholdersEquityReconciliationofBeginningandEndingCommonStockOutstandingDetails", "longName": "9954500 - Disclosure - Stockholders' Equity - Reconciliation of Beginning and Ending Common Stock Outstanding (Details)", "shortName": "Stockholders' Equity - Reconciliation of Beginning and Ending Common Stock Outstanding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "us-gaap:CommonStockSharesIssued", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-29", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "unique": true } }, "R49": { "role": "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails", "longName": "9954501 - Disclosure - Stockholders' Equity - Stock Transactions - Narrative (Details)", "shortName": "Stockholders' Equity - Stock Transactions - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommonStockDividendsPerShareCashPaid", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-170", "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "unique": true } }, "R50": { "role": "http://healthcarerealty.com/role/StockholdersEquityComputationofBasicandDilutedEarningsLossPerCommonShareDetails", "longName": "9954502 - Disclosure - Stockholders' Equity - Computation of Basic and Diluted Earnings (Loss) Per Common Share (Details)", "shortName": "Stockholders' Equity - Computation of Basic and Diluted Earnings (Loss) Per Common Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:WeightedAverageNumberOfSharesIssuedBasic", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:WeightedAverageNumberOfSharesIssuedBasic", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true } }, "R51": { "role": "http://healthcarerealty.com/role/StockholdersEquityScheduleofStockOptionsValuationAssumptionsDetails", "longName": "9954503 - Disclosure - Stockholders' Equity - Schedule of Stock Options, Valuation Assumptions (Details)", "shortName": "Stockholders' Equity - Schedule of Stock Options, Valuation Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-179", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-179", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true } }, "R52": { "role": "http://healthcarerealty.com/role/StockholdersEquitySummaryoftheActivityUndertheIncentivePlanandRSUActivityDetails", "longName": "9954504 - Disclosure - Stockholders' Equity - Summary of the Activity Under the Incentive Plan and RSU Activity (Details)", "shortName": "Stockholders' Equity - Summary of the Activity Under the Incentive Plan and RSU Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-188", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-188", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true } }, "R53": { "role": "http://healthcarerealty.com/role/StockholdersEquityAmortizationofCompensationforNonvestedSharesDetails", "longName": "9954505 - Disclosure - Stockholders' Equity - Amortization of Compensation for Nonvested Shares (Details)", "shortName": "Stockholders' Equity - Amortization of Compensation for Nonvested Shares (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-3", "name": "hr:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "hr:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true } }, "R54": { "role": "http://healthcarerealty.com/role/FairValueofFinancialInstrumentsDetails", "longName": "9954506 - Disclosure - Fair Value of Financial Instruments (Details)", "shortName": "Fair Value of Financial Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-196", "name": "us-gaap:DebtInstrumentFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-196", "name": "us-gaap:DebtInstrumentFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hr-20240331.htm", "first": true, "unique": true } } }, "tag": { "stpr_AZ": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2023", "localname": "AZ", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesScheduleofNotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Arizona", "label": "ARIZONA" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsNotesAndLoansReceivableLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsNotesAndLoansReceivableLineItems", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesScheduleofNotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]", "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable and accrued liabilities", "label": "Accounts Payable and Accrued Liabilities", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations." } } }, "auth_ref": [ "r116" ] }, "us-gaap_AccountsPayableAndOtherAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndOtherAccruedLiabilities", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesConsolidatedbalancesheetsDetails": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesConsolidatedbalancesheetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other liabilities", "label": "Accounts Payable and Other Accrued Liabilities", "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other." } } }, "auth_ref": [ "r544" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "negatedLabel": "Accumulated other comprehensive income (loss)", "label": "Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax", "documentation": "Amount, after tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit)." } } }, "auth_ref": [ "r4", "r34", "r807" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofEquityandRedeemableNonControllingInterests" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss)", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r3", "r13", "r34", "r433", "r436", "r479", "r525", "r526", "r771", "r772", "r773", "r784", "r785", "r786" ] }, "us-gaap_AcquisitionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AcquisitionCosts", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "hr_OperatingExpensesandCostofGoodsSold", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Transaction costs", "label": "Acquisition Costs, Period Cost", "documentation": "The capitalized costs incurred during the period (excluded from amortization) to purchase, lease or otherwise acquire an unproved property, including costs of lease bonuses and options to purchase or lease properties, the portion of costs applicable to minerals when land including mineral rights is purchased in fee, brokers' fees, recording fees, legal costs, and other costs incurred in acquiring properties." } } }, "auth_ref": [ "r161", "r162" ] }, "hr_AcquisitionsAndDispositionsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "AcquisitionsAndDispositionsTextBlock", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestments" ], "lang": { "en-us": { "role": { "verboseLabel": "Real Estate Investments", "label": "Acquisitions and Dispositions [Text Block]", "documentation": "Acquisitions and dispositions." } } }, "auth_ref": [] }, "hr_ActiveDevelopmentPropertiesMember": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "ActiveDevelopmentPropertiesMember", "presentation": [ "http://healthcarerealty.com/role/CommitmentandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Active Development Properties", "label": "Active Development Properties [Member]", "documentation": "Active Development Properties" } } }, "auth_ref": [] }, "hr_ActiveInterestRateSwapsMember": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "ActiveInterestRateSwapsMember", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedasCashFlowHedgesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Active Interest Rate Swap", "label": "Active Interest Rate Swaps [Member]", "documentation": "Active Interest Rate Swaps [Member]" } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r722" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r126" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofEquityandRedeemableNonControllingInterests" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-In Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r414", "r415", "r416", "r535", "r784", "r785", "r786", "r837", "r862" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r728" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r728" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r728" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r728" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofEquityandRedeemableNonControllingInterests" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r66", "r67", "r385" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Adjustments to reconcile net loss to net cash provided by operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r693", "r704", "r714", "r739" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r696", "r707", "r717", "r742" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r728" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r735" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r700", "r708", "r718", "r735", "r743", "r747", "r755" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r753" ] }, "us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Company's Allowance For Credit Losses", "label": "Financing Receivable, Allowance for Credit Loss [Table Text Block]", "documentation": "Tabular disclosure of allowance for credit loss on financing receivable." } } }, "auth_ref": [ "r52", "r792" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "hr_AmortizationofPrepaidRent": { "xbrltype": "monetaryItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "AmortizationofPrepaidRent", "crdr": "debit", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of prepaid rent", "label": "Amortization of Prepaid Rent", "documentation": "Amortization of Prepaid Rent" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average incremental shares of common stock excluded from the computation (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r264" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r47" ] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r47" ] }, "hr_ApproximateSquareFeetInvestedInByCompany": { "xbrltype": "areaItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "ApproximateSquareFeetInvestedInByCompany", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Approximate square feet invested in by company", "label": "Approximate Square Feet Invested in by Company", "documentation": "Approximate Square Feet Invested in by Company" } } }, "auth_ref": [] }, "hr_AreaCoveredUnderRealEstateInvestmentSoldInMeasurementUnits": { "xbrltype": "areaItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "AreaCoveredUnderRealEstateInvestmentSoldInMeasurementUnits", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Area covered under real estate investment sold in measurement units", "label": "Area Covered Under Real Estate Investment Sold in Measurement Units", "documentation": "Area covered under real estate investment sold in measurement units." } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionLineItems", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Line Items]", "label": "Asset Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r834" ] }, "us-gaap_AssetAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionTable", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Table]", "label": "Asset Acquisition [Table]", "documentation": "Disclosure of information about asset acquisition." } } }, "auth_ref": [ "r834" ] }, "us-gaap_AssetImpairmentChargesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetImpairmentChargesAbstract", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Impairment:", "label": "Asset Impairment Charges [Abstract]" } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesConsolidatedbalancesheetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets", "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesConsolidatedbalancesheetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r164", "r207", "r239", "r269", "r277", "r281", "r292", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r421", "r425", "r447", "r503", "r563", "r668", "r684", "r801", "r802", "r846" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets", "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesConsolidatedbalancesheetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "ASSETS", "terseLabel": "Assets:", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "hr_AssetsHeldForSaleAndDiscontinuedOperationsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "AssetsHeldForSaleAndDiscontinuedOperationsNet", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 }, "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets", "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Assets held for sale, net", "totalLabel": "Assets held for sale, net", "label": "Assets Held-for-sale and Discontinued Operations Net", "documentation": "Assets held for sale and discontinued operations, net." } } }, "auth_ref": [] }, "us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsHeldForSaleLongLivedFairValueDisclosure", "crdr": "debit", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Properties measured at fair value", "label": "Long-Lived Asset, Held-for-Sale, Fair Value Disclosure", "documentation": "Fair value portion of assets classified as held for sale." } } }, "auth_ref": [ "r666" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r750" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r751" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r746" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r746" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r746" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r746" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r746" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r746" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityScheduleofStockOptionsValuationAssumptionsDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r749" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r748" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r747" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r747" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueofDerivativeInstrumentsontheBalanceSheetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Axis]", "label": "Balance Sheet Location [Axis]", "documentation": "Information by location on balance sheet (statement of financial position)." } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueofDerivativeInstrumentsontheBalanceSheetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Domain]", "label": "Balance Sheet Location [Domain]", "documentation": "Location in the balance sheet (statement of financial position)." } } }, "auth_ref": [ "r94", "r99" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r419", "r660", "r661" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r68", "r70", "r419", "r660", "r661" ] }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity interest owned (percent)", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination." } } }, "auth_ref": [ "r69" ] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Business Combination and Asset Acquisition [Abstract]", "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "auth_ref": [] }, "hr_BusinessOverviewAbstract": { "xbrltype": "stringItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "BusinessOverviewAbstract", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Overview:", "label": "Business Overview [Abstract]", "documentation": "Business Overview [Abstract]" } } }, "auth_ref": [] }, "stpr_CA": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2023", "localname": "CA", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableNarrativeDetails", "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesScheduleofNotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "California", "label": "CALIFORNIA" } } }, "auth_ref": [] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Invoices accrued for construction, tenant improvements and other capitalized costs", "label": "Capital Expenditures Incurred but Not yet Paid", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r42", "r43", "r44" ] }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CarryingReportedAmountFairValueDisclosureMember", "presentation": [ "http://healthcarerealty.com/role/FairValueofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CARRYING VALUE", "label": "Reported Value Measurement [Member]", "documentation": "Measured as reported on the statement of financial position (balance sheet)." } } }, "auth_ref": [ "r110", "r111" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesConsolidatedbalancesheetsDetails": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails": { "parentTag": "hr_AssetsHeldForSaleAndDiscontinuedOperationsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets", "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails", "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesConsolidatedbalancesheetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash and cash equivalents", "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r41", "r204", "r634" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents at beginning of period", "periodEndLabel": "Cash and cash equivalents at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r41", "r141", "r235" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Increase (decrease) in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r141" ] }, "us-gaap_CashFlowHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowHedgingMember", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsCashFlowHedgesofInterestRateRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flow hedging", "label": "Cash Flow Hedging [Member]", "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk." } } }, "auth_ref": [ "r92" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r726" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityReconciliationofBeginningandEndingCommonStockOutstandingDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r208", "r209", "r210", "r268", "r350", "r351", "r352", "r354", "r357", "r362", "r364", "r529", "r530", "r531", "r532", "r649", "r761", "r780" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r727" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r727" ] }, "hr_ColumbusOHMember": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "ColumbusOHMember", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesScheduleofNotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Columbus, OH", "label": "Columbus, OH [Member]", "documentation": "Columbus, OH" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Commitments and contingencies", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r29", "r118", "r504", "r551" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://healthcarerealty.com/role/CommitmentsandContingencies" ], "lang": { "en-us": { "role": { "verboseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r149", "r305", "r306", "r615", "r797" ] }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockDividendsPerShareCashPaid", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofEquityandRedeemableNonControllingInterestsParenthetical", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Dividends to common stockholders and distributions to non-controlling interest holders (in dollars per share)", "terseLabel": "Dividends paid per common share, during the period (in dollars per share)", "label": "Common Stock, Dividends, Per Share, Cash Paid", "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding." } } }, "auth_ref": [ "r154" ] }, "us-gaap_CommonStockDividendsPerShareDeclared": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockDividendsPerShareDeclared", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends declared per common share, during the period (in dollars per share)", "label": "Common Stock, Dividends, Per Share, Declared", "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding." } } }, "auth_ref": [ "r154" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofEquityandRedeemableNonControllingInterests", "http://healthcarerealty.com/role/StockholdersEquityReconciliationofBeginningandEndingCommonStockOutstandingDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r671", "r672", "r673", "r675", "r676", "r677", "r680", "r784", "r785", "r837", "r858", "r862" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r125" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock, authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r125", "r552" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock, issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r125" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://healthcarerealty.com/role/StockholdersEquityReconciliationofBeginningandEndingCommonStockOutstandingDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock, outstanding (in shares)", "periodStartLabel": "Balance, beginning of period (in shares)", "periodEndLabel": "Balance, end of period (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r14", "r125", "r552", "r569", "r862", "r863" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Class A Common stock, $.01 par value per share; 1,000,000 shares authorized; 381,502 and 380,964 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r125", "r506", "r668" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r732" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r731" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r733" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r730" ] }, "hr_CompletedDevelpomentAndRedevelopmentPropertiesMember": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "CompletedDevelpomentAndRedevelopmentPropertiesMember", "presentation": [ "http://healthcarerealty.com/role/CommitmentandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Completed Develpoment and Redevelopment Properties", "label": "Completed Develpoment and Redevelopment Properties [Member]", "documentation": "Completed Develpoment and Redevelopment Properties" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss attributable to common stockholders", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r35", "r217", "r219", "r228", "r495", "r516" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: comprehensive loss attributable to non-controlling interests", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r7", "r73", "r87", "r217", "r219", "r227", "r494", "r515" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r87", "r158", "r217", "r219", "r226", "r493", "r514" ] }, "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidatedEntitiesAxis", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesConsolidatedbalancesheetsDetails", "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails", "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesVariableinterestentityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidated Entities [Axis]", "label": "Consolidated Entities [Axis]", "documentation": "Information by consolidated entity or group of entities." } } }, "auth_ref": [ "r190", "r240", "r421", "r422", "r425", "r426", "r480", "r625", "r766", "r767", "r768", "r800", "r803", "r804" ] }, "srt_ConsolidatedEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidatedEntitiesDomain", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesConsolidatedbalancesheetsDetails", "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails", "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesVariableinterestentityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidated Entities [Domain]", "label": "Consolidated Entities [Domain]", "documentation": "Entity or group of entities consolidated into reporting entity." } } }, "auth_ref": [ "r190", "r240", "r421", "r422", "r425", "r426", "r480", "r625", "r766", "r767", "r768", "r800", "r803", "r804" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Principles of Consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r74", "r637" ] }, "us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Redeemable Non-Controlling Interests", "label": "Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest." } } }, "auth_ref": [ "r177" ] }, "us-gaap_ConsolidationVariableInterestEntityPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationVariableInterestEntityPolicy", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Interest Entities", "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined)." } } }, "auth_ref": [ "r75", "r78", "r81" ] }, "hr_ConstructionActivityTotalFundingDuringthePeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "ConstructionActivityTotalFundingDuringthePeriod", "crdr": "debit", "presentation": [ "http://healthcarerealty.com/role/CommitmentandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Construction activity and development properties", "label": "Construction Activity, Total Funding During the Period", "documentation": "Construction Activity, Total Funding During the Period" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CumulativeDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CumulativeDividends", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "negatedLabel": "Cumulative dividends", "label": "Cumulative Dividends", "documentation": "Amount of cumulative cash dividends distributed to shareholders." } } }, "auth_ref": [] }, "hr_CumulativeDividendsMember": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "CumulativeDividendsMember", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofEquityandRedeemableNonControllingInterests" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative Dividends", "label": "Cumulative Dividends [Member]", "documentation": "Cumulative Dividends [Member]." } } }, "auth_ref": [] }, "hr_CumulativeNetIncomeAttributableToCommonStockholders": { "xbrltype": "monetaryItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "CumulativeNetIncomeAttributableToCommonStockholders", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Cumulative net income attributable to common stockholders", "label": "Cumulative Net Income Attributable to Common Stockholders", "documentation": "Cumulative net income attributable to common stockholders." } } }, "auth_ref": [] }, "hr_CumulativeNetIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "CumulativeNetIncomeMember", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofEquityandRedeemableNonControllingInterests" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative Net Income", "label": "Cumulative Net Income [Member]", "documentation": "Cumulative Net Income [Member]." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayable" ], "lang": { "en-us": { "role": { "verboseLabel": "Notes and Bonds Payable", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r150", "r237", "r320", "r326", "r327", "r328", "r329", "r330", "r331", "r336", "r343", "r344", "r346" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r23", "r122", "r123", "r165", "r166", "r240", "r321", "r322", "r323", "r324", "r325", "r327", "r332", "r333", "r334", "r335", "r337", "r338", "r339", "r340", "r341", "r342", "r457", "r644", "r645", "r646", "r647", "r648", "r781" ] }, "hr_DebtInstrumentExtensionPeriodForMaturityDate": { "xbrltype": "durationItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "DebtInstrumentExtensionPeriodForMaturityDate", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Extension period for maturity date", "label": "Debt Instrument, Extension Period for Maturity Date", "documentation": "Debt Instrument, Extension Period for Maturity Date" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Face amount", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r113", "r115", "r321", "r457", "r645", "r646" ] }, "us-gaap_DebtInstrumentFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFairValue", "crdr": "credit", "presentation": [ "http://healthcarerealty.com/role/FairValueofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Notes and bonds payable", "label": "Debt Instrument, Fair Value Disclosure", "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable." } } }, "auth_ref": [ "r334", "r446", "r645", "r646" ] }, "us-gaap_DebtInstrumentFeeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFeeAmount", "crdr": "debit", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt fees", "label": "Debt Instrument, Fee Amount", "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument." } } }, "auth_ref": [ "r27" ] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails", "http://healthcarerealty.com/role/NotesandBondsPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective interest rate", "label": "Debt Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r26", "r113", "r348", "r457" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails", "http://healthcarerealty.com/role/NotesandBondsPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r240", "r321", "r322", "r323", "r324", "r325", "r327", "r332", "r333", "r334", "r335", "r337", "r338", "r339", "r340", "r341", "r342", "r345", "r457", "r644", "r645", "r646", "r647", "r648", "r781" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r28", "r240", "r321", "r322", "r323", "r324", "r325", "r327", "r332", "r333", "r334", "r335", "r337", "r338", "r339", "r340", "r341", "r342", "r457", "r644", "r645", "r646", "r647", "r648", "r781" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails", "http://healthcarerealty.com/role/NotesandBondsPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r28", "r60", "r63", "r112", "r113", "r115", "r119", "r152", "r153", "r240", "r321", "r322", "r323", "r324", "r325", "r327", "r332", "r333", "r334", "r335", "r337", "r338", "r339", "r340", "r341", "r342", "r345", "r457", "r644", "r645", "r646", "r647", "r648", "r781" ] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationAndAmortization", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "hr_OperatingExpensesandCostofGoodsSold", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization, Nonproduction", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": [ "r10", "r53" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r10", "r273" ] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsCashFlowHedgesofInterestRateRiskDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedasCashFlowHedgesDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectofCashFlowHedgingonAOCIDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueofDerivativeInstrumentsontheBalanceSheetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r540", "r542", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r564", "r565", "r566", "r567", "r579", "r580", "r581", "r582", "r585", "r586", "r587", "r588", "r603", "r604", "r605", "r606", "r671", "r673" ] }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFairValueOfDerivativeLiability", "crdr": "credit", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueofDerivativeInstrumentsontheBalanceSheetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liability derivatives", "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement." } } }, "auth_ref": [ "r19", "r97", "r130", "r211", "r635" ] }, "us-gaap_DerivativeFixedInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFixedInterestRate", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsCashFlowHedgesofInterestRateRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average interest rate (percent)", "label": "Derivative, Fixed Interest Rate", "documentation": "Fixed interest rate related to the interest rate derivative." } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsCashFlowHedgesofInterestRateRiskDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedasCashFlowHedgesDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectofCashFlowHedgingonAOCIDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueofDerivativeInstrumentsontheBalanceSheetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r95", "r98", "r100", "r102", "r540", "r542", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r564", "r565", "r566", "r567", "r579", "r580", "r581", "r582", "r585", "r586", "r587", "r588", "r603", "r604", "r605", "r606", "r635", "r671", "r673" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstruments" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Financial Instruments", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts." } } }, "auth_ref": [ "r160", "r430", "r438" ] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsCashFlowHedgesofInterestRateRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Axis]", "label": "Hedging Relationship [Axis]", "documentation": "Information by type of hedging relationship." } } }, "auth_ref": [ "r15", "r95", "r100" ] }, "us-gaap_DerivativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLineItems", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsCashFlowHedgesofInterestRateRiskDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedasCashFlowHedgesDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectofCashFlowHedgingonAOCIDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueofDerivativeInstrumentsontheBalanceSheetDetails", "http://healthcarerealty.com/role/FairValueofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Line Items]", "label": "Derivative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r438" ] }, "hr_DerivativeNetAssetPositionAggregateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "DerivativeNetAssetPositionAggregateFairValue", "crdr": "debit", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedasCashFlowHedgesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives in net asset position", "label": "Derivative Net Asset Position Aggregate Fair Value", "documentation": "Derivative Net Asset Position Aggregate Fair Value" } } }, "auth_ref": [] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeNotionalAmount", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsCashFlowHedgesofInterestRateRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AMOUNT", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": [ "r835", "r836" ] }, "us-gaap_DerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeTable", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsCashFlowHedgesofInterestRateRiskDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedasCashFlowHedgesDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectofCashFlowHedgingonAOCIDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueofDerivativeInstrumentsontheBalanceSheetDetails", "http://healthcarerealty.com/role/FairValueofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Table]", "label": "Derivative [Table]", "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item." } } }, "auth_ref": [ "r15", "r88", "r89", "r91", "r93", "r96", "r100", "r103", "r104", "r106", "r438" ] }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DesignatedAsHedgingInstrumentMember", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsCashFlowHedgesofInterestRateRiskDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueofDerivativeInstrumentsontheBalanceSheetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Designated as hedging instrument", "label": "Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r15" ] }, "us-gaap_DevelopmentInProcess": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DevelopmentInProcess", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Construction in progress", "label": "Development in Process", "documentation": "The current amount of expenditures for a real estate project that has not yet been completed." } } }, "auth_ref": [ "r855" ] }, "us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DilutiveSecuritiesEffectOnBasicEarningsPerShareOther", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/StockholdersEquityComputationofBasicandDilutedEarningsLossPerCommonShareDetails": { "parentTag": "hr_NetIncomeLossfromContinuingOperationsAvailabletoCommonStockholdersBasic", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityComputationofBasicandDilutedEarningsLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to loss attributable to non-controlling interest for legally outstanding restricted units", "label": "Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities", "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of dilutive convertible securities excluding adjustments related to ESOP convertible preferred stock, stock options, and restrictive stock units." } } }, "auth_ref": [] }, "us-gaap_DirectCostsOfLeasedAndRentedPropertyOrEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DirectCostsOfLeasedAndRentedPropertyOrEquipment", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "hr_OperatingExpensesandCostofGoodsSold", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "verboseLabel": "Property operating", "label": "Direct Costs of Leased and Rented Property or Equipment", "documentation": "Amount of expense incurred and directly related to generating revenue by lessor from operating lease of rented property and equipment." } } }, "auth_ref": [ "r764" ] }, "hr_DirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "DirectorsMember", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Directors", "label": "Directors [Member]", "documentation": "Directors" } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r375", "r650", "r651", "r652", "r653", "r654", "r655", "r656" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r375", "r650", "r651", "r652", "r653", "r654", "r655", "r656" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Disaggregation of revenue", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r806" ] }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of the Activity Under the Incentive Plan and RSU Activity", "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]", "documentation": "Tabular disclosure of share-based payment arrangement." } } }, "auth_ref": [ "r11", "r65" ] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupClassificationAxis", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Axis]", "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": [ "r202" ] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupClassificationDomain", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Domain]", "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupHeldforsaleNotDiscontinuedOperationsMember", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group, Held-for-sale, Not Discontinued Operations", "label": "Disposal Group, Held-for-Sale, Not Discontinued Operations [Member]", "documentation": "Disposal group that is classified as held-for-sale. Excludes disposals classified as discontinued operations." } } }, "auth_ref": [ "r5", "r17", "r202" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails": { "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued liabilities", "label": "Disposal Group, Including Discontinued Operation, Accounts Payable and Accrued Liabilities", "documentation": "Amount classified as accounts payable and accrued liabilities attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r2", "r120", "r121", "r147" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherAssets", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails": { "parentTag": "hr_AssetsHeldForSaleAndDiscontinuedOperationsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets, net", "label": "Disposal Group, Including Discontinued Operation, Other Assets", "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r2", "r120", "r121", "r147" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherLiabilities", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails": { "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other liabilities", "label": "Disposal Group, Including Discontinued Operation, Other Liabilities", "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r2", "r120", "r121", "r147" ] }, "us-gaap_DistributionMadeToLimitedLiabilityCompanyLLCMemberCashDistributionsDeclared": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DistributionMadeToLimitedLiabilityCompanyLLCMemberCashDistributionsDeclared", "crdr": "debit", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsUnconsolidatedJointVentureAcquisitionsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Owner distributions", "label": "Distribution Made to Limited Liability Company (LLC) Member, Cash Distributions Declared", "documentation": "Amount of equity impact of cash distributions declared to unit-holder of limited liability company (LLC)." } } }, "auth_ref": [ "r154", "r267" ] }, "us-gaap_DividendsCommonStockCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsCommonStockCash", "crdr": "debit", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofEquityandRedeemableNonControllingInterests" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Dividends to common stockholders and distributions to non-controlling interest holders", "label": "Dividends, Common Stock, Cash", "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash." } } }, "auth_ref": [ "r154" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r688" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r721" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofOperations", "http://healthcarerealty.com/role/StockholdersEquityComputationofBasicandDilutedEarningsLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic earnings per common share (in dollars per share)", "verboseLabel": "Basic earnings per common share - net loss (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r229", "r246", "r247", "r248", "r249", "r250", "r254", "r256", "r259", "r262", "r263", "r265", "r441", "r442", "r496", "r517", "r639" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofOperations", "http://healthcarerealty.com/role/StockholdersEquityComputationofBasicandDilutedEarningsLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted earnings per common share (in dollars per share)", "verboseLabel": "Diluted earnings per common share- net loss (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r229", "r246", "r247", "r248", "r249", "r250", "r256", "r259", "r262", "r263", "r265", "r441", "r442", "r496", "r517", "r639" ] }, "hr_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedAfterYearFour", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/StockholdersEquityAmortizationofCompensationforNonvestedSharesDetails": { "parentTag": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityAmortizationofCompensationforNonvestedSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028 and thereafter", "label": "Employee Service Share-based Compensation, Non Vested Awards, Compensation Cost Not yet Recognized, after Year Four", "documentation": "Employee Service Share-based Compensation, Non Vested Awards, Compensation Cost Not yet Recognized, After Year Four" } } }, "auth_ref": [] }, "hr_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedYearThree", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/StockholdersEquityAmortizationofCompensationforNonvestedSharesDetails": { "parentTag": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityAmortizationofCompensationforNonvestedSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Employee Service Share-based Compensation, Non Vested Awards, Compensation Cost Not yet Recognized, Year Three", "documentation": "Employee Service Share-based Compensation, Non Vested Awards, Compensation Cost Not yet Recognized, Year Three" } } }, "auth_ref": [] }, "hr_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedYearTwo", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/StockholdersEquityAmortizationofCompensationforNonvestedSharesDetails": { "parentTag": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityAmortizationofCompensationforNonvestedSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Employee Service Share-based Compensation, Non Vested Awards, Compensation Cost Not yet Recognized, Year Two", "documentation": "Employee Service Share-based Compensation, Non Vested Awards, Compensation Cost Not yet Recognized, Year Two" } } }, "auth_ref": [] }, "hr_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedNextTwelveMonths", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/StockholdersEquityAmortizationofCompensationforNonvestedSharesDetails": { "parentTag": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityAmortizationofCompensationforNonvestedSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Next Twelve Months", "documentation": "Employee Service Share-based Compensation, Non Vested Awards, Compensation Cost Not yet Recognized, Next Twelve Months" } } }, "auth_ref": [] }, "hr_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/StockholdersEquityAmortizationofCompensationforNonvestedSharesDetails": { "parentTag": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityAmortizationofCompensationforNonvestedSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Remainder Of Fiscal Year", "documentation": "Employee Service Share-based Compensation, Non Vested Awards, Compensation Cost Not yet Recognized, Remainder Of Fiscal Year" } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/StockholdersEquityAmortizationofCompensationforNonvestedSharesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityAmortizationofCompensationforNonvestedSharesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r413" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Options under the Employee Stock Option Plan", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r686" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entity [Domain]", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r686" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r686" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r760" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r686" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r686" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r686" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r686" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity [Abstract]", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofEquityandRedeemableNonControllingInterests", "http://healthcarerealty.com/role/StockholdersEquityReconciliationofBeginningandEndingCommonStockOutstandingDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r14", "r200", "r220", "r221", "r222", "r241", "r242", "r243", "r245", "r251", "r253", "r267", "r293", "r294", "r365", "r414", "r415", "r416", "r417", "r418", "r432", "r433", "r434", "r435", "r436", "r437", "r440", "r448", "r450", "r451", "r452", "r453", "r454", "r479", "r525", "r526", "r527", "r535", "r591" ] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Domain]", "label": "Investment, Name [Domain]", "documentation": "Name of investment including named security. Excludes entity that is consolidated." } } }, "auth_ref": [ "r289", "r290", "r291" ] }, "us-gaap_EquityMethodInvestmentDividendsOrDistributions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentDividendsOrDistributions", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Distributions from unconsolidated joint ventures", "label": "Proceeds from Equity Method Investment, Distribution", "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities." } } }, "auth_ref": [ "r8", "r10", "r131", "r509" ] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Joint venture ownership (percent)", "label": "Equity Method Investment, Ownership Percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": [ "r289" ] }, "hr_EquityMethodInvestmentsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "EquityMethodInvestmentsRollForward", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsUnconsolidatedJointVentureAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Method Investments [Roll Forward]", "label": "Equity Method Investments [Roll Forward]", "documentation": "Equity Method Investments" } } }, "auth_ref": [] }, "us-gaap_EquityMethodInvestmentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentsTextBlock", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Equity Method Investments", "label": "Equity Method Investments [Table Text Block]", "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information." } } }, "auth_ref": [ "r288" ] }, "hr_EquityOwnershipForConsolidationPercent": { "xbrltype": "percentItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "EquityOwnershipForConsolidationPercent", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity ownership for consolidation (percent)", "label": "Equity Ownership for Consolidation, Percent", "documentation": "Equity Ownership for Consolidation, Percent" } } }, "auth_ref": [] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r729" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r693", "r704", "r714", "r739" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r690", "r701", "r711", "r736" ] }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EstimateOfFairValueFairValueDisclosureMember", "presentation": [ "http://healthcarerealty.com/role/FairValueofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "FAIR VALUE", "label": "Estimate of Fair Value Measurement [Member]", "documentation": "Measured as an estimate of fair value." } } }, "auth_ref": [ "r334", "r446", "r645", "r646" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r735" ] }, "hr_ExecutiveIncentiveProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "ExecutiveIncentiveProgramMember", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Incentive Program", "label": "Executive Incentive Program [Member]", "documentation": "Executive Incentive Program [Member]" } } }, "auth_ref": [] }, "us-gaap_ExtinguishmentOfDebtAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ExtinguishmentOfDebtAmount", "crdr": "debit", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding principal repaid", "label": "Extinguishment of Debt, Amount", "documentation": "Gross amount of debt extinguished." } } }, "auth_ref": [] }, "us-gaap_ExtinguishmentOfDebtAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ExtinguishmentOfDebtAxis", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Extinguishment of Debt [Axis]", "label": "Extinguishment of Debt [Axis]", "documentation": "Information pertaining to the debt extinguished including the amount of gain (loss), the income tax effect on the gain (loss), and the amount of gain (loss), net or the related income tax, by debt instrument." } } }, "auth_ref": [ "r55" ] }, "hr_ExtinguishmentOfDebtEncumberedSquareFootage": { "xbrltype": "areaItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "ExtinguishmentOfDebtEncumberedSquareFootage", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Encumbered square footage", "label": "Extinguishment of Debt, Encumbered Square Footage", "documentation": "Extinguishment of Debt, Encumbered Square Footage" } } }, "auth_ref": [] }, "us-gaap_ExtinguishmentOfDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ExtinguishmentOfDebtTypeDomain", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Extinguishment of Debt, Type [Domain]", "label": "Extinguishment of Debt, Type [Domain]", "documentation": "Type of debt extinguished." } } }, "auth_ref": [ "r55" ] }, "stpr_FL": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2023", "localname": "FL", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesScheduleofNotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Florida", "label": "FLORIDA" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails", "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesScheduleofNotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Class [Domain]", "label": "Asset Class [Domain]", "documentation": "Class of asset." } } }, "auth_ref": [ "r16" ] }, "us-gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByAssetClassAxis", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails", "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesScheduleofNotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Class [Axis]", "label": "Asset Class [Axis]", "documentation": "Information by class of asset." } } }, "auth_ref": [ "r108", "r109" ] }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByBalanceSheetGroupingTextBlock", "presentation": [ "http://healthcarerealty.com/role/FairValueofFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value And Carrying Values For Notes And Bonds Payable, Real Estate Notes Receivable, And Notes Receivable", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": [ "r108", "r110" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r334", "r377", "r378", "r379", "r380", "r381", "r382", "r444", "r482", "r483", "r484", "r645", "r646", "r657", "r658", "r659" ] }, "us-gaap_FairValueByMeasurementBasisAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementBasisAxis", "presentation": [ "http://healthcarerealty.com/role/FairValueofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Basis [Axis]", "label": "Measurement Basis [Axis]", "documentation": "Information by measurement basis." } } }, "auth_ref": [ "r20", "r108", "r334", "r645", "r646" ] }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosureItemAmountsDomain", "presentation": [ "http://healthcarerealty.com/role/FairValueofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement [Domain]", "label": "Fair Value Measurement [Domain]", "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value." } } }, "auth_ref": [ "r334", "r645", "r646" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://healthcarerealty.com/role/FairValueofFinancialInstruments" ], "lang": { "en-us": { "role": { "verboseLabel": "Fair Value of Financial Instruments", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r443" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Inputs, Level 3", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r334", "r377", "r378", "r379", "r380", "r381", "r382", "r444", "r484", "r645", "r646", "r657", "r658", "r659" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r334", "r377", "r378", "r379", "r380", "r381", "r382", "r482", "r483", "r484", "r645", "r646", "r657", "r658", "r659" ] }, "us-gaap_FinanceLeaseInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseInterestExpense", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/LeasesLeaseCostDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest on lease liabilities", "label": "Finance Lease, Interest Expense", "documentation": "Amount of interest expense on finance lease liability." } } }, "auth_ref": [ "r461", "r467", "r667" ] }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseInterestPaymentOnLiability", "crdr": "credit", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating cash flows outflows related to financing leases", "label": "Finance Lease, Interest Payment on Liability", "documentation": "Amount of interest paid on finance lease liability." } } }, "auth_ref": [ "r463", "r470" ] }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "FINANCING", "label": "Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiability", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 }, "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets", "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financing lease liabilities", "verboseLabel": "Lease liabilities", "label": "Finance Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease." } } }, "auth_ref": [ "r460", "r473" ] }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://healthcarerealty.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Future Minimum Financing Lease Payments", "label": "Finance Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r842" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total undiscounted lease payments", "label": "Finance Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease." } } }, "auth_ref": [ "r473" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finance Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r473" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Finance Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r473" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finance Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r473" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Finance Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r473" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r842" ] }, "hr_FinanceLeaseLiabilityToBePaidAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "FinanceLeaseLiabilityToBePaidAfterYearFour", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029 and thereafter", "label": "Finance Lease, Liability, to be Paid, after Year Four", "documentation": "Finance Lease, Liability, to be Paid, after Year Four" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Discount", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease." } } }, "auth_ref": [ "r473" ] }, "hr_FinanceLeasePrincipalOnlyPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "FinanceLeasePrincipalOnlyPayments", "crdr": "credit", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financing cash flows outflows related to financing leases", "label": "Finance Lease, Principal Only Payments", "documentation": "Finance Lease, Principal Only Payments" } } }, "auth_ref": [] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments made on finance leases", "label": "Finance Lease, Principal Payments", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": [ "r462", "r470" ] }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseRightOfUseAssetAmortization", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/LeasesLeaseCostDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of right-of-use assets", "label": "Finance Lease, Right-of-Use Asset, Amortization", "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease." } } }, "auth_ref": [ "r461", "r467", "r667" ] }, "us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Financing lease right-of-use assets", "label": "Finance Lease, Right-of-Use Asset, before Accumulated Amortization", "documentation": "Amount, before accumulated amortization, of right-of-use asset from finance lease." } } }, "auth_ref": [ "r762" ] }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average discount rate - finance leases", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for finance lease calculated at point in time." } } }, "auth_ref": [ "r472", "r667" ] }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average years remaining lease term (excluding renewal options) - finance leases", "label": "Finance Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r471", "r667" ] }, "us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest", "crdr": "credit", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesScheduleofCompanysAllowanceForCreditLossesDetails", "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesScheduleofNotesReceivableDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "ALLOWANCE FOR CREDIT LOSSES", "periodStartLabel": "Allowance for credit losses, beginning of period", "periodEndLabel": "Allowance for credit losses, end of period", "label": "Financing Receivable, Allowance for Credit Loss, Excluding Accrued Interest", "documentation": "Amount excluding accrued interest, of allowance for credit loss on financing receivable. Excludes net investment in lease." } } }, "auth_ref": [ "r791" ] }, "hr_FinancingReceivableAllowanceForCreditLossReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "FinancingReceivableAllowanceForCreditLossReserves", "crdr": "credit", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails", "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesScheduleofCompanysAllowanceForCreditLossesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit loss reserves", "label": "Financing Receivable, Allowance for Credit Loss, Reserves", "documentation": "Financing Receivable, Allowance for Credit Loss, Reserves" } } }, "auth_ref": [] }, "us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancingReceivableAllowanceForCreditLossesRollForward", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesScheduleofCompanysAllowanceForCreditLossesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financing Receivable, Allowance for Credit Loss [Roll Forward]", "label": "Financing Receivable, Allowance for Credit Loss [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_FinancingReceivableCoveredAndNotCoveredAfterAllowanceForCreditLossFeePremiumAndDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancingReceivableCoveredAndNotCoveredAfterAllowanceForCreditLossFeePremiumAndDiscount", "crdr": "debit", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesScheduleofNotesReceivableDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "FAIR VALUE DISCOUNT AND FEES", "label": "Financing Receivable, Covered and Not Covered, after Allowance for Credit Loss, Fee, Premium, and Discount", "documentation": "Amount, after allowance for credit loss and unamortized deferred fee, premium, and discount, of financing receivable covered under loss sharing agreement and financing receivable not covered under loss sharing agreement." } } }, "auth_ref": [ "r789" ] }, "us-gaap_FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in financing receivable, net", "label": "Financing Receivable, Excluding Accrued Interest, after Allowance for Credit Loss", "documentation": "Amortized cost excluding accrued interest, after allowance for credit loss, of financing receivable. Excludes net investment in lease." } } }, "auth_ref": [ "r791" ] }, "us-gaap_FinancingReceivableExcludingAccruedInterestBeforeAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancingReceivableExcludingAccruedInterestBeforeAllowanceForCreditLoss", "crdr": "debit", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesScheduleofNotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "REAL ESTATE NOTES RECEIVABLE, GROSS", "label": "Financing Receivable, Excluding Accrued Interest, before Allowance for Credit Loss", "documentation": "Amortized cost excluding accrued interest, before allowance for credit loss, of financing receivable. Excludes net investment in lease." } } }, "auth_ref": [ "r296", "r297", "r791" ] }, "us-gaap_FinancingReceivableExcludingAccruedInterestNonaccrual": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancingReceivableExcludingAccruedInterestNonaccrual", "crdr": "debit", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financing receivable, nonaccrual", "label": "Financing Receivable, Excluding Accrued Interest, Nonaccrual", "documentation": "Amortized cost excluding accrued interest, of financing receivable on nonaccrual status. Excludes net investment in lease." } } }, "auth_ref": [ "r295" ] }, "hr_Florida1Member": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "Florida1Member", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesScheduleofNotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Florida 1", "label": "Florida 1 [Member]", "documentation": "Florida 1" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r697", "r708", "r718", "r743" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r697", "r708", "r718", "r743" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r697", "r708", "r718", "r743" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r697", "r708", "r718", "r743" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r697", "r708", "r718", "r743" ] }, "stpr_GA": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2023", "localname": "GA", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Georgia", "label": "GEORGIA" } } }, "auth_ref": [] }, "us-gaap_GainsLossesOnSalesOfInvestmentRealEstate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainsLossesOnSalesOfInvestmentRealEstate", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Gain on sales of real estate properties", "label": "Gains (Losses) on Sales of Investment Real Estate", "documentation": "The net gain (loss) resulting from sales and other disposals of real estate owned for investment purposes." } } }, "auth_ref": [ "r175", "r176", "r178", "r774", "r775", "r778", "r854", "r861" ] }, "hr_GainsLossesonSalesofInvestmentRealEstateIncludingDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "GainsLossesonSalesofInvestmentRealEstateIncludingDiscontinuedOperation", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Gain on sales of real estate properties", "label": "Gains (Losses) on Sales of Investment Real Estate, Including Discontinued Operation", "documentation": "Gains (Losses) on Sales of Investment Real Estate, Including Discontinued Operation" } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "hr_OperatingExpensesandCostofGoodsSold", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "verboseLabel": "General and administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r135", "r574" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r205", "r298", "r491", "r643", "r668", "r793", "r794" ] }, "us-gaap_GoodwillImpairedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillImpairedAbstract", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill Impairment", "label": "Goodwill, Impaired [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillImpairmentLoss", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 5.0 }, "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows", "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofOperations", "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Impairment of goodwill", "verboseLabel": "Impairment of goodwill", "terseLabel": "Impairment of goodwill", "label": "Goodwill, Impairment Loss", "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r10", "r299", "r300", "r302", "r643" ] }, "us-gaap_GranteeStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GranteeStatusAxis", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Grantee Status [Axis]", "label": "Grantee Status [Axis]", "documentation": "Information by status of recipient to whom award is granted." } } }, "auth_ref": [ "r384", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412" ] }, "us-gaap_GranteeStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GranteeStatusDomain", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Grantee Status [Domain]", "label": "Grantee Status [Domain]", "documentation": "Status of recipient to whom award is granted." } } }, "auth_ref": [ "r384", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412" ] }, "hr_HealthCareRealtyTrustIncorporatedMember": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "HealthCareRealtyTrustIncorporatedMember", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "HealthCare Realty Trust Incorporated", "label": "HealthCare Realty Trust Incorporated [Member]", "documentation": "HealthCare Realty Trust Incorporated" } } }, "auth_ref": [] }, "hr_HealthcareTrustofAmericaHoldingsLPMember": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "HealthcareTrustofAmericaHoldingsLPMember", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Healthcare Trust of America Holdings L P", "label": "Healthcare Trustof America Holdings L P [Member]", "documentation": "Healthcare Trustof America Holdings L P" } } }, "auth_ref": [] }, "us-gaap_HedgingDesignationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingDesignationAxis", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsCashFlowHedgesofInterestRateRiskDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueofDerivativeInstrumentsontheBalanceSheetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Axis]", "label": "Hedging Designation [Axis]", "documentation": "Information by designation of purpose of derivative instrument." } } }, "auth_ref": [ "r15", "r429" ] }, "us-gaap_HedgingDesignationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingDesignationDomain", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsCashFlowHedgesofInterestRateRiskDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueofDerivativeInstrumentsontheBalanceSheetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Domain]", "label": "Hedging Designation [Domain]", "documentation": "Designation of purpose of derivative instrument." } } }, "auth_ref": [ "r15" ] }, "us-gaap_HedgingRelationshipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingRelationshipDomain", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsCashFlowHedgesofInterestRateRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Domain]", "label": "Hedging Relationship [Domain]", "documentation": "Nature or intent of a hedge." } } }, "auth_ref": [ "r15" ] }, "hr_HoustonTexasMember": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "HoustonTexasMember", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesVariableinterestentityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Houston, TX", "label": "Houston, Texas [Member]", "documentation": "Houston, Texas [Member]" } } }, "auth_ref": [] }, "hr_ImpairmentChargeOnRealEstateAssetsHeldForSale": { "xbrltype": "monetaryItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "ImpairmentChargeOnRealEstateAssetsHeldForSale", "crdr": "debit", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment charges on net real estate assets held for sale", "label": "Impairment Charge on Real Estate Assets Held for Sale", "documentation": "Impairment Charge on Real Estate Assets Held for Sale" } } }, "auth_ref": [] }, "us-gaap_ImpairmentOfRealEstate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfRealEstate", "crdr": "debit", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of real estate assets", "label": "Impairment of Real Estate", "documentation": "The charge against earnings in the period to reduce the carrying amount of real property to fair value." } } }, "auth_ref": [ "r778", "r795" ] }, "hr_ImpairmentOfRealEstateAndCreditLossReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "ImpairmentOfRealEstateAndCreditLossReserves", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Impairment of real estate properties and credit loss reserves", "label": "Impairment of Real Estate and Credit Loss Reserves", "documentation": "Impairment of Real Estate and Credit Loss Reserves" } } }, "auth_ref": [] }, "hr_ImpairmentOfRealEstateContinuingAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "ImpairmentOfRealEstateContinuingAndDiscontinuedOperations", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of real estate properties and credit loss reserves", "label": "Impairment of Real Estate, Continuing and Discontinued Operations", "documentation": "Impairment of Real Estate, Continuing and Discontinued Operations" } } }, "auth_ref": [] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill Impairment", "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets." } } }, "auth_ref": [] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Impairment", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": [ "r0", "r148" ] }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 6.0 }, "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows", "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofOperations", "http://healthcarerealty.com/role/RealEstateInvestmentsUnconsolidatedJointVentureAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity loss from unconsolidated joint ventures", "negatedTerseLabel": "Equity loss from unconsolidated joint ventures", "verboseLabel": "Equity loss recognized during the period", "label": "Income (Loss) from Equity Method Investments", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } } }, "auth_ref": [ "r10", "r131", "r169", "r274", "r287", "r509" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectofCashFlowHedgingonAOCIDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r303", "r304", "r575" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectofCashFlowHedgingonAOCIDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r304", "r575" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable and accrued liabilities", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r9" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Other assets, including right-of-use-assets", "label": "Increase (Decrease) in Other Operating Assets", "documentation": "Amount of increase (decrease) in operating assets classified as other." } } }, "auth_ref": [ "r9" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Other liabilities", "label": "Increase (Decrease) in Other Operating Liabilities", "documentation": "Amount of increase (decrease) in operating liabilities classified as other." } } }, "auth_ref": [ "r9" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofEquityandRedeemableNonControllingInterests" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInTemporaryEquityRollForward", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofEquityandRedeemableNonControllingInterests" ], "lang": { "en-us": { "role": { "terseLabel": "Redeemable Non-controlling Interests", "label": "Increase (Decrease) in Temporary Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "hr_IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan": { "xbrltype": "sharesItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan", "calculation": { "http://healthcarerealty.com/role/StockholdersEquityComputationofBasicandDilutedEarningsLossPerCommonShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityComputationofBasicandDilutedEarningsLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Dilutive effect of employee stock purchase plan (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Employee Stock Purchase Plan", "documentation": "Incremental common shares attributable to dilutive effect of employee stock purchase plan." } } }, "auth_ref": [] }, "hr_IncrementalCommonSharesAttributableToDilutiveEffectOfOPUnits": { "xbrltype": "sharesItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "IncrementalCommonSharesAttributableToDilutiveEffectOfOPUnits", "calculation": { "http://healthcarerealty.com/role/StockholdersEquityComputationofBasicandDilutedEarningsLossPerCommonShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityComputationofBasicandDilutedEarningsLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dilutive effect of OP Units (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of OP Units", "documentation": "Incremental Common Shares Attributable to Dilutive Effect of OP Units" } } }, "auth_ref": [] }, "us-gaap_IncrementalCommonSharesAttributableToEquityForwardAgreements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncrementalCommonSharesAttributableToEquityForwardAgreements", "calculation": { "http://healthcarerealty.com/role/StockholdersEquityComputationofBasicandDilutedEarningsLossPerCommonShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityComputationofBasicandDilutedEarningsLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dilutive effect of forward equity shares (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Equity Forward Agreements", "documentation": "Additional shared included in the calculation of diluted EPS as a result of the potentially dilutive effect of equity forward arrangements using the reverse treasury stock method." } } }, "auth_ref": [ "r263", "r638" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r700", "r708", "r718", "r735", "r743", "r747", "r755" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r753" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r689", "r759" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r689", "r759" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r689", "r759" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r114", "r171", "r223", "r272", "r456", "r576", "r682", "r860" ] }, "us-gaap_InterestExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseMember", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectofCashFlowHedgingonAOCIDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "label": "Interest Expense [Member]", "documentation": "Primary financial statement caption encompassing interest expense." } } }, "auth_ref": [ "r18" ] }, "us-gaap_InterestIncomeFinancingReceivableBeforeAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeFinancingReceivableBeforeAllowanceForCreditLoss", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Interest Income, Financing Receivable, before Allowance for Credit Loss", "documentation": "Amount of interest income from financing receivable before allowance for credit loss." } } }, "auth_ref": [ "r187", "r188" ] }, "hr_InterestIncomeFinancingReceivableNoncash": { "xbrltype": "monetaryItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "InterestIncomeFinancingReceivableNoncash", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Non-cash interest from financing and notes receivable", "label": "Interest Income, Financing Receivable, Noncash", "documentation": "Interest Income, Financing Receivable, Noncash" } } }, "auth_ref": [] }, "us-gaap_InterestIncomeOperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeOperating", "crdr": "credit", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Interest Income, Operating", "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities." } } }, "auth_ref": [ "r133", "r572", "r608", "r609", "r681", "r682", "r864" ] }, "us-gaap_InterestPaidCapitalized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidCapitalized", "crdr": "credit", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Capitalized interest", "label": "Interest Paid, Capitalized, Investing Activities", "documentation": "Amount of cash paid for interest capitalized, classified as investing activity." } } }, "auth_ref": [ "r636", "r779" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Interest paid", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r230", "r233", "r234" ] }, "us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet", "crdr": "credit", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedasCashFlowHedgesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate cash flow hedge gain (loss) to be reclassified to interest expense during the next 12 months", "label": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net", "documentation": "The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months." } } }, "auth_ref": [ "r107" ] }, "us-gaap_InterestRateContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestRateContractMember", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectofCashFlowHedgingonAOCIDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate swaps", "label": "Interest Rate Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate." } } }, "auth_ref": [ "r629", "r635", "r657" ] }, "hr_InterestRateSwapExpiringDecember12026Member": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "InterestRateSwapExpiringDecember12026Member", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsCashFlowHedgesofInterestRateRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap, Expiring December 1, 2026", "label": "Interest Rate Swap, Expiring December 1, 2026 [Member]", "documentation": "Interest Rate Swap, Expiring December 1, 2026" } } }, "auth_ref": [] }, "hr_InterestRateSwapExpiringDecember12027Member": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "InterestRateSwapExpiringDecember12027Member", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsCashFlowHedgesofInterestRateRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap, Expiring December 1, 2027", "label": "Interest Rate Swap, Expiring December 1, 2027 [Member]", "documentation": "Interest Rate Swap, Expiring December 1, 2027" } } }, "auth_ref": [] }, "hr_InterestRateSwapExpiringJune12026Member": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "InterestRateSwapExpiringJune12026Member", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsCashFlowHedgesofInterestRateRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap, Expiring June 1, 2026", "label": "Interest Rate Swap, Expiring June 1, 2026 [Member]", "documentation": "Interest Rate Swap, Expiring June 1, 2026" } } }, "auth_ref": [] }, "hr_InterestRateSwapExpiringJune12027Member": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "InterestRateSwapExpiringJune12027Member", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsCashFlowHedgesofInterestRateRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap, Expiring June 1, 2027", "label": "Interest Rate Swap, Expiring June 1, 2027 [Member]", "documentation": "Interest Rate Swap, Expiring June 1, 2027" } } }, "auth_ref": [] }, "hr_InterestRateSwapExpiringMay12026Member": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "InterestRateSwapExpiringMay12026Member", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsCashFlowHedgesofInterestRateRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap, Expiring May 1, 2026", "label": "Interest Rate Swap, Expiring May 1, 2026 [Member]", "documentation": "Interest Rate Swap, Expiring May 1, 2026" } } }, "auth_ref": [] }, "us-gaap_InterestRateSwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestRateSwapMember", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsCashFlowHedgesofInterestRateRiskDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectofCashFlowHedgingonAOCIDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueofDerivativeInstrumentsontheBalanceSheetDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Interest Rate Swaps", "terseLabel": "Settled interest rate swaps", "label": "Interest Rate Swap [Member]", "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period." } } }, "auth_ref": [ "r629", "r678", "r679" ] }, "us-gaap_InvestmentBuildingAndBuildingImprovements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentBuildingAndBuildingImprovements", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0, "order": 2.0 }, "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails": { "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets", "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Buildings and improvements", "terseLabel": "Building and improvements", "label": "Investment Building and Building Improvements", "documentation": "Aggregate of the carrying amounts as of the balance sheet date of investments in building and building improvements." } } }, "auth_ref": [ "r855" ] }, "hr_InvestmentInRealEstatePropertiesAndMortgageNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "InvestmentInRealEstatePropertiesAndMortgageNotes", "crdr": "debit", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross investment amount, total", "label": "Investment in Real Estate Properties and Mortgage Notes", "documentation": "Investment in real estate properties and mortgage notes." } } }, "auth_ref": [] }, "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets", "http://healthcarerealty.com/role/RealEstateInvestmentsUnconsolidatedJointVentureAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investments in unconsolidated joint ventures", "periodStartLabel": "Investments in unconsolidated joint ventures, beginning of period", "periodEndLabel": "Investments in unconsolidated joint ventures, end of period", "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures", "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate." } } }, "auth_ref": [ "r770" ] }, "hr_InvestmentsInAndAdvanceToAffiliatesSubsidiariesAssociatesAndJointVenturesInPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "InvestmentsInAndAdvanceToAffiliatesSubsidiariesAssociatesAndJointVenturesInPeriod", "crdr": "debit", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsUnconsolidatedJointVentureAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "New investments during the period", "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures in Period", "documentation": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures in Period" } } }, "auth_ref": [] }, "hr_JointVentureCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "JointVentureCarryingAmount", "crdr": "debit", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesVariableinterestentityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Joint venture, carrying amount", "label": "Joint Venture, Carrying Amount", "documentation": "Joint Venture, Carrying Amount" } } }, "auth_ref": [] }, "hr_JointVentureOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "JointVentureOwnershipPercentage", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsUnconsolidatedJointVentureAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Joint venture, ownership (in percentage)", "label": "Joint Venture, Ownership Percentage", "documentation": "Joint Venture, Ownership Percentage" } } }, "auth_ref": [] }, "hr_LTIPSeriesCUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "LTIPSeriesCUnitsMember", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "LTIP Series C Units", "label": "LTIP Series C Units [Member]", "documentation": "LTIP Series C Units" } } }, "auth_ref": [] }, "us-gaap_Land": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Land", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0, "order": 1.0 }, "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails": { "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets", "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Land", "terseLabel": "Land", "label": "Land", "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale." } } }, "auth_ref": [ "r769" ] }, "us-gaap_LandAvailableForDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LandAvailableForDevelopment", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Land held for development", "label": "Land Available for Development", "documentation": "Carrying amount of land available for development." } } }, "auth_ref": [ "r855" ] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/LeasesLeaseCostDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease expense", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r466", "r667" ] }, "us-gaap_LeaseCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostAbstract", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease cost", "label": "Lease, Cost [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://healthcarerealty.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Lease Cost", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r841" ] }, "hr_LeaseIntangibles": { "xbrltype": "monetaryItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "LeaseIntangibles", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails": { "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease intangibles", "label": "Lease Intangibles", "documentation": "Lease Intangibles" } } }, "auth_ref": [] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Allowance for Credit Losses, Interest Income, Income from Real Estate Notes Receivable:", "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LeasesOperatingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesOperatingAbstract", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other information", "label": "Leases, Operating [Abstract]" } } }, "auth_ref": [] }, "hr_LeasingAndPropertyManagementServicesProvidedAsPercentageOfNationwidePortfolio": { "xbrltype": "percentItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "LeasingAndPropertyManagementServicesProvidedAsPercentageOfNationwidePortfolio", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nationwide portfolio (percent)", "label": "Leasing and Property Management Services Provided as Percentage of Nationwide Portfolio", "documentation": "Leasing and Property Management Services Provided as Percentage of Nationwide Portfolio" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Entity [Axis]", "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LesseeFinanceLeaseDescriptionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeFinanceLeaseDescriptionAbstract", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease cost", "label": "Lessee, Finance Lease, Description [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeFinanceLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeFinanceLeasesTextBlock", "presentation": [ "http://healthcarerealty.com/role/Leases" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Finance Leases [Text Block]", "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability." } } }, "auth_ref": [ "r458" ] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Line Items]", "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r465" ] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionTable", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Table]", "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [ "r465" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://healthcarerealty.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Future Minimum Operating Lease Payments", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r842" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total undiscounted lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r473" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r473" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r473" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r473" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r473" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r842" ] }, "hr_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029 and thereafter", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Four", "documentation": "Lessee, Operating Lease, Liability, to be Paid, after Year Four" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Discount", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r473" ] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ground lease, initial term", "label": "Lessee, Operating Lease, Term of Contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r840" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://healthcarerealty.com/role/Leases" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r458" ] }, "us-gaap_LessorLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorLeasesPolicyTextBlock", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Investments in Leases - Financing Receivables, Net and Real Estate Notes Receivable and Interest Income", "label": "Lessor, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangements entered into by lessor." } } }, "auth_ref": [ "r183", "r184", "r185", "r475" ] }, "us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsFiscalYearMaturityAbstract", "presentation": [ "http://healthcarerealty.com/role/LeasesLessorAccountingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OPERATING", "label": "Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceived", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/LeasesLessorAccountingDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://healthcarerealty.com/role/LeasesLessorAccountingDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Lessor, Operating Lease, Payment to be Received", "documentation": "Amount of lease payments to be received by lessor for operating lease." } } }, "auth_ref": [ "r476" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedFourYears", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/LeasesLessorAccountingDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://healthcarerealty.com/role/LeasesLessorAccountingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessor, Operating Lease, Payment to be Received, Year Four", "documentation": "Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r476" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "presentation": [ "http://healthcarerealty.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Future Minimum Operating Lease Payments Receivable", "label": "Lessor, Operating Lease, Payment to be Received, Maturity [Table Text Block]", "documentation": "Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease." } } }, "auth_ref": [ "r843" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/LeasesLessorAccountingDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://healthcarerealty.com/role/LeasesLessorAccountingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessor, Operating Lease, Payment to be Received, Year One", "documentation": "Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r476" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/LeasesLessorAccountingDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://healthcarerealty.com/role/LeasesLessorAccountingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Lessor, Operating Lease, Payment to be Received, Remainder of Fiscal Year", "documentation": "Amount of lease payment to be received by lessor for operating lease in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r843" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedThreeYears", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/LeasesLessorAccountingDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://healthcarerealty.com/role/LeasesLessorAccountingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessor, Operating Lease, Payment to be Received, Year Three", "documentation": "Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r476" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/LeasesLessorAccountingDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://healthcarerealty.com/role/LeasesLessorAccountingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessor, Operating Lease, Payment to be Received, Year Two", "documentation": "Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r476" ] }, "hr_LessorOperatingLeasePaymenttobeReceivedafterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "LessorOperatingLeasePaymenttobeReceivedafterYearFour", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/LeasesLessorAccountingDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://healthcarerealty.com/role/LeasesLessorAccountingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029 and thereafter", "label": "Lessor, Operating Lease, Payment to be Received, after Year Four", "documentation": "Lessor, Operating Lease, Payment to be Received, after Year Four" } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r25", "r239", "r292", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r422", "r425", "r426", "r447", "r550", "r640", "r684", "r801", "r846", "r847" ] }, "us-gaap_LiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAbstract", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Liabilities", "label": "Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesConsolidatedbalancesheetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets", "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesConsolidatedbalancesheetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r129", "r168", "r508", "r668", "r782", "r790", "r839" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets", "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesConsolidatedbalancesheetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY", "terseLabel": "Liabilities:", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 }, "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets", "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Liabilities of assets held for sale", "totalLabel": "Liabilities of assets held for sale", "label": "Disposal Group, Including Discontinued Operation, Liabilities", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r2", "r120", "r121", "r147", "r202", "r203" ] }, "us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Limited partners ownership interest (in percent)", "label": "Limited Liability Company or Limited Partnership, Members or Limited Partners, Ownership Interest", "documentation": "Percentage investment held by members or limited partners of limited liability company (LLC) or limited partnership (LP)." } } }, "auth_ref": [ "r48" ] }, "hr_LimitedLiabilityCompanyOneMember": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "LimitedLiabilityCompanyOneMember", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsUnconsolidatedJointVentureAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Limited Liability Company One", "label": "Limited Liability Company One [Member]", "documentation": "Limited Liability Company One" } } }, "auth_ref": [] }, "us-gaap_LimitedPartnersCapitalAccountUnitsOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LimitedPartnersCapitalAccountUnitsOutstanding", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Limited partner's capital, units outstanding (in shares)", "label": "Limited Partners' Capital Account, Units Outstanding", "documentation": "The number of limited partner units outstanding." } } }, "auth_ref": [ "r155" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit facility", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r24" ] }, "us-gaap_LineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditMember", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit", "label": "Line of Credit [Member]", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongLivedAssetsHeldForSaleLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongLivedAssetsHeldForSaleLineItems", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long Lived Assets Held-for-sale [Line Items]", "label": "Long-Lived Assets Held-for-Sale [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets", "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Notes and bonds payable", "terseLabel": "Notes and bonds payable", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r23", "r166", "r333", "r347", "r645", "r646", "r856" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails", "http://healthcarerealty.com/role/NotesandBondsPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r28" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails", "http://healthcarerealty.com/role/NotesandBondsPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r28", "r54" ] }, "hr_LosAngelesCaliforniaMember": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "LosAngelesCaliforniaMember", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsUnconsolidatedJointVentureAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Los Angeles, California [Member]", "label": "Los Angeles, California [Member]", "documentation": "Los Angeles, California [Member]" } } }, "auth_ref": [] }, "hr_ManagementFeeIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "ManagementFeeIncomeMember", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Management fee income/other", "label": "Management Fee Income [Member]", "documentation": "Management Fee Income [Member]" } } }, "auth_ref": [] }, "hr_MarketCondition2Member": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "MarketCondition2Member", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Relative TSR Component", "label": "Market Condition 2 [Member]", "documentation": "Market Condition 2" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails", "http://healthcarerealty.com/role/NotesandBondsPayableDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]", "documentation": "Upper limit of the provided range." } } }, "auth_ref": [ "r307", "r308", "r309", "r310", "r383", "r489", "r524", "r541", "r542", "r596", "r598", "r600", "r601", "r607", "r626", "r627", "r642", "r649", "r662", "r670", "r805", "r848", "r849", "r850", "r851", "r852", "r853" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r727" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r727" ] }, "us-gaap_MediumTermNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MediumTermNotesMember", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Medium-term notes", "label": "Medium-term Notes [Member]", "documentation": "Debt instruments with maturities ranging from five to ten years." } } }, "auth_ref": [] }, "hr_MergerRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "MergerRelatedCosts", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "hr_OperatingExpensesandCostofGoodsSold", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Merger-related costs", "label": "Merger Related Costs", "documentation": "Merger Related Costs" } } }, "auth_ref": [] }, "hr_MezzanineLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "MezzanineLoanMember", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesScheduleofNotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mezzanine loans", "label": "Mezzanine Loan [Member]", "documentation": "Mezzanine Loan" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails", "http://healthcarerealty.com/role/NotesandBondsPayableDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]", "documentation": "Lower limit of the provided range." } } }, "auth_ref": [ "r307", "r308", "r309", "r310", "r383", "r489", "r524", "r541", "r542", "r596", "r598", "r600", "r601", "r607", "r626", "r627", "r642", "r649", "r662", "r670", "r805", "r848", "r849", "r850", "r851", "r852", "r853" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Non-controlling interest", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r33", "r167", "r239", "r292", "r311", "r313", "r314", "r315", "r318", "r319", "r447", "r507", "r553" ] }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsidiary, ownership percentage, noncontrolling owner", "label": "Subsidiary, Ownership Percentage, Noncontrolling Owner", "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity." } } }, "auth_ref": [] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r746" ] }, "hr_MortgageLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "MortgageLoanMember", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesScheduleofNotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mortgage loans", "label": "Mortgage Loan [Member]", "documentation": "Mortgage Loan" } } }, "auth_ref": [] }, "us-gaap_MortgageLoanRelatedToPropertySales1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MortgageLoanRelatedToPropertySales1", "crdr": "credit", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Mortgage note receivables taken in connection with sale of real estate", "label": "Mortgage Loan Related to Property Sales", "documentation": "Mortgage loan related to property sales in noncash investing and financing activities." } } }, "auth_ref": [ "r42", "r43", "r44" ] }, "us-gaap_MortgageLoansOnRealEstateCommercialAndConsumerNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MortgageLoansOnRealEstateCommercialAndConsumerNet", "crdr": "debit", "presentation": [ "http://healthcarerealty.com/role/FairValueofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real estate notes receivable", "label": "Mortgage Loans on Real Estate, Commercial and Consumer, Net", "documentation": "The balance represents the amount of loans that are secured by real estate mortgages, offset by the reserve to cover probable credit losses on the loan portfolio." } } }, "auth_ref": [ "r500" ] }, "srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsUnconsolidatedJointVentureAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real Estate, Type of Property [Axis]", "label": "Real Estate, Type of Property [Axis]", "documentation": "Information by type of real estate property." } } }, "auth_ref": [ "r189", "r199", "r614", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624" ] }, "srt_MortgageLoansOnRealEstateNamePropertyTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MortgageLoansOnRealEstateNamePropertyTypeDomain", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsUnconsolidatedJointVentureAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real Estate [Domain]", "label": "Real Estate [Domain]", "documentation": "Land and any structures permanently fixed to it." } } }, "auth_ref": [ "r189", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624" ] }, "hr_MortgageNotesPayableNetMember": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "MortgageNotesPayableNetMember", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mortgage notes payable", "label": "Mortgage Notes Payable, Net [Member]", "documentation": "Mortgage Notes Payable, Net [Member]" } } }, "auth_ref": [] }, "us-gaap_MortgagesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MortgagesMember", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails", "http://healthcarerealty.com/role/NotesandBondsPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mortgages", "label": "Mortgages [Member]", "documentation": "A loan to finance the purchase of real estate where the lender has a lien on the property as collateral for the loan." } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r754" ] }, "stpr_NC": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2023", "localname": "NC", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesScheduleofNotesReceivableDetails", "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesVariableinterestentityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "North Carolina", "label": "NORTH CAROLINA" } } }, "auth_ref": [] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r728" ] }, "hr_NatureOfOperationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "NatureOfOperationsPolicyTextBlock", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Business Overview", "label": "Nature of Operations [Policy Text Block]", "documentation": "Nature Of Operations Policy." } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r232" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "FINANCING ACTIVITIES", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash (used in) provided by investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r232" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "INVESTING ACTIVITIES", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r141", "r142", "r143" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "OPERATING ACTIVITIES", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofOperations", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss attributable to common stockholders", "terseLabel": "Net income (loss)", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r132", "r143", "r170", "r203", "r215", "r218", "r222", "r239", "r244", "r246", "r247", "r248", "r249", "r252", "r253", "r257", "r269", "r276", "r280", "r282", "r292", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r442", "r447", "r512", "r571", "r589", "r590", "r641", "r682", "r801" ] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0 }, "http://healthcarerealty.com/role/StockholdersEquityComputationofBasicandDilutedEarningsLossPerCommonShareDetails": { "parentTag": "hr_NetIncomeLossfromContinuingOperationsAvailabletoCommonStockholdersBasic", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofOperations", "http://healthcarerealty.com/role/StockholdersEquityComputationofBasicandDilutedEarningsLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Net loss attributable to non-controlling interests", "negatedTerseLabel": "Loss attributable to non-controlling interest", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r86", "r159", "r215", "r218", "r252", "r253", "r511", "r773" ] }, "hr_NetIncomeLossfromContinuingOperationsAvailabletoCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "NetIncomeLossfromContinuingOperationsAvailabletoCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/StockholdersEquityComputationofBasicandDilutedEarningsLossPerCommonShareDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityComputationofBasicandDilutedEarningsLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss applicable to common stockholders - basic", "label": "Net Income (Loss) from Continuing Operations Available to Common Stockholders, Basic", "documentation": "Net Income (Loss) from Continuing Operations Available to Common Stockholders, Basic" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "New Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "hr_NonControllingInterestHoldersMember": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "NonControllingInterestHoldersMember", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Controlling Interest Holders", "label": "Non-Controlling Interest Holders [Member]", "documentation": "Non-Controlling Interest Holders" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r727" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r697", "r708", "r718", "r735", "r743" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r725" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r724" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r735" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r754" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r754" ] }, "hr_NonVestedStockAwardMember": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "NonVestedStockAwardMember", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-vested Stock Award", "label": "Non Vested Stock Award [Member]", "documentation": "Non Vested Stock Award" } } }, "auth_ref": [] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestMember", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofEquityandRedeemableNonControllingInterests" ], "lang": { "en-us": { "role": { "terseLabel": "Non-controlling Interests", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r71", "r365", "r784", "r785", "r786", "r862" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total other income (expense)", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r136" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "verboseLabel": "Other income (expense)", "label": "Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "hr_NotesReceivableCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "NotesReceivableCarryingAmount", "crdr": "debit", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesVariableinterestentityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notes receivable, carrying amount", "label": "Notes Receivable, Carrying Amount", "documentation": "Notes Receivable, Carrying Amount" } } }, "auth_ref": [] }, "us-gaap_NotesReceivableFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesReceivableFairValueDisclosure", "crdr": "debit", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesScheduleofNotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CARRYING VALUE", "label": "Notes Receivable, Fair Value Disclosure", "documentation": "Fair value portion of an agreement for an unconditional promise by the maker to pay the holder a definite sum of money at a future date." } } }, "auth_ref": [ "r838" ] }, "hr_NotesReceivableInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "NotesReceivableInterestRate", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesScheduleofNotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "INTEREST RATE", "label": "Notes Receivable, Interest Rate", "documentation": "Notes Receivable, Interest Rate" } } }, "auth_ref": [] }, "hr_NotesReceivableMaximumLoanCommitment": { "xbrltype": "monetaryItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "NotesReceivableMaximumLoanCommitment", "crdr": "debit", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesScheduleofNotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "MAXIMUM LOAN COMMITMENT", "label": "Notes Receivable, Maximum Loan Commitment", "documentation": "Notes Receivable, Maximum Loan Commitment" } } }, "auth_ref": [] }, "us-gaap_NotesReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesReceivableMember", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notes Receivable", "label": "Notes Receivable [Member]", "documentation": "An amount representing an agreement for an unconditional promise by the maker to pay the Entity (holder) a definite sum of money at a future date(s) within one year of the balance sheet date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics." } } }, "auth_ref": [] }, "us-gaap_NumberOfInterestRateDerivativesHeld": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfInterestRateDerivativesHeld", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsCashFlowHedgesofInterestRateRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of instruments", "label": "Number of Interest Rate Derivatives Held", "documentation": "Number of interest rate derivative instruments held by the entity at the reporting date." } } }, "auth_ref": [ "r90", "r91" ] }, "hr_NumberOfJointVentures": { "xbrltype": "integerItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "NumberOfJointVentures", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of joint ventures", "label": "Number of Joint Ventures", "documentation": "Number of Joint Ventures" } } }, "auth_ref": [] }, "hr_NumberOfNotesReceivable": { "xbrltype": "integerItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "NumberOfNotesReceivable", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails", "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesVariableinterestentityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of notes receivable", "label": "Number of Notes Receivable", "documentation": "Number of Notes Receivable" } } }, "auth_ref": [] }, "hr_NumberOfPropertiesClassifiedAsHeldForSale": { "xbrltype": "integerItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "NumberOfPropertiesClassifiedAsHeldForSale", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of owned real estate properties", "label": "Number of Properties Classified as Held for Sale", "documentation": "Number of Properties Classified as Held for Sale" } } }, "auth_ref": [] }, "hr_NumberOfPropertiesHeldInUnconsolidatedJointVentures": { "xbrltype": "integerItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "NumberOfPropertiesHeldInUnconsolidatedJointVentures", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of properties held in unconsolidated joint ventures", "label": "Number of Properties Held in Unconsolidated Joint Ventures", "documentation": "Number of Properties Held in Unconsolidated Joint Ventures" } } }, "auth_ref": [] }, "hr_NumberOfPropertiesMeasuredAtFairValue": { "xbrltype": "integerItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "NumberOfPropertiesMeasuredAtFairValue", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of properties measured at fair value", "label": "Number of Properties Measured at Fair Value", "documentation": "Number of Properties Measured at Fair Value" } } }, "auth_ref": [] }, "hr_NumberOfPropertyDispositions": { "xbrltype": "integerItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "NumberOfPropertyDispositions", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of property dispositions", "label": "Number of Property Dispositions", "documentation": "Number of Property Dispositions" } } }, "auth_ref": [] }, "hr_NumberOfRealEstateInvestments": { "xbrltype": "integerItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "NumberOfRealEstateInvestments", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of real estate properties", "label": "Number of Real Estate Investments", "documentation": "Number of real estate investments." } } }, "auth_ref": [] }, "hr_NumberOfRealEstateNotesReceivable": { "xbrltype": "integerItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "NumberOfRealEstateNotesReceivable", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of real estate notes receivable", "label": "Number of Real Estate Notes Receivable", "documentation": "Number of Real Estate Notes Receivable" } } }, "auth_ref": [] }, "us-gaap_NumberOfRealEstateProperties": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfRealEstateProperties", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesVariableinterestentityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of owned real estate properties", "label": "Number of Real Estate Properties", "documentation": "The number of real estate properties owned as of the balance sheet date." } } }, "auth_ref": [] }, "hr_NumberOfRecognizedLeaseFinancialReceivables": { "xbrltype": "integerItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "NumberOfRecognizedLeaseFinancialReceivables", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of recognized lease financial receivables", "label": "Number of Recognized Lease Financial Receivables", "documentation": "Number of Recognized Lease Financial Receivables" } } }, "auth_ref": [] }, "hr_NumberOfVariableInterestEntities": { "xbrltype": "integerItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "NumberOfVariableInterestEntities", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of variable interest entities", "label": "Number of Variable Interest Entities", "documentation": "Number of Variable Interest Entities" } } }, "auth_ref": [] }, "hr_NumberofGroundLeasesExcludingPrepaidLeases": { "xbrltype": "integerItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "NumberofGroundLeasesExcludingPrepaidLeases", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of non-prepaid ground leases", "label": "Number of Ground Leases, Excluding Prepaid Leases", "documentation": "Number of Ground Leases, Excluding Prepaid Leases" } } }, "auth_ref": [] }, "hr_NumberofGroundLeasesPrepaid": { "xbrltype": "integerItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "NumberofGroundLeasesPrepaid", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of prepaid ground leases", "label": "Number of Ground Leases Prepaid", "documentation": "Number of Ground Leases Prepaid" } } }, "auth_ref": [] }, "hr_OneMember": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "OneMember", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "One", "label": "One [Member]", "documentation": "One" } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "verboseLabel": "Expenses", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "hr_OperatingExpensesandCostofGoodsSold": { "xbrltype": "monetaryItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "OperatingExpensesandCostofGoodsSold", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Expenses", "label": "Operating Expenses and Cost of Goods Sold", "documentation": "Operating Expenses and Cost of Goods Sold" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/LeasesLeaseCostDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease expense", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r468", "r667" ] }, "us-gaap_OperatingLeaseLeaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLeaseIncome", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofOperations", "http://healthcarerealty.com/role/LeasesLeaseIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rental income", "label": "Operating Lease, Lease Income", "documentation": "Amount of operating lease income from lease payments and variable lease payments paid and payable to lessor. Includes, but is not limited to, variable lease payments not included in measurement of lease receivable." } } }, "auth_ref": [ "r266", "r474", "r477" ] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OPERATING", "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails": { "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 2.0 }, "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 }, "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets", "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "verboseLabel": "Lease liabilities", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r460" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating cash flows outflows related to operating leases", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r464", "r470" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails": { "parentTag": "hr_AssetsHeldForSaleAndDiscontinuedOperationsNet", "weight": 1.0, "order": 3.0 }, "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets", "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets", "verboseLabel": "Operating lease right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r459" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average discount rate - operating leases", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r472", "r667" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average years remaining lease term (excluding renewal options) - operating leases", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r471", "r667" ] }, "hr_OperatingPartnershipPerformanceUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "OperatingPartnershipPerformanceUnitsMember", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityScheduleofStockOptionsValuationAssumptionsDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Partnership Performance Units", "label": "Operating Partnership Performance Units [Member]", "documentation": "Operating Partnership Performance Units" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Principles of Consolidation:", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherAmortizationOfDeferredCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAmortizationOfDeferredCharges", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Other amortization", "label": "Amortization of Other Deferred Charges", "documentation": "Amount of amortization of other deferred costs recognized in the income statement." } } }, "auth_ref": [ "r10", "r134" ] }, "us-gaap_OtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssets", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Other assets, net", "label": "Other Assets", "documentation": "Amount of assets classified as other." } } }, "auth_ref": [ "r163", "r206", "r502", "r684" ] }, "us-gaap_OtherAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsMember", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueofDerivativeInstrumentsontheBalanceSheetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets [Member]", "documentation": "Primary financial statement caption encompassing other assets." } } }, "auth_ref": [ "r94", "r105" ] }, "us-gaap_OtherCommitmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCommitmentsAxis", "presentation": [ "http://healthcarerealty.com/role/CommitmentandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Commitments [Axis]", "label": "Other Commitments [Axis]", "documentation": "Information by type of other commitment." } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCommitmentsDomain", "presentation": [ "http://healthcarerealty.com/role/CommitmentandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Commitments [Domain]", "label": "Other Commitments [Domain]", "documentation": "Other future obligation." } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCommitmentsLineItems", "presentation": [ "http://healthcarerealty.com/role/CommitmentandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Commitments [Line Items]", "label": "Other Commitments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCommitmentsTable", "presentation": [ "http://healthcarerealty.com/role/CommitmentandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Commitments [Table]", "label": "Other Commitments [Table]", "documentation": "Disclosure of information about obligations resulting from other commitments." } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate derivatives", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofEquityandRedeemableNonControllingInterests" ], "lang": { "en-us": { "role": { "terseLabel": "Gains (losses) arising during the period on interest rate swaps", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax", "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r212", "r213" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectofCashFlowHedgingonAOCIDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "(Gain)/loss recognized in AOCI on derivative", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r212", "r213", "r427", "r428", "r431" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofEquityandRedeemableNonControllingInterests", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectofCashFlowHedgingonAOCIDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Reclassification adjustments for gains included in interest expense", "negatedTerseLabel": "Reclassification adjustments for gains included in net income (interest expense)", "negatedNetLabel": "(Gain) Loss, Reclassified from AOCI into income", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax", "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r213", "r214" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive income", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r14", "r21", "r216", "r219", "r225", "r448", "r449", "r454", "r492", "r513", "r771", "r772" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherFiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherFiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Lease intangibles", "label": "Other Finite-Lived Intangible Assets, Gross", "documentation": "Amount before accumulated amortization of finite-lived intangible assets classified as other." } } }, "auth_ref": [ "r146" ] }, "hr_OtherInvestorsMember": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "OtherInvestorsMember", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Investors", "label": "Other Investors [Member]", "documentation": "Other Investors" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilities", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Other liabilities", "label": "Other Liabilities", "documentation": "Amount of liabilities classified as other." } } }, "auth_ref": [ "r117", "r498", "r546", "r547", "r684", "r859" ] }, "us-gaap_OtherLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesMember", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueofDerivativeInstrumentsontheBalanceSheetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other liabilities", "label": "Other Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other liabilities." } } }, "auth_ref": [ "r94", "r105" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Interest and other income, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r137" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r727" ] }, "srt_OtherPropertyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OtherPropertyMember", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsUnconsolidatedJointVentureAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Parking Garages", "label": "Other Property [Member]", "documentation": "Property classified as other." } } }, "auth_ref": [ "r632", "r633", "r865", "r866" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r695", "r706", "r716", "r741" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r698", "r709", "r719", "r744" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r698", "r709", "r719", "r744" ] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipAxis", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsUnconsolidatedJointVentureAcquisitionsDetails", "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Axis]", "label": "Ownership [Axis]", "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment." } } }, "auth_ref": [] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipDomain", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsUnconsolidatedJointVentureAcquisitionsDetails", "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Domain]", "label": "Ownership [Domain]", "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment." } } }, "auth_ref": [] }, "us-gaap_ParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ParentMember", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofEquityandRedeemableNonControllingInterests" ], "lang": { "en-us": { "role": { "terseLabel": "Total Stockholders\u2019 Equity", "label": "Parent [Member]", "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests." } } }, "auth_ref": [] }, "hr_ParkingIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "ParkingIncomeMember", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Parking income", "label": "Parking Income [Member]", "documentation": "Parking Income [Member]" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r723" ] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Common stock redemptions", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r40" ] }, "us-gaap_PaymentsOfDividendsCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDividendsCommonStock", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Dividends paid", "label": "Payments of Ordinary Dividends, Common Stock", "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity." } } }, "auth_ref": [ "r40" ] }, "us-gaap_PaymentsToAcquireFinanceReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireFinanceReceivables", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Investment in financing receivable", "label": "Payments to Acquire Finance Receivables", "documentation": "The cash outflow for the purchase of amounts due from customers, clients, lessees, borrowers, or others under the terms of its agreements therewith." } } }, "auth_ref": [ "r139" ] }, "us-gaap_PaymentsToAcquireInterestInJointVenture": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireInterestInJointVenture", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Investments in unconsolidated joint ventures", "label": "Payments to Acquire Interest in Joint Venture", "documentation": "The cash outflow associated with the investment in or advances to an entity in which the reporting entity shares control of the entity with another party or group." } } }, "auth_ref": [ "r38" ] }, "us-gaap_PaymentsToAcquireNotesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireNotesReceivable", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Funding of mortgages and notes receivable", "label": "Payments to Acquire Notes Receivable", "documentation": "The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics." } } }, "auth_ref": [ "r37" ] }, "us-gaap_PaymentsToAcquireOtherProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireOtherProductiveAssets", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Additional long-lived assets", "label": "Payments to Acquire Other Productive Assets", "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other." } } }, "auth_ref": [ "r140" ] }, "us-gaap_PaymentsToAcquireRealEstate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireRealEstate", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Acquisitions of real estate", "label": "Payments to Acquire Real Estate", "documentation": "The cash outflow from the acquisition of a piece of land, anything permanently fixed to it, including buildings, structures on it and so forth; includes real estate intended to generate income for the owner; excludes real estate acquired for use by the owner." } } }, "auth_ref": [ "r140" ] }, "us-gaap_PaymentsToDevelopRealEstateAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToDevelopRealEstateAssets", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Development of real estate", "label": "Payments to Develop Real Estate Assets", "documentation": "Payments to develop real estate assets is the process of adding improvements on or to a parcel of land. Such improvements may include drainage, utilities, subdividing, access, buildings, and any combination of these elements; and are generally classified as cash flow from investing activities." } } }, "auth_ref": [ "r140" ] }, "us-gaap_PaymentsToMinorityShareholders": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToMinorityShareholders", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Distributions to non-controlling interest holders", "label": "Payments to Noncontrolling Interests", "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest." } } }, "auth_ref": [ "r39" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r726" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r726" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r725" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r735" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r728" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r724" ] }, "hr_PercentageOfRestrictedStockUnits": { "xbrltype": "percentItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "PercentageOfRestrictedStockUnits", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of restricted stock units", "label": "Percentage Of Restricted Stock Units", "documentation": "Percentage Of Restricted Stock Units" } } }, "auth_ref": [] }, "hr_PerformanceConditionsMember": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "PerformanceConditionsMember", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance conditions", "label": "Performance Conditions [Member]", "documentation": "Performance Conditions" } } }, "auth_ref": [] }, "hr_PersonalProperty": { "xbrltype": "monetaryItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "PersonalProperty", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Personal property", "label": "Personal Property", "documentation": "Personal property." } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails", "http://healthcarerealty.com/role/StockholdersEquitySummaryoftheActivityUndertheIncentivePlanandRSUActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Axis]", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails", "http://healthcarerealty.com/role/StockholdersEquitySummaryoftheActivityUndertheIncentivePlanandRSUActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Domain]", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833" ] }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PortionAtFairValueFairValueDisclosureMember", "presentation": [ "http://healthcarerealty.com/role/FairValueofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Portion at Fair Value Measurement", "label": "Portion at Fair Value Measurement [Member]", "documentation": "Measured at fair value for financial reporting purposes." } } }, "auth_ref": [ "r445" ] }, "hr_PowayCAMember": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "PowayCAMember", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesScheduleofNotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Poway, CA", "label": "Poway, CA [Member]", "documentation": "Poway, CA" } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "verboseLabel": "Preferred stock, par value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r124", "r350" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "verboseLabel": "Preferred stock, authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r124", "r552" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "verboseLabel": "Preferred stock, issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r124", "r350" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "verboseLabel": "Preferred stock, outstanding (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r124", "r552", "r569", "r862", "r863" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Preferred stock, $.01 par value per share; 200,000 shares authorized; none issued and outstanding", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r124", "r505", "r668" ] }, "us-gaap_ProceedsFromCollectionOfFinanceReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromCollectionOfFinanceReceivables", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in financing receivable", "label": "Proceeds from Collection of Finance Receivables", "documentation": "The cash inflow associated with the collection of receivables arising from the financing of goods and services." } } }, "auth_ref": [ "r776" ] }, "hr_ProceedsFromContributionsFromRedeemableNoncontrollingInterests": { "xbrltype": "monetaryItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "ProceedsFromContributionsFromRedeemableNoncontrollingInterests", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Contributions from redeemable non-controlling interests", "label": "Proceeds from Contributions from Redeemable Noncontrolling Interests", "documentation": "Proceeds from Contributions from Redeemable Noncontrolling Interests" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Net proceeds from issuance of common stock", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r6" ] }, "us-gaap_ProceedsFromRepaymentsOfLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromRepaymentsOfLinesOfCredit", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Net borrowings on unsecured credit facility", "label": "Proceeds from (Repayments of) Lines of Credit", "documentation": "The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets)." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleAndCollectionOfNotesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleAndCollectionOfNotesReceivable", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from notes receivable repayments", "label": "Proceeds from Sale and Collection of Notes Receivable", "documentation": "The cash inflow associated with the proceeds from sale of notes receivable, as well as principal collections from a borrowing supported by a written promise to pay an obligation (note receivable)." } } }, "auth_ref": [ "r36" ] }, "us-gaap_ProceedsFromSaleOfPropertyHeldForSale": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfPropertyHeldForSale", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sales of real estate properties and additional long-lived assets", "label": "Proceeds from Sale, Property, Held-for-Sale", "documentation": "The cash inflow from the sale of formerly productive land held for sale, anything permanently fixed to it, including buildings, structures on it, and so forth." } } }, "auth_ref": [ "r138" ] }, "us-gaap_ProceedsFromSaleOfRealEstateHeldforinvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfRealEstateHeldforinvestment", "crdr": "debit", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale, real estate, held-for-investment", "label": "Proceeds from Sale, Real Estate, Held-for-Investment", "documentation": "Cash received from the sale of real estate that is held for investment, that is, it is part of an investing activity during the period." } } }, "auth_ref": [ "r138" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]", "documentation": "Information by product and service, or group of similar products and similar services." } } }, "auth_ref": [ "r283", "r490", "r518", "r519", "r520", "r521", "r522", "r523", "r630", "r650", "r669", "r763", "r798", "r799", "r806", "r857" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]", "documentation": "Product or service, or a group of similar products or similar services." } } }, "auth_ref": [ "r283", "r490", "r518", "r519", "r520", "r521", "r522", "r523", "r630", "r650", "r669", "r763", "r798", "r799", "r806", "r857" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://healthcarerealty.com/role/StockholdersEquityComputationofBasicandDilutedEarningsLossPerCommonShareDetails": { "parentTag": "hr_NetIncomeLossfromContinuingOperationsAvailabletoCommonStockholdersBasic", "weight": 1.0, "order": 1.0 }, "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 }, "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows", "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofEquityandRedeemableNonControllingInterests", "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofOperations", "http://healthcarerealty.com/role/StockholdersEquityComputationofBasicandDilutedEarningsLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "terseLabel": "Net loss", "verboseLabel": "Net loss", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r203", "r215", "r218", "r231", "r239", "r244", "r252", "r253", "r269", "r276", "r280", "r282", "r292", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r420", "r423", "r424", "r442", "r447", "r497", "r510", "r534", "r571", "r589", "r590", "r641", "r664", "r665", "r683", "r773", "r801" ] }, "hr_PropertyEntitiesNotDeterminedToBeVIEsMember": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "PropertyEntitiesNotDeterminedToBeVIEsMember", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property Entities Not Determined to be VIEs", "label": "Property Entities Not Determined to be VIEs [Member]", "documentation": "Property Entities Not Determined to be VIEs" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r723" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r723" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails", "http://healthcarerealty.com/role/NotesandBondsPayableDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r307", "r308", "r309", "r310", "r376", "r383", "r409", "r410", "r411", "r485", "r489", "r524", "r541", "r542", "r596", "r598", "r600", "r601", "r607", "r626", "r627", "r642", "r649", "r662", "r670", "r673", "r796", "r805", "r849", "r850", "r851", "r852", "r853" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails", "http://healthcarerealty.com/role/NotesandBondsPayableDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r307", "r308", "r309", "r310", "r376", "r383", "r409", "r410", "r411", "r485", "r489", "r524", "r541", "r542", "r596", "r598", "r600", "r601", "r607", "r626", "r627", "r642", "r649", "r662", "r670", "r673", "r796", "r805", "r849", "r850", "r851", "r852", "r853" ] }, "us-gaap_RealEstateAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateAbstract", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real Estate Notes Receivable:", "label": "Real Estate [Abstract]" } } }, "auth_ref": [] }, "hr_RealEstateDispositionsAndMortgageNoteRepaymentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "RealEstateDispositionsAndMortgageNoteRepaymentsAxis", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real Estate Dispositions and Mortgage Note Repayments [Axis]", "label": "Real Estate Dispositions and Mortgage Note Repayments [Axis]", "documentation": "Real Estate Dispositions and Mortgage Note Repayments [Axis]" } } }, "auth_ref": [] }, "hr_RealEstateDispositionsAndMortgageNoteRepaymentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "RealEstateDispositionsAndMortgageNoteRepaymentsDomain", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real Estate Dispositions and Mortgage Note Repayments [Domain]", "label": "Real Estate Dispositions and Mortgage Note Repayments [Domain]", "documentation": "Real Estate Dispositions and Mortgage Note Repayments [Domain]" } } }, "auth_ref": [] }, "hr_RealEstateDispositionsMember": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "RealEstateDispositionsMember", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real Estate Dispositions", "label": "Real Estate Dispositions [Member]", "documentation": "Real Estate Dispositions [Member]" } } }, "auth_ref": [] }, "us-gaap_RealEstateInvestmentPropertyAccumulatedDepreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateInvestmentPropertyAccumulatedDepreciation", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_RealEstateInvestmentPropertyNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets", "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less accumulated depreciation and amortization", "negatedTerseLabel": "Accumulated depreciation", "label": "Real Estate Investment Property, Accumulated Depreciation", "documentation": "The cumulative amount of depreciation for real estate property held for investment purposes." } } }, "auth_ref": [ "r499" ] }, "us-gaap_RealEstateInvestmentPropertyAtCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateInvestmentPropertyAtCost", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_RealEstateInvestmentPropertyNet", "weight": 1.0, "order": 1.0 }, "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets", "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total real estate properties", "label": "Real Estate Investment Property, at Cost", "documentation": "Amount of real estate investment property which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; and (7) other real estate investments." } } }, "auth_ref": [ "r501" ] }, "us-gaap_RealEstateInvestmentPropertyNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateInvestmentPropertyNet", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 }, "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesConsolidatedbalancesheetsDetails": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 }, "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails": { "parentTag": "hr_AssetsHeldForSaleAndDiscontinuedOperationsNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets", "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails", "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesConsolidatedbalancesheetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total real estate properties, net", "verboseLabel": "Net real estate investments", "terseLabel": "Real estate assets held for sale, net", "label": "Real Estate Investment Property, Net", "documentation": "Amount of real estate investment property, net of accumulated depreciation, which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; and (7) other real estate investments." } } }, "auth_ref": [ "r855" ] }, "us-gaap_RealEstateInvestmentPropertyNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateInvestmentPropertyNetAbstract", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Real estate properties", "label": "Real Estate Investment Property, Net [Abstract]" } } }, "auth_ref": [] }, "hr_RealEstateInvestmentsPropertyOwnedInNumberOfStates": { "xbrltype": "integerItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "RealEstateInvestmentsPropertyOwnedInNumberOfStates", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Number of states that the company owns real estate in, whole units", "label": "Real Estate Investments Property Owned in Number of States", "documentation": "Real estate investments property owned in number of states." } } }, "auth_ref": [] }, "us-gaap_RealEstateLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateLineItems", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsUnconsolidatedJointVentureAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real Estate [Line Items]", "label": "Real Estate [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r626" ] }, "hr_RealEstateNotesReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "RealEstateNotesReceivableNet", "crdr": "debit", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in financing receivable, net", "label": "Real Estate Notes Receivable, Net", "documentation": "Real Estate Notes Receivable, Net" } } }, "auth_ref": [] }, "hr_RealEstatePropertiesHeldInJointVenturesMember": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "RealEstatePropertiesHeldInJointVenturesMember", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real Estate Properties Held in Joint Ventures", "label": "Real Estate Properties Held in Joint Ventures [Member]", "documentation": "Real Estate Properties Held in Joint Ventures" } } }, "auth_ref": [] }, "us-gaap_RealEstatePropertiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstatePropertiesLineItems", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real Estate Properties [Line Items]", "label": "Real Estate Properties [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_RealEstateTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateTable", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsUnconsolidatedJointVentureAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real Estate [Table]", "label": "Real Estate [Table]", "documentation": "Disclosure of information about real estate investment companies including, but not limited to, real estate investment trusts, real estate owned, retail land sales, and time share transactions." } } }, "auth_ref": [ "r626" ] }, "hr_ReceivablesAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "ReceivablesAndOtherAssets", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesConsolidatedbalancesheetsDetails": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesConsolidatedbalancesheetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Receivables and other assets", "label": "Receivables And Other Assets", "documentation": "Receivables And Other Assets" } } }, "auth_ref": [] }, "hr_ReconciliationOfBeginningAndEndingCommonStockOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "ReconciliationOfBeginningAndEndingCommonStockOutstandingRollForward", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityReconciliationofBeginningandEndingCommonStockOutstandingDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Reconciliation of the beginning and ending common stock outstanding", "label": "Reconciliation of Beginning and Ending Common Stock Outstanding [Roll Forward]", "documentation": "Reconciliation of the beginning and ending common stock outstanding." } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r690", "r701", "r711", "r736" ] }, "hr_RedevelopmentPropertiesMember": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "RedevelopmentPropertiesMember", "presentation": [ "http://healthcarerealty.com/role/CommitmentandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Redevelopment Properties", "label": "Redevelopment Properties [Member]", "documentation": "Redevelopment Properties" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfDebt", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayments of notes and bonds payable", "label": "Repayments of Debt", "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation." } } }, "auth_ref": [ "r777" ] }, "us-gaap_ReportingUnitAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReportingUnitAxis", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reporting Unit [Axis]", "label": "Reporting Unit [Axis]", "documentation": "Information by reporting unit." } } }, "auth_ref": [ "r301", "r302", "r643" ] }, "hr_ReportingUnitCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "ReportingUnitCarryingValue", "crdr": "debit", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reporting unit, carrying value", "label": "Reporting Unit, Carrying Value", "documentation": "Reporting Unit, Carrying Value" } } }, "auth_ref": [] }, "us-gaap_ReportingUnitDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReportingUnitDomain", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reporting Unit [Domain]", "label": "Reporting Unit [Domain]", "documentation": "Level of reporting at which goodwill is tested for impairment." } } }, "auth_ref": [ "r301", "r302", "r643" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r691", "r702", "r712", "r737" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r692", "r703", "r713", "r738" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r699", "r710", "r720", "r745" ] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockMember", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Restricted stock", "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r47" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityScheduleofStockOptionsValuationAssumptionsDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Units (RSUs)", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofOperations", "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other operating", "terseLabel": "Type of Revenue", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r270", "r271", "r275", "r278", "r279", "r283", "r284", "r286", "r374", "r375", "r490" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contracts with Customers (ASC Topic 606)", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r186", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r628" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Revenues", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Revenues", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r224", "r239", "r270", "r271", "r275", "r278", "r279", "r283", "r284", "r286", "r292", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r447", "r497", "r801" ] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuesAbstract", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "verboseLabel": "Revenues", "label": "Revenues [Abstract]" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r754" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r754" ] }, "us-gaap_SaleLeasebackTransactionNetBookValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleLeasebackTransactionNetBookValue", "crdr": "debit", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesScheduleofNotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financing receivable, carrying value", "label": "Sale Leaseback Transaction, Net Book Value", "documentation": "The net book value of the asset(s) sold in connection with the sale of the property to another party and lease back to the seller." } } }, "auth_ref": [ "r172", "r173", "r174", "r844" ] }, "us-gaap_SalesTypeLeaseInterestIncomeLeaseReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesTypeLeaseInterestIncomeLeaseReceivable", "crdr": "credit", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income from financing receivables", "label": "Sales-type Lease, Interest Income, Lease Receivable", "documentation": "Amount of interest income from lease receivable of sales-type lease." } } }, "auth_ref": [ "r266", "r478" ] }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesScheduleofNotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]", "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables." } } }, "auth_ref": [ "r32" ] }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables." } } }, "auth_ref": [ "r32" ] }, "hr_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Assets and Liabilities Held for Sale", "label": "Schedule of Assets and Liabilities Held for Sale [Table Text Block]", "documentation": "Schedule of Assets and Liabilities Held for Sale" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss)", "label": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings." } } }, "auth_ref": [ "r101" ] }, "us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reconciliation of Common Stock Outstanding", "label": "Schedule of Common Stock Outstanding Roll Forward [Table Text Block]", "documentation": "Tabular disclosure of the change in common stock outstanding." } } }, "auth_ref": [] }, "srt_ScheduleOfCondensedBalanceSheetTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScheduleOfCondensedBalanceSheetTableTextBlock", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Condensed Balance Sheet", "label": "Condensed Balance Sheet [Table Text Block]", "documentation": "Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations." } } }, "auth_ref": [ "r765", "r783" ] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtTableTextBlock", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Debt", "label": "Schedule of Debt [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position." } } }, "auth_ref": [ "r96" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Earnings (Loss) per Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r787" ] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Axis]", "label": "Investment, Name [Axis]", "documentation": "Information by name of investment including named security. Excludes entity that is consolidated." } } }, "auth_ref": [ "r289", "r290", "r291" ] }, "us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfLongLivedAssetsHeldForSaleTable", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAssetsHeldforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long Lived Assets Held-for-sale [Table]", "label": "Long-Lived Assets Held-for-Sale [Table]", "documentation": "Description and amounts of long lived assets held for sale. Disclosure may include the description of the facts and circumstances leading to the expected disposal, manner and timing of disposal, the carrying value of the assets held for sale, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss)." } } }, "auth_ref": [ "r12", "r17" ] }, "us-gaap_ScheduleOfRealEstatePropertiesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRealEstatePropertiesTable", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Real Estate Properties [Table]", "label": "Schedule of Real Estate Properties [Table]", "documentation": "Schedule detailing quantitative information concerning real estate properties and units within those properties by ownership of the property." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityScheduleofStockOptionsValuationAssumptionsDetails", "http://healthcarerealty.com/role/StockholdersEquitySummaryoftheActivityUndertheIncentivePlanandRSUActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r384", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock Options, Valuation Assumptions", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r156" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityReconciliationofBeginningandEndingCommonStockOutstandingDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock by Class [Table]", "label": "Schedule of Stock by Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r57", "r58", "r59", "r60", "r61", "r62", "r63", "r152", "r153", "r154", "r208", "r209", "r210", "r268", "r350", "r351", "r352", "r354", "r357", "r362", "r364", "r529", "r530", "r531", "r532", "r649", "r761", "r780" ] }, "us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Unrecognized Compensation Cost, Nonvested Awards", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost [Table Text Block]", "documentation": "Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r157" ] }, "us-gaap_ScheduleOfVariableInterestEntitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfVariableInterestEntitiesTable", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesConsolidatedbalancesheetsDetails", "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesVariableinterestentityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Variable Interest Entities [Table]", "label": "Schedule of Variable Interest Entities [Table]", "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide." } } }, "auth_ref": [ "r76", "r77", "r80", "r82", "r84", "r421", "r422", "r425", "r426", "r486", "r487", "r488" ] }, "us-gaap_ScheduleOfVariableInterestEntitiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfVariableInterestEntitiesTextBlock", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Variable Interest Entities", "label": "Schedule of Variable Interest Entities [Table Text Block]", "documentation": "Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide." } } }, "auth_ref": [ "r76", "r77", "r80", "r82", "r84" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r685" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r687" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableNarrativeDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsUnconsolidatedJointVentureAcquisitionsDetails", "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesScheduleofNotesReceivableDetails", "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesVariableinterestentityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]", "documentation": "Geographical area." } } }, "auth_ref": [ "r189", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r284", "r285", "r537", "r538", "r539", "r597", "r599", "r602", "r610", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r631", "r651", "r673", "r806", "r857" ] }, "hr_SeniorNotesDue2026Member": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "SeniorNotesDue2026Member", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes due 2026", "label": "Senior Notes due 2026 [Member]", "documentation": "Senior Notes due 2026" } } }, "auth_ref": [] }, "hr_SeniorNotesDue2027Member": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "SeniorNotesDue2027Member", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes due 2027", "label": "Senior Notes due 2027 [Member]", "documentation": "Senior Notes due 2027" } } }, "auth_ref": [] }, "hr_SeniorNotesDue2030NetOfDiscountAndIssuanceCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "SeniorNotesDue2030NetOfDiscountAndIssuanceCostsMember", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes due 2030", "label": "Senior Notes due 2030, Net of Discount and Issuance Costs [Member]", "documentation": "Senior Notes due 2030, Net of Discount and Issuance Costs" } } }, "auth_ref": [] }, "hr_SeniorNotesDue2031Member": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "SeniorNotesDue2031Member", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes due 2031", "label": "Senior Notes due 2031 [Member]", "documentation": "Senior Notes due 2031" } } }, "auth_ref": [] }, "hr_SeniorNotesDue2031NetOfDiscountAndIssuanceCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "SeniorNotesDue2031NetOfDiscountAndIssuanceCostsMember", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes due 2031", "label": "Senior Notes due 2031, Net of Discount and Issuance Costs [Member]", "documentation": "Senior Notes due 2031, Net of Discount and Issuance Costs" } } }, "auth_ref": [] }, "us-gaap_SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeniorNotesMember", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior notes", "label": "Senior Notes [Member]", "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors." } } }, "auth_ref": [] }, "hr_SeniorNotesdue2025Member": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "SeniorNotesdue2025Member", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes due 2025", "label": "Senior Notes due 2025 [Member]", "documentation": "Senior Notes due 2025 [Member]" } } }, "auth_ref": [] }, "hr_SeniorNotesdue2028Member": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "SeniorNotesdue2028Member", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes due 2028", "label": "Senior Notes due 2028 [Member]", "documentation": "Senior Notes due 2028 [Member]" } } }, "auth_ref": [] }, "hr_SeniorNotesdue2030Member": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "SeniorNotesdue2030Member", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes due 2030", "label": "Senior Notes due 2030 [Member]", "documentation": "Senior Notes due 2030 [Member]" } } }, "auth_ref": [] }, "hr_SettledInterestRateSwapsMember": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "SettledInterestRateSwapsMember", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedasCashFlowHedgesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Settled Interest Rate Swaps", "label": "Settled Interest Rate Swaps [Member]", "documentation": "Settled Interest Rate Swaps" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Share-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r9" ] }, "hr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod": { "xbrltype": "durationItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award performance period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Performance Period", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Performance Period" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r663" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryoftheActivityUndertheIncentivePlanandRSUActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r403" ] }, "hr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue", "crdr": "debit", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Grant date fair value", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Granted in Period, Total Fair Value", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Granted in Period, Total Fair Value" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails", "http://healthcarerealty.com/role/StockholdersEquitySummaryoftheActivityUndertheIncentivePlanandRSUActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r401" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryoftheActivityUndertheIncentivePlanandRSUActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Share-based awards, beginning of period (in shares)", "periodEndLabel": "Share-based awards, ending of period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r398", "r399" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryoftheActivityUndertheIncentivePlanandRSUActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Summary of the activity under the incentive plans", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryoftheActivityUndertheIncentivePlanandRSUActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Vested/Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r402" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityScheduleofStockOptionsValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]" } } }, "auth_ref": [] }, "hr_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedStockPrice": { "xbrltype": "perShareItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedStockPrice", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityScheduleofStockOptionsValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock price (in dollar per share)", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Stock Price", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Stock Price" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityScheduleofStockOptionsValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r409" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityScheduleofStockOptionsValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r411" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityScheduleofStockOptionsValuationAssumptionsDetails", "http://healthcarerealty.com/role/StockholdersEquitySummaryoftheActivityUndertheIncentivePlanandRSUActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r384", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityScheduleofStockOptionsValuationAssumptionsDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412" ] }, "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedPaymentArrangementNonemployeeMember", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payment Arrangement, Nonemployee", "label": "Share-Based Payment Arrangement, Nonemployee [Member]", "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires." } } }, "auth_ref": [ "r384", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityScheduleofStockOptionsValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r408" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nonvested shares (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares", "documentation": "Number of non-vested options outstanding." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "crdr": "credit", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Grant date fair value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value", "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock." } } }, "auth_ref": [ "r405" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average grant date fair value (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value", "documentation": "Weighted average grant-date fair value of options vested." } } }, "auth_ref": [] }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares withheld to pay estimated withholding taxes (in shares)", "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r144", "r236" ] }, "hr_SquareFeetSubjecttoGroundLeases": { "xbrltype": "areaItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "SquareFeetSubjecttoGroundLeases", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Square feet subject to ground leases", "label": "Square Feet Subject to Ground Leases", "documentation": "Square Feet Subject to Ground Leases" } } }, "auth_ref": [] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofEquityandRedeemableNonControllingInterests", "http://healthcarerealty.com/role/StockholdersEquityReconciliationofBeginningandEndingCommonStockOutstandingDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r14", "r31", "r200", "r220", "r221", "r222", "r241", "r242", "r243", "r245", "r251", "r253", "r267", "r293", "r294", "r365", "r414", "r415", "r416", "r417", "r418", "r432", "r433", "r434", "r435", "r436", "r437", "r440", "r448", "r450", "r451", "r452", "r453", "r454", "r479", "r525", "r526", "r527", "r535", "r591" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableNarrativeDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsUnconsolidatedJointVentureAcquisitionsDetails", "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesScheduleofNotesReceivableDetails", "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesVariableinterestentityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]", "documentation": "Information by geographical components." } } }, "auth_ref": [ "r189", "r199", "r284", "r285", "r537", "r538", "r539", "r597", "r599", "r602", "r610", "r614", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r631", "r651", "r673", "r806", "r857" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofEquityandRedeemableNonControllingInterests" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r241", "r242", "r243", "r267", "r490", "r528", "r536", "r543", "r545", "r546", "r547", "r548", "r549", "r552", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r564", "r565", "r566", "r567", "r568", "r570", "r573", "r574", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r591", "r674" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofEquityandRedeemableNonControllingInterests" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r241", "r242", "r243", "r267", "r490", "r528", "r536", "r543", "r545", "r546", "r547", "r548", "r549", "r552", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r564", "r565", "r566", "r567", "r568", "r570", "r573", "r574", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r591", "r674" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r694", "r705", "r715", "r740" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "hr_StockIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "StockIncentivePlanMember", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails", "http://healthcarerealty.com/role/StockholdersEquitySummaryoftheActivityUndertheIncentivePlanandRSUActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock incentive plan", "label": "Stock Incentive Plan [Member]", "documentation": "Stock Incentive Plan [Member]" } } }, "auth_ref": [] }, "hr_StockIssuanceProgramAxis": { "xbrltype": "stringItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "StockIssuanceProgramAxis", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Issuance Program [Axis]", "label": "Stock Issuance Program [Axis]", "documentation": "Stock Issuance Program [Axis]" } } }, "auth_ref": [] }, "hr_StockIssuanceProgramDomain": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "StockIssuanceProgramDomain", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Issuance Program [Domain]", "label": "Stock Issuance Program [Domain]", "documentation": "[Domain] for Stock Issuance Program [Axis]" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesConversionOfUnits", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityReconciliationofBeginningandEndingCommonStockOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock issued during period, shares, conversion of units", "label": "Stock Issued During Period, Shares, Conversion of Units", "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)." } } }, "auth_ref": [ "r14", "r60", "r124", "r125", "r154" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityReconciliationofBeginningandEndingCommonStockOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock (in shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r14", "r124", "r125", "r154", "r529", "r591", "r611" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityReconciliationofBeginningandEndingCommonStockOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-vested share-based awards, net of withheld shares and forfeitures (in shares)", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": [ "r14", "r124", "r125", "r154" ] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueConversionOfUnits", "crdr": "credit", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofEquityandRedeemableNonControllingInterests" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion of OP Units to common stock", "label": "Stock Issued During Period, Value, Conversion of Units", "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)." } } }, "auth_ref": [ "r14", "r31", "r154" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofEquityandRedeemableNonControllingInterests" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock, net of issuance costs", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r14", "r124", "r125", "r154", "r535", "r591", "r611", "r683" ] }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock repurchase program, authorized amount", "label": "Stock Repurchase Program, Authorized Amount", "documentation": "Amount of stock repurchase plan authorized." } } }, "auth_ref": [] }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedAndRetiredDuringPeriodValue", "crdr": "debit", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofEquityandRedeemableNonControllingInterests" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Common stock redemptions", "label": "Stock Repurchased and Retired During Period, Value", "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital)." } } }, "auth_ref": [ "r14", "r124", "r125", "r154" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 }, "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesConsolidatedbalancesheetsDetails": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets", "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesConsolidatedbalancesheetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders' equity", "terseLabel": "Total equity", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r125", "r127", "r128", "r145", "r553", "r569", "r592", "r593", "r668", "r684", "r782", "r790", "r839", "r862" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets", "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofEquityandRedeemableNonControllingInterests" ], "lang": { "en-us": { "role": { "totalLabel": "Total equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r71", "r72", "r85", "r200", "r201", "r221", "r241", "r242", "r243", "r245", "r251", "r293", "r294", "r365", "r414", "r415", "r416", "r417", "r418", "r432", "r433", "r434", "r435", "r436", "r437", "r440", "r448", "r450", "r454", "r479", "r526", "r527", "r533", "r553", "r569", "r592", "r593", "r612", "r683", "r782", "r790", "r839", "r862" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Stockholders' equity", "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquity" ], "lang": { "en-us": { "role": { "verboseLabel": "Stockholders' Equity", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r151", "r238", "r349", "r351", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r363", "r365", "r439", "r594", "r595", "r613" ] }, "hr_StraightLineRentReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "StraightLineRentReceivable", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Amortization of straight-line rent receivable (lessor)", "label": "Straight-line Rent Receivable", "documentation": "Straight-line rent receivable." } } }, "auth_ref": [] }, "hr_StraightlineRentLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "StraightlineRentLiability", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of straight-line rent on operating leases (lessee)", "label": "Straight-line Rent Liability", "documentation": "Straight-line rent liability." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails", "http://healthcarerealty.com/role/NotesandBondsPayableNarrativeDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsNarrativeDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r455", "r481" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails", "http://healthcarerealty.com/role/NotesandBondsPayableNarrativeDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsNarrativeDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r455", "r481" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails", "http://healthcarerealty.com/role/NotesandBondsPayableNarrativeDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsNarrativeDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r455", "r481" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental Cash Flow Information", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "stpr_TX": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2023", "localname": "TX", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesScheduleofNotesReceivableDetails", "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesVariableinterestentityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Texas", "terseLabel": "Texas", "label": "TEXAS" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r734" ] }, "us-gaap_TemporaryEquityAccretionToRedemptionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityAccretionToRedemptionValue", "crdr": "credit", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofEquityandRedeemableNonControllingInterests" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Adjustments to redemption value of redeemable non-controlling interests", "label": "Temporary Equity, Accretion to Redemption Value", "documentation": "Value of accretion of temporary equity to its redemption value during the period." } } }, "auth_ref": [] }, "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests", "crdr": "credit", "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheets", "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofEquityandRedeemableNonControllingInterests", "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Redeemable non-controlling interests", "periodStartLabel": "Redeemable Non-controlling Interests, beginning balance", "periodEndLabel": "Redeemable Non-controlling Interests, ending balance", "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests", "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r30", "r239", "r292", "r447" ] }, "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterestsAbstract", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Redeemable Non-Controlling Interests:", "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests [Abstract]" } } }, "auth_ref": [] }, "us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityIssuePeriodIncreaseOrDecrease", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofEquityandRedeemableNonControllingInterests" ], "lang": { "en-us": { "role": { "terseLabel": "Contributions from redeemable non-controlling interests", "label": "Temporary Equity, Carrying Amount, Period Increase (Decrease)", "documentation": "Change in the value of each type or class of stock classified as temporary equity during the period. The redemption requirement does not constitute an unconditional obligation that will be settled in a variable number of shares constituting a monetary value predominantly indexed to (a) a fixed monetary amount known at inception, (b) an amount inversely correlated with the residual value of the entity, or (c) an amount determined by reference to something other than the fair value of issuer's stock. Does not include mandatorily redeemable stock. The exception is if redemption is required upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r22", "r56" ] }, "hr_TermLoanDue2025Member": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "TermLoanDue2025Member", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$300 million Unsecured Term Loan", "label": "Term Loan due 2025 [Member]", "documentation": "Term Loan due 2025" } } }, "auth_ref": [] }, "hr_TermLoanDue2027Member": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "TermLoanDue2027Member", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$200 million Unsecured Term Loan", "label": "Term Loan due 2027 [Member]", "documentation": "Term Loan due 2027" } } }, "auth_ref": [] }, "hr_TermLoanDue2028Member": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "TermLoanDue2028Member", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$300 million Unsecured Term Loan", "label": "Term Loan due 2028 [Member]", "documentation": "Term Loan due 2028" } } }, "auth_ref": [] }, "hr_TermLoanDueJuly2024Member": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "TermLoanDueJuly2024Member", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$350 million Unsecured Term Loan", "label": "Term Loan due July 2024 [Member]", "documentation": "Term Loan due July 2024" } } }, "auth_ref": [] }, "hr_TermLoanDueMay2025Member": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "TermLoanDueMay2025Member", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$200 million Unsecured Term Loan", "label": "Term Loan due May 2025 [Member]", "documentation": "Term Loan due 2024 [Member]" } } }, "auth_ref": [] }, "hr_TermLoandue2026Member": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "TermLoandue2026Member", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$150 million Unsecured Term Loan", "label": "Term Loan due 2026 [Member]", "documentation": "Term Loan due 2026 [Member]" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Title of Individual [Axis]", "label": "Title of Individual [Axis]", "documentation": "Information by title of individual or nature of relationship to individual or group of individuals." } } }, "auth_ref": [ "r788", "r845" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Title of Individual [Domain]", "label": "Title of Individual [Domain]", "documentation": "Title of individual, or nature of relationship to individual or group of individuals." } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r726" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r733" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r753" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r755" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r756" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r757" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r755" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r755" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r758" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r756" ] }, "us-gaap_TreasuryLockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryLockMember", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectofCashFlowHedgingonAOCIDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Settled treasury hedges", "label": "Treasury Lock [Member]", "documentation": "Customized agreement that fixes the yield or price on a specified treasury security for a specific period." } } }, "auth_ref": [] }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockAcquiredAverageCostPerShare", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares acquired, average cost per share (in dollars per shares)", "label": "Shares Acquired, Average Cost Per Share", "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased." } } }, "auth_ref": [ "r64" ] }, "us-gaap_TreasuryStockSharesAcquired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockSharesAcquired", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock, shares, acquired (in shares)", "label": "Treasury Stock, Shares, Acquired", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } }, "auth_ref": [ "r14", "r125", "r154" ] }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock, value, acquired, cost method", "label": "Treasury Stock, Value, Acquired, Cost Method", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": [ "r14", "r64", "r154" ] }, "us-gaap_TypeOfRevenueExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfRevenueExtensibleList", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue, Product and Service [Extensible List]", "label": "Revenue, Product and Service [Extensible Enumeration]", "documentation": "Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources." } } }, "auth_ref": [] }, "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/StockholdersEquityComputationofBasicandDilutedEarningsLossPerCommonShareDetails": { "parentTag": "hr_NetIncomeLossfromContinuingOperationsAvailabletoCommonStockholdersBasic", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityComputationofBasicandDilutedEarningsLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Income allocated to participating securities", "label": "Undistributed Earnings (Loss) Allocated to Participating Securities, Basic", "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method." } } }, "auth_ref": [ "r258", "r260", "r261" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r752" ] }, "hr_UnsecuredCreditFacilityOneMember": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "UnsecuredCreditFacilityOneMember", "presentation": [ "http://healthcarerealty.com/role/NotesandBondsPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$1.5 billion Unsecured Credit Facility", "label": "Unsecured Credit Facility One [Member]", "documentation": "Unsecured Credit Facility One" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates in the Condensed Consolidated Financial Statements", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r49", "r50", "r51", "r179", "r180", "r181", "r182" ] }, "us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableInterestEntityEntityMaximumLossExposureAmount", "crdr": "credit", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesVariableinterestentityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "MAXIMUM EXPOSURE TO LOSS", "label": "Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount", "documentation": "The reporting entity's maximum amount of exposure to loss as a result of its involvement with the Variable Interest Entity (VIE)." } } }, "auth_ref": [ "r79", "r83" ] }, "us-gaap_VariableInterestEntityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableInterestEntityLineItems", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesConsolidatedbalancesheetsDetails", "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesVariableinterestentityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Interest Entity [Line Items]", "label": "Variable Interest Entity [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r421", "r422", "r425", "r426", "r486", "r487", "r488" ] }, "hr_VariableInterestEntityMember": { "xbrltype": "domainItemType", "nsuri": "http://healthcarerealty.com/20240331", "localname": "VariableInterestEntityMember", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesDetails", "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesVariableinterestentityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Interest Entity", "label": "Variable Interest Entity [Member]", "documentation": "Variable Interest Entity" } } }, "auth_ref": [] }, "us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableInterestEntityNotPrimaryBeneficiaryMember", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesVariableinterestentityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Interest Entity, Not Primary Beneficiary", "label": "Variable Interest Entity, Not Primary Beneficiary [Member]", "documentation": "Variable Interest Entities (VIE) in which the entity does not have a controlling financial interest (as defined) and of which it is therefore not the primary beneficiary. VIEs of which the entity is not the primary beneficiary because it does not have the power to direct the activities of the VIE that most significantly impact the VIE's economic performance and for which it does not have the obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE are not included in the consolidated financial statements of the entity." } } }, "auth_ref": [] }, "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableInterestEntityPrimaryBeneficiaryMember", "presentation": [ "http://healthcarerealty.com/role/SummaryofSignificantAccountingPoliciesConsolidatedbalancesheetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable interest entity", "label": "Variable Interest Entity, Primary Beneficiary [Member]", "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity." } } }, "auth_ref": [ "r76", "r421", "r422", "r425", "r426" ] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableLeaseCost", "crdr": "debit", "calculation": { "http://healthcarerealty.com/role/LeasesLeaseCostDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable lease expense", "label": "Variable Lease, Cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": [ "r469", "r667" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://healthcarerealty.com/role/StockholdersEquityComputationofBasicandDilutedEarningsLossPerCommonShareDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofOperations", "http://healthcarerealty.com/role/StockholdersEquityComputationofBasicandDilutedEarningsLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average common shares outstanding - diluted (in shares)", "totalLabel": "Weighted average common shares outstanding - diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r255", "r263" ] }, "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesIssuedBasic", "calculation": { "http://healthcarerealty.com/role/StockholdersEquityComputationofBasicandDilutedEarningsLossPerCommonShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityComputationofBasicandDilutedEarningsLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average common shares outstanding (in shares)", "label": "Weighted Average Number of Shares Issued, Basic", "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic)." } } }, "auth_ref": [ "r45", "r46" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityComputationofBasicandDilutedEarningsLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average common shares outstanding", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://healthcarerealty.com/role/StockholdersEquityComputationofBasicandDilutedEarningsLossPerCommonShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsofOperations", "http://healthcarerealty.com/role/StockholdersEquityComputationofBasicandDilutedEarningsLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average common shares outstanding - basic (in shares)", "totalLabel": "Weighted average common shares outstanding - basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r254", "r263" ] }, "us-gaap_WeightedAverageNumberOfSharesRestrictedStock": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesRestrictedStock", "calculation": { "http://healthcarerealty.com/role/StockholdersEquityComputationofBasicandDilutedEarningsLossPerCommonShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityComputationofBasicandDilutedEarningsLossPerCommonShareDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Non-vested shares (in shares)", "label": "Weighted Average Number of Shares, Restricted Stock", "documentation": "Number of shares of restricted stock determined by relating the portion of time within a reporting period that restricted shares have been outstanding to the total time in that period. Restricted shares are subject to sales, contractual, regulatory or other restrictions that prevent or inhibit the holder from freely disposing of them before the restriction ends." } } }, "auth_ref": [ "r46" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-10" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i-k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-14" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21D", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-21D" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(c)(2)", "SubTopic": "20", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4D" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(27)", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.27(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.3,4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-13" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "272", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "310", "SubTopic": "10", "Section": "50", "Paragraph": "11B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481244/470-50-50-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-21" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "2AA", "Subparagraph": "a", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-2AA" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-4" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-4" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Subparagraph": "b", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-4" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-5A" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-5A" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-6" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-6" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-9" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a),(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-8" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480401/815-10-55-182" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480238/815-25-50-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480870/815-30-50-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15(1),(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-11" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-7" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 4.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-5" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(i)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//815/tableOfContent" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "932", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479664/932-10-S99-1" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "932", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-10(c)(7)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479664/932-10-S99-1" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481266/840-40-55-50" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "51", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481266/840-40-55-51" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481266/840-40-55-52" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "SubTopic": "360", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479638/944-360-45-3" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "SubTopic": "360", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479638/944-360-45-4" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "360", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479607/944-360-50-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "SubTopic": "30", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-14" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(a)", "SubTopic": "30", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-3A" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-3A" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Footnote": "2", "Publisher": "SEC" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Footnote": "4", "Publisher": "SEC" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column B", "Publisher": "SEC" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column C", "Publisher": "SEC" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column D", "Publisher": "SEC" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column E", "Publisher": "SEC" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column F", "Publisher": "SEC" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column G", "Publisher": "SEC" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column H", "Publisher": "SEC" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column I", "Publisher": "SEC" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Footnote": "4", "Publisher": "SEC" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-15" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "65", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-65" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "66", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-66" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482964/270-10-50-6A" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-3B" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4E" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5C" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480627/815-20-45-3" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-2" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479016/842-30-45-3" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-12" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-5" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-5" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-1A" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-1A" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-1A" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(10)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r629": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r630": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r631": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r632": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Footnote": "2", "Publisher": "SEC" }, "r633": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Footnote": "4", "Publisher": "SEC" }, "r634": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r636": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r637": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r638": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "35", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-35" }, "r639": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r640": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r641": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r642": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r643": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r644": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r645": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r646": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r647": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r648": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r649": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r650": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r651": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r652": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r653": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r654": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r655": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r656": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r657": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r660": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r661": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r662": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r663": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r664": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r665": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r666": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r667": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r668": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r669": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r670": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r671": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r673": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r677": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r678": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r679": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column B)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r680": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r681": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "39", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480228/946-830-45-39" }, "r682": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r683": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r684": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r685": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r686": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r687": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r689": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r690": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r691": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r692": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r693": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r694": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r695": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r696": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r697": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r698": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r699": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r700": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r701": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r702": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r703": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r704": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r705": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r706": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r707": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r708": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r709": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r710": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r711": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r712": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r713": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r714": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r715": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r716": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r717": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r718": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r719": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r720": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r721": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r723": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r724": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r725": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r726": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r727": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r728": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r729": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r730": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r731": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r732": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r733": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r734": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r735": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r736": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r737": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r738": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r739": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r740": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r741": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r742": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r743": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r744": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r745": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r746": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r747": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r748": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r749": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r750": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r751": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r752": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r753": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r754": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r755": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r756": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r757": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r758": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r759": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r760": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r761": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r762": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r763": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r764": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(c))", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r765": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "04", "Paragraph": "(a)", "Publisher": "SEC" }, "r766": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "(a)", "Subparagraph": "(4)(i)", "Publisher": "SEC" }, "r767": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "(a)", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r768": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "(a)", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r769": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(b)(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(b)(9)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-3" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-12" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479741/842-40-50-2" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(14)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" } } } ZIP 74 0001360604-24-000045-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001360604-24-000045-xbrl.zip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end XML 76 hr-20240331_htm.xml IDEA: XBRL DOCUMENT 0001360604 2024-01-01 2024-03-31 0001360604 2024-05-03 0001360604 2024-03-31 0001360604 2023-12-31 0001360604 2023-01-01 2023-03-31 0001360604 us-gaap:InterestRateSwapMember 2024-01-01 2024-03-31 0001360604 us-gaap:InterestRateSwapMember 2023-01-01 2023-03-31 0001360604 us-gaap:CommonStockMember 2023-12-31 0001360604 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001360604 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001360604 hr:CumulativeNetIncomeMember 2023-12-31 0001360604 hr:CumulativeDividendsMember 2023-12-31 0001360604 us-gaap:ParentMember 2023-12-31 0001360604 us-gaap:NoncontrollingInterestMember 2023-12-31 0001360604 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001360604 us-gaap:ParentMember 2024-01-01 2024-03-31 0001360604 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001360604 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-03-31 0001360604 hr:CumulativeNetIncomeMember 2024-01-01 2024-03-31 0001360604 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001360604 hr:CumulativeDividendsMember 2024-01-01 2024-03-31 0001360604 us-gaap:CommonStockMember 2024-03-31 0001360604 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001360604 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001360604 hr:CumulativeNetIncomeMember 2024-03-31 0001360604 hr:CumulativeDividendsMember 2024-03-31 0001360604 us-gaap:ParentMember 2024-03-31 0001360604 us-gaap:NoncontrollingInterestMember 2024-03-31 0001360604 us-gaap:CommonStockMember 2022-12-31 0001360604 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001360604 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001360604 hr:CumulativeNetIncomeMember 2022-12-31 0001360604 hr:CumulativeDividendsMember 2022-12-31 0001360604 us-gaap:ParentMember 2022-12-31 0001360604 us-gaap:NoncontrollingInterestMember 2022-12-31 0001360604 2022-12-31 0001360604 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001360604 us-gaap:ParentMember 2023-01-01 2023-03-31 0001360604 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001360604 hr:CumulativeNetIncomeMember 2023-01-01 2023-03-31 0001360604 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-03-31 0001360604 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001360604 hr:CumulativeDividendsMember 2023-01-01 2023-03-31 0001360604 us-gaap:CommonStockMember 2023-03-31 0001360604 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001360604 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001360604 hr:CumulativeNetIncomeMember 2023-03-31 0001360604 hr:CumulativeDividendsMember 2023-03-31 0001360604 us-gaap:ParentMember 2023-03-31 0001360604 us-gaap:NoncontrollingInterestMember 2023-03-31 0001360604 2023-03-31 0001360604 hr:HealthCareRealtyTrustIncorporatedMember 2021-07-20 0001360604 hr:HealthcareTrustofAmericaHoldingsLPMember 2024-03-31 0001360604 hr:HealthCareRealtyTrustIncorporatedMember hr:OtherInvestorsMember 2024-03-31 0001360604 hr:RealEstatePropertiesHeldInJointVenturesMember 2024-03-31 0001360604 hr:PropertyEntitiesNotDeterminedToBeVIEsMember 2024-03-31 0001360604 hr:NonControllingInterestHoldersMember hr:HealthcareTrustofAmericaHoldingsLPMember 2024-03-31 0001360604 hr:NonControllingInterestHoldersMember hr:HealthcareTrustofAmericaHoldingsLPMember 2024-01-01 2024-03-31 0001360604 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2024-03-31 0001360604 hr:VariableInterestEntityMember 2024-03-31 0001360604 hr:VariableInterestEntityMember 2024-01-01 2024-03-31 0001360604 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember hr:HoustonTexasMember 2024-03-31 0001360604 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember stpr:NC 2024-03-31 0001360604 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember stpr:TX 2024-03-31 0001360604 us-gaap:FairValueInputsLevel3Member 2024-03-31 0001360604 hr:OneMember 2024-03-31 0001360604 hr:PowayCAMember 2024-03-31 0001360604 hr:ColumbusOHMember 2024-03-31 0001360604 stpr:TX hr:MezzanineLoanMember 2024-03-31 0001360604 stpr:AZ hr:MezzanineLoanMember 2024-03-31 0001360604 hr:MezzanineLoanMember 2024-03-31 0001360604 stpr:TX hr:MortgageLoanMember 2024-03-31 0001360604 stpr:NC hr:MortgageLoanMember 2024-03-31 0001360604 stpr:FL hr:MortgageLoanMember 2024-03-31 0001360604 stpr:CA hr:MortgageLoanMember 2024-03-31 0001360604 hr:Florida1Member hr:MortgageLoanMember 2024-03-31 0001360604 hr:MortgageLoanMember 2024-03-31 0001360604 2023-01-01 2023-12-31 0001360604 us-gaap:NotesReceivableMember 2024-01-01 2024-03-31 0001360604 us-gaap:NotesReceivableMember 2023-01-01 2023-03-31 0001360604 hr:ParkingIncomeMember 2024-01-01 2024-03-31 0001360604 hr:ParkingIncomeMember 2023-01-01 2023-03-31 0001360604 hr:ManagementFeeIncomeMember 2024-01-01 2024-03-31 0001360604 hr:ManagementFeeIncomeMember 2023-01-01 2023-03-31 0001360604 srt:OtherPropertyMember 2023-12-31 0001360604 srt:OtherPropertyMember 2022-12-31 0001360604 srt:OtherPropertyMember 2024-01-01 2024-03-31 0001360604 srt:OtherPropertyMember 2023-01-01 2023-03-31 0001360604 srt:OtherPropertyMember 2024-03-31 0001360604 srt:OtherPropertyMember 2023-03-31 0001360604 srt:OtherPropertyMember hr:LimitedLiabilityCompanyOneMember hr:LosAngelesCaliforniaMember 2024-01-01 2024-03-31 0001360604 us-gaap:SubsequentEventMember 2024-05-07 0001360604 us-gaap:SubsequentEventMember hr:RealEstateDispositionsMember 2024-05-07 0001360604 us-gaap:SubsequentEventMember hr:RealEstateDispositionsMember 2024-04-01 2024-05-07 0001360604 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2024-03-31 0001360604 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2023-12-31 0001360604 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2024-01-01 2024-03-31 0001360604 srt:MinimumMember 2024-03-31 0001360604 srt:MaximumMember 2024-03-31 0001360604 hr:UnsecuredCreditFacilityOneMember us-gaap:LineOfCreditMember 2024-03-31 0001360604 hr:UnsecuredCreditFacilityOneMember us-gaap:LineOfCreditMember 2023-12-31 0001360604 hr:TermLoanDueMay2025Member us-gaap:MediumTermNotesMember 2024-03-31 0001360604 hr:TermLoanDueMay2025Member us-gaap:MediumTermNotesMember 2023-12-31 0001360604 hr:TermLoanDueJuly2024Member us-gaap:MediumTermNotesMember 2024-03-31 0001360604 hr:TermLoanDueJuly2024Member us-gaap:MediumTermNotesMember 2023-12-31 0001360604 hr:TermLoanDue2025Member us-gaap:MediumTermNotesMember 2024-03-31 0001360604 hr:TermLoanDue2025Member us-gaap:MediumTermNotesMember 2023-12-31 0001360604 hr:TermLoandue2026Member us-gaap:MediumTermNotesMember 2024-03-31 0001360604 hr:TermLoandue2026Member us-gaap:MediumTermNotesMember 2023-12-31 0001360604 hr:TermLoanDue2027Member us-gaap:MediumTermNotesMember 2024-03-31 0001360604 hr:TermLoanDue2027Member us-gaap:MediumTermNotesMember 2023-12-31 0001360604 hr:TermLoanDue2028Member us-gaap:MediumTermNotesMember 2024-03-31 0001360604 hr:TermLoanDue2028Member us-gaap:MediumTermNotesMember 2023-12-31 0001360604 hr:SeniorNotesdue2025Member us-gaap:SeniorNotesMember 2024-03-31 0001360604 hr:SeniorNotesdue2025Member us-gaap:SeniorNotesMember 2023-12-31 0001360604 hr:SeniorNotesDue2026Member us-gaap:SeniorNotesMember 2024-03-31 0001360604 hr:SeniorNotesDue2026Member us-gaap:SeniorNotesMember 2023-12-31 0001360604 hr:SeniorNotesDue2027Member us-gaap:SeniorNotesMember 2024-03-31 0001360604 hr:SeniorNotesDue2027Member us-gaap:SeniorNotesMember 2023-12-31 0001360604 hr:SeniorNotesdue2028Member us-gaap:SeniorNotesMember 2024-03-31 0001360604 hr:SeniorNotesdue2028Member us-gaap:SeniorNotesMember 2023-12-31 0001360604 hr:SeniorNotesDue2030NetOfDiscountAndIssuanceCostsMember us-gaap:SeniorNotesMember 2024-03-31 0001360604 hr:SeniorNotesDue2030NetOfDiscountAndIssuanceCostsMember us-gaap:SeniorNotesMember 2023-12-31 0001360604 hr:SeniorNotesdue2030Member us-gaap:SeniorNotesMember 2024-03-31 0001360604 hr:SeniorNotesdue2030Member us-gaap:SeniorNotesMember 2023-12-31 0001360604 hr:SeniorNotesDue2031Member us-gaap:SeniorNotesMember 2024-03-31 0001360604 hr:SeniorNotesDue2031Member us-gaap:SeniorNotesMember 2023-12-31 0001360604 hr:SeniorNotesDue2031NetOfDiscountAndIssuanceCostsMember us-gaap:SeniorNotesMember 2024-03-31 0001360604 hr:SeniorNotesDue2031NetOfDiscountAndIssuanceCostsMember us-gaap:SeniorNotesMember 2023-12-31 0001360604 hr:MortgageNotesPayableNetMember us-gaap:MortgagesMember 2024-03-31 0001360604 hr:MortgageNotesPayableNetMember us-gaap:MortgagesMember 2023-12-31 0001360604 srt:MinimumMember hr:MortgageNotesPayableNetMember 2024-03-31 0001360604 srt:MaximumMember hr:MortgageNotesPayableNetMember 2024-03-31 0001360604 us-gaap:SubsequentEventMember 2024-04-01 2024-04-30 0001360604 us-gaap:SubsequentEventMember 2024-04-30 0001360604 us-gaap:MortgagesMember 2024-01-06 0001360604 us-gaap:MortgagesMember 2024-01-06 2024-01-06 0001360604 stpr:CA us-gaap:MortgagesMember 2024-01-06 0001360604 us-gaap:MortgagesMember 2024-02-01 0001360604 us-gaap:MortgagesMember 2024-02-01 2024-02-01 0001360604 stpr:GA us-gaap:MortgagesMember 2024-02-01 0001360604 hr:InterestRateSwapExpiringMay12026Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0001360604 hr:InterestRateSwapExpiringJune12026Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0001360604 hr:InterestRateSwapExpiringDecember12026Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0001360604 hr:InterestRateSwapExpiringJune12027Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0001360604 hr:InterestRateSwapExpiringDecember12027Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0001360604 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0001360604 us-gaap:OtherLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0001360604 us-gaap:OtherAssetsMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0001360604 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0001360604 us-gaap:InterestRateContractMember 2024-01-01 2024-03-31 0001360604 us-gaap:InterestRateContractMember 2023-01-01 2023-03-31 0001360604 us-gaap:InterestRateContractMember us-gaap:InterestExpenseMember 2024-01-01 2024-03-31 0001360604 us-gaap:InterestRateContractMember us-gaap:InterestExpenseMember 2023-01-01 2023-03-31 0001360604 us-gaap:TreasuryLockMember 2024-01-01 2024-03-31 0001360604 us-gaap:TreasuryLockMember 2023-01-01 2023-03-31 0001360604 us-gaap:TreasuryLockMember us-gaap:InterestExpenseMember 2024-01-01 2024-03-31 0001360604 us-gaap:TreasuryLockMember us-gaap:InterestExpenseMember 2023-01-01 2023-03-31 0001360604 us-gaap:InterestRateSwapMember us-gaap:InterestExpenseMember 2024-01-01 2024-03-31 0001360604 us-gaap:InterestRateSwapMember us-gaap:InterestExpenseMember 2023-01-01 2023-03-31 0001360604 us-gaap:InterestExpenseMember 2024-01-01 2024-03-31 0001360604 us-gaap:InterestExpenseMember 2023-01-01 2023-03-31 0001360604 hr:ActiveInterestRateSwapsMember 2024-03-31 0001360604 hr:SettledInterestRateSwapsMember 2024-03-31 0001360604 hr:ActiveDevelopmentPropertiesMember 2024-01-01 2024-03-31 0001360604 hr:RedevelopmentPropertiesMember 2024-01-01 2024-03-31 0001360604 hr:CompletedDevelpomentAndRedevelopmentPropertiesMember 2024-01-01 2024-03-31 0001360604 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001360604 us-gaap:SubsequentEventMember 2024-04-30 2024-04-30 0001360604 2023-05-31 0001360604 us-gaap:EmployeeStockOptionMember hr:OperatingPartnershipPerformanceUnitsMember 2024-03-31 0001360604 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0001360604 hr:NonVestedStockAwardMember hr:ExecutiveIncentiveProgramMember 2024-01-01 2024-03-31 0001360604 srt:MinimumMember hr:NonVestedStockAwardMember hr:ExecutiveIncentiveProgramMember 2024-01-01 2024-03-31 0001360604 srt:MaximumMember hr:NonVestedStockAwardMember hr:ExecutiveIncentiveProgramMember 2024-01-01 2024-03-31 0001360604 us-gaap:RestrictedStockUnitsRSUMember hr:ExecutiveIncentiveProgramMember 2024-02-13 2024-02-13 0001360604 us-gaap:RestrictedStockUnitsRSUMember 2024-02-13 2024-02-13 0001360604 us-gaap:RestrictedStockUnitsRSUMember hr:MarketCondition2Member 2024-02-13 2024-02-13 0001360604 us-gaap:RestrictedStockUnitsRSUMember 2023-01-04 2023-01-04 0001360604 us-gaap:RestrictedStockUnitsRSUMember hr:PerformanceConditionsMember 2024-02-13 2024-02-13 0001360604 hr:DirectorsMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember hr:LTIPSeriesCUnitsMember 2024-02-13 2024-02-13 0001360604 hr:OperatingPartnershipPerformanceUnitsMember 2024-02-01 2024-02-29 0001360604 hr:DirectorsMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember hr:LTIPSeriesCUnitsMember 2024-02-01 2024-02-29 0001360604 hr:OperatingPartnershipPerformanceUnitsMember hr:LTIPSeriesCUnitsMember 2024-02-01 2024-02-29 0001360604 hr:OperatingPartnershipPerformanceUnitsMember hr:MarketCondition2Member 2024-02-01 2024-02-29 0001360604 hr:OperatingPartnershipPerformanceUnitsMember 2023-01-01 2023-01-31 0001360604 hr:OperatingPartnershipPerformanceUnitsMember hr:PerformanceConditionsMember 2023-01-01 2023-01-31 0001360604 hr:StockIncentivePlanMember 2023-12-31 0001360604 hr:StockIncentivePlanMember 2022-12-31 0001360604 hr:StockIncentivePlanMember 2024-01-01 2024-03-31 0001360604 hr:StockIncentivePlanMember 2023-01-01 2023-03-31 0001360604 hr:StockIncentivePlanMember 2024-03-31 0001360604 hr:StockIncentivePlanMember 2023-03-31 0001360604 us-gaap:RestrictedStockMember hr:StockIncentivePlanMember 2024-01-01 2024-03-31 0001360604 us-gaap:RestrictedStockMember hr:StockIncentivePlanMember 2023-01-01 2023-03-31 0001360604 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2024-03-31 0001360604 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2024-03-31 0001360604 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-12-31 0001360604 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-12-31 shares iso4217:USD iso4217:USD shares hr:property hr:state utr:sqft pure hr:variable_interest_entity hr:note_receivable hr:joint_venture hr:financing_receivable hr:lease hr:derivative 0001360604 --12-31 2024 Q1 false http://fasb.org/us-gaap/2023#ServiceMember http://fasb.org/us-gaap/2023#ServiceMember http://fasb.org/us-gaap/2023#ServiceMember http://fasb.org/us-gaap/2023#ServiceMember P3Y 10-Q true 2024-03-31 false 001-35568 HEALTHCARE REALTY TRUST INCORPORATED MD 20-4738467 3310 West End Avenue Suite 700 Nashville TN 37203 615 269-8175 Class A Common Stock, $0.01 par value per share HR NYSE Yes Yes Large Accelerated Filer false false false false 378544088 1342895000 1343265000 10902835000 10881373000 816303000 836302000 12720000 12718000 122001000 122602000 81805000 82209000 70651000 60727000 59871000 59871000 13409081000 13399067000 2374047000 2226853000 11035034000 11172214000 26172000 25699000 30968000 8834000 273949000 275975000 309754000 311511000 0 250530000 605047000 592368000 12280924000 12637131000 5108279000 4994859000 163172000 211994000 700000 295000 229223000 229714000 74769000 74503000 197763000 202984000 5773906000 5714349000 3880000 3868000 0.01 0.01 200000000 200000000 0 0 0 0 0 0 0.01 0.01 1000000000 1000000000 381502000 381502000 380964000 380964000 3815000 3810000 9609530000 9602592000 -4791000 10741000 717958000 1028794000 3920199000 3801793000 6415895000 6822662000 87243000 96252000 6503138000 6918914000 12280924000 12637131000 318076000 324093000 4538000 4214000 4191000 4618000 326805000 332925000 121078000 122040000 14787000 14935000 395000 287000 0 4855000 178119000 184479000 314379000 326596000 22000 1007000 61054000 63759000 15937000 31422000 250530000 0 -422000 -780000 275000 547000 -327646000 -94407000 -315220000 -88078000 -4384000 -953000 -310836000 -87125000 -0.82 -0.23 -0.82 -0.23 379455000 378840000 379455000 378840000 -315220000 -88078000 3865000 2284000 19611000 -8541000 15746000 -10825000 -299474000 -98903000 -4170000 -1084000 -295304000 -97819000 3810000 9602592000 -10741000 1028794000 -3801793000 6822662000 96252000 6918914000 3868000 104000 104000 104000 135000 135000 135000 2000 3410000 3412000 -3412000 0 3000 3559000 3562000 3562000 -310836000 -310836000 -4384000 -315220000 3813000 3813000 52000 3865000 19345000 19345000 266000 19611000 13000 1000 0.31 118406000 118406000 1427000 119833000 3815000 9609530000 4791000 717958000 -3920199000 6415895000 87243000 6503138000 3880000 3806000 9587637000 2140000 1307055000 -3329562000 7571076000 108742000 7679818000 2014000 51000 51000 51000 1000 1483000 1484000 1484000 3000 4989000 4992000 4992000 -87125000 -87125000 -953000 -88078000 2256000 2256000 28000 2284000 -8438000 -8438000 -103000 -8541000 14000 0.31 118188000 118188000 1447000 119635000 3808000 9591194000 -8554000 1219930000 -3447750000 7358628000 106211000 7464839000 2000000 -315220000 -88078000 178119000 184479000 11829000 11104000 3562000 4992000 8568000 9783000 935000 1537000 22000 1007000 15937000 31422000 250530000 0 -422000 -780000 1335000 2542000 242000 1385000 14989000 8360000 -52163000 -66954000 4687000 7901000 76152000 69190000 0 30725000 8383000 6707000 50388000 60159000 1052000 6230000 0 3824000 746000 302000 13000 0 226000 149171000 277000 336000 -58561000 41560000 120000000 17326000 667000 118269000 118052000 104000 51000 318000 1729000 1199000 1272000 110000 101000 -17118000 -121770000 473000 -11020000 25699000 60961000 26172000 49941000 73518000 75082000 0 45000000 35777000 28138000 942000 570000 Summary of Significant Accounting Policies<div style="margin-top:3pt">Business Overview</div><div style="margin-bottom:6pt">Healthcare Realty Trust Incorporated ("Company") is a real estate investment trust ("REIT") that owns, leases, manages, acquires, finances, develops and redevelops income-producing real estate properties associated primarily with the delivery of outpatient healthcare services throughout the United States. As of March 31, 2024, the Company had gross investments of approximately $13.4 billion in 654 consolidated real estate properties, construction in progress, redevelopments, financing receivables, financing lease right-of-use assets, land held for development and corporate property, excluding held for sale assets. The Company's real estate properties are located in 35 states and total approximately 38.4 million square feet. The Company provided leasing and property management services to 92% of its portfolio nationwide as of March 31, 2024. </div><div style="margin-bottom:6pt">On July 20, 2022, pursuant to that certain Agreement and Plan of Merger dated as of February 28, 2022, by and among Healthcare Realty Trust Incorporated, a Maryland corporation (now known as HRTI, LLC, a Maryland limited liability company) (“Legacy HR”), Healthcare Trust of America, Inc., a Maryland corporation (now known as Healthcare Realty Trust Incorporated) (“Legacy HTA”), Healthcare Trust of America Holdings, LP, a Delaware limited partnership (now known as Healthcare Realty Holdings, L.P.) (the “OP”), and HR Acquisition 2, LLC, a Maryland limited liability company (“Merger Sub”), Merger Sub merged with and into Legacy HR, with Legacy HR continuing as the surviving entity and a wholly-owned subsidiary of Legacy HTA (the “Merger”). The combined company operates under the name “Healthcare Realty Trust Incorporated” and its shares of class A common stock, $0.01 par value per share, trade on the New York Stock Exchange under the ticker symbol “HR”.</div><div style="margin-bottom:6pt">The Company is structured as an umbrella partnership REIT under which substantially all of its business is conducted through the OP, the day-to-day management of which is exclusively controlled by the Company. As of March 31, 2024, the Company owned 98.6% of the issued and outstanding units of the OP, with other investors owning the remaining 1.4% of outstanding units.</div><div style="margin-bottom:6pt">In addition, as of March 31, 2024, the Company had a weighted average ownership interest of approximately 43% in 33 real estate properties held in unconsolidated joint ventures. See Note 2 below for more details regarding the Company's unconsolidated joint ventures. </div><div style="margin-bottom:6pt">Any references to square footage or occupancy percentage, and any amounts derived from these values in these notes to the Company's Condensed Consolidated Financial Statements, are outside the scope of our independent registered public accounting firm’s review. </div><div>Basis of Presentation</div><div style="margin-bottom:6pt;text-align:justify">The Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. They do not include all of the information and footnotes required by GAAP for complete financial statements. All material intercompany transactions and balances have been eliminated in consolidation.</div><div style="margin-bottom:6pt">This interim financial information should be read in conjunction with the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. Management believes that all adjustments of a normal, recurring nature considered necessary for a fair presentation have been included. In addition, the interim financial information does not necessarily represent or indicate what the operating results will be for the year ending December 31, 2024 for many reasons including, but not limited to, acquisitions, dispositions, capital financing transactions, changes in interest rates and the effects of other trends, risks and uncertainties.</div><div>Principles of Consolidation</div><div style="margin-bottom:6pt">The Company’s Condensed Consolidated Financial Statements include the accounts of the Company, its wholly owned subsidiaries, and joint ventures and partnerships where the Company controls the operating activities. GAAP requires us to identify entities for which control is achieved through means other than voting rights and to determine which business enterprise is the primary beneficiary of variable interest entities (“VIEs”). Accounting Standards Codification (“ASC”) Topic 810, Consolidation broadly defines a VIE as an entity in which either (i) the equity investors as a group, if any, lack the power through voting or similar rights to direct the activities of such entity that most significantly impact such entity’s economic performance or (ii) the equity investment at risk is insufficient to </div><div style="margin-bottom:6pt">finance that entity’s activities without additional subordinated financial support. The Company identifies the primary beneficiary of a VIE as the enterprise that has both of the following characteristics: (i) the power to direct the activities of the VIE that most significantly impact the entity’s economic performance and (ii) the obligation to absorb losses or receive benefits of the VIE that could potentially be significant to the entity. The Company consolidates its investment in a VIE when it determines that it is the VIE’s primary beneficiary, with any minority interests reflected as non-controlling interests or redeemable non-controlling interests in the accompanying Condensed Consolidated Financial Statements. </div><div style="margin-bottom:6pt">The Company may change its original assessment of a VIE upon subsequent events, such as the modification of contractual arrangements that affect the characteristics or adequacy of the entity’s equity investments at risk, the disposition of all or a portion of an interest held by the primary beneficiary, or changes in facts and circumstances that impact the power to direct activities of the VIE that most significantly impacts economic performance. The Company performs this analysis on an ongoing basis.</div><div style="margin-bottom:6pt">For property holding entities not determined to be VIEs, the Company consolidates such entities in which it owns 100% of the equity or has a controlling financial interest evidenced by ownership of a majority voting interest. All intercompany balances and transactions are eliminated in consolidation. For entities in which the Company owns less than 100% of the equity interest, the Company consolidates the entity if it has the direct or indirect ability to control the entities’ activities based upon the terms of the respective entities’ ownership agreements. </div><div style="margin-bottom:6pt">The OP is 98.6% owned by the Company. Holders of operating partnership units (“OP Units”) are considered to be non-controlling interest holders in the OP and their ownership interests are reflected as equity on the accompanying Condensed Consolidated Balance Sheets. Further, a portion of the earnings and losses of the OP are allocated to non-controlling interest holders based on their respective ownership percentages. Upon conversion of OP Units to common stock, any difference between the fair value of the common stock issued and the carrying value of the OP Units converted to common stock is recorded as a component of equity. As of March 31, 2024, there were approximately 5.2 million OP Units, or 1.4% of OP Units issued and outstanding, held by non-controlling interest holders. Additionally, the Company is the primary beneficiary of this VIE. Accordingly, the Company consolidates its interests in the OP. </div><div style="margin-bottom:6pt">As of March 31, 2024, the Company had four consolidated VIEs, in addition to the OP, consisting of joint venture investments in which the Company is the primary beneficiary of the VIE based on the combination of operational control and the rights to receive residual returns or the obligation to absorb losses arising from the joint ventures. Accordingly, such joint ventures have been consolidated, and the table below summarizes the balance sheets of consolidated VIEs, excluding the OP, in the aggregate:</div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:45.259%"><tr><td style="width:1.0%"></td><td style="width:66.129%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.671%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(dollars in thousands)</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">MARCH 31, 2024</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Assets:</td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Net real estate investments</td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">92,028 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Cash and cash equivalents</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,548 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Receivables and other assets</div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,687 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Total assets</div></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">97,263 </td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Liabilities:</div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Accrued expenses and other liabilities</div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">5,681 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Total equity</div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">91,582 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Total liabilities and equity</div></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">97,263 </td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt">As of March 31, 2024, the Company had three unconsolidated VIEs consisting of two notes receivables and one joint venture. The Company does not have the power or economic interests to direct the activities of the VIEs on a stand-alone basis, and therefore it was determined that the Company was not the primary beneficiary. As a result, the Company accounts for the two notes receivables as amortized cost and a joint venture arrangement under the equity method. See below for additional information regarding the Company's unconsolidated VIEs.</div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.119%"><tr><td style="width:1.0%"></td><td style="width:21.067%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.858%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.246%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.663%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.666%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(dollars in thousands) ORIGINATION DATE</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">LOCATION</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">SOURCE</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">CARRYING AMOUNT </td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">MAXIMUM EXPOSURE TO LOSS</td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">2021</td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Houston, TX 1</div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Note receivable</td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">31,150 </td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">31,150 </td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">2021</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Charlotte, NC 1</div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Note receivable</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,848 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,000 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">2022</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Texas 2</div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Joint venture</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">60,476 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">60,476 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt">1Assumed mortgage note receivable in connection with the Merger.</div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt">2Includes investments in seven properties.</div><div style="margin-bottom:6pt">As of March 31, 2024, the Company's unconsolidated joint venture arrangements were accounted for using the equity method of accounting as the Company exercised significant influence over but did not control these entities. See Note 2 below for more details regarding the Company's unconsolidated joint ventures.</div><div>Use of Estimates in the Condensed Consolidated Financial Statements</div><div style="margin-bottom:6pt">Preparation of the Condensed Consolidated Financial Statements in accordance with GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Actual results may differ from those estimates. </div><div style="margin-top:5pt">Redeemable Non-Controlling Interests</div><div style="margin-bottom:6pt">The Company accounts for redeemable equity securities in accordance with ASC Topic 480: Accounting for Redeemable Equity Instruments, which requires that equity securities redeemable at the option of the holder, not solely within our control, be classified outside permanent stockholders’ equity. The Company classifies redeemable equity securities as redeemable non-controlling interests in the accompanying Condensed Consolidated Balance Sheets. Accordingly, the Company records the carrying amount at the greater of the initial carrying amount (increased or decreased for the non-controlling interest’s share of net income or loss and distributions) or the redemption value. We measure the redemption value and record an adjustment to the carrying value of the equity securities as a component of redeemable non-controlling interest. As of March 31, 2024, the Company had redeemable non-controlling interests of $3.9 million.</div><div>Asset Impairment</div><div style="margin-bottom:6pt">The Company assesses the potential for impairment of identifiable, definite-lived, intangible assets and long-lived assets, including real estate properties, whenever the occurrence of an event or a change in circumstances indicates that the carrying value might not be fully recoverable. Indicators of impairment may include significant underperformance of an asset relative to historical or expected operating results; significant changes in the Company’s use of assets or the strategy for its overall business; plans to sell an asset before its depreciable life has ended; the expiration of a significant portion of leases in a property; or significant negative economic trends or negative industry trends for the Company or its tenants. During the three months ended March 31, 2024, the Company recognized real estate impairments totaling $15.9 million as a result of planned disposition activity.</div><div style="margin-bottom:6pt">As of March 31, 2024, three properties totaling $2.9 million were measured at fair value using level 3 fair value hierarchy. The level 3 fair value techniques included brokerage estimates and unexecuted purchase and sale agreements, less estimated closing costs. </div><div>Goodwill Impairment</div><div style="margin-bottom:6pt">During the first quarter of 2024, the Company experienced a sustained decline in the price per share of its common stock, which was identified as an indicator of goodwill impairment. As a result, a goodwill evaluation was performed. The Company's current operations are carried out through a single reporting unit with a carrying value of approximately $12.0 billion. The Company determined that the carrying value exceeded estimated fair value and therefore an impairment of goodwill was recorded. The Company recorded a $250.5 million full impairment of its goodwill, which is recorded as a non-cash charge in “Impairment of goodwill” in the Condensed Consolidated Statements of Operations. </div><div>Investments in Leases - Financing Receivables, Net </div><div style="margin-bottom:6pt">In accordance with ASC Topic 842: Leases, for transactions in which the Company enters into a contract to acquire an asset and leases it back to the seller (i.e., a sale leaseback transaction), control of the asset is not considered to have transferred when the seller-lessee has a purchase option. As a result, the Company does not recognize the underlying real estate asset but instead recognizes a financial asset in accordance with ASC Topic 310: Receivables. See below for additional information regarding the Company's financing receivables.</div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.241%"><tr><td style="width:1.0%"></td><td style="width:26.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.667%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(dollars in thousands) ORIGINATION DATE</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">LOCATION</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">INTEREST RATE</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">CARRYING VALUE as of MARCH 31, 2024</td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">May 2021</td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Poway, CA</td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">5.73%</td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">114,643 </td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">November 2021</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Columbus, OH</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">6.48%</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,358 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">122,001 </td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div> </div><div>Real Estate Notes Receivable</div><div style="margin-bottom:6pt">Real estate notes receivable consists of mezzanine and other real estate loans, which are generally collateralized by a pledge of the borrower’s ownership interest in the respective real estate owner, a mortgage or deed of trust, and/or corporate guarantees. Real estate notes receivable are intended to be held-to-maturity and are recorded at amortized cost, net of unamortized loan origination costs and fees and allowance for credit losses. As of March 31, 2024, real estate notes receivable, net, which are included in Other assets on the Company's Condensed Consolidated Balance Sheets, totaled $174.4 million.</div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.694%"><tr><td style="width:1.0%"></td><td style="width:15.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.942%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.333%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(dollars in thousands)</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">ORIGINATION</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">MATURITY</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">STATED INTEREST RATE</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">MAXIMUM LOAN COMMITMENT</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">OUTSTANDING as of MAR 31, 2024</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">ALLOWANCE FOR CREDIT LOSSES</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">FAIR VALUE DISCOUNT AND FEES</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">CARRYING VALUE as of MAR 31, 2024</td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Mezzanine loans</td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Texas</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">6/24/2021</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">6/24/2024</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8.00 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">54,119 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">54,119 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">(5,196)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">(3,067)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">45,856 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Arizona</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">12/21/2023</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">12/20/2026</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9.00 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,000 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,000 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,000 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">60,119 </td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">60,119 </td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5,196)</td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3,067)</td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">51,856 </td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Mortgage loans </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Texas</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">6/30/2021</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">7/01/2024</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7.00 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">31,150 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">31,150 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">31,150 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">North Carolina</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">12/22/2021</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">12/22/2024</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8.00 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,000 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,000 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(152)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,848 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Florida</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">5/17/2022</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">2/27/2026</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.00 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">65,000 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">33,209 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(39)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">33,170 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">California</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">3/30/2023</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">3/29/2026</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.00 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">45,000 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">45,000 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">45,000 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Florida</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">12/28/2023</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">12/28/2026</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9.00 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,700 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,423 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,423 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">154,850 </td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">122,782 </td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(191)</td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">122,591 </td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">214,969 </td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">182,901 </td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(5,196)</td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(3,258)</td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">174,447 </td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt">Allowance for Credit Losses</div><div style="margin-bottom:6pt;text-align:justify">Pursuant to ASC Topic 326, Financial Instruments - Credit Losses, the Company adopted a policy to evaluate current expected credit losses at the inception of loans qualifying for treatment under ASC Topic 326. The Company utilizes a probability of default method approach for estimating current expected credit losses and evaluates the liquidity and creditworthiness of its borrowers on a quarterly basis to determine whether any updates to the future expected losses recognized upon inception are necessary. The Company’s evaluation considers industry and economic conditions, credit enhancements, liquidity, and other factors. The determination of the credit allowance is based on a quarterly evaluation of all outstanding loans, including general economic conditions and estimated collectability of loan payments. The Company evaluates the collectability of loan receivables based on a combination of credit quality indicators, including, but not limited to, payment status, historical loan charge-offs, financial strength of the borrower and guarantors, and nature, extent, and value of the underlying collateral. A loan is considered to have deteriorated credit quality when, based on current information and events, it is probable that the Company will be unable to collect all amounts due as scheduled according to the contractual terms of the loan agreement. For those loans identified as having deteriorated credit quality, the amount of credit loss is determined on an individual basis. Placement on non-accrual status may be required. Consistent with this definition, all loans on non-accrual status are deemed to have deteriorated credit quality. To the extent circumstances improve and the risk of collectability is diminished, the loan may return to income accrual status. While a loan is on non-accrual status, any cash receipts are applied against the outstanding principal balance. </div><div style="margin-bottom:6pt">During the first quarter of 2023, the Company determined that the risk of credit loss on a few of its mezzanine loans were no longer remote and recorded a credit loss reserve of $5.2 million. During the three months ended March 31, 2024, the Company determined that no additional credit loss reserve was needed for its real estate notes receivable. </div><div style="margin-bottom:6pt">The following table summarizes the Company's allowance for credit losses on real estate notes receivable:</div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.672%"><tr><td style="width:1.0%"></td><td style="width:59.439%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.631%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Dollars in thousands</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">THREE MONTHS ENDED MARCH 31, 2024</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">TWELVE MONTHS ENDED DECEMBER 31, 2023</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Allowance for credit losses, beginning of period</td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">5,196 </td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">— </td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Credit loss reserves</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">5,196 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle">Allowance for credit losses, end of period</td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">5,196 </td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">5,196 </td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div>Interest Income</div><div>Income from Lease Financing Receivables</div><div style="margin-bottom:6pt">The Company recognized the related income from two financing receivables totaling $2.1 million for each of the three months ended March 31, 2024 and 2023, based on an imputed interest rate over the terms of the applicable lease. As a result, the interest recognized from the financing receivable in any particular period will not equal the cash payments from the lease agreement in that period. </div><div style="margin-bottom:6pt">Acquisition costs incurred in connection with entering into the financing receivable are treated as loan origination fees. These costs are classified with the financing receivable and are included in the balance of the net investment. Amortization of these amounts will be recognized as a reduction to Interest income over the life of the lease.</div><div>Income from Real Estate Notes Receivable</div><div style="margin-bottom:6pt">During the three months ended March 31, 2024 and 2023, the Company recognized interest income of $2.4 million and $2.1 million, respectively, related to real estate notes receivable. The Company recognizes interest income on an accrual basis unless the Company has determined that collectability of contractual amounts is not reasonably assured, at which point the note is placed on non-accrual status and interest income is recognized on a cash basis. In 2023, the Company placed two of its real estate notes receivable with principal balances, net of credit loss, of $48.9 million on non-accrual status and accordingly did not recognize any interest income for the three months ended March 31, 2024. </div><div>Revenue from Contracts with Customers (ASC Topic 606)</div><div style="margin-bottom:6pt">The Company recognizes certain revenue under the core principle of ASC Topic 606. This topic requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Lease revenue is not within the scope of ASC Topic 606. To achieve the core principle, the Company applies the five-step model specified in the guidance. </div><div style="margin-bottom:6pt">Revenue that is accounted for under ASC Topic 606 is segregated on the Company’s Condensed Consolidated Statements of Operations in the Other operating line item. This line item includes parking income, management fee income and other miscellaneous income. Below is a detail of the amounts by category:</div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.470%"><tr><td style="width:1.0%"></td><td style="width:53.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.612%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.614%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="background-color:#000000;border-left:0.25pt solid #000;border-right:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">THREE MONTHS ENDED March 31,</td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">in thousands</td><td colspan="3" style="border-left:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">2024</td><td colspan="3" style="border-right:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">2023</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Type of Revenue</td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Parking income</td><td style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">2,545 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">2,391 </td><td style="border-right:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Management fee income/other 1</div></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,646 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,227 </td><td style="border-right:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">4,191 </td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">4,618 </td><td style="border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> </div><div style="margin-bottom:3pt">1 Includes the recovery of certain expenses under the financing receivable as outlined in the management agreement. </div><div style="margin-bottom:3pt"> </div><div style="margin-bottom:6pt">The Company’s major types of revenue that are accounted for under Topic 606 that are listed above are all accounted for as the performance obligation is satisfied. The performance obligations that are identified for each of these items are satisfied over time, and the Company recognizes revenue monthly based on this principle.</div><div style="margin-top:5pt">New Accounting Pronouncements</div><div style="margin-bottom:6pt">On November 27, 2023, the Financial Accounting Standards Board ("FASB") issued ASU 2023-07, Segment Reporting (Topic 280). Some of the main provisions of this update to segment reporting include; (i) a requirement to disclose significant segment expenses, on an annual and interim basis, that are regularly provided to the chief operating decision maker ("CODM") and included within each reported measure of segment profit or loss; (ii) a requirement to </div><div style="margin-bottom:6pt">disclose the title and position of the CODM and an explanation of how the CODM uses the reported measures of segment profit or loss in assessing segment performance and deciding how to allocate resources, and (iii) a requirement that an entity that has a single reportable segment provide all the disclosures required by the amendments in this update. </div>The update is effective for annual reporting periods beginning after December 15, 2023, and interim periods beginning after December 15, 2024. Early adoption is permitted. At this time, the Company does not expect that the adoption of this ASU will have a material impact on its consolidated financial statements and compliance of these new disclosure requirements will begin with the Company's Annual Report on Form 10-K for the year ending December 31, 2024. <div style="margin-top:3pt">Business Overview</div><div style="margin-bottom:6pt">Healthcare Realty Trust Incorporated ("Company") is a real estate investment trust ("REIT") that owns, leases, manages, acquires, finances, develops and redevelops income-producing real estate properties associated primarily with the delivery of outpatient healthcare services throughout the United States. As of March 31, 2024, the Company had gross investments of approximately $13.4 billion in 654 consolidated real estate properties, construction in progress, redevelopments, financing receivables, financing lease right-of-use assets, land held for development and corporate property, excluding held for sale assets. The Company's real estate properties are located in 35 states and total approximately 38.4 million square feet. The Company provided leasing and property management services to 92% of its portfolio nationwide as of March 31, 2024. </div><div style="margin-bottom:6pt">On July 20, 2022, pursuant to that certain Agreement and Plan of Merger dated as of February 28, 2022, by and among Healthcare Realty Trust Incorporated, a Maryland corporation (now known as HRTI, LLC, a Maryland limited liability company) (“Legacy HR”), Healthcare Trust of America, Inc., a Maryland corporation (now known as Healthcare Realty Trust Incorporated) (“Legacy HTA”), Healthcare Trust of America Holdings, LP, a Delaware limited partnership (now known as Healthcare Realty Holdings, L.P.) (the “OP”), and HR Acquisition 2, LLC, a Maryland limited liability company (“Merger Sub”), Merger Sub merged with and into Legacy HR, with Legacy HR continuing as the surviving entity and a wholly-owned subsidiary of Legacy HTA (the “Merger”). The combined company operates under the name “Healthcare Realty Trust Incorporated” and its shares of class A common stock, $0.01 par value per share, trade on the New York Stock Exchange under the ticker symbol “HR”.</div><div style="margin-bottom:6pt">The Company is structured as an umbrella partnership REIT under which substantially all of its business is conducted through the OP, the day-to-day management of which is exclusively controlled by the Company. As of March 31, 2024, the Company owned 98.6% of the issued and outstanding units of the OP, with other investors owning the remaining 1.4% of outstanding units.</div><div style="margin-bottom:6pt">In addition, as of March 31, 2024, the Company had a weighted average ownership interest of approximately 43% in 33 real estate properties held in unconsolidated joint ventures. See Note 2 below for more details regarding the Company's unconsolidated joint ventures. </div>Any references to square footage or occupancy percentage, and any amounts derived from these values in these notes to the Company's Condensed Consolidated Financial Statements, are outside the scope of our independent registered public accounting firm’s review. 13400000000 654 35 38400000 0.92 0.01 0.986 0.014 0.43 33 <div>Basis of Presentation</div><div style="margin-bottom:6pt;text-align:justify">The Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. They do not include all of the information and footnotes required by GAAP for complete financial statements. All material intercompany transactions and balances have been eliminated in consolidation.</div><div style="margin-bottom:6pt">This interim financial information should be read in conjunction with the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. Management believes that all adjustments of a normal, recurring nature considered necessary for a fair presentation have been included. In addition, the interim financial information does not necessarily represent or indicate what the operating results will be for the year ending December 31, 2024 for many reasons including, but not limited to, acquisitions, dispositions, capital financing transactions, changes in interest rates and the effects of other trends, risks and uncertainties.</div> <div>Principles of Consolidation</div><div style="margin-bottom:6pt">The Company’s Condensed Consolidated Financial Statements include the accounts of the Company, its wholly owned subsidiaries, and joint ventures and partnerships where the Company controls the operating activities. GAAP requires us to identify entities for which control is achieved through means other than voting rights and to determine which business enterprise is the primary beneficiary of variable interest entities (“VIEs”). Accounting Standards Codification (“ASC”) Topic 810, Consolidation broadly defines a VIE as an entity in which either (i) the equity investors as a group, if any, lack the power through voting or similar rights to direct the activities of such entity that most significantly impact such entity’s economic performance or (ii) the equity investment at risk is insufficient to </div><div style="margin-bottom:6pt">finance that entity’s activities without additional subordinated financial support. The Company identifies the primary beneficiary of a VIE as the enterprise that has both of the following characteristics: (i) the power to direct the activities of the VIE that most significantly impact the entity’s economic performance and (ii) the obligation to absorb losses or receive benefits of the VIE that could potentially be significant to the entity. The Company consolidates its investment in a VIE when it determines that it is the VIE’s primary beneficiary, with any minority interests reflected as non-controlling interests or redeemable non-controlling interests in the accompanying Condensed Consolidated Financial Statements. </div><div style="margin-bottom:6pt">The Company may change its original assessment of a VIE upon subsequent events, such as the modification of contractual arrangements that affect the characteristics or adequacy of the entity’s equity investments at risk, the disposition of all or a portion of an interest held by the primary beneficiary, or changes in facts and circumstances that impact the power to direct activities of the VIE that most significantly impacts economic performance. The Company performs this analysis on an ongoing basis.</div><div style="margin-bottom:6pt">For property holding entities not determined to be VIEs, the Company consolidates such entities in which it owns 100% of the equity or has a controlling financial interest evidenced by ownership of a majority voting interest. All intercompany balances and transactions are eliminated in consolidation. For entities in which the Company owns less than 100% of the equity interest, the Company consolidates the entity if it has the direct or indirect ability to control the entities’ activities based upon the terms of the respective entities’ ownership agreements. </div>The OP is 98.6% owned by the Company. Holders of operating partnership units (“OP Units”) are considered to be non-controlling interest holders in the OP and their ownership interests are reflected as equity on the accompanying Condensed Consolidated Balance Sheets. Further, a portion of the earnings and losses of the OP are allocated to non-controlling interest holders based on their respective ownership percentages. Upon conversion of OP Units to common stock, any difference between the fair value of the common stock issued and the carrying value of the OP Units converted to common stock is recorded as a component of equity. As of March 31, 2024, there were approximately 5.2 million OP Units, or 1.4% of OP Units issued and outstanding, held by non-controlling interest holders. Additionally, the Company is the primary beneficiary of this VIE. Accordingly, the Company consolidates its interests in the OP. 1 1 0.986 5200000 0.014 4 Accordingly, such joint ventures have been consolidated, and the table below summarizes the balance sheets of consolidated VIEs, excluding the OP, in the aggregate:<div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:45.259%"><tr><td style="width:1.0%"></td><td style="width:66.129%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.671%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(dollars in thousands)</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">MARCH 31, 2024</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Assets:</td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Net real estate investments</td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">92,028 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Cash and cash equivalents</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,548 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Receivables and other assets</div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,687 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Total assets</div></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">97,263 </td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Liabilities:</div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Accrued expenses and other liabilities</div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">5,681 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Total equity</div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">91,582 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Total liabilities and equity</div></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">97,263 </td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 92028000 2548000 2687000 97263000 5681000 91582000 97263000 3 2 1 As a result, the Company accounts for the two notes receivables as amortized cost and a joint venture arrangement under the equity method. See below for additional information regarding the Company's unconsolidated VIEs.<div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.119%"><tr><td style="width:1.0%"></td><td style="width:21.067%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.858%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.246%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.663%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.666%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(dollars in thousands) ORIGINATION DATE</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">LOCATION</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">SOURCE</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">CARRYING AMOUNT </td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">MAXIMUM EXPOSURE TO LOSS</td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">2021</td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Houston, TX 1</div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Note receivable</td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">31,150 </td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">31,150 </td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">2021</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Charlotte, NC 1</div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Note receivable</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,848 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,000 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">2022</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Texas 2</div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Joint venture</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">60,476 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">60,476 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt">1Assumed mortgage note receivable in connection with the Merger.</div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt">2Includes investments in seven properties.</div> 2 31150000 31150000 5848000 6000000 60476000 60476000 7 As of March 31, 2024, the Company's unconsolidated joint venture arrangements were accounted for using the equity method of accounting as the Company exercised significant influence over but did not control these entities. <div>Use of Estimates in the Condensed Consolidated Financial Statements</div>Preparation of the Condensed Consolidated Financial Statements in accordance with GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Actual results may differ from those estimates. <div style="margin-top:5pt">Redeemable Non-Controlling Interests</div>The Company accounts for redeemable equity securities in accordance with ASC Topic 480: Accounting for Redeemable Equity Instruments, which requires that equity securities redeemable at the option of the holder, not solely within our control, be classified outside permanent stockholders’ equity. The Company classifies redeemable equity securities as redeemable non-controlling interests in the accompanying Condensed Consolidated Balance Sheets. Accordingly, the Company records the carrying amount at the greater of the initial carrying amount (increased or decreased for the non-controlling interest’s share of net income or loss and distributions) or the redemption value. We measure the redemption value and record an adjustment to the carrying value of the equity securities as a component of redeemable non-controlling interest. 3900000 <div>Asset Impairment</div>The Company assesses the potential for impairment of identifiable, definite-lived, intangible assets and long-lived assets, including real estate properties, whenever the occurrence of an event or a change in circumstances indicates that the carrying value might not be fully recoverable. Indicators of impairment may include significant underperformance of an asset relative to historical or expected operating results; significant changes in the Company’s use of assets or the strategy for its overall business; plans to sell an asset before its depreciable life has ended; the expiration of a significant portion of leases in a property; or significant negative economic trends or negative industry trends for the Company or its tenants. 15900000 3 2900000 <div>Goodwill Impairment</div>During the first quarter of 2024, the Company experienced a sustained decline in the price per share of its common stock, which was identified as an indicator of goodwill impairment. As a result, a goodwill evaluation was performed. The Company's current operations are carried out through a single reporting unit with a carrying value of approximately $12.0 billion. The Company determined that the carrying value exceeded estimated fair value and therefore an impairment of goodwill was recorded. The Company recorded a $250.5 million full impairment of its goodwill, which is recorded as a non-cash charge in “Impairment of goodwill” in the Condensed Consolidated Statements of Operations. 12000000000 250500000 <div>Investments in Leases - Financing Receivables, Net </div>In accordance with ASC Topic 842: Leases, for transactions in which the Company enters into a contract to acquire an asset and leases it back to the seller (i.e., a sale leaseback transaction), control of the asset is not considered to have transferred when the seller-lessee has a purchase option. As a result, the Company does not recognize the underlying real estate asset but instead recognizes a financial asset in accordance with ASC Topic 310: Receivables.<div>Real Estate Notes Receivable</div>Real estate notes receivable consists of mezzanine and other real estate loans, which are generally collateralized by a pledge of the borrower’s ownership interest in the respective real estate owner, a mortgage or deed of trust, and/or corporate guarantees. Real estate notes receivable are intended to be held-to-maturity and are recorded at amortized cost, net of unamortized loan origination costs and fees and allowance for credit losses.<div style="margin-top:5pt">Allowance for Credit Losses</div><div style="margin-bottom:6pt;text-align:justify">Pursuant to ASC Topic 326, Financial Instruments - Credit Losses, the Company adopted a policy to evaluate current expected credit losses at the inception of loans qualifying for treatment under ASC Topic 326. The Company utilizes a probability of default method approach for estimating current expected credit losses and evaluates the liquidity and creditworthiness of its borrowers on a quarterly basis to determine whether any updates to the future expected losses recognized upon inception are necessary. The Company’s evaluation considers industry and economic conditions, credit enhancements, liquidity, and other factors. The determination of the credit allowance is based on a quarterly evaluation of all outstanding loans, including general economic conditions and estimated collectability of loan payments. The Company evaluates the collectability of loan receivables based on a combination of credit quality indicators, including, but not limited to, payment status, historical loan charge-offs, financial strength of the borrower and guarantors, and nature, extent, and value of the underlying collateral. A loan is considered to have deteriorated credit quality when, based on current information and events, it is probable that the Company will be unable to collect all amounts due as scheduled according to the contractual terms of the loan agreement. For those loans identified as having deteriorated credit quality, the amount of credit loss is determined on an individual basis. Placement on non-accrual status may be required. Consistent with this definition, all loans on non-accrual status are deemed to have deteriorated credit quality. To the extent circumstances improve and the risk of collectability is diminished, the loan may return to income accrual status. While a loan is on non-accrual status, any cash receipts are applied against the outstanding principal balance. </div><div>Interest Income</div><div>Income from Lease Financing Receivables</div><div style="margin-bottom:6pt">The Company recognized the related income from two financing receivables totaling $2.1 million for each of the three months ended March 31, 2024 and 2023, based on an imputed interest rate over the terms of the applicable lease. As a result, the interest recognized from the financing receivable in any particular period will not equal the cash payments from the lease agreement in that period. </div><div style="margin-bottom:6pt">Acquisition costs incurred in connection with entering into the financing receivable are treated as loan origination fees. These costs are classified with the financing receivable and are included in the balance of the net investment. Amortization of these amounts will be recognized as a reduction to Interest income over the life of the lease.</div> See below for additional information regarding the Company's financing receivables.<div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.241%"><tr><td style="width:1.0%"></td><td style="width:26.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.667%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(dollars in thousands) ORIGINATION DATE</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">LOCATION</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">INTEREST RATE</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">CARRYING VALUE as of MARCH 31, 2024</td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">May 2021</td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Poway, CA</td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">5.73%</td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">114,643 </td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">November 2021</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Columbus, OH</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">6.48%</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,358 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">122,001 </td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.694%"><tr><td style="width:1.0%"></td><td style="width:15.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.942%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.333%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(dollars in thousands)</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">ORIGINATION</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">MATURITY</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">STATED INTEREST RATE</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">MAXIMUM LOAN COMMITMENT</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">OUTSTANDING as of MAR 31, 2024</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">ALLOWANCE FOR CREDIT LOSSES</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">FAIR VALUE DISCOUNT AND FEES</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">CARRYING VALUE as of MAR 31, 2024</td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Mezzanine loans</td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Texas</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">6/24/2021</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">6/24/2024</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8.00 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">54,119 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">54,119 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">(5,196)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">(3,067)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">45,856 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Arizona</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">12/21/2023</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">12/20/2026</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9.00 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,000 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,000 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,000 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">60,119 </td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">60,119 </td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5,196)</td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3,067)</td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">51,856 </td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Mortgage loans </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Texas</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">6/30/2021</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">7/01/2024</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7.00 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">31,150 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">31,150 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">31,150 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">North Carolina</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">12/22/2021</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">12/22/2024</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8.00 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,000 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,000 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(152)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,848 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Florida</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">5/17/2022</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">2/27/2026</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.00 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">65,000 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">33,209 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(39)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">33,170 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">California</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">3/30/2023</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">3/29/2026</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.00 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">45,000 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">45,000 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">45,000 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Florida</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">12/28/2023</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">12/28/2026</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9.00 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,700 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,423 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,423 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">154,850 </td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">122,782 </td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(191)</td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">122,591 </td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">214,969 </td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">182,901 </td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(5,196)</td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(3,258)</td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">174,447 </td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0.0573 114643000 0.0648 7358000 122001000 174400000 0.0800 54119000 54119000 5196000 3067000 45856000 0.0900 6000000 6000000 0 0 6000000 60119000 60119000 5196000 3067000 51856000 0.0700 31150000 31150000 0 0 31150000 0.0800 6000000 6000000 0 152000 5848000 0.0600 65000000 33209000 0 39000 33170000 0.0600 45000000 45000000 0 0 45000000 0.0900 7700000 7423000 0 0 7423000 154850000 122782000 0 191000 122591000 214969000 182901000 5196000 3258000 174447000 5200000 <div style="margin-bottom:6pt">The following table summarizes the Company's allowance for credit losses on real estate notes receivable:</div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.672%"><tr><td style="width:1.0%"></td><td style="width:59.439%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.631%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Dollars in thousands</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">THREE MONTHS ENDED MARCH 31, 2024</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">TWELVE MONTHS ENDED DECEMBER 31, 2023</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Allowance for credit losses, beginning of period</td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">5,196 </td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">— </td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Credit loss reserves</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">5,196 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle">Allowance for credit losses, end of period</td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">5,196 </td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">5,196 </td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 5196000 0 0 5196000 5196000 5196000 2 2100000 2400000 2100000 2 48900000 <div>Revenue from Contracts with Customers (ASC Topic 606)</div><div style="margin-bottom:6pt">The Company recognizes certain revenue under the core principle of ASC Topic 606. This topic requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Lease revenue is not within the scope of ASC Topic 606. To achieve the core principle, the Company applies the five-step model specified in the guidance. </div>Revenue that is accounted for under ASC Topic 606 is segregated on the Company’s Condensed Consolidated Statements of Operations in the Other operating line item. This line item includes parking income, management fee income and other miscellaneous income.<div style="margin-bottom:6pt">The Company’s major types of revenue that are accounted for under Topic 606 that are listed above are all accounted for as the performance obligation is satisfied. The performance obligations that are identified for each of these items are satisfied over time, and the Company recognizes revenue monthly based on this principle.</div> Below is a detail of the amounts by category:<div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.470%"><tr><td style="width:1.0%"></td><td style="width:53.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.612%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.614%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="background-color:#000000;border-left:0.25pt solid #000;border-right:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">THREE MONTHS ENDED March 31,</td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">in thousands</td><td colspan="3" style="border-left:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">2024</td><td colspan="3" style="border-right:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">2023</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Type of Revenue</td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Parking income</td><td style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">2,545 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">2,391 </td><td style="border-right:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Management fee income/other 1</div></td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,646 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,227 </td><td style="border-right:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">4,191 </td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">4,618 </td><td style="border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> </div>1 Includes the recovery of certain expenses under the financing receivable as outlined in the management agreement. 2545000 2391000 1646000 2227000 4191000 4618000 <div style="margin-top:5pt">New Accounting Pronouncements</div><div style="margin-bottom:6pt">On November 27, 2023, the Financial Accounting Standards Board ("FASB") issued ASU 2023-07, Segment Reporting (Topic 280). Some of the main provisions of this update to segment reporting include; (i) a requirement to disclose significant segment expenses, on an annual and interim basis, that are regularly provided to the chief operating decision maker ("CODM") and included within each reported measure of segment profit or loss; (ii) a requirement to </div><div style="margin-bottom:6pt">disclose the title and position of the CODM and an explanation of how the CODM uses the reported measures of segment profit or loss in assessing segment performance and deciding how to allocate resources, and (iii) a requirement that an entity that has a single reportable segment provide all the disclosures required by the amendments in this update. </div>The update is effective for annual reporting periods beginning after December 15, 2023, and interim periods beginning after December 15, 2024. Early adoption is permitted. At this time, the Company does not expect that the adoption of this ASU will have a material impact on its consolidated financial statements and compliance of these new disclosure requirements will begin with the Company's Annual Report on Form 10-K for the year ending December 31, 2024. Real Estate Investments<div style="margin-top:3pt">2024 Acquisition Activity </div><div style="margin-bottom:6pt">The Company had no real estate acquisition activity for the three months ended March 31, 2024.</div><div> </div><div>Unconsolidated Joint Ventures</div><div style="margin-bottom:6pt">The Company's investment in and loss recognized for the three months ended March 31, 2024 and 2023 related to its unconsolidated joint ventures accounted for under the equity method are shown in the table below:</div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.993%"><tr><td style="width:1.0%"></td><td style="width:71.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.784%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="background-color:#000000;border-left:0.25pt solid #000000;border-right:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">THREE MONTHS ENDED March 31,</td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Dollars in thousands</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">2024</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">2023</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Investments in unconsolidated joint ventures, beginning of period </td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">311,511 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">327,248 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div>New investment during the period 1</div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">3,824 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Equity loss recognized during the period </td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(422)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(780)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Owner distributions</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(1,335)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(2,546)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Investments in unconsolidated joint ventures, end of period </td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">309,754 </td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">327,746 </td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt">1In 2023, this was an additional investment in an existing joint venture in which the Company retained a 40% ownership interest. The investment consisted of the Company's sale of a property in Dallas, Texas to the joint venture. </div><div style="margin-top:6pt">2024 Real Estate Asset Dispositions </div><div style="margin-bottom:6pt">The Company had no real estate dispositions for the three months ended March 31, 2024.</div><div style="margin-bottom:6pt">Subsequent to March 31, 2024, the Company disposed of two medical outpatient buildings totaling 39,000 square feet for an aggregate of $5.8 million. The two properties were classified as held for sale as of March 31, 2024.</div><div>Assets Held for Sale</div><div style="margin-bottom:6pt">The table below reflects the assets and liabilities classified as held for sale as of March 31, 2024 and December 31, 2023:</div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.073%"><tr><td style="width:1.0%"></td><td style="width:41.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.879%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.469%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.471%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Dollars in thousands</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">March 31, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Balance Sheet data:</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Land</td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">2,023 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">1,850 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Building and improvements</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12,440 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,779 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Lease intangibles</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,001 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,017 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16,464 </td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,646 </td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Accumulated depreciation</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,050)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(913)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt">Real estate assets held for sale, net 1</div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14,414 </td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,733 </td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Cash and cash equivalents</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">260 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Operating lease right-of-use assets</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">193 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Other assets, net</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16,101 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">101 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">Assets held for sale, net</td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">30,968 </td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">8,834 </td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Accounts payable and accrued liabilities</td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">135 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">23 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Operating lease liabilities</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">211 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Other liabilities</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">354 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">272 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">Liabilities of assets held for sale</td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">700 </td><td style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">295 </td><td style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt">1 Net real estate assets held for sale includes the impact of $1.5 million of impairment charges for the three months ended March 31, 2024.</div> <div style="margin-bottom:6pt">The Company's investment in and loss recognized for the three months ended March 31, 2024 and 2023 related to its unconsolidated joint ventures accounted for under the equity method are shown in the table below:</div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.993%"><tr><td style="width:1.0%"></td><td style="width:71.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.784%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="background-color:#000000;border-left:0.25pt solid #000000;border-right:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">THREE MONTHS ENDED March 31,</td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Dollars in thousands</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">2024</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">2023</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Investments in unconsolidated joint ventures, beginning of period </td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">311,511 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">327,248 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div>New investment during the period 1</div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">3,824 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Equity loss recognized during the period </td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(422)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(780)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Owner distributions</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(1,335)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(2,546)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Investments in unconsolidated joint ventures, end of period </td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">309,754 </td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">327,746 </td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div>1In 2023, this was an additional investment in an existing joint venture in which the Company retained a 40% ownership interest. The investment consisted of the Company's sale of a property in Dallas, Texas to the joint venture. 311511000 327248000 0 3824000 -422000 -780000 1335000 2546000 309754000 327746000 0.40 2 39000 5800000 2 <div style="margin-bottom:6pt">The table below reflects the assets and liabilities classified as held for sale as of March 31, 2024 and December 31, 2023:</div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.073%"><tr><td style="width:1.0%"></td><td style="width:41.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.879%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.469%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.471%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Dollars in thousands</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">March 31, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Balance Sheet data:</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Land</td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">2,023 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">1,850 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Building and improvements</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12,440 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,779 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Lease intangibles</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,001 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,017 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16,464 </td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,646 </td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Accumulated depreciation</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,050)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(913)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt">Real estate assets held for sale, net 1</div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14,414 </td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,733 </td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Cash and cash equivalents</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">260 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Operating lease right-of-use assets</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">193 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Other assets, net</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16,101 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">101 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">Assets held for sale, net</td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">30,968 </td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">8,834 </td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Accounts payable and accrued liabilities</td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">135 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">23 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Operating lease liabilities</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">211 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Other liabilities</td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">354 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">272 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">Liabilities of assets held for sale</td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">700 </td><td style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">295 </td><td style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt">1 Net real estate assets held for sale includes the impact of $1.5 million of impairment charges for the three months ended March 31, 2024.</div> 2023000 1850000 12440000 6779000 2001000 1017000 16464000 9646000 2050000 913000 14414000 8733000 260000 0 193000 0 16101000 101000 30968000 8834000 135000 23000 211000 0 354000 272000 700000 295000 1500000 Leases<div style="margin-top:3pt">Lessor Accounting</div><div style="margin-bottom:6pt">The Company’s properties generally are leased pursuant to non-cancelable, fixed-term operating leases with expiration dates through 2052. Some leases provide tenants with fixed rent renewal terms while others have market rent renewal terms. Some leases provide the lessee, during the term of the lease, with an option or right of first refusal to purchase the leased property. The Company’s single-tenant net leases generally require the lessee to pay minimum rent and all taxes (including property tax), insurance, maintenance and other operating costs associated with the leased property.</div><div style="margin-bottom:6pt">The Company's leases typically have escalators that are either based on a stated percentage or an index such as the consumer price index ("CPI"). In addition, most of the Company's leases include nonlease components, such as reimbursement of operating expenses as additional rent, or include the reimbursement of expected operating expenses as part of the lease payment. The Company adopted an accounting policy to combine lease and nonlease components. Rent escalators based on indices and reimbursements of operating expenses that are not included in the lease rate are considered variable lease payments. Variable payments are recognized in the period earned. Lease income for the Company's operating leases recognized for the three months ended March 31, 2024 was $318.1 million. Lease income for the Company's operating leases recognized for the three months ended March 31, 2023 was $324.1 million.</div><div style="margin-bottom:3pt">Future lease payments under the non-cancelable operating leases, excluding any reimbursements and one sale-type lease, as of March 31, 2024 were as follows:</div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:37.461%"><tr><td style="width:1.0%"></td><td style="width:42.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.064%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Dollars in thousands</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">OPERATING</td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">2024</td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">680,129 </td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2025</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">831,775 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2026</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">734,080 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2027</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">611,277 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2028</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">497,470 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2029 and thereafter</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,665,663 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:0 1pt"></td><td style="border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.25pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">5,020,394 </td><td style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div>Lessee Accounting </div><div style="margin-bottom:6pt">As of March 31, 2024, the Company was obligated, as the lessee, under operating lease agreements consisting primarily of the Company’s ground leases. As of March 31, 2024, the Company had 231 properties totaling 16.9 million square feet that were held under ground leases. Some of the ground lease renewal terms are based on fixed rent renewal terms and others have market rent renewal terms. These ground leases typically have initial terms of 40 to 99 years with expiration dates through 2119. Any rental increases related to the Company’s ground leases are generally either stated or based on CPI. The Company had 75 prepaid ground leases as of March 31, 2024. The amortization of the prepaid rent, included in the operating lease right-of-use asset, represented approximately $0.3 million of the Company’s rental expense for the three months ended March 31, 2024 and March 31, 2023. </div><div style="margin-bottom:6pt">The Company’s future lease payments (primarily for its 156 non-prepaid ground leases) as of March 31, 2024 were as follows:</div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.165%"><tr><td style="width:1.0%"></td><td style="width:58.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Dollars in thousands</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">OPERATING</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">FINANCING</td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">2024</td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">8,760 </td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">1,523 </td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2025</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">12,415 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">2,218 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2026</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">12,503 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">2,255 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2027</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">12,689 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">2,294 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2028</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">12,809 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">2,326 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2029 and thereafter</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">698,464 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">394,072 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Total undiscounted lease payments</td><td colspan="2" style="border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">757,640 </td><td style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">404,688 </td><td style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Discount</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(528,417)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(329,919)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Lease liabilities</td><td style="border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.25pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">229,223 </td><td style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.25pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">74,769 </td><td style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:6pt">The following table provides details of the Company's total lease expense for the three months ended March 31, 2024 and 2023:</div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.981%"><tr><td style="width:1.0%"></td><td style="width:70.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.019%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="background-color:#000000;border-left:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">THREE MONTHS ENDED March 31,</td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Dollars in thousands</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">2024</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">2023</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Operating lease cost</td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Operating lease expense</td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">4,465 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">5,107 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Variable lease expense</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,228 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">2,136 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Finance lease cost</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Amortization of right-of-use assets</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">387 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">388 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Interest on lease liabilities</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">937 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">918 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Total lease expense</td><td style="border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.25pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">7,017 </td><td style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.25pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">8,549 </td><td style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Other information</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Operating cash flows outflows related to operating leases</td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">4,040 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">5,960 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Operating cash flows outflows related to financing leases</td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">563 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">553 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Financing cash flows outflows related to financing leases</td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">110 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">101 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Weighted-average years remaining lease term (excluding renewal options) - operating leases</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle">45.8</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle">47.4</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Weighted-average years remaining lease term (excluding renewal options) - finance leases</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle">57.7</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle">58.7</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Weighted-average discount rate - operating leases</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">5.7 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">5.8 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Weighted-average discount rate - finance leases</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">5.0 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">5.0 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> Leases<div style="margin-top:3pt">Lessor Accounting</div><div style="margin-bottom:6pt">The Company’s properties generally are leased pursuant to non-cancelable, fixed-term operating leases with expiration dates through 2052. Some leases provide tenants with fixed rent renewal terms while others have market rent renewal terms. Some leases provide the lessee, during the term of the lease, with an option or right of first refusal to purchase the leased property. The Company’s single-tenant net leases generally require the lessee to pay minimum rent and all taxes (including property tax), insurance, maintenance and other operating costs associated with the leased property.</div><div style="margin-bottom:6pt">The Company's leases typically have escalators that are either based on a stated percentage or an index such as the consumer price index ("CPI"). In addition, most of the Company's leases include nonlease components, such as reimbursement of operating expenses as additional rent, or include the reimbursement of expected operating expenses as part of the lease payment. The Company adopted an accounting policy to combine lease and nonlease components. Rent escalators based on indices and reimbursements of operating expenses that are not included in the lease rate are considered variable lease payments. Variable payments are recognized in the period earned. Lease income for the Company's operating leases recognized for the three months ended March 31, 2024 was $318.1 million. Lease income for the Company's operating leases recognized for the three months ended March 31, 2023 was $324.1 million.</div><div style="margin-bottom:3pt">Future lease payments under the non-cancelable operating leases, excluding any reimbursements and one sale-type lease, as of March 31, 2024 were as follows:</div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:37.461%"><tr><td style="width:1.0%"></td><td style="width:42.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.064%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Dollars in thousands</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">OPERATING</td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">2024</td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">680,129 </td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2025</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">831,775 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2026</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">734,080 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2027</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">611,277 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2028</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">497,470 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2029 and thereafter</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,665,663 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:0 1pt"></td><td style="border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.25pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">5,020,394 </td><td style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div>Lessee Accounting </div><div style="margin-bottom:6pt">As of March 31, 2024, the Company was obligated, as the lessee, under operating lease agreements consisting primarily of the Company’s ground leases. As of March 31, 2024, the Company had 231 properties totaling 16.9 million square feet that were held under ground leases. Some of the ground lease renewal terms are based on fixed rent renewal terms and others have market rent renewal terms. These ground leases typically have initial terms of 40 to 99 years with expiration dates through 2119. Any rental increases related to the Company’s ground leases are generally either stated or based on CPI. The Company had 75 prepaid ground leases as of March 31, 2024. The amortization of the prepaid rent, included in the operating lease right-of-use asset, represented approximately $0.3 million of the Company’s rental expense for the three months ended March 31, 2024 and March 31, 2023. </div><div style="margin-bottom:6pt">The Company’s future lease payments (primarily for its 156 non-prepaid ground leases) as of March 31, 2024 were as follows:</div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.165%"><tr><td style="width:1.0%"></td><td style="width:58.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Dollars in thousands</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">OPERATING</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">FINANCING</td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">2024</td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">8,760 </td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">1,523 </td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2025</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">12,415 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">2,218 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2026</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">12,503 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">2,255 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2027</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">12,689 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">2,294 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2028</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">12,809 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">2,326 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2029 and thereafter</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">698,464 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">394,072 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Total undiscounted lease payments</td><td colspan="2" style="border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">757,640 </td><td style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">404,688 </td><td style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Discount</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(528,417)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(329,919)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Lease liabilities</td><td style="border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.25pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">229,223 </td><td style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.25pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">74,769 </td><td style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:6pt">The following table provides details of the Company's total lease expense for the three months ended March 31, 2024 and 2023:</div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.981%"><tr><td style="width:1.0%"></td><td style="width:70.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.019%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="background-color:#000000;border-left:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">THREE MONTHS ENDED March 31,</td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Dollars in thousands</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">2024</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">2023</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Operating lease cost</td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Operating lease expense</td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">4,465 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">5,107 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Variable lease expense</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,228 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">2,136 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Finance lease cost</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Amortization of right-of-use assets</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">387 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">388 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Interest on lease liabilities</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">937 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">918 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Total lease expense</td><td style="border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.25pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">7,017 </td><td style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.25pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">8,549 </td><td style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Other information</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Operating cash flows outflows related to operating leases</td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">4,040 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">5,960 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Operating cash flows outflows related to financing leases</td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">563 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">553 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Financing cash flows outflows related to financing leases</td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">110 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">101 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Weighted-average years remaining lease term (excluding renewal options) - operating leases</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle">45.8</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle">47.4</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Weighted-average years remaining lease term (excluding renewal options) - finance leases</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle">57.7</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle">58.7</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Weighted-average discount rate - operating leases</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">5.7 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">5.8 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Weighted-average discount rate - finance leases</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">5.0 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">5.0 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 318100000 324100000 <div style="margin-bottom:3pt">Future lease payments under the non-cancelable operating leases, excluding any reimbursements and one sale-type lease, as of March 31, 2024 were as follows:</div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:37.461%"><tr><td style="width:1.0%"></td><td style="width:42.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.064%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Dollars in thousands</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">OPERATING</td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">2024</td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">680,129 </td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2025</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">831,775 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2026</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">734,080 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2027</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">611,277 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2028</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">497,470 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2029 and thereafter</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,665,663 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:0 1pt"></td><td style="border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.25pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">5,020,394 </td><td style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div> 680129000 831775000 734080000 611277000 497470000 1665663000 5020394000 16900000 P40Y P99Y 75 300000 300000 <div style="margin-bottom:6pt">The Company’s future lease payments (primarily for its 156 non-prepaid ground leases) as of March 31, 2024 were as follows:</div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.165%"><tr><td style="width:1.0%"></td><td style="width:58.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Dollars in thousands</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">OPERATING</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">FINANCING</td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">2024</td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">8,760 </td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">1,523 </td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2025</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">12,415 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">2,218 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2026</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">12,503 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">2,255 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2027</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">12,689 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">2,294 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2028</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">12,809 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">2,326 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2029 and thereafter</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">698,464 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">394,072 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Total undiscounted lease payments</td><td colspan="2" style="border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">757,640 </td><td style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">404,688 </td><td style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Discount</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(528,417)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(329,919)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Lease liabilities</td><td style="border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.25pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">229,223 </td><td style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.25pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">74,769 </td><td style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div> <div style="margin-bottom:6pt">The Company’s future lease payments (primarily for its 156 non-prepaid ground leases) as of March 31, 2024 were as follows:</div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.165%"><tr><td style="width:1.0%"></td><td style="width:58.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Dollars in thousands</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">OPERATING</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">FINANCING</td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">2024</td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">8,760 </td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">1,523 </td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2025</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">12,415 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">2,218 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2026</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">12,503 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">2,255 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2027</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">12,689 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">2,294 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2028</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">12,809 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">2,326 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2029 and thereafter</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">698,464 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">394,072 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Total undiscounted lease payments</td><td colspan="2" style="border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">757,640 </td><td style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">404,688 </td><td style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Discount</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(528,417)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(329,919)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Lease liabilities</td><td style="border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.25pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">229,223 </td><td style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.25pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">74,769 </td><td style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div> 156 8760000 1523000 12415000 2218000 12503000 2255000 12689000 2294000 12809000 2326000 698464000 394072000 757640000 404688000 528417000 329919000 229223000 74769000 <div style="margin-bottom:6pt">The following table provides details of the Company's total lease expense for the three months ended March 31, 2024 and 2023:</div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.981%"><tr><td style="width:1.0%"></td><td style="width:70.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.019%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="background-color:#000000;border-left:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">THREE MONTHS ENDED March 31,</td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Dollars in thousands</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">2024</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">2023</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Operating lease cost</td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Operating lease expense</td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">4,465 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">5,107 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Variable lease expense</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,228 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">2,136 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Finance lease cost</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Amortization of right-of-use assets</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">387 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">388 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Interest on lease liabilities</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">937 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">918 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Total lease expense</td><td style="border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.25pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">7,017 </td><td style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.25pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">8,549 </td><td style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Other information</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Operating cash flows outflows related to operating leases</td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">4,040 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">5,960 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Operating cash flows outflows related to financing leases</td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">563 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">553 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Financing cash flows outflows related to financing leases</td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">110 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">101 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Weighted-average years remaining lease term (excluding renewal options) - operating leases</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle">45.8</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle">47.4</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Weighted-average years remaining lease term (excluding renewal options) - finance leases</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle">57.7</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle">58.7</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Weighted-average discount rate - operating leases</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">5.7 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">5.8 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Weighted-average discount rate - finance leases</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">5.0 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">5.0 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 4465000 5107000 1228000 2136000 387000 388000 937000 918000 7017000 8549000 4040000 5960000 563000 553000 110000 101000 P45Y9M18D P47Y4M24D P57Y8M12D P58Y8M12D 0.057 0.058 0.050 0.050 Notes and Bonds Payable<div style="margin-bottom:6pt;margin-top:3pt">The table below details the Company’s notes and bonds payable as of March 31, 2024 and December 31, 2023. </div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.522%"><tr><td style="width:1.0%"></td><td style="width:39.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.091%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom">MATURITY DATES </td><td colspan="6" style="background-color:#000000;border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">BALANCE 1 AS OF </div></td><td colspan="3" rowspan="2" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">EFFECTIVE INTEREST RATE as of 3/31/2024</td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Dollars in thousands</td><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">3/31/2024</td><td colspan="3" style="border-right:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">12/31/2023</td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div>$1.5 billion Unsecured Credit Facility </div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle">10/25</td><td style="background-color:#ffffff;border-left:0.25pt solid #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">120,000 </td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">— </td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">6.27 </td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div>$200 million Unsecured Term Loan 2</div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle">5/24</td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">199,961 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">199,903 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">6.36 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div>$350 million Unsecured Term Loan </div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle">7/24</td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">349,885 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">349,798 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">6.36 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div>$300 million Unsecured Term Loan </div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle">10/25</td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">299,964 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">299,958 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">6.36 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div>$150 million Unsecured Term Loan </div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle">6/26</td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">149,679 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">149,643 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.36 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>$200 million Unsecured Term Loan </div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle">7/27</td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">199,536 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">199,502 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.36 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div>$300 million Unsecured Term Loan</div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle">1/28</td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">298,393 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">298,288 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">6.36 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Senior Notes due 2025</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle">5/25</td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">249,579 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">249,484 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">4.12 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div>Senior Notes due 2026 </div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle">8/26</td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">580,933 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">579,017 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">4.94 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Senior Notes due 2027 </td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle">7/27</td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">484,802 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">483,727 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">4.76 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Senior Notes due 2028</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle">1/28</td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">297,577 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">297,429 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">3.85 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Senior Notes due 2030 </td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle">2/30</td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">578,038 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">575,443 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">5.30 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Senior Notes due 2030</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle">3/30</td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">296,881 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">296,780 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">2.72 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Senior Notes due 2031 </td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle">3/31</td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">295,958 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">295,832 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">2.25 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Senior Notes due 2031 </td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle">3/31</td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">653,864 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">649,521 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">5.13 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div>Mortgage notes payable </div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle">9/24-12/26</td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">53,229 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">70,534 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right">3.57%-6.88%</div></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">5,108,279 </td><td style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">4,994,859 </td><td style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr></table>.</div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt">1Balance is presented net of discounts and issuance costs and inclusive of premiums, where applicable. </div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt">2In April 2024, the Company exercised its option to extend the maturity date for one year to May 2025 for a fee of approximately $0.3 million. </div><div> </div><div>Changes in Mortgage Notes Payable</div><div>On January 6, 2024, the Company repaid in full at maturity a mortgage note payable bearing interest at a rate of 4.77% per annum with an outstanding principal balance of $11.3 million. The mortgage note encumbered a 63,012 square foot property in California. </div><div style="margin-bottom:6pt"> </div><div style="margin-bottom:6pt">On February 1, 2024, the Company repaid in full at maturity a mortgage note payable bearing interest at a rate of 4.12% per annum with an outstanding principal balance of $5.6 million. The mortgage note encumbered a 40,324 square foot property in Georgia.</div> <div style="margin-bottom:6pt;margin-top:3pt">The table below details the Company’s notes and bonds payable as of March 31, 2024 and December 31, 2023. </div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.522%"><tr><td style="width:1.0%"></td><td style="width:39.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.091%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom">MATURITY DATES </td><td colspan="6" style="background-color:#000000;border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">BALANCE 1 AS OF </div></td><td colspan="3" rowspan="2" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">EFFECTIVE INTEREST RATE as of 3/31/2024</td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Dollars in thousands</td><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">3/31/2024</td><td colspan="3" style="border-right:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">12/31/2023</td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div>$1.5 billion Unsecured Credit Facility </div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle">10/25</td><td style="background-color:#ffffff;border-left:0.25pt solid #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">120,000 </td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">— </td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">6.27 </td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div>$200 million Unsecured Term Loan 2</div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle">5/24</td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">199,961 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">199,903 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">6.36 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div>$350 million Unsecured Term Loan </div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle">7/24</td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">349,885 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">349,798 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">6.36 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div>$300 million Unsecured Term Loan </div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle">10/25</td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">299,964 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">299,958 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">6.36 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div>$150 million Unsecured Term Loan </div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle">6/26</td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">149,679 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">149,643 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.36 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>$200 million Unsecured Term Loan </div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle">7/27</td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">199,536 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">199,502 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.36 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div>$300 million Unsecured Term Loan</div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle">1/28</td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">298,393 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">298,288 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">6.36 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Senior Notes due 2025</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle">5/25</td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">249,579 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">249,484 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">4.12 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div>Senior Notes due 2026 </div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle">8/26</td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">580,933 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">579,017 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">4.94 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Senior Notes due 2027 </td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle">7/27</td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">484,802 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">483,727 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">4.76 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Senior Notes due 2028</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle">1/28</td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">297,577 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">297,429 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">3.85 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Senior Notes due 2030 </td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle">2/30</td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">578,038 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">575,443 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">5.30 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Senior Notes due 2030</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle">3/30</td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">296,881 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">296,780 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">2.72 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Senior Notes due 2031 </td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle">3/31</td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">295,958 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">295,832 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">2.25 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Senior Notes due 2031 </td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle">3/31</td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">653,864 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">649,521 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">5.13 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div>Mortgage notes payable </div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle">9/24-12/26</td><td colspan="2" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">53,229 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">70,534 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-left:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right">3.57%-6.88%</div></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">5,108,279 </td><td style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">4,994,859 </td><td style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr></table>.</div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt">1Balance is presented net of discounts and issuance costs and inclusive of premiums, where applicable. </div>2In April 2024, the Company exercised its option to extend the maturity date for one year to May 2025 for a fee of approximately $0.3 million. 1500000000 120000000 0 0.0627 200000000 199961000 199903000 0.0636 350000000 349885000 349798000 0.0636 300000000 299964000 299958000 0.0636 150000000 149679000 149643000 0.0636 200000000 199536000 199502000 0.0636 300000000 298393000 298288000 0.0636 249579000 249484000 0.0412 580933000 579017000 0.0494 484802000 483727000 0.0476 297577000 297429000 0.0385 578038000 575443000 0.0530 296881000 296780000 0.0272 295958000 295832000 0.0225 653864000 649521000 0.0513 53229000 70534000 0.0357 0.0688 5108279000 4994859000 P1Y 300000 0.0477 11300000 63012 0.0412 5600000 40324 Derivative Financial Instruments<div style="margin-top:3pt">Risk Management Objective of Using Derivatives</div><div style="margin-bottom:6pt">The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest rate, liquidity, and credit risk, primarily by managing the amount, sources, and duration of its assets and liabilities and the use of derivative financial instruments. Specifically, the Company enters into derivative financial instruments to manage exposures that arise from business activities that result in the receipt or payment of future known and uncertain cash amounts, the value of which are determined by interest rates. The Company’s derivative financial instruments are used to manage differences in the amount, timing, and duration of the Company’s known or expected cash receipts and its known or expected cash payments principally related to the Company’s borrowings.</div><div>Cash Flow Hedges of Interest Rate Risk</div><div style="margin-bottom:6pt">The Company’s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish this objective, the Company primarily uses interest rate swaps as part of its interest rate risk management strategy. Interest rate swaps designated as cash flow hedges involve the receipt of variable amounts from a counterparty in exchange for the Company making fixed-rate payments over the </div><div style="margin-bottom:6pt">life of the agreements without exchange of the underlying notional amount. Such derivatives were used to hedge the variable cash flows associated with existing variable-rate debt.</div><div style="margin-bottom:6pt">For derivatives designated, and that qualify, as cash flow hedges of interest rate risk, the gain or loss on the derivative is recorded in Accumulated Other Comprehensive Income (Loss) ("AOCI") and subsequently reclassified into interest expense in the same period(s) during which the hedged transaction affects earnings. Amounts reported in AOCI related to derivatives will be reclassified to interest expense as interest payments are made on the Company’s variable-rate debt. </div><div style="margin-bottom:6pt">As of March 31, 2024, the Company had 15 outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk:</div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.978%"><tr><td style="width:1.0%"></td><td style="width:41.810%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.646%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.244%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">AMOUNT</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">WEIGHTED AVERAGE RATE</td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle">May 2026</td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">275,000 </td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">3.74 </td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">June 2026</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">150,000 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">3.83 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">December 2026</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">150,000 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">3.84 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">June 2027</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">200,000 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">4.27 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">December 2027</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">300,000 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">3.93 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td style="border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.25pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">1,075,000 </td><td style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">3.92 </td><td style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr></table></div><div style="margin-top:5pt">Tabular Disclosure of Fair Values of Derivative Instruments on the Balance Sheet</div><div style="margin-bottom:6pt">The table below presents the fair value of the Company's derivative financial instruments, as well as their classification on the Condensed Consolidated Balance Sheet as of March 31, 2024.</div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.394%"><tr><td style="width:1.0%"></td><td style="width:57.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.608%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.859%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="background-color:#000000;padding:2px 1pt;text-align:center;vertical-align:bottom">BALANCE AT MARCH 31, 2024</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">In thousands</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">BALANCE SHEET LOCATION</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">FAIR VALUE</td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Derivatives designated as hedging instruments</td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Interest rate swaps</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Other liabilities</td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">(2,973)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Interest rate swaps</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Other assets</td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">10,603 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Total derivatives designated as hedging instruments</td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">7,630 </td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table> </div><div> </div><div>Tabular Disclosure of the Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Income (Loss)</div><div style="margin-bottom:6pt">The table below presents the effect of cash flow hedge accounting on AOCI during the three months ended March 31, 2024 and 2023 related to the Company's outstanding interest rate swaps.</div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.694%"><tr><td style="width:1.0%"></td><td style="width:24.206%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.940%"></td><td style="width:0.1%"></td></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="background-color:#000000;border-left:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(GAIN)/LOSS RECOGNIZED IN AOCI ON DERIVATIVE three months ended March 31,</td><td colspan="3" rowspan="2" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="6" style="background-color:#000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(GAIN)/LOSS RECLASSIFIED FROM AOCI INTO INCOME three months ended March 31,</td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">In thousands</td><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2024</td><td colspan="3" style="border-right:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2023</td><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2024</td><td colspan="3" style="border-right:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Interest rate swaps</td><td style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">(19,611)</td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">8,541 </td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle">Interest expense</td><td style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">(4,014)</td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">(2,433)</td><td style="border-right:0.25pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Settled treasury hedges</td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle">Interest expense</td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">107 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">107 </td><td style="border-right:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Settled interest rate swaps</td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle">Interest expense</td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">42 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">42 </td><td style="border-right:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"> </td><td style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.25pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">(19,611)</td><td style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.25pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">8,541 </td><td style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle">Total interest expense</td><td style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.25pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">(3,865)</td><td style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.25pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">(2,284)</td><td style="border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt">The Company estimates that an additional $10.5 million related to active interest rate swaps will be reclassified from AOCI as a decrease to interest expense over the next 12 months, and that an additional $0.6 million related to settled interest rate swaps will be amortized from AOCI as an increase to interest expense over the next 12 months.</div><div>Credit-risk-related Contingent Features</div><div style="margin-bottom:6pt">The Company's agreements with each of its derivative counterparties contain a cross-default provision under which the Company could be declared in default of its derivative obligations if repayment of the underlying indebtedness is accelerated by the lender due to the Company's default on the indebtedness.</div><div style="margin-bottom:6pt">As of March 31, 2024, the fair value of derivatives in a net asset position including accrued interest but excluding any adjustment for nonperformance risk related to these agreements was $7.6 million. As of March 31, 2024, the Company had not posted any collateral related to these agreements and was not in breach of any agreement.</div> <div style="margin-bottom:6pt">As of March 31, 2024, the Company had 15 outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk:</div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.978%"><tr><td style="width:1.0%"></td><td style="width:41.810%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.646%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.244%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">AMOUNT</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">WEIGHTED AVERAGE RATE</td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle">May 2026</td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">275,000 </td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">3.74 </td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">June 2026</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">150,000 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">3.83 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">December 2026</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">150,000 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">3.84 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">June 2027</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">200,000 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">4.27 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">December 2027</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">300,000 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">3.93 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td style="border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.25pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">1,075,000 </td><td style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">3.92 </td><td style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr></table></div><div style="margin-bottom:6pt">The table below presents the effect of cash flow hedge accounting on AOCI during the three months ended March 31, 2024 and 2023 related to the Company's outstanding interest rate swaps.</div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.694%"><tr><td style="width:1.0%"></td><td style="width:24.206%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.940%"></td><td style="width:0.1%"></td></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="background-color:#000000;border-left:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(GAIN)/LOSS RECOGNIZED IN AOCI ON DERIVATIVE three months ended March 31,</td><td colspan="3" rowspan="2" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="6" style="background-color:#000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(GAIN)/LOSS RECLASSIFIED FROM AOCI INTO INCOME three months ended March 31,</td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">In thousands</td><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2024</td><td colspan="3" style="border-right:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2023</td><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2024</td><td colspan="3" style="border-right:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Interest rate swaps</td><td style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">(19,611)</td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">8,541 </td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle">Interest expense</td><td style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">(4,014)</td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">(2,433)</td><td style="border-right:0.25pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Settled treasury hedges</td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle">Interest expense</td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">107 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">107 </td><td style="border-right:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Settled interest rate swaps</td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle">Interest expense</td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">42 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">42 </td><td style="border-right:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"> </td><td style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.25pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">(19,611)</td><td style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.25pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">8,541 </td><td style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle">Total interest expense</td><td style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.25pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">(3,865)</td><td style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.25pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">(2,284)</td><td style="border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div> 15 275000000 0.0374 150000000 0.0383 150000000 0.0384 200000000 0.0427 300000000 0.0393 1075000000 0.0392 <div style="margin-bottom:6pt">The table below presents the fair value of the Company's derivative financial instruments, as well as their classification on the Condensed Consolidated Balance Sheet as of March 31, 2024.</div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.394%"><tr><td style="width:1.0%"></td><td style="width:57.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.608%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.859%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="background-color:#000000;padding:2px 1pt;text-align:center;vertical-align:bottom">BALANCE AT MARCH 31, 2024</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">In thousands</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">BALANCE SHEET LOCATION</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">FAIR VALUE</td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Derivatives designated as hedging instruments</td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Interest rate swaps</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Other liabilities</td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">(2,973)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Interest rate swaps</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Other assets</td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">10,603 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Total derivatives designated as hedging instruments</td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">7,630 </td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table> -2973000 10603000 7630000 19611000 -8541000 4014000 2433000 0 0 -107000 -107000 0 0 -42000 -42000 19611000 -8541000 3865000 2284000 10500000 -600000 7600000 Commitments and Contingencies<div style="margin-top:3pt">Legal Proceedings</div><div style="margin-bottom:6pt">The Company is, from time to time, involved in litigation arising in the ordinary course of business. The Company is not aware of any pending or threatened litigation that, if resolved against the Company, would have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows.</div><div>Development and Redevelopment Activity</div><div style="margin-bottom:6pt">For the three months ended March 31, 2024, the Company invested $7.7 million and $2.8 million toward active development and redevelopment of properties, respectively, and $11.1 million toward recently completed development and redevelopment projects.</div> 7700000 2800000 11100000 Stockholders' Equity<div style="margin-top:3pt">Common Stock </div><div style="margin-bottom:6pt">The following table provides a reconciliation of the beginning and ending shares of common stock outstanding for the three months ended March 31, 2024 and the twelve months ended December 31, 2023:</div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.981%"><tr><td style="width:1.0%"></td><td style="width:55.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.450%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">THREE MONTHS ENDED MARCH 31, 2024</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">TWELVE MONTHS ENDED DECEMBER 31, 2023</td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Balance, beginning of period</td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">380,964,433 </td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">380,589,894 </td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Issuance of common stock</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">8,623 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">8,627 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Conversion of OP unit to Common stock</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">194,767 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">190,544 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Non-vested share-based awards, net of withheld shares and forfeitures</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">333,679 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">175,368 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Balance, end of period</td><td colspan="2" style="border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">381,501,502 </td><td style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">380,964,433 </td><td style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:7pt">Common Stock Dividends</div><div style="margin-bottom:6pt">During the three months ended March 31, 2024, the Company declared and paid common stock dividends totaling $0.31 per share. On April 30, 2024, the Company declared a quarterly common stock dividend in the amount of $0.31 per share payable on May 23, 2024 to stockholders of record on May 13, 2024.</div><div>Authorization to Repurchase Common Stock</div><div style="margin-bottom:6pt">On May 31, 2023, the Company’s Board of Directors authorized the repurchase of up to $500.0 million of outstanding shares of the Company’s common stock either in the open market or through privately negotiated transactions, subject to market conditions, regulatory constraints, and other customary conditions. The Company is not obligated under this authorization to repurchase any specific number of shares. This authorization supersedes all previous stock repurchase authorizations. In April 2024, the Company repurchased 2,966,764 shares of its common stock at a weighted average price of $14.07 for a total of $41.7 million under this authorization.</div><div style="margin-bottom:6pt">On April 30, 2024, the Company's Board of directors authorized the repurchase of up to $500.0 million of outstanding shares of the Company's common stock, superseding the previous stock repurchase authorization.</div><div>Earnings Per Common Share</div><div style="margin-bottom:6pt">The Company uses the two-class method of computing net earnings per common shares. The Company's non-vested share-based awards are considered participating securities pursuant to the two-class method. </div><div style="margin-bottom:6pt">The following table sets forth the computation of basic and diluted earnings per common share for the three months ended March 31, 2024 and 2023.</div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.617%"><tr><td style="width:1.0%"></td><td style="width:64.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.113%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.114%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="background-color:#000000;border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">THREE MONTHS ENDED MARCH 31,</td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Dollars in thousands, except per share data</td><td colspan="3" style="border-left:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">2024</td><td colspan="3" style="border-right:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">2023</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Weighted average common shares outstanding</td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Weighted average common shares outstanding</td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">381,335,208 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">380,796,773 </td><td style="border-right:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Non-vested shares</td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(1,880,401)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(1,956,353)</td><td style="border-right:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Weighted average common shares outstanding - basic</td><td colspan="2" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">379,454,807 </td><td style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">378,840,420 </td><td style="border-right:0.25pt solid #000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Weighted average common shares outstanding - basic</td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">379,454,807 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">378,840,420 </td><td style="border-right:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Dilutive effect of forward equity shares</td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="border-right:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Dilutive effect of OP Units</td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="border-right:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Dilutive effect of employee stock purchase plan</td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="border-right:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Weighted average common shares outstanding - diluted</td><td colspan="2" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">379,454,807 </td><td style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">378,840,420 </td><td style="border-right:0.25pt solid #000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Net loss</td><td style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">(315,220)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">(88,078)</td><td style="border-right:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Income allocated to participating securities</td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(693)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(625)</td><td style="border-right:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Loss attributable to non-controlling interest</td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">4,384 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">953 </td><td style="border-right:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Adjustment to loss attributable to non-controlling interest for legally outstanding restricted units</td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(1,341)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(16)</td><td style="border-right:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Net loss applicable to common stockholders - basic</td><td style="border-left:0.25pt solid #000;border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.25pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">(312,870)</td><td style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.25pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">(87,766)</td><td style="border-right:0.25pt solid #000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Basic earnings per common share - net loss</td><td style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">(0.82)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">(0.23)</td><td style="border-right:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Diluted earnings per common share - net loss</td><td style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">(0.82)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">(0.23)</td><td style="border-right:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt">The effect of OP Units redeemable for 3,681,225 shares and options under the Company's Employee Stock Purchase Plan (the "ESPP") to purchase 23,140 shares of the Company's common stock for the three months ended March 31, 2024 were excluded from the calculation of diluted loss per common share because the effect was anti-dilutive due to the loss from continuing operations incurred during that period.</div><div style="margin-bottom:3pt;text-align:justify">Stock Incentive Plan</div><div style="margin-bottom:6pt;text-align:justify">The Company's stock incentive plan ("Incentive Plan") permits the grant of incentive awards to its employees and directors in any of the following forms: options, stock appreciation rights, restricted stock, restricted or deferred stock units, performance awards, dividend equivalents, or other stock-based awards, including units in the OP.</div><div style="margin-bottom:3pt;text-align:justify">Equity Incentive Plans</div><div style="margin-bottom:6pt">During the three months ended March 31, 2024, the Company made the following equity awards:</div><div style="padding-left:36pt;text-indent:-18pt">•Restricted Stock </div><div style="margin-bottom:6pt;padding-left:36pt">During the first quarter of 2024, the Company granted non-vested stock awards to its named executive officers and other members of senior management and employees with an aggregate grant date fair value of $5.6 million, which consisted of an aggregate of 361,712 non-vested shares with vesting periods ranging from three to eight years.</div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt">•Restricted Stock Units ("RSUs")</div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify">On February 13, 2024, the Company granted an aggregate of 208,055 RSUs to members of senior management, with an aggregate grant date fair value of $3.5 million and a five-year vesting period. </div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:36pt;text-align:justify">Approximately 36% of the RSUs vest based on relative total shareholder return ("TSR") and were valued using independent specialists. The Company utilized a Monte Carlo simulation to calculate the weighted </div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:36pt;text-align:justify">average grant date fair value of $19.10 for the relative TSR component for the February 2024 grant using the following assumptions:</div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:35.932%"><tr><td style="width:1.0%"></td><td style="width:56.346%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:41.454%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">THREE MONTHS ENDED MARCH 31, </td></tr><tr><td colspan="3" style="border-left:0.5pt solid #929292;border-top:0.5pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle">Volatility</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:0.5pt solid #929292;border-top:0.5pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">28.0 </td><td style="border-right:0.5pt solid #929292;border-top:0.5pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="border-left:0.5pt solid #929292;border-top:0.5pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle">Dividend assumption</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:0.5pt solid #929292;border-right:0.5pt solid #929292;border-top:0.5pt solid #929292;padding:2px 1pt;text-align:right;vertical-align:middle">Accrued</td></tr><tr><td colspan="3" style="border-left:0.5pt solid #929292;border-top:0.5pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle">Expected term </td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:0.5pt solid #929292;border-right:0.5pt solid #929292;border-top:0.5pt solid #929292;padding:2px 1pt;text-align:right;vertical-align:middle">3 years</td></tr><tr><td colspan="3" style="border-left:0.5pt solid #929292;border-top:0.5pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle">Risk-free rate</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:0.5pt solid #929292;border-top:0.5pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">4.44 </td><td style="border-right:0.5pt solid #929292;border-top:0.5pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #929292;border-left:0.5pt solid #929292;border-top:0.5pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle">Stock price (per share)</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:0.5pt solid #929292;border-left:0.5pt solid #929292;border-right:0.5pt solid #929292;border-top:0.5pt solid #929292;padding:2px 1pt;text-align:right;vertical-align:middle">$15.22</td></tr></table></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify">The remaining 64% of the RSUs vest based upon certain operating performance conditions. With respect to the operating performance conditions of the February 13, 2024 grant, the grant date fair value was $15.22 based on the Company's share price on the date of grant.</div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt">•LTIP Series C Units</div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify">On February 13, 2024, the Company granted an aggregate of 906,044 LTIP Series C units ("LTIP-C units) in the OP with three-year forward-looking performance targets, a five-year vesting period and an aggregate grant date fair value of $7.5 million. </div><div style="margin-bottom:6pt;margin-top:9pt;padding-left:36pt;text-align:justify">Approximately 36% of the LTIP-C units vest based on relative TSR and were valued using independent specialists. The Company utilized a Monte Carlo simulation to calculate the weighted average grant date fair value of $9.62 for the relative TSR component for the February 2024 grant using the following assumptions:</div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:35.932%"><tr><td style="width:1.0%"></td><td style="width:56.346%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:41.454%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">THREE MONTHS ENDED MARCH 31, </td></tr><tr><td colspan="3" style="border-left:0.5pt solid #929292;border-top:0.5pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle">Volatility</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:0.5pt solid #929292;border-top:0.5pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">28.0 </td><td style="border-right:0.5pt solid #929292;border-top:0.5pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="border-left:0.5pt solid #929292;border-top:0.5pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle">Dividend assumption</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:0.5pt solid #929292;border-right:0.5pt solid #929292;border-top:0.5pt solid #929292;padding:2px 1pt;text-align:right;vertical-align:middle">Accrued</td></tr><tr><td colspan="3" style="border-left:0.5pt solid #929292;border-top:0.5pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle">Expected term </td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:0.5pt solid #929292;border-right:0.5pt solid #929292;border-top:0.5pt solid #929292;padding:2px 1pt;text-align:right;vertical-align:middle">3 years</td></tr><tr><td colspan="3" style="border-left:0.5pt solid #929292;border-top:0.5pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle">Risk-free rate</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:0.5pt solid #929292;border-top:0.5pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">4.44 </td><td style="border-right:0.5pt solid #929292;border-top:0.5pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #929292;border-left:0.5pt solid #929292;border-top:0.5pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle">Stock price (per share)</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:0.5pt solid #929292;border-left:0.5pt solid #929292;border-right:0.5pt solid #929292;border-top:0.5pt solid #929292;padding:2px 1pt;text-align:right;vertical-align:middle">$15.22</td></tr></table></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify">The remaining 64% of the LTIP-C units vest based upon certain operating performance conditions. With respect to the operating performance conditions of the February 13, 2024 grant, the grant date fair value was $15.22 based on the Company's share price on the date of grant. The Company records amortization expense based on the probability of achieving certain operating performance conditions, which is evaluated throughout the performance period. </div><div style="margin-top:9pt;text-align:justify">The following table represents the summary of non-vested share-based awards under the Incentive Plans for the three months ended March 31, 2024 and 2023:</div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.464%"><tr><td style="width:1.0%"></td><td style="width:64.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.148%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.149%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="background-color:#000000;border-left:1pt solid #ffffff;border-right:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">THREE MONTHS ENDED MARCH 31,</td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="border-left:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">2024</td><td colspan="3" style="border-right:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">2023</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Share-based awards, beginning of period</td><td colspan="2" style="background-color:#ffffff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">2,615,562 </td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">2,090,060 </td><td style="background-color:#ffffff;border-right:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div>Granted 1</div></td><td colspan="2" style="background-color:#ffffff;border-left:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,475,811 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,075,261 </td><td style="background-color:#ffffff;border-right:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Vested</td><td colspan="2" style="background-color:#ffffff;border-left:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(28,414)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(113,766)</td><td style="background-color:#ffffff;border-right:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Forfeited</td><td colspan="2" style="background-color:#ffffff;border-left:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(19,805)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(26,063)</td><td style="background-color:#ffffff;border-right:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Share-based awards, end of period</td><td colspan="2" style="background-color:#ffffff;border-bottom:0.25pt solid #000;border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">4,043,154 </td><td style="background-color:#ffffff;border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">3,025,492 </td><td style="background-color:#ffffff;border-bottom:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt">1.LTIP-C units are issued at the maximum possible value of the award and are reflected as such in this table until the performance period has been satisfied and the exact number of awards are determinable.</div><div style="margin-bottom:3pt;padding-left:18pt">During the three months ended March 31, 2024 and 2023, the Company withheld 8,228 and 38,632 shares of common stock, respectively, from participants to pay estimated withholding taxes related to shares that vested.</div><div style="margin-bottom:3pt">The following table represents expected amortization of the Company's non-vested shares issued as of March 31, 2024:</div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:35.321%"><tr><td style="width:1.0%"></td><td style="width:48.683%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.117%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Dollars in millions</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">FUTURE AMORTIZATION of non-vested shares</td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">2024</td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">11.5 </td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2025</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">13.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2026</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">10.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2027</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">5.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2028 and thereafter</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">2.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle">Total</td><td style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">43.9 </td><td style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div> <div style="margin-bottom:6pt">The following table provides a reconciliation of the beginning and ending shares of common stock outstanding for the three months ended March 31, 2024 and the twelve months ended December 31, 2023:</div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.981%"><tr><td style="width:1.0%"></td><td style="width:55.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.450%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">THREE MONTHS ENDED MARCH 31, 2024</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">TWELVE MONTHS ENDED DECEMBER 31, 2023</td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Balance, beginning of period</td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">380,964,433 </td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">380,589,894 </td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Issuance of common stock</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">8,623 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">8,627 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Conversion of OP unit to Common stock</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">194,767 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">190,544 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Non-vested share-based awards, net of withheld shares and forfeitures</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">333,679 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">175,368 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Balance, end of period</td><td colspan="2" style="border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">381,501,502 </td><td style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">380,964,433 </td><td style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div> 380964433 380589894 8623 8627 194767 190544 333679 175368 381501502 380964433 0.31 0.31 500000000 2966764 14.07 41700000 500000000 <div style="margin-bottom:6pt">The following table sets forth the computation of basic and diluted earnings per common share for the three months ended March 31, 2024 and 2023.</div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.617%"><tr><td style="width:1.0%"></td><td style="width:64.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.113%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.114%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="background-color:#000000;border-left:0.25pt solid #000;border-right:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">THREE MONTHS ENDED MARCH 31,</td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Dollars in thousands, except per share data</td><td colspan="3" style="border-left:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">2024</td><td colspan="3" style="border-right:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">2023</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Weighted average common shares outstanding</td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-right:0.25pt solid #000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Weighted average common shares outstanding</td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">381,335,208 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">380,796,773 </td><td style="border-right:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Non-vested shares</td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(1,880,401)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(1,956,353)</td><td style="border-right:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Weighted average common shares outstanding - basic</td><td colspan="2" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">379,454,807 </td><td style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">378,840,420 </td><td style="border-right:0.25pt solid #000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Weighted average common shares outstanding - basic</td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">379,454,807 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">378,840,420 </td><td style="border-right:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Dilutive effect of forward equity shares</td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="border-right:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Dilutive effect of OP Units</td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="border-right:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Dilutive effect of employee stock purchase plan</td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="border-right:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Weighted average common shares outstanding - diluted</td><td colspan="2" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">379,454,807 </td><td style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">378,840,420 </td><td style="border-right:0.25pt solid #000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Net loss</td><td style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">(315,220)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">(88,078)</td><td style="border-right:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Income allocated to participating securities</td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(693)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(625)</td><td style="border-right:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Loss attributable to non-controlling interest</td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">4,384 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">953 </td><td style="border-right:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Adjustment to loss attributable to non-controlling interest for legally outstanding restricted units</td><td colspan="2" style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(1,341)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(16)</td><td style="border-right:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Net loss applicable to common stockholders - basic</td><td style="border-left:0.25pt solid #000;border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.25pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">(312,870)</td><td style="border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="border-top:0.25pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">(87,766)</td><td style="border-right:0.25pt solid #000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Basic earnings per common share - net loss</td><td style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">(0.82)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">(0.23)</td><td style="border-right:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Diluted earnings per common share - net loss</td><td style="border-left:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">(0.82)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="padding:2px 0;text-align:right;vertical-align:middle">(0.23)</td><td style="border-right:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 381335208 380796773 1880401 1956353 379454807 378840420 379454807 378840420 0 0 0 0 0 379454807 378840420 -315220000 -88078000 693000 625000 -4384000 -953000 -1341000 -16000 -312870000 -87766000 -0.82 -0.23 -0.82 -0.23 3681225 23140 5600000 361712 P8Y 208055 3500000 P5Y 0.36 19.10 <div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:35.932%"><tr><td style="width:1.0%"></td><td style="width:56.346%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:41.454%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">THREE MONTHS ENDED MARCH 31, </td></tr><tr><td colspan="3" style="border-left:0.5pt solid #929292;border-top:0.5pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle">Volatility</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:0.5pt solid #929292;border-top:0.5pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">28.0 </td><td style="border-right:0.5pt solid #929292;border-top:0.5pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="border-left:0.5pt solid #929292;border-top:0.5pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle">Dividend assumption</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:0.5pt solid #929292;border-right:0.5pt solid #929292;border-top:0.5pt solid #929292;padding:2px 1pt;text-align:right;vertical-align:middle">Accrued</td></tr><tr><td colspan="3" style="border-left:0.5pt solid #929292;border-top:0.5pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle">Expected term </td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:0.5pt solid #929292;border-right:0.5pt solid #929292;border-top:0.5pt solid #929292;padding:2px 1pt;text-align:right;vertical-align:middle">3 years</td></tr><tr><td colspan="3" style="border-left:0.5pt solid #929292;border-top:0.5pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle">Risk-free rate</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:0.5pt solid #929292;border-top:0.5pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">4.44 </td><td style="border-right:0.5pt solid #929292;border-top:0.5pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #929292;border-left:0.5pt solid #929292;border-top:0.5pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle">Stock price (per share)</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:0.5pt solid #929292;border-left:0.5pt solid #929292;border-right:0.5pt solid #929292;border-top:0.5pt solid #929292;padding:2px 1pt;text-align:right;vertical-align:middle">$15.22</td></tr></table></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:35.932%"><tr><td style="width:1.0%"></td><td style="width:56.346%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:41.454%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">THREE MONTHS ENDED MARCH 31, </td></tr><tr><td colspan="3" style="border-left:0.5pt solid #929292;border-top:0.5pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle">Volatility</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:0.5pt solid #929292;border-top:0.5pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">28.0 </td><td style="border-right:0.5pt solid #929292;border-top:0.5pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="border-left:0.5pt solid #929292;border-top:0.5pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle">Dividend assumption</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:0.5pt solid #929292;border-right:0.5pt solid #929292;border-top:0.5pt solid #929292;padding:2px 1pt;text-align:right;vertical-align:middle">Accrued</td></tr><tr><td colspan="3" style="border-left:0.5pt solid #929292;border-top:0.5pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle">Expected term </td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:0.5pt solid #929292;border-right:0.5pt solid #929292;border-top:0.5pt solid #929292;padding:2px 1pt;text-align:right;vertical-align:middle">3 years</td></tr><tr><td colspan="3" style="border-left:0.5pt solid #929292;border-top:0.5pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle">Risk-free rate</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:0.5pt solid #929292;border-top:0.5pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">4.44 </td><td style="border-right:0.5pt solid #929292;border-top:0.5pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #929292;border-left:0.5pt solid #929292;border-top:0.5pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle">Stock price (per share)</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:0.5pt solid #929292;border-left:0.5pt solid #929292;border-right:0.5pt solid #929292;border-top:0.5pt solid #929292;padding:2px 1pt;text-align:right;vertical-align:middle">$15.22</td></tr></table></div> 0.280 P3Y 0.0444 15.22 0.64 15.22 906044 P3Y 7500000 0.36 9.62 0.280 P3Y 0.0444 15.22 0.64 15.22 <div style="margin-top:9pt;text-align:justify">The following table represents the summary of non-vested share-based awards under the Incentive Plans for the three months ended March 31, 2024 and 2023:</div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.464%"><tr><td style="width:1.0%"></td><td style="width:64.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.148%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.149%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="background-color:#000000;border-left:1pt solid #ffffff;border-right:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">THREE MONTHS ENDED MARCH 31,</td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="border-left:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">2024</td><td colspan="3" style="border-right:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">2023</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Share-based awards, beginning of period</td><td colspan="2" style="background-color:#ffffff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">2,615,562 </td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">2,090,060 </td><td style="background-color:#ffffff;border-right:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div>Granted 1</div></td><td colspan="2" style="background-color:#ffffff;border-left:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,475,811 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,075,261 </td><td style="background-color:#ffffff;border-right:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Vested</td><td colspan="2" style="background-color:#ffffff;border-left:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(28,414)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(113,766)</td><td style="background-color:#ffffff;border-right:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">Forfeited</td><td colspan="2" style="background-color:#ffffff;border-left:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(19,805)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(26,063)</td><td style="background-color:#ffffff;border-right:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Share-based awards, end of period</td><td colspan="2" style="background-color:#ffffff;border-bottom:0.25pt solid #000;border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">4,043,154 </td><td style="background-color:#ffffff;border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">3,025,492 </td><td style="background-color:#ffffff;border-bottom:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt">1.LTIP-C units are issued at the maximum possible value of the award and are reflected as such in this table until the performance period has been satisfied and the exact number of awards are determinable.</div> 2615562 2090060 1475811 1075261 28414 113766 19805 26063 4043154 3025492 8228 38632 <div style="margin-bottom:3pt">The following table represents expected amortization of the Company's non-vested shares issued as of March 31, 2024:</div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:35.321%"><tr><td style="width:1.0%"></td><td style="width:48.683%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.117%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Dollars in millions</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">FUTURE AMORTIZATION of non-vested shares</td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">2024</td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">11.5 </td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2025</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">13.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2026</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">10.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2027</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">5.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">2028 and thereafter</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">2.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle">Total</td><td style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">43.9 </td><td style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div> 11500000 13300000 10600000 5700000 2800000 43900000 Fair Value of Financial Instruments<div style="margin-bottom:6pt">The following methods and assumptions were used to estimate the fair value of each class of financial instrument for which it is practical to estimate that value.</div><div style="padding-left:18pt;text-indent:-18pt">•Cash and cash equivalents - The carrying amount approximates fair value (level 1 inputs) due to the short-term maturity of these investments. </div><div style="padding-left:18pt;text-indent:-18pt">•Real estate notes receivable - Real estate notes receivable are recorded in other assets on the Company's Condensed Consolidated Balance Sheets. Fair value is estimated using cash flow analyses, based on current interest rates for similar types of arrangements. </div><div style="padding-left:18pt;text-indent:-18pt">•Borrowings under the Unsecured Credit Facility and the Term Loans Due 2024 and 2026 - The carrying amount approximates fair value because the borrowings are based on variable market interest rates.</div><div style="padding-left:18pt;text-indent:-18pt">•Senior Notes and Mortgage Notes payable - The fair value of notes and bonds payable is estimated using cash flow analyses, based on the Company’s current interest rates for similar types of borrowing arrangements.</div><div style="padding-left:18pt;text-indent:-18pt">•Interest rate swap agreements - Interest rate swap agreements are recorded in other liabilities on the Company's Condensed Consolidated Balance Sheets at fair value. Fair value is estimated by utilizing pricing models, level 2 inputs, which consider forward yield curves and discount rates. See Note 5 for additional information.</div><div style="margin-bottom:6pt;margin-top:9pt">The table below details the fair values and carrying values for notes and bonds payable and real estate notes receivable at March 31, 2024 and December 31, 2023.</div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.697%"><tr><td style="width:1.0%"></td><td style="width:26.236%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.716%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.716%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.540%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="6" style="background-color:#000000;border-left:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">March 31, 2024</td><td colspan="6" style="background-color:#000000;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Dollars in millions</td><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">CARRYING VALUE</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">FAIR VALUE</td><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">CARRYING VALUE</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">FAIR VALUE</td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Notes and bonds payable 1</div></td><td style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5,108.3 </td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">4,931.9 </td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">4,994.9 </td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">4,872.7 </td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Real estate notes receivable 1</div></td><td style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">174.4 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">172.8 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">173.6 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">172.5 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt">1Level 2 – model-derived valuations in which significant inputs and significant value drivers are observable in active markets.</div> <div style="margin-bottom:6pt;margin-top:9pt">The table below details the fair values and carrying values for notes and bonds payable and real estate notes receivable at March 31, 2024 and December 31, 2023.</div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.697%"><tr><td style="width:1.0%"></td><td style="width:26.236%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.716%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.716%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.540%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="6" style="background-color:#000000;border-left:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">March 31, 2024</td><td colspan="6" style="background-color:#000000;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Dollars in millions</td><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">CARRYING VALUE</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">FAIR VALUE</td><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">CARRYING VALUE</td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">FAIR VALUE</td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Notes and bonds payable 1</div></td><td style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5,108.3 </td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">4,931.9 </td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">4,994.9 </td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">4,872.7 </td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Real estate notes receivable 1</div></td><td style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">174.4 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">172.8 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">173.6 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">172.5 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt">1Level 2 – model-derived valuations in which significant inputs and significant value drivers are observable in active markets.</div> 5108300000 4931900000 4994900000 4872700000 174400000 172800000 173600000 172500000 false false false false